{"data": [{"Element": "<div class=\"WordSection1\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <h1><span lang=\"EN-GB\">ANNEX I </span></h1> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p class=\"TitleA\"><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS</span></p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:green'><br clear=\"all\" style=\"page-break-before:always\"/> </span> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\"><img alt=\"Description: Description: Description: BT_1000x858px\" height=\"18\" id=\"Picture 1\" src=\"Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image001.gif\" width=\"21\"/>This medicinal\r product is subject to additional monitoring. This will allow quick\r identification of new safety information. Healthcare professionals are asked to\r report any suspected adverse reactions. See section 4.8 for how to report\r adverse reactions.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <h2 style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>1.</span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>NAME\r OF THE MEDICINAL PRODUCT</span></h2> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">ADCETRIS 50 mg powder for concentrate\r for solution for infusion.</span></p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"></p> <h2><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>2.       QUALITATIVE\r AND QUANTITATIVE COMPOSITION</span></h2> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Each vial contains 50 mg of\r brentuximab vedotin. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">After reconstitution (see section 6.6),\r each mL contains 5 mg of brentuximab vedotin.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">ADCETRIS is an antibody\u2011drug\r conjugate composed of a CD30\u2011directed monoclonal antibody (recombinant\r chimeric immunoglobulin G1 [IgG1], produced by recombinant DNA technology in\r Chinese Hamster ovary cells) that is covalently linked to the antimicrotubule\r agent monomethyl auristatin E (MMAE).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Excipient with known effect</span></u></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Each vial contains approximately\r 13.2 mg of sodium. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">For the full list of excipients, see section 6.1.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <h2><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>3.       PHARMACEUTICAL\r form</span></h2> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r page-break-after:avoid;text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\">Powder for concentrate for solution for\r infusion.</span></p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\">White to off\u2011white cake or powder. </span></p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"></p> <p class=\"MsoNormal\"></p> <h2><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.       Clinical\r particulars</span></h2> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <h3><span lang=\"EN-GB\">4.1     Therapeutic indications</span></h3> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><a name=\"OLE_LINK2\"></a><a name=\"OLE_LINK5\"></a></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hodgkin\r lymphoma</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">ADCETRIS is indicated for adult patients\r with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in\r combination with doxorubicin, vinblastine and dacarbazine (AVD) (see sections 4.2 and 5.1).</span></p> <p class=\"MsoPlainText\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">ADCETRIS is indicated for the treatment of adult patients with CD30+ HL\r at increased risk of relapse or progression following </span><span style=\"font-size:11.0pt\">autologous stem cell transplant</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> (ASCT) (see section 5.1).</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"MsoPlainText\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\r \"Times New Roman\",serif'>ADCETRIS is indicated for the treatment of adult\r patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): </span></p> <p class=\"MsoPlainText\" style=\"margin-left:66.55pt;text-indent:-.25in\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1.</span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>following\r ASCT, or</span></p> <p class=\"MsoPlainText\" style=\"margin-left:66.55pt;text-indent:-.25in\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>2.</span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>following\r at least two prior therapies when ASCT or multi-agent chemotherapy is not a\r treatment option.</span></p> <p class=\"MsoNormal\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Systemic anaplastic large cell lymphoma</span></u></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">ADCETRIS in combination with cyclophosphamide, doxorubicin and\r prednisone (CHP) is indicated for adult patients with previously untreated systemic\r anaplastic large cell lymphoma (sALCL) (see section 5.1).</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">ADCETRIS is indicated for the treatment of adult patients with relapsed\r or refractory sALCL.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Cutaneous T\u2011cell lymphoma </span></u></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">ADCETRIS is indicated for the treatment of adult patients with CD30+\r cutaneous T\u2011cell lymphoma (CTCL) after at least 1 prior systemic therapy (see\r section 5.1).</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <h3><span lang=\"EN-GB\">4.2     Posology and method of\r administration</span></h3> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">ADCETRIS should\r be administered under the supervision of a physician experienced in the use of\r anti\u2011cancer agents.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span lang=\"EN-GB\"></span></u></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Previously\r Untreated HL</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended dose in combination with\r chemotherapy (doxorubicin [A], vinblastine [V] and dacarbazine [D] [AVD]) is\r 1.2 mg/kg administered as an intravenous infusion over 30 minutes on\r days 1 and 15 of each 28\u2011day cycle for 6 cycles (see section 5.1).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Primary prophylaxis with growth factor\r support (G-CSF), beginning with the first dose, is recommended for all patients\r with previously untreated HL receiving combination therapy (see section 4.4).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Refer to the summary of product\r characteristics (SmPC) of chemotherapy agents given in combination with\r ADCETRIS for patients with previously untreated HL. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">HL at\r increased risk of relapse or progression </span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"></span></u></i></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended dose is 1.8 mg/kg\r administered as an intravenous infusion over 30 minutes every 3 weeks.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">ADCETRIS treatment should start following\r recovery from ASCT based on clinical judgment. These patients should receive up\r to 16 cycles (see section 5.1).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Relapsed\r or refractory HL</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended dose is 1.8 mg/kg\r administered as an intravenous infusion over 30 minutes every\r 3 weeks.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended starting dose for the\r retreatment of patients who have previously responded to treatment with\r ADCETRIS is 1.8 mg/kg administered as an intravenous infusion over\r 30 minutes every 3 weeks. Alternatively, treatment may be started at\r the last tolerated dose (see section 5.1).</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\"><a name=\"OLE_LINK6\"></a><a name=\"OLE_LINK7\"><span lang=\"EN-GB\">Treatment should be continued until disease progression or\r unacceptable toxicity<sup> </sup>(see section 4.4).</span></a></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients who achieve stable disease or\r better should receive a minimum of 8 cycles and </span><span lang=\"EN-GB\">up\r to a maximum of 16 cycles (approximately 1 year) (see section 5.1).\r </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Previously\r untreated sALCL</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended dose in combination with\r chemotherapy (cyclophosphamide [C], doxorubicin [H] and prednisone [P] [CHP])\r is 1.8 mg/kg administered as an intravenous infusion over 30 minutes\r every 3 weeks for 6 to 8 cycles </span><span lang=\"EN-GB\">(see\r section 5.1). </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Primary prophylaxis with G-CSF, beginning\r with the first dose, is recommended for all patients </span><span lang=\"EN-GB\">with\r previously untreated sALCL receiving combination therapy (see\r section 4.4).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Refer to the SmPCs of chemotherapy agents\r given in combination with ADCETRIS for patients with previously untreated sALCL.\r </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Relapsed\r or refractory sALCL</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended dose is 1.8 mg/kg\r administered as an intravenous infusion over 30 minutes every\r 3 weeks.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended starting dose for the\r retreatment of patients who have previously responded to treatment with\r ADCETRIS is 1.8 mg/kg administered as an intravenous infusion over\r 30 minutes every 3 weeks. Alternatively, treatment may be started at\r the last tolerated dose (see section 5.1).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Treatment should be continued until disease\r progression or unacceptable toxicity<sup> </sup>(see section 4.4).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients who achieve stable disease or\r better should receive a minimum of 8 cycles and up to a maximum of\r 16 cycles (approximately 1 year) (see section 5.1). </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">CTCL</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended dose is 1.8 mg/kg\r administered as an intravenous infusion over 30 minutes every\r 3 weeks.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients with CTCL should receive up to 16\r cycles (see section 5.1).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">General</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">If the\r patient\u2019s weight is more than 100 kg, the dose calculation should\r use 100 kg (see section 6.6).</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Complete blood\r counts should be monitored prior to administration of each dose of this\r treatment (see section 4.4). </span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Patients should\r be monitored during and after infusion (see section 4.4). </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Dose\r adjustments</span></u></p> <p class=\"Default\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Neutropenia</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">If\r neutropenia develops during treatment it should be managed by dose delays. See\r Table 1 and Table 2 for appropriate dosing recommendations for\r monotherapy and combination therapy, respectively (see also section 4.4). </span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 1:\r Dosing recommendations for neutropenia with monotherapy<br/> <br/> </span></b></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:99.22%;margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"99%\"> <tr> <td style=\"width:37.12%;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"37%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><a name=\"_Hlk8891520\"><b><span lang=\"EN-GB\">Severity grade of\r   neutropenia</span></b></a></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">(signs and symptoms </span></b><span lang=\"EN-GB\">[abbreviated\r   description of CTCAE<sup>a</sup>])</span></p> </td> <td style=\"width:62.88%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"62%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Modification of dosing schedule</span></b></p> </td> </tr> <tr> <td style=\"width:37.12%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"37%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"SV\">Grade 1\r   (&lt; LLN\u20111500/mm<sup>3</sup></span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"SV\">           \r      &lt; LLN\u20111.5 x 10<sup>9</sup>/L) or</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Grade 2\r   (&lt; 1500\u20111000/mm<sup>3</sup></span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup></sup><span lang=\"EN-GB\">&lt; 1.5\u20111.0 x 10<sup>9</sup>/L)</span></p> </td> <td style=\"width:62.88%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"62%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Continue\r   with the same dose and schedule.</span></p> </td> </tr> <tr> <td style=\"width:37.12%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"37%\"> <p class=\"MsoNormal\" style=\"margin-left:41.3pt;text-indent:-41.3pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 3 (&lt; 1,000\u2011500/mm<sup>3</sup></span></p> <p class=\"MsoNormal\" style=\"margin-left:41.3pt;text-indent:-41.3pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">               \r   &lt; 1.0\u20110.5 x 10<sup>9</sup>/L) or</span></p> <p class=\"MsoNormal\" style=\"margin-left:41.3pt;text-indent:-41.3pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 4 (&lt; 500/mm<sup>3</sup></span></p> <p class=\"MsoNormal\" style=\"margin-left:41.3pt;text-indent:-41.3pt;page-break-after:\r   avoid\"><sup></sup><span lang=\"EN-GB\">&lt; 0.5 x 10<sup>9</sup>/L)</span></p> </td> <td style=\"width:62.88%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"62%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Withhold\r   dose until toxicity returns to \u2264 Grade 2 or baseline then\r   resume treatment at the same dose and schedule<sup>b</sup>. Consider G\u2011CSF\r   or GM\u2011CSF in subsequent cycles for patients who develop Grade 3 or\r   Grade 4 neutropenia.</span></p> </td> </tr> </table> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Grading based on\r National Cancer Institute (NCI) Common Terminology Criteria for Adverse\r Events (CTCAE) v3.0; see Neutrophils/granulocytes; LLN = lower limit\r of normal.</span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:17.85pt;text-indent:-17.85pt\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">b.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Patients who\r develop Grade 3 or Grade 4 lymphopenia may continue treatment without\r interruption.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Table 2: Dosing recommendations for\r neutropenia during combination therapy </span></b></p> <p class=\"MsoNormal\"></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:98.84%;margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"98%\"> <tr> <td style=\"width:36.54%;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"36%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Severity grade of neutropenia</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">(signs and symptoms </span></b><span lang=\"EN-GB\">[abbreviated\r   description of CTCAE<sup>a</sup>])</span></p> </td> <td style=\"width:63.46%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"63%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Modification of dosing schedule</span></b></p> </td> </tr> <tr style=\"height:101.7pt\"> <td style=\"width:36.54%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:101.7pt\" valign=\"top\" width=\"36%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"SV\">Grade 1\r   (&lt; LLN\u20111500/mm<sup>3</sup></span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"SV\">              \r   &lt; LLN\u20111.5 x 10<sup>9</sup>/L) or</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"SV\">Grade 2\r   (&lt; 1500\u20111000/mm<sup>3</sup></span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup></sup><span lang=\"SV\">&lt; 1.5\u20111.0 x 10<sup>9</sup>/L)</span></p> <p class=\"MsoNormal\" style=\"margin-left:41.3pt;text-indent:-41.3pt;page-break-after:\r   avoid\"><span lang=\"SV\">Grade 3 (&lt; 1,000\u2011500/mm<sup>3</sup></span></p> <p class=\"MsoNormal\" style=\"margin-left:41.3pt;text-indent:-41.3pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">&lt; 1.0\u20110.5 x 10<sup>9</sup>/L) or</span></p> <p class=\"MsoNormal\" style=\"margin-left:41.3pt;text-indent:-41.3pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 4 (&lt; 500/mm<sup>3</sup></span></p> <p class=\"MsoNormal\" style=\"margin-left:41.3pt;text-indent:-41.3pt;page-break-after:\r   avoid\"><sup></sup><span lang=\"EN-GB\">&lt; 0.5 x 10<sup>9</sup>/L)</span></p> </td> <td style=\"width:63.46%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:101.7pt\" valign=\"top\" width=\"63%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Primary\r   prophylaxis with G-CSF, beginning with the first dose, is recommended for all\r   patients receiving combination therapy. </span><span lang=\"EN-GB\">Continue with\r   the same dose and schedule.</span></p> </td> </tr> </table> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Grading based on\r National Cancer Institute (NCI) Common Terminology Criteria for Adverse\r Events (CTCAE) v4.03; see Neutrophils/granulocytes; LLN = lower limit\r of normal.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Peripheral\r neuropathy</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">If\r peripheral sensory or motor neuropathy emerges or worsens during treatment see\r Table 3 and 4 for appropriate dosing recommendations for monotherapy\r and combination therapy, respectively (see section 4.4).</span></p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r page-break-after:avoid;text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Table 3: Dosing recommendations for new or worsening peripheral\r sensory or motor neuropathy with monotherapy</span></b></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:99.22%;margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"99%\"> <tr> <td style=\"width:43.98%;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"43%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Severity of peripheral sensory or motor neuropathy\r   </span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">(signs and symptoms </span></b><span lang=\"EN-GB\">[abbreviated\r   description of CTCAE<sup>a</sup>])</span></p> </td> <td style=\"width:56.02%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"56%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Modification of dose and schedule</span></b></p> </td> </tr> <tr> <td style=\"width:43.98%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"43%\"> <p class=\"MsoNormal\" style=\"margin-left:39.7pt;text-indent:-39.7pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 1 (paraesthesia and/or loss of reflexes,\r   with no loss of function)</span></p> </td> <td style=\"width:56.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Continue\r   with the same dose and schedule. </span></p> </td> </tr> <tr> <td style=\"width:43.98%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"43%\"> <p class=\"MsoNormal\" style=\"margin-left:39.7pt;text-indent:-39.7pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 2 (interfering with function but not with\r   activities of daily living) </span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> </td> <td style=\"width:56.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Withhold\r   dose until toxicity returns to \u2264 Grade 1 or baseline,\r   then restart treatment at a reduced dose of 1.2 mg/kg </span><span lang=\"EN-GB\">up to a maximum of 120 mg</span><span lang=\"EN-GB\"> every\r   3 weeks.</span></p> </td> </tr> <tr> <td style=\"width:43.98%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"43%\"> <p class=\"MsoNormal\" style=\"margin-left:39.7pt;text-indent:-39.7pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 3 (interfering with activities of daily\r   living)</span></p> </td> <td style=\"width:56.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Withhold\r   dose until toxicity returns to \u2264 Grade 1 or baseline, then\r   restart treatment at a reduced dose of 1.2 mg/kg </span><span lang=\"EN-GB\">up to a maximum of 120 mg</span><span lang=\"EN-GB\"> every\r   3 weeks.</span></p> </td> </tr> <tr> <td style=\"width:43.98%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"43%\"> <p class=\"MsoNormal\" style=\"margin-left:39.7pt;text-indent:-39.7pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 4 (sensory neuropathy that is disabling or\r   motor neuropathy that is life threatening or leads to paralysis)</span></p> </td> <td style=\"width:56.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Discontinue\r   treatment.</span></p> </td> </tr> </table> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in\"><sup><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Grading based on\r National Cancer Institute (NCI) Common Terminology Criteria for Adverse\r Events (CTCAE) v3.0; see neuropathy: motor; neuropathy: sensory; and\r neuropathic pain. </span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Table 4: Dosing recommendations for new or worsening peripheral\r sensory or motor neuropathy during combination therapy</span></b></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:102.58%;margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"102%\"> <tr> <td style=\"width:42.54%;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td style=\"width:28.74%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Combination therapy with AVD</span></b></p> </td> <td style=\"width:28.74%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Combination therapy with CHP</span></b></p> </td> </tr> <tr> <td style=\"width:42.54%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Severity of peripheral sensory or motor neuropathy\r   </span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">(signs and symptoms </span></b><span lang=\"EN-GB\">[abbreviated\r   description of CTCAE<sup>a</sup>])</span></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Modification of dose and schedule </span></b></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Modification of dose and schedule </span></b></p> </td> </tr> <tr> <td style=\"width:42.54%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\"> <p class=\"MsoNormal\" style=\"margin-left:39.7pt;text-indent:-39.7pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 1 (paraesthesia and/or loss of reflexes,\r   with no loss of function)</span></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Continue\r   with the same dose and schedule.</span></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Continue\r   with the same dose and schedule.</span></p> </td> </tr> <tr> <td style=\"width:42.54%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\"> <p class=\"MsoNormal\" style=\"margin-left:41.1pt;text-indent:-39.7pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 2 (interfering with function but not with\r   activities of daily living)</span></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Reduce\r   dose to 0.9 mg/kg up </span><span lang=\"EN-GB\">to a maximum of 90 mg</span><span lang=\"EN-GB\"> every 2 weeks.</span></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p class=\"MsoNormal\" style=\"margin-bottom:3.0pt\"><u><span lang=\"EN-GB\">Sensory\r   neuropathy</span></u><span lang=\"EN-GB\">: Continue treatment at same dose level.</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Motor\r   neuropathy</span></u><span lang=\"EN-GB\">: Reduce dose to 1.2 mg/kg, up to\r   a maximum of 120 mg every 3 weeks.</span></p> </td> </tr> <tr> <td style=\"width:42.54%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\"> <p class=\"MsoNormal\" style=\"margin-left:39.7pt;text-indent:-39.7pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 3 (interfering with activities of daily\r   living)</span></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Withhold\r   treatment with ADCETRIS until toxicity is \u2264 Grade 2, then\r   restart treatment at a reduced dose to 0.9 mg/kg up </span><span lang=\"EN-GB\">to a maximum of 90 mg</span><span lang=\"EN-GB\">every 2 weeks.</span></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p class=\"MsoNormal\" style=\"margin-bottom:3.0pt\"><u><span lang=\"EN-GB\">Sensory\r   neuropathy</span></u><span lang=\"EN-GB\">: Reduce dose to 1.2 mg/kg up to a\r   maximum of 120 mg every 3 weeks.</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Motor\r   neuropathy</span></u><span lang=\"EN-GB\">: Discontinue treatment.</span></p> </td> </tr> <tr> <td style=\"width:42.54%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\"> <p class=\"MsoNormal\" style=\"margin-left:39.7pt;text-indent:-39.7pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 4 (sensory neuropathy which is disabling or\r   motor neuropathy that is life threatening or leads to paralysis)</span></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Discontinue\r   treatment.</span></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Discontinue\r   treatment.</span></p> </td> </tr> </table> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:4.5pt\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\"> Grading based on National Cancer Institute\r (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03; see\r neuropathy: motor; neuropathy: sensory; and neuropathic pain. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Special\r patient populations</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Renal and\r hepatic impairment</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Combination\r therapy</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Patients with\r renal impairment should be closely monitored for adverse events. </span><span lang=\"EN-GB\">There is no clinical trial experience using ADCETRIS in combination\r with chemotherapy in patients with renal impairment, where serum creatinine is\r \u2265 2.0 mg/dL and/or creatinine clearance or calculated\r creatinine clearance is \u2264 40 mL/minute. Use of ADCETRIS in\r combination with chemotherapy should be avoided in patients with severe renal\r impairment. </span></p> <h5 align=\"left\" style=\"text-align:left;page-break-after:auto\"></h5> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients with hepatic impairment should be\r closely monitored for adverse events. The recommended starting dose in patients\r with mild hepatic impairment receiving ADCETRIS in combination with AVD is\r 0.9 mg/kg administered as an intravenous infusion over 30 minutes\r every 2 weeks. The recommended starting dose in patients with mild hepatic\r impairment receiving ADCETRIS in combination with CHP is 1.2 mg/kg\r administered as an intravenous infusion over 30 minutes every\r 3 weeks. There is no clinical trial experience using ADCETRIS in\r combination with chemotherapy in patients with hepatic impairment, where total\r bilirubin is &gt; 1.5 times the upper limit of normal (ULN) (unless due to\r Gilbert syndrome), or aspartate aminotransferase (AST) or alanine\r aminotransferase (ALT) are &gt; 3 times the ULN, or &gt; 5 times the\r ULN if their elevation may be reasonably ascribed to the presence of HL in the\r liver. Use of ADCETRIS in combination with chemotherapy should be avoided in patients\r with moderate and severe hepatic impairment.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Monotherapy</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">The recommended starting dose in patients with severe renal\r impairment is 1.2 mg/kg administered as an intravenous infusion over\r 30 minutes every 3 weeks. Patients with renal impairment should be\r closely monitored for adverse events (see section 5.2).</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The recommended\r starting dose in patients with hepatic impairment is 1.2 mg/kg\r administered as an intravenous infusion over 30 minutes every\r 3 weeks. Patients with hepatic impairment should be closely monitored for\r adverse events (see section 5.2).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Elderly</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">The dosing\r recommendations for patients aged 65 and older are the same as for adults.</span><span style=\"color:windowtext\"> Currently available data are described in sections 4.8,\r 5.1 and 5.2.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Paediatric\r population </span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of</span><span lang=\"EN-GB\"> ADCETRIS in</span><span lang=\"EN-GB\"> children less than\r 18 years have not yet been established. </span>Currently available data\r are described in sections 4.8, 5.1 and 5.2 but no recommendation on a\r posology can be made.</p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In nonclinical studies, thymus depletion\r has been observed (see section 5.3).</span></p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><b></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Method of\r administration </span></u></p> <p class=\"default0\" style=\"page-break-after:avoid\"></p> <p class=\"default0\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The recommended\r dose of ADCETRIS is infused over 30 minutes. </span></p> <p class=\"default0\"></p> <p class=\"default0\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">For instructions on\r reconstitution and dilution of the medicinal product before administration, see\r section 6.6.</span></p> <p class=\"MsoNormal\"><b><u><span lang=\"EN-GB\"></span></u></b></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">ADCETRIS must not be administered as an\r intravenous push or bolus. ADCETRIS should be administered through a dedicated\r intravenous line and it must not be mixed with other medicinal products (see\r section 6.2).</span></p> <p class=\"default0\"></p> <h3><span lang=\"EN-GB\">4.3     Contraindications</span></h3> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Hypersensitivity to the active substance or\r to any of the excipients listed in section 6.1. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Combined use of bleomycin and ADCETRIS\r causes pulmonary toxicity (see section 4.5). </span></p> <p class=\"MsoNormal\"></p> <h3><span lang=\"EN-GB\">4.4     Special warnings and\r precautions for use</span></h3> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Progressive\r multifocal leukoencephalopathy</span></u></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><u><span lang=\"EN-GB\"></span></u></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">John Cunningham virus (JCV) reactivation\r resulting in progressive multifocal leukoencephalopathy (PML) and death can\r occur in ADCETRIS\u2011treated patients. PML has been reported in patients who\r received this treatment after receiving multiple prior chemotherapy regimens.\r PML is a rare demyelinating disease of the central nervous system that results\r from reactivation of latent JCV and is often fatal. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients should be closely monitored for\r new or worsening neurological, cognitive, or behavioural signs or symptoms,\r which may be suggestive of PML. ADCETRIS should be held for any suspected case\r of PML. Suggested evaluation of PML includes neurology consultation, gadolinium\u2011enhanced\r magnetic resonance imaging of the brain and cerebrospinal fluid analysis for\r JCV DNA by polymerase chain reaction or a brain biopsy with evidence of JCV. A\r negative JCV PCR does not exclude PML. Additional follow up and evaluation may\r be warranted if no alternative diagnosis can be established. ADCETRIS dosing should\r be permanently discontinued if a diagnosis of PML is confirmed.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The physician should be particularly alert\r to symptoms suggestive of PML that the patient may not notice (e.g., cognitive,\r neurological, or psychiatric symptoms).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:0in;page-break-after:\r avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Pancreatitis</span></u></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:0in;page-break-after:\r avoid;text-autospace:none\"><u><span lang=\"EN-GB\"></span></u></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:0in;text-autospace:none\"><span lang=\"EN-GB\">Acute pancreatitis has been observed in patients treated with ADCETRIS.\r Fatal outcomes have been reported.</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:0in;text-autospace:none\"></p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:0in;text-autospace:none\"><span lang=\"EN-GB\">Patients should be closely monitored for new or worsening abdominal\r pain, which may be suggestive of acute pancreatitis. Patient evaluation may\r include physical examination, laboratory evaluation for serum amylase and serum\r lipase, and abdominal imaging, such as ultrasound and other appropriate\r diagnostic measures. ADCETRIS should be held for any suspected case of acute\r pancreatitis. ADCETRIS should be discontinued if a diagnosis of acute\r pancreatitis is confirmed. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pulmonary\r toxicity</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Cases of pulmonary toxicity</span><span lang=\"EN-GB\">, including pneumonitis, interstitial lung disease, and acute\r respiratory distress syndrome (ARDS), some with fatal outcomes,</span><span lang=\"EN-GB\"> have </span><span lang=\"EN-GB\">been </span><span lang=\"EN-GB\">reported </span><span lang=\"EN-GB\">in patients </span><span lang=\"EN-GB\">receiving ADCETRIS. Although a\r causal association </span><span lang=\"EN-GB\">with ADCETRIS</span><span lang=\"EN-GB\"> has not been established, the risk of pulmonary toxicity cannot be\r ruled out. In the event of new or worsening pulmonary symptoms (e.g. cough,\r dyspnoea), a prompt diagnostic evaluation should be performed and patients\r should be treated appropriately.</span><span lang=\"EN-GB\">Consider holding ADCETRIS dosing during evaluation and until\r symptomatic improvement.</span></p> <p class=\"MsoListParagraph\" style=\"margin-left:0in;text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Serious\r infections and opportunistic infections</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Serious infections such as pneumonia,\r staphylococcal bacteraemia, sepsis/septic shock (including fatal outcomes) and\r herpes zoster, cytomegalovirus (CMV) (reactivation) and opportunistic\r infections such as Pneumocystis jiroveci pneumonia and oral candidiasis have\r been reported in patients treated with ADCETRIS. Patients should be carefully\r monitored during treatment for the emergence of possible serious and\r opportunistic infections.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Infusion\u2011related\r reactions</span></u></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">Immediate and delayed infusion\u2011related reactions (IRR), as well\r as anaphylactic reactions, have been reported. </span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt;color:black\">Patients should be carefully monitored during and after\r infusion.</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <span style=\"color:black\">If an anaphylactic reaction occurs, administration of ADCETRIS\r should be immediately and permanently discontinued and appropriate medical\r therapy should be administered.</span></span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">If an IRR occurs, the infusion should be interrupted and appropriate\r medical management instituted. The infusion may be restarted at a slower rate\r after symptom resolution. Patients who have experienced a prior IRR should be\r premedicated for subsequent infusions. Premedication may include paracetamol,\r an antihistamine and a corticosteroid. </span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">IRRs are more\r frequent and more severe in patients with antibodies to brentuximab vedotin\r (see section 4.8).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Tumour\r lysis syndrome</span></u></p> <p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in;page-break-after:\r avoid\"></p> <p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Tumour lysis syndrome (TLS) has been\r reported with ADCETRIS. Patients with rapidly proliferating tumour and high\r tumour burden are at risk of tumour lysis syndrome. These patients should be\r monitored closely and managed according to best medical practice. Management of\r TLS may include aggressive hydration, monitoring of renal function, correction\r of electrolyte abnormalities, anti\u2011hyperuricaemic therapy, and supportive\r care.</span></p> <p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Peripheral\r neuropathy</span></u></p> <p class=\"Default\" style=\"page-break-after:avoid\"></p> <p class=\"Default\"><a name=\"_Hlk519675029\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">ADCETRIS may cause peripheral neuropathy, both sensory and motor. ADCETRIS\u2011induced\r peripheral neuropathy is typically an effect of cumulative exposure to this\r medicinal product and is reversible in most cases. In clinical trials, the\r majority of patients had resolution or improvement of their symptoms (see\r section 4.8). Patients should be monitored for symptoms of neuropathy,\r such as hypoesthesia, hyperesthesia, paraesthesia, discomfort, a burning\r sensation, neuropathic pain or weakness. Patients experiencing new or worsening\r peripheral neuropathy may require a delay and a dose </span></a><span lang=\"EN-GB\" style=\"font-size:11.0pt\">reduction of ADCETRIS or discontinuation of\r treatment (see section 4.2). </span></p> <p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Haematological\r toxicities</span></u></p> <p class=\"Default\" style=\"page-break-after:avoid\"></p> <p class=\"Default\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Grade 3 or\r Grade 4 anaemia, thrombocytopenia, and prolonged (\u2265 1 week)\r Grade 3 or Grade 4 neutropenia can occur with ADCETRIS. Complete\r blood counts should be monitored prior to administration of each dose. If\r Grade 3 or Grade 4 neutropenia develops, refer to section 4.2.</span></p> <p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Febrile\r neutropenia</span></u></p> <p class=\"Default\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"></span></u></p> <p class=\"Default\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Febrile neutropenia\r (fever of unknown origin without clinically or microbiologically documented\r infection with an absolute neutrophil count &lt; 1.0 x 10<sup>9</sup>/L,\r fever \u2265 38.5 <sup>0</sup>C; ref CTCAE v3) has been reported\r with treatment with ADCETRIS. Complete blood counts should be monitored prior\r to administration of each dose of treatment. Patients should be monitored\r closely for fever and managed according to best medical practice if febrile\r neutropenia develops.</span></p> <p class=\"Default\"></p> <p class=\"Default\"><span style=\"font-size:11.0pt\">In combination therapy with AVD\r or CHP, advanced age was a risk factor for febrile neutropenia. </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">When ADCETRIS is administered in\r combination with AVD or CHP, primary prophylaxis with G\u2011CSF, beginning\r with the first dose, is recommended for all patients regardless of age.</span></p> <p class=\"ListEnd\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Stevens\u2011Johnson\r syndrome and toxic epidermal necrolysis</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stevens\u2011Johnson syndrome (SJS) and\r toxic epidermal necrolysis (TEN) have been reported with ADCETRIS. Fatal\r outcomes have been reported. If SJS or TEN occur, ADCETRIS should be\r discontinued and appropriate medical therapy should be administered.</span></p> <p class=\"MsoNormal\"></p> <p class=\"ListEnd\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">Gastrointestinal complications</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in;page-break-after:\r avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Gastrointestinal (GI)\r complications including intestinal obstruction, ileus, enterocolitis,\r neutropenic colitis, erosion, ulcer, perforation and haemorrhage, some with\r fatal outcomes, have been reported in patients treated with ADCETRIS. In the\r event of new or worsening GI symptoms, perform a prompt diagnostic evaluation\r and treat appropriately.</span></p> <p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in;page-break-after:\r avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatotoxicity</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"></span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:windowtext\">Hepatotoxicity in the form of elevations in\r alanine aminotransferase (ALT) and aspartate aminotransferase (AST) has been\r reported with ADCETRIS. </span><span lang=\"EN-GB\" style=\"color:windowtext\">Serious\r cases of hepatotoxicity, including fatal outcomes, have also occurred. Pre\u2011existing\r liver disease, comorbidities, and concomitant medications may also increase the\r risk. </span><span lang=\"EN-GB\" style=\"color:windowtext\">Liver function </span><span lang=\"EN-GB\" style=\"color:windowtext\">should be </span><span lang=\"EN-GB\" style=\"color:windowtext\">tested before initiating the treatment and </span><span lang=\"EN-GB\" style=\"color:windowtext\">routinely</span><span lang=\"EN-GB\" style=\"color:windowtext\"> monitored in patients receiving ADCETRIS. </span><span lang=\"EN-GB\" style=\"color:windowtext\">Patients experiencing hepatotoxicity may\r require a delay, change in dose or discontinuation of ADCETRIS.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hyperglycaemia</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Hyperglycaemia has been reported during\r clinical trials in patients with an elevated Body Mass Index (BMI) with or\r without a history of diabetes mellitus. However, any patient who experiences an\r event of hyperglycaemia should have their serum glucose closely monitored. Anti\u2011diabetic\r treatment should be administered as appropriate. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Renal and\r hepatic impairment</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">There is limited experience in patients\r with renal and hepatic impairment. Available data indicate that MMAE clearance\r might be affected by severe renal impairment, hepatic impairment, and by low\r serum albumin concentrations (see section 5.2). </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">CD30+\r CTCL</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The size of the treatment effect in CD30 +\r CTCL subtypes other than mycosis fungoides (MF) and primary cutaneous\r anaplastic large cell lymphoma (pcALCL) is not clear due to lack of high level\r evidence. In two single arm phase II studies of ADCETRIS, disease activity has\r been shown in the subtypes S\u00e9zary syndrome (SS), lymphomatoid papulosis\r (LyP) and mixed CTCL histology. These data suggest that efficacy and safety can\r be extrapolated to other CTCL CD30+ subtypes. Nevertheless, ADCETRIS should be\r used with caution in other CD30+ CTCL patients after careful consideration of\r the potential benefit\u2011risk on an individual basis (see section 5.1).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Sodium\r content in excipients</span></u></p> <p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in;page-break-after:\r avoid\"></p> <p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">This medicinal product contains 13.2 mg\r sodium per vial, equivalent to 0.7% of the WHO recommended maximum daily intake\r of 2 g sodium for an adult. </span></p> <p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Traceability</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"></span></u></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In order to improve the traceability of\r biological medicinal products, the name and the batch number of the\r administered product should be clearly recorded.</span></p> <p class=\"MsoNormal\"></p> <h3><span lang=\"EN-GB\">4.5     Interaction with other\r medicinal products and other forms of interaction</span></h3> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Interaction\r with medicinal products metabolised through CYP3A4 route (CYP3A4\r inhibitors/inducers)</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Co\u2011administration of brentuximab\r vedotin with ketoconazole, a strong CYP3A4 and P\u2011gp inhibitor, increased\r the exposure to the antimicrotubule agent MMAE by approximately 73%, and did\r not alter the plasma exposure to brentuximab vedotin. Therefore, co\u2011administration\r of brentuximab vedotin with strong CYP3A4 and P\u2011gp inhibitors may\r increase the incidence of neutropenia. If neutropenia develops, refer to </span><span lang=\"EN-GB\">Tables 1 and 2 for dosing recommendations for neutropenia\r (see section 4.2). </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Co\u2011administration of </span><span lang=\"EN-GB\">brentuximab vedotin</span><span lang=\"EN-GB\"> with rifampicin, a\r strong CYP3A4 inducer, did not alter the plasma exposure to </span><span lang=\"EN-GB\">brentuximab vedotin</span><span lang=\"EN-GB\">. Though PK data are\r limited, co-administration of rifampicin appeared to reduce plasma\r concentrations of MMAE metabolites that could be assayed. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Co</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration of midazolam, a CYP3A4 substrate, with brentuximab\r vedotin did not alter the metabolism of midazolam; therefore brentuximab\r vedotin is not expected to alter the exposure to medicines that are metabolised\r by CYP3A4 enzymes.</span></p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\"></span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Doxorubicin,\r vinblastine and dacarbazine (AVD) </span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The serum\r and plasma pharmacokinetic characteristics of </span><span lang=\"EN-GB\">antibody\r drug conjugate (</span><span lang=\"EN-GB\">ADC) and MMAE respectively following\r administration of brentuximab vedotin in combination with AVD were similar to\r that in monotherapy.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Co\u2011administration of brentuximab\r vedotin did not affect the plasma exposure of AVD.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:windowtext\">Cyclophosphamide, Doxorubicin and Prednisone (CHP)</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">The serum and plasma pharmacokinetic characteristics\r of ADC and MMAE, respectively, following administration of brentuximab vedotin\r in combination with CHP were similar to that in monotherapy.</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Co\u2011administration of brentuximab\r vedotin is not expected to affect the exposure of CHP.</span></p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:windowtext\"></span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:windowtext\">Bleomycin</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">There were no formal drug\u2011drug interaction\r studies with brentuximab vedotin and bleomycin (B). In a phase 1 dose\r finding and safety study (SGN35\u2011009), unacceptable pulmonary toxicity\r (including 2 fatal events) was noted in 11 of 25 patients (44%)\r treated with brentuximab vedotin plus ABVD. No pulmonary toxicity or fatal\r events were reported with brentuximab vedotin + AVD. Therefore, co\u2011administration\r of ADCETRIS with bleomycin is contraindicated (see section 4.3).</span></p> <p class=\"MsoNormal\"></p> <h3><span lang=\"EN-GB\">4.6     </span><span lang=\"EN-GB\">Fertility,\r p</span><span lang=\"EN-GB\">regnancy and lactation</span></h3> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Women of\r childbearing potential </span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Women of childbearing potential should be\r using two methods of effective contraception during treatment with ADCETRIS and\r until 6 months after treatment. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy</span></u></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">There are no data from the use of ADCETRIS\r in pregnant women. Studies in animals have shown reproductive toxicity (see\r section 5.3). </span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">ADCETRIS should not be used during\r pregnancy unless the benefit to the mother outweighs the potential risks to the\r foetus. If a pregnant woman needs to be treated she should be clearly advised\r on the potential risk to the foetus.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">See the fertility section below pertaining\r to advice for women whose male partners are being treated with ADCETRIS.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast\u2011feeding</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">There are no data as to whether brentuximab\r vedotin or its metabolites are excreted in human milk. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">A risk to the newborn/infant cannot be\r excluded. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">A decision should be made whether to\r discontinue breast\u2011feeding or to discontinue/abstain from this therapy,\r taking into account a potential risk of breast\u2011feeding for the child and\r the benefit of therapy for the woman.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Fertility</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In non\u2011clinical studies, </span><span lang=\"EN-GB\">brentuximab vedotin</span><span lang=\"EN-GB\"> treatment has resulted\r in testicular toxicity, and may alter male fertility. MMAE has been shown to\r have aneugenic properties (see section 5.3). Therefore, men being treated\r with this medicine are advised to have sperm samples frozen and stored before\r treatment. Men being treated with this medicine are advised not to father a\r child during treatment and for up to 6 months following the last dose. </span></p> <p class=\"MsoNormal\"></p> <h3><span lang=\"EN-GB\">4.7     Effects on ability to drive\r and use machines</span></h3> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">ADCETRIS may have\r a moderate influence on the ability to drive and use machines (e.g. dizziness),\r see section 4.8. </span></p> <p class=\"MsoNormal\"></p> <h3><span lang=\"EN-GB\">4.8     Undesirable effects</span></h3> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Summary\r of the safety profile</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The safety\r profile of ADCETRIS is based on available clinical trial data, the Named\r Patient Program (NPP), and post\u2011marketing experience to date. Frequencies\r of adverse reactions described below and in Table 5 have been determined\r based on data generated from clinical studies. </span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Monotherapy</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:windowtext\">In the pooled dataset of </span><span lang=\"EN-GB\" style=\"color:windowtext\">ADCETRIS</span><span lang=\"EN-GB\" style=\"color:windowtext\">\r as monotherapy across HL, sALCL and CTCL studies (SG035\u20110003, SG035\u20110004,\r SGN35\u2011005, SGN35\u2011006, C25001 and C</span><span lang=\"EN-GB\" style=\"color:windowtext\">25007, see section 5.1)</span><span lang=\"EN-GB\" style=\"color:windowtext\"> the most frequent adverse reactions (\u2265 10%)\r were infections,</span><span lang=\"EN-GB\" style=\"color:windowtext\"> peripheral\r sensory neuropathy, nausea</span><span lang=\"EN-GB\" style=\"color:windowtext\">,\r fatigue, diarrhoea, pyrexia, upper respiratory tract infection, neutropenia, rash,\r cough, vomiting, arthralgia, peripheral motor neuropathy</span><span lang=\"EN-GB\" style=\"color:windowtext\">, infusion-related reactions, pruritus,\r constipation, dyspnoea, weight decreased, myalgia and abdominal pain.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Serious adverse\r drug reactions occurred in 12% of patients. The frequency of unique serious\r adverse drug reactions was \u2264 1%.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Adverse events\r led to treatment discontinuation in 24% of patients receiving ADCETRIS. </span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:windowtext\">The safety data in patients retreated with ADCETRIS\r (SGN35\u2011006, see section 5.1) were consistent with those observed in\r the combined pivotal phase 2 studies, with the exception of peripheral\r motor neuropathy, which had a higher incidence (28% vs. 9% in the pivotal phase\r 2 studies) and was primarily Grade 2. Patients also had a higher incidence\r of arthralgia, Grade 3 anaemia, and back pain compared to patients\r observed in the combined pivotal phase 2 studies.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">T</span><span lang=\"EN-GB\">he safety data in\r patients with relapsed or refractory HL who had not received an autologous stem\r cell transplant and were treated with the recommended dose of 1.8 mg/kg\r every three weeks in a single\u2011arm phase 4 study (n = 60), the\r phase 1 dose escalation and clinical pharmacology studies (n = 15 patients)\r and in the NPP (n = 26 patients) (see section 5.1) were\r consistent with the safety profile of the pivotal clinical studies. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Combination\r therapy </span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">For safety information of chemotherapy\r agents given in combination with ADCETRIS (doxorubicin, vinblastine and\r dacarbazine (AVD) or cyclophosphamide, doxorubicin and prednisone (CHP)), refer\r to their summary of product characteristics. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In the studies of ADCETRIS as combination\r therapy in 662 patients with previously untreated advanced HL (C25003) and\r 223 patients with previously untreated CD30+ </span>peripheral T-cell lymphoma\r (<span lang=\"EN-GB\">PTCL) (SGN35\u2011014), the most common adverse reactions\r (\u2265 10%) were: infections, neutropenia, peripheral sensory\r neuropathy, nausea, constipation, vomiting, diarrhoea, fatigue, pyrexia,\r alopecia, anaemia, weight decreased, stomatitis, febrile neutropenia, abdominal\r pain, decreased appetite, insomnia, bone pain, rash, cough, dyspnoea, arthralgia,\r myalgia, back pain, peripheral motor neuropathy, upper respiratory tract\r infection, and dizziness. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In patients receiving ADCETRIS combination\r therapy, serious adverse reactions occurred in 34% of patients. Serious adverse\r reactions occurring in \u2265 3% of patients included febrile neutropenia\r (15%), pyrexia (5%), and neutropenia (3%). </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Adverse events led to treatment discontinuation\r in 10% of patients. Adverse events that led to treatment discontinuation in\r \u2265 2% of patients included peripheral sensory neuropathy, and peripheral\r neuropathy.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Tabulated\r list of adverse reactions</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Adverse\r reactions for ADCETRIS are listed by MedDRA System Organ Class and Preferred\r Term (see Table 5). Within each System Organ Class, adverse reactions are\r listed under frequency categories of: Very common (\u2265 1/10); Common\r (\u2265 1/100 to &lt; 1/10); Uncommon (\u2265 1/1,000 to &lt; 1/100);\r Rare (\u2265 1/10,000 to &lt; 1/1,000); Very rare (&lt; 1/10,000);\r not known (cannot be estimated from the available data). </span><span lang=\"EN-GB\">Within each frequency grouping, adverse reactions are presented in\r the order of decreasing seriousness.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 5:\r Adverse reactions to ADCETRIS <br/> <br/> </span></b></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:493.5pt;border-collapse:collapse;border:none\" width=\"658\"> <thead> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><a name=\"_Hlk5943718\"><b><span lang=\"EN-GB\">System organ class</span></b></a></p> </td> <td style=\"width:212.6pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Adverse reactions (monotherapy)</span></b></p> </td> <td style=\"width:169.15pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Adverse reactions <br/>\r    (combination therapy)</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Infections\r    and infestations</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very\r    common: </span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infection</span><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\">, upper respiratory tract\r    infection</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Infection</span><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\">, upper respiratory tract infection</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"PT\">Herpes\r    zoster, pneumonia, herpes simplex, oral candidiasis</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Pneumonia, oral candidiasis,\r    sepsis/septic shock, herpes zoster</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pneumocystis\r    jiroveci pneumonia, staphylococcal bacteraemia, cytomegalovirus infection or\r    reactivation,</span><span lang=\"EN-GB\"> sepsis/septic shock</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Herpes simplex, Pneumocystis jiroveci\r    pneumonia</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Frequency not known:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Progressive multifocal\r    leukoencephalopathy</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Blood\r    and lymphatic system disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very\r    common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Neutropenia</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Neutropenia<sup>a</sup>, anaemia,\r    febrile neutropenia</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaemia, thrombocytopenia</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Thrombocytopenia</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Febrile neutropenia</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Immune\r    system disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic reaction</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic transfusion reaction</span></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Metabolism\r    and nutrition disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very\r    common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Decreased appetite</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Hyperglycaemia</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Hyperglycaemia</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tumour lysis syndrome</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tumour lysis syndrome</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Psychiatric disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Very common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Insomnia</span></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Nervous\r    system disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very\r    common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Peripheral sensory neuropathy,\r    peripheral motor neuropathy</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Peripheral sensory neuropathy<sup>a</sup>,\r    peripheral motor neuropathy<sup>a</sup>, dizziness</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Dizziness</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Demyelinating polyneuropathy</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Respiratory,\r    thoracic and mediastinal disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Very common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Cough, dyspnoea</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Cough, dyspnoea</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Gastrointestinal\r    disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very\r    common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Nausea, diarrhoea, vomiting, constipation,\r    abdominal pain</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Nausea, constipation, vomiting,\r    diarrhoea, abdominal pain, stomatitis</span></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Pancreatitis acute</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Pancreatitis acute</span></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Hepatobiliary\r    disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Alanine\r    aminotransferase/aspartate aminotransferase (ALT/AST) increased</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Alanine\r    aminotransferase/aspartate aminotransferase (ALT/AST) increased</span></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Skin\r    and subcutaneous tissue disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very\r    common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Rash<sup>a</sup>, pruritus</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Alopecia, rash<sup>a</sup></span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Alopecia</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Pruritus</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stevens-Johnson syndrome/toxic epidermal\r    necrolysis</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stevens-Johnson syndrome<sup>b</sup></span></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Musculoskeletal\r    and connective tissue disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very\r    common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Arthralgia, myalgia</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Bone pain, arthralgia, myalgia, back\r    pain</span></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:14.35pt\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Back pain</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">General\r    disorders and administration site conditions</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very\r    common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Fatigue,\r    pyrexia, infusion-related reactions<sup>a</sup></span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Fatigue,\r    pyrexia</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Chills</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infusion-related\r    reactions<sup>a</sup>, chills</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Investigations</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Very common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Weight\r    decreased</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Weight\r    decreased</span></p> </td> </tr> </thead> </table> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in\"><sup><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Represents pooling\r of preferred terms.</span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in\"><sup><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">b.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Toxic epidermal\r necrolysis was not reported in the combination therapy setting.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Description\r of selected adverse reactions</span></u></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Neutropenia and febrile neutropenia</span></i></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;text-indent:28.35pt;page-break-after:\r avoid\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Monotherapy</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">In clinical trials, neutropenia</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> led to dose delays in 14% of patients. Grade 3\r neutropenia was reported in </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">13%\r and Grade 4 neutropenia was reported in 5% of patients. No patients\r required dose reduction or discontinued treatment for neutropenia. </span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Severe and prolonged (\u2265 1 week)\r neutropenia can occur with this treatment which may increase the risk of\r patients developing serious infections. Febrile neutropenia reported in &lt; 1%\r of the patients (see section 4.2).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">In the pivotal phase\r 2 population </span><span lang=\"EN-GB\" style=\"color:windowtext\">(SG035\u20110003\r and SG035\u20110004)</span><span lang=\"EN-GB\" style=\"color:windowtext\">, </span><span lang=\"EN-GB\" style=\"color:windowtext\">the median duration of Grade 3 or\r Grade 4 neutropenia was limited (1 week); 2% of patients had\r Grade 4 neutropenia that lasted \u2265 7 days. Less </span><span lang=\"EN-GB\" style=\"color:windowtext\">than half of the patients in the pivotal\r phase 2 population with Grade 3 or Grade 4 neutropenia had\r temporally associated infections, and the majority of temporally associated\r infections were Grade 1 or Grade 2.</span></p> <p class=\"MsoNormal\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">Combination therapy</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In the clinical\r trials of </span><span lang=\"EN-GB\">ADCETRIS</span><span lang=\"EN-GB\"> as\r combination therapy, neutropenia led to dose delays in 19% of patients. Grade 3\r neutropenia was reported in 17% and Grade 4 neutropenia was reported in 41%\r of patients. Two percent of patients required dose reduction and &lt; 1%\r discontinued one of more of the study drugs due to neutropenia. </span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Febrile\r neutropenia was reported in 20% of the patients who did not receive primary\r prophylaxis with G-CSF (see section 4.2). The frequency of febrile\r neutropenia was 13% in patients who received primary prophylaxis with G-CSF. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Serious\r infections and opportunistic infections</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Monotherapy</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">In clinical\r trials, serious infections </span><span lang=\"EN-GB\">and opportunistic infections\r occurred in 10% of patients, sepsis or septic shock occurred in &lt; 1% of\r the patients. The most commonly reported opportunistic infections were herpes\r zoster and herpes simplex.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Combination therapy</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">In the clinical trials of </span><span lang=\"EN-GB\">ADCETRIS</span><span lang=\"EN-GB\"> as combination therapy, </span><span lang=\"EN-GB\">serious infections\r including opportunistic infections occurred in 15% of patients; sepsis,\r neutropenic sepsis, septic shock or bacteraemia occurred in 4% of the patients.\r The most commonly reported opportunistic infections were herpes viral\r infections.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Peripheral neuropathy</span></i></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Monotherapy </span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span style=\"font-size:11.0pt\">In\r clinical trials treatment emergent neuropathy occurred </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">in 59% of the population, peripheral motor neuropathy occurred\r in 14% of patients. </span><span style=\"font-size:11.0pt\">Peripheral neuropathy\r led to treatment discontinuation in 15%, dose reductions in 15%, and </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">dose delays in 17% of patients. </span><span style=\"font-size:11.0pt\">For patients who experienced peripheral neuropathy the\r median time of onset of peripheral neuropathy was 12 weeks. The median\r duration of treatment for patients who discontinued due to peripheral\r neuropathy was 12 cycles.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Among patients who\r experienced peripheral neuropathy in the pivotal phase 2 studies\r (SG035-0003 and SG035\u20110004) and randomised phase 3 monotherapy\r studies (SGN35\u2011005 and C25001), the median follow up time from end of\r treatment until last evaluation ranged from 48.9 to 98 weeks. At the time\r of last evaluation, most of the patients (82-85%) who experienced peripheral\r neuropathy had resolution or improvement of their peripheral neuropathy\r symptoms. The median time from onset to resolution or improvement for all\r events ranged from 16 to 23.4 weeks. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In patients with relapsed or refractory HL\r or sALCL who were retreated with ADCETRIS (SGN35\u2011006), the majority of\r patients (80%) also had improvement or resolution of their peripheral\r neuropathy symptoms at the time of last evaluation.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><a name=\"_Hlk519675104\"><span lang=\"EN-GB\">Combination therapy</span></a></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">In the clinical\r trial of ADCETRIS as combination therapy with AVD, </span><span lang=\"EN-GB\" style=\"color:windowtext\">treatment emergent neuropathy occurred in 67% of the\r population; peripheral motor neuropathy occurred in 11% of patients. Peripheral\r neuropathy led to treatment discontinuation in 7%, dose reductions in 21%, and\r dose delays in 1% of patients. For patients who experienced peripheral\r neuropathy the median time of onset of peripheral neuropathy was 8 weeks.\r Patients who discontinued due to peripheral neuropathy received a median of 8\r doses of ADCETRIS+AVD (A+AVD) before discontinuation of one or more agents. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Among patients who\r experienced peripheral neuropathy, the median follow up time from end of\r treatment until last evaluation was approximately 91 weeks. At the time of\r last evaluation, most of the patients (76%) who experienced peripheral\r neuropathy had resolution or improvement of their peripheral neuropathy\r symptoms. The median time from onset to resolution or improvement of peripheral\r neuropathy events was 10 weeks (ranged from 0 weeks to 139 weeks).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In the clinical trial of ADCETRIS as\r combination therapy with CHP, </span><span lang=\"EN-GB\" style=\"color:windowtext\">treatment\r emergent neuropathy occurred in 52% of the population; peripheral motor\r neuropathy occurred in 9% of patients. Peripheral neuropathy led to treatment\r discontinuation in 1%, dose reductions in 7% and dose delays in </span><span lang=\"EN-GB\">&lt;</span><span lang=\"EN-GB\" style=\"color:windowtext\">1% of patients.\r For patients who experienced peripheral neuropathy the median time of onset was\r 9.1 weeks. Patients who discontinued due to peripheral neuropathy received\r a median of 5 doses of ADCETRIS + CHP (A+CHP) before\r discontinuation of one or more agents.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Among patients who\r experienced peripheral neuropathy, the median follow up time from end of\r treatment until last evaluation was approximately 177 weeks. At the time\r of last evaluation, 64% who experienced peripheral neuropathy had resolution or\r improvement of their peripheral neuropathy symptoms. The median time from onset\r to resolution or improvement of peripheral neuropathy events was 19.0 weeks\r (ranged from 0 weeks to 205 weeks).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Infusion-related\r reactions</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Monotherapy</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">IRRs, such as headache, rash, back pain,\r vomiting, chills, nausea, dyspnoea, pruritus and cough were reported in 13% of\r patients. </span><span lang=\"EN-GB\">Anaphylactic reactions have been reported\r (see section 4.4). Symptoms of an anaphylactic reaction may include, but\r are not limited to, urticaria, angioedema, hypotension and bronchospasm. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Combination\r therapy</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">IRRs, such as headache, rash, back pain,\r vomiting, chills, nausea, dyspnoea, pruritus, cough, infusion site pain and\r pyrexia were reported in 8% of patients. Anaphylactic reactions have been\r reported (see section 4.4). Symptoms of an anaphylactic reaction may\r include, but are not limited to, urticaria, angioedema, hypotension and\r bronchospasm.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Immunogenicity</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In clinical trials, patients were\r periodically tested for antibodies to brentuximab vedotin using a sensitive\r electrochemiluminescent immunoassay. There was a higher incidence of </span><span lang=\"EN-GB\">infusion-related reactions observed in</span><span lang=\"EN-GB\"> patients\r with antibodies </span><span lang=\"EN-GB\">to brentuximab vedotin relative to</span><span lang=\"EN-GB\"> patients </span><span lang=\"EN-GB\">who tested transiently positive or\r negative.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The presence of antibodies to brentux</span><span lang=\"EN-GB\">imab vedotin did not correlate with a clinically meaningful\r reduction in serum brentuximab vedotin levels and did not result in a decrease\r in the efficacy of brentuximab vedotin. While the presence of antibodies to\r brentuximab vedotin does not necessarily predict the development of an IRR,\r there was a higher incidence of IRRs observed in patients with persistently\r positive anti-drug antibodies (ADA) relative to patients with transiently\r positive ADA and never positive ADA. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">There was a trend of increased clearance of\r brentuximab vedotin in paediatric patients confirmed positive for ADAs. No\r patients aged &lt; 12 years (0 of 11) and 2 patients aged\r \u2265 12 years (2 of 23) became persistently ADA positive.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\"></span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Paediatric population</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:windowtext\">Safety was evaluated in a phase 1/2 study in\r paediatric patients aged 7\u201117 years of age (n = 36) with\r relapsed or refractory (r/r) HL and sALCL (see section 5.1).In\r this study in 36 patients, no new safety concerns were reported.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Elderly </span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Monotherapy\r </span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety profile in elderly patients is\r generally in line with that of adult patients. However, elderly patients may be\r more susceptible to events such as pneumonia, neutropenia and febrile\r neutropenia.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Combination\r therapy </span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In older\r patients (\u2265 60 years of age; n = 186 [21%]), the incidence\r of adverse events was similar across treatment arms. More serious adverse\r events and dose modifications (including dose delays, reductions, and\r discontinuations) were reported in the older patients compared with the overall\r study population. Advanced age was a risk factor for febrile neutropenia in\r patients in both arms. Older patients who received G-CSF primary prophylaxis\r had lower incidence of neutropenia and febrile neutropenia than those who did\r not receive G-CSF primary prophylaxis.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\"></span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\"></span></u></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Reporting\r suspected adverse reactions after authorisation of the medicinal product is\r important. It allows continued monitoring of the benefit/risk balance of the medicinal\r product. Healthcare professionals are asked to report any suspected adverse\r reactions via <span style=\"background:silver\">the national reporting system\r listed in </span></span><span lang=\"EN-GB\"><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background:silver\">Appendix V</span></a></span><span lang=\"EN-GB\">.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <h3><span lang=\"EN-GB\">4.9     Overdose</span></h3> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">There is no known antidote for overdose of ADCETRIS.\r In case of overdose, the patient should be closely monitored for adverse\r reactions, particularly neutropenia, and supportive treatment should be\r administered (see section 4.4). </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <h2><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>5.       PHARMACOLOGICAL\r PROPERTIES</span></h2> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <h3><span lang=\"EN-GB\">5.1     Pharmacodynamic properties</span></h3> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Pharmacotherapeutic group: Antineoplastic\r agents; other antineoplastic agents; monoclonal antibodies, ATC code: L01XC12.</span></p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Mechanism\r of action</span></u></p> <p class=\"paragraph0\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"paragraph0\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Brentuximab vedotin</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> is an ADC that delivers an antineoplastic agent that\r results in apoptotic cell death selectively in CD30\u2011expressing tumour\r cells. Nonclinical data suggest that the biological activity of </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">brentuximab vedotin</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> results from a multi-step process. Binding of the ADC\r to CD30 on the cell surface initiates internalisation of the ADC\u2011CD30\r complex, which then traffics to the lysosomal compartment. Within the cell, a\r single defined active species, MMAE, is released via proteolytic cleavage.\r Binding of MMAE to tubulin disrupts the microtubule network within the cell,\r induces cell cycle arrest and results in apoptotic death of the CD30\u2011expressing\r tumour cell.</span></p> <p class=\"paragraph0\" style=\"margin-bottom:0in\"></p> <p class=\"paragraph0\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Classical HL, sALCL and subtypes of CTCL (including MF\r and pcALCL) express CD30 as an antigen on the surface of their malignant cells.\r This expression is independent of disease stage, line of therapy or transplant\r status.</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> These features make\r CD30 a target for therapeutic intervention. Because of the CD30\u2011targeted\r mechanism of action brentuximab vedotin is able to overcome chemo-resistance as\r CD30 is consistently expressed in patients who are refractory to multi-agent\r chemotherapy, irrespective of prior transplant status. </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The CD30\u2011targeted mechanism of action of\r brentuximab vedotin, the consistent expression of CD30 throughout the classical\r HL, sALCL and CD30+ CTCL disease and therapeutic spectrums andclinical\r evidence in CD30\u2011positive malignancies following multiple lines of\r treatment provide a biologic rationale for its use in patients with relapsed\r and refractory classical HL, sALCL with or without prior ASCT and CD30+ CTCL after\r at least 1 prior systemic therapy.</span></p> <p class=\"paragraph0\" style=\"margin-bottom:0in\"></p> <p class=\"paragraph0\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Contributions to the mechanism of action by other\r antibody associated functions have not been excluded. </span></p> <p class=\"paragraph0\" style=\"margin-bottom:0in\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pharmacodynamic\r effects</span></u></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Cardiac\r electrophysiology</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Forty\u2011six (46) patients with CD30\u2011expressing\r haematologic malignancies were evaluable of the 52 patients who received\r 1.8 mg/kg of brentuximab vedotin every 3 weeks as part of a phase 1,\r single\u2011arm, open-label, multicenter cardiac safety study. The primary\r objective was to evaluate the effect of</span><span lang=\"EN-GB\"> brentuximab\r vedotin on cardiac ventricular re-polarization and the predefined primary\r analysis was the change in QTc from baseline to multiple time points in Cycle 1.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The upper 90% confidence interval (CI)\r around the mean effect on QTc was &lt; 10</span><span lang=\"EN-GB\">msec at each of the Cycle 1 and Cycle 3 post-baseline time\r points. These data indicate the absence of clinically relevant QT prolongation\r due to brentuximab vedotin administered at a dose of 1.8 mg/kg every\r 3 weeks in patients with CD30\u2011expressing malignancies.</span></p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"></p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Clinical efficacy and safety</span></u></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Hodgkin lymphoma</span></i></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Study C25003</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy and safety of ADCETRIS were\r evaluated in a randomised, open-label, 2\u2011arm, multicenter trial in 1334 patients\r with previously untreated advanced HL in combination with chemotherapy\r (doxorubicin [A], vinblastine [V] and dacarbazine [D] [AVD]). All patients had\r a histologically confirmed CD30\u2011expressing disease. Sixty\u2011two\r percent of patients had extranodal site involvement. Of the 1334 patients,\r 664 patients were randomised to the ADCETRIS + AVD arm and 670 patients\r were randomised to the ABVD (doxorubicin [A], bleomycin [B], vinblastine [V]\r and dacarbazine [D]) arm and stratified by number of International Prognostic\r Factor Project (IPFP) risk factors and region. Patients were treated on days 1\r and 15 of each 28\u2011day cycle with 1.2 mg/kg of ADCETRIS administered\r as an intravenous infusion over 30 minutes + doxorubicin 25 mg/m<sup>2</sup>,\r vinblastine 6 mg/m<sup>2</sup>, and dacarbazine 375 mg/m<sup>2</sup>.\r The median number of cycles received was 6 (range, 1 to 6 cycles).\r Table 6 provides a summary of the baseline patient and disease\r characteristics.</span> There were no relevant differences in the patient and\r disease characteristics between the two arms.</p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 6:\r Summary of baseline patient and disease characteristics in the phase 3 previously\r untreated HL study<br/> <br/> </span></b></p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:6.45in;border-collapse:collapse\" width=\"619\"> <tr style=\"height:26.4pt\"> <td style=\"width:252.9pt;border-top:windowtext;\r   border-left:windowtext;border-bottom:black;border-right:white;border-style:\r   solid;border-width:1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:26.4pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Patient\r   Characteristics </span></b></p> </td> <td style=\"width:117.0pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:26.4pt\" valign=\"top\" width=\"156\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS + AVD</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 664</span></b></p> </td> <td style=\"width:94.5pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:26.4pt\" valign=\"top\" width=\"126\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ABVD</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 670</span></b></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median age\r   (range) </span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">35 years\r   (18\u201182)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">37 years\r   (18\u201183)</span></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Patients\r   \u2265 65 years old n (%)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">60 (9)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">62 (9)</span></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Gender, n\r   (%)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">378M (57)</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">286F (43)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">398M (59)</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">272F (41)</span></p> </td> </tr> <tr style=\"height:13.2pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">ECOG\r   status, n (%)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"156\"></td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"126\"></td> </tr> <tr style=\"height:13.2pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">0 </span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">376 (57)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">378 (57)</span></p> </td> </tr> <tr style=\"height:13.2pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">1 </span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">260 (39)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">263 (39)</span></p> </td> </tr> <tr style=\"height:13.2pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">2</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28 (4)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">27 (4)</span></p> </td> </tr> <tr style=\"height:13.2pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">Missing</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">2</span></p> </td> </tr> <tr style=\"height:15.4pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\r   Characteristics </span></b></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"156\"></td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"126\"></td> </tr> <tr style=\"height:15.4pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\r   time from HL diagnosis to first dose (range)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">0.92 mo\r   (0.1\u201121.4)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">0.89 mo\r   (0.0\u201181.4)</span></p> </td> </tr> <tr style=\"height:15.4pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Disease\r   stage<sup>a</sup> at initial diagnosis of HL, n (%)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"156\"></td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"126\"></td> </tr> <tr style=\"height:15.4pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">III</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">237 (36)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">246 (37)</span></p> </td> </tr> <tr style=\"height:15.4pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">IV</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">425 (64)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">421 (63)</span></p> </td> </tr> <tr style=\"height:15.4pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">Not applicable</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">1 (&lt; 1)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">1 (&lt; 1)</span></p> </td> </tr> <tr style=\"height:15.4pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">Missing</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">2 (&lt; 1 )</span></p> </td> </tr> <tr style=\"height:15.85pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Extranodal\r   involvement at time of diagnosis, n (%)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">411 (62)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">416 (62)</span></p> </td> </tr> <tr style=\"height:15.85pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">IPFP<sup>b</sup>\r   risk factors, n (%)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> </td> </tr> <tr style=\"height:15.85pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">0\u20111</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">141 (21)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">141 (21)</span></p> </td> </tr> <tr style=\"height:15.85pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">2\u20113</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">354 (53)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">351 (52)</span></p> </td> </tr> <tr style=\"height:15.85pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">4\u20117</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">169 (25)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">178 (27)</span></p> </td> </tr> <tr style=\"height:15.85pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Bone\r   marrow involvement at time of diagnosis or study entry, n (%)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">147(22)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">151 (23)</span></p> </td> </tr> <tr style=\"height:16.75pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">B symptoms<sup>a\r   </sup>n (%)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">400 (60)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">381 (57)</span></p> </td> </tr> </table> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\r Per Ann Arbor Staging.</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">IPFP = International\r Prognostic Factor Project.</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The primary\r endpoint in Study C25003 was modified PFS (mPFS) per independent review\r facility (IRF), defined as time from randomisation to disease progression,\r death, or evidence of non-complete response (non-CR) after completion of first-line\r therapy per IRF followed by subsequent anticancer therapy. Timing of the\r modified event was the date of the first PET scan post completion of first-line\r therapy demonstrating the absence of complete response (CR), defined as\r Deauville score of \u22653. The median modified PFS by IRF assessment was\r not reached in either treatment arm. The results in the intent-to-treat (ITT)\r population showed a statistically significant improvement in modified PFS for\r ADCETRIS+ AVD, with a stratified hazard ratio of 0.770 (95% CI, 0.603; 0.983,\r p =<sup> </sup>0.035), indicating a 23% reduction in the risk of modified\r PFS events for ADCETRIS+ AVD versus ABVD. </span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\">A pre-specified subgroup\r analysis of mPFS <span lang=\"EN-GB\" style=\"letter-spacing:-.1pt\">by disease stage\r showed that patients with Stage IV disease had a larger effect compared\r with the ITT population</span><span lang=\"EN-GB\">,</span><span lang=\"EN-GB\">with an unstratified hazard ratio of 0.71 (95% CI, 0.53;\r 0.96), compatible with a 29% reduction in the risk of modified PFS events for\r ADCETRIS+ AVD versus ABVD. Of the ITT population, 846 patients (64%) had\r Stage IV disease.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Table 7 provides the efficacy results\r for modified PFS and overall survival (OS) in the ITT population and patients\r with Stage IV disease.</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 7:\r Efficacy results for previously untreated HL patients treated with\r 1.2 mg/kg of ADCETRIS + AVD on days 1 and 15 of a 28-day cycle (ITT and\r Stage IV)</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:454.4pt;margin-left:-.15pt;border-collapse:collapse;border:none\" width=\"606\"> <tr style=\"page-break-inside:avoid;height:33.0pt\"> <td rowspan=\"2\" style=\"width:82.85pt;border:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:33.0pt\" width=\"110\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td colspan=\"3\" style=\"width:199.15pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:33.0pt\" width=\"266\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Intent to Treat (ITT) Population</span></b></p> </td> <td colspan=\"3\" style=\"width:172.4pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:33.0pt\" width=\"230\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Patients with Stage IV Disease</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:33.0pt\"> <td style=\"width:66.8pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:33.0pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b><b><span lang=\"EN-GB\"> + AVD</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 664</span></b></p> </td> <td style=\"width:58.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:33.0pt\" valign=\"top\" width=\"78\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ABVD</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 670</span></b></p> </td> <td style=\"width:73.7pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:33.0pt\" valign=\"top\" width=\"98\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Stratified Hazard Ratio and p-value</span></b></p> </td> <td style=\"width:57.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:33.0pt\" valign=\"top\" width=\"77\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b><b><span lang=\"EN-GB\"> + AVD</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 425</span></b></p> </td> <td style=\"width:47.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:33.0pt\" valign=\"top\" width=\"63\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ABVD</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 421</span></b></p> </td> <td style=\"width:67.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:33.0pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Unstratified Hazard Ratio and p-value<sup>c</sup></span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:50.05pt\"> <td style=\"width:82.85pt;border:solid windowtext 1.0pt;border-top:\r   none;padding:0in 0in 0in 0in;height:50.05pt\" width=\"110\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:8.0pt;\r   margin-left:4.9pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Number of\r   events (%)</span></b></p> </td> <td style=\"width:66.8pt;border-top:none;border-left:none;border-bottom:\r   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:.7pt 4.9pt 0in 4.9pt;\r   height:50.05pt\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">117 (18)</span></p> </td> <td style=\"width:58.65pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:50.05pt\" width=\"78\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">146 (22)</span></p> </td> <td rowspan=\"2\" style=\"width:73.7pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:50.05pt\" width=\"98\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">0.77</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">(95% CI [0.60, 0.98])</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">p-value=</span><span lang=\"EN-GB\" style=\"color:windowtext\">0.035</span></p> </td> <td style=\"width:57.85pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:50.05pt\" width=\"77\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">77 (18)</span></p> </td> <td style=\"width:47.05pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:50.05pt\" width=\"63\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">102 (24)</span></p> </td> <td rowspan=\"2\" style=\"width:67.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:50.05pt\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">0.71 </span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">(95% CI [0.53, 0.96])</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">p-value=0.023</span></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:33.5pt\"> <td style=\"width:82.85pt;border:solid windowtext 1.0pt;border-top:\r   none;padding:0in 0in 0in 0in;height:33.5pt\" width=\"110\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:8.0pt;\r   margin-left:4.9pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Estimated mPFS<sup>a</sup>\r   per IRF at 2 Year (%)</span></b></p> </td> <td style=\"width:66.8pt;border-top:none;border-left:none;border-bottom:\r   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:.7pt 4.9pt 0in 4.9pt;\r   height:33.5pt\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">82.1</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">(95% CI [78.8, 85.0])</span></p> </td> <td style=\"width:58.65pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:33.5pt\" width=\"78\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">77.2</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">(95% CI [73.7, 80.4])</span></p> </td> <td style=\"width:57.85pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:33.5pt\" width=\"77\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">82.0 (95%\r   CI [77.8, 85.5])</span></p> </td> <td style=\"width:47.05pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:33.5pt\" width=\"63\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">75.3 (95%\r   CI [70.6, 79.3])</span></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:33.5pt\"> <td style=\"width:82.85pt;border:solid windowtext 1.0pt;border-top:\r   none;padding:0in 0in 0in 0in;height:33.5pt\" width=\"110\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:8.0pt;\r   margin-left:4.9pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Overall Survival<sup>b</sup>\r   Number of deaths (%)</span></b></p> </td> <td style=\"width:66.8pt;border-top:none;border-left:none;border-bottom:\r   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:.7pt 4.9pt 0in 4.9pt;\r   height:33.5pt\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">28 (4)</span></p> </td> <td style=\"width:58.65pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:33.5pt\" width=\"78\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">39 (6)</span></p> </td> <td style=\"width:73.7pt;border-top:none;border-left:none;border-bottom:\r   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\r   height:33.5pt\" width=\"98\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">0.73</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">(95% CI [0.45, 1.18])</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">p-value=0.199</span></p> </td> <td style=\"width:57.85pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:33.5pt\" width=\"77\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">14 (3)</span></p> </td> <td style=\"width:47.05pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:33.5pt\" width=\"63\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">26 (6)</span></p> </td> <td style=\"width:67.5pt;border-top:none;border-left:none;border-bottom:\r   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\r   height:33.5pt\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">0.51 </span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">(95% CI [0.27, 0.97])</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">p-value=0.037</span></p> </td> </tr> </table> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">At\r the time of analysis, the median modified PFS follow-up time for both arms was\r 24.6 months.</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Data\r from an interim OS analysis. </span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">p-value\r for Stage IV disease is not adjusted for multiplicity.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Figure 1: Modified progression-free survival per IRF in the ITT\r population (ADCETRIS + AVD vs. ABVD)</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\"><img border=\"0\" height=\"302\" src=\"Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image002.gif\" width=\"604\"/></span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><a name=\"IDX\"></a><b><span lang=\"EN-GB\">Figure 2: Modified progression-free survival\r per IRF in patients with Stage IV disease (ADCETRIS + AVD vs. ABVD)</span></b></p> <p class=\"MsoNormal\" style=\"line-height:150%;page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"><img border=\"0\" height=\"284\" src=\"Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image003.gif\" width=\"598\"/></span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><b></b></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Other secondary efficacy endpoints\r including CR rate and ORR at the end of randomisation regimen, CR rate at the\r end of first-line therapy, and the rate of PET negativity at the end of Cycle\r 2, duration of response (DOR), duration of complete remission (DOCR),\r disease-free survival (DFS) and event\u2011free survival (EFS) all trended in\r favour of ADCETRIS + AVD<a name=\"_Hlk519081083\"> in both the ITT and Stage IV\r population</a>.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Pre\u2011specified subgroup analyses of\r modified PFS per IRF were performed for the ITT population including age,\r region, cancer stage at baseline, baseline extranodal sites, number of IPFP\r risk factors, baseline B symptoms, Cycle 2 PET assessment, Cycle 2 PET\r Deauville score, and receipt of alternative first-line medication (AFM). The\r analyses showed a consistent trend towards benefit for patients who received\r ADCETRIS + AVD compared with patients who received ABVD in most subgroups.\r The efficacy in elderly patient population (patients \u2265 60 years of\r age [n = 186] [HR = 1.00, 95% CI (0.58, 1.72)] and \u2265 65\r years of age [n = 122] [HR = 1.01, 95% CI (0.53, 1.94)])\r and patients with no extranodal sites (n = 445) (HR = 1.04,\r 95% CI [0.67, 1.62]) showed no clinically meaningful difference between the two\r arms.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Post\u2011hoc\r subgroup analyses of modified PFS per IRF for patients with Stage IV\r disease were performed including age, region, baseline extranodal sites, number\r of IPFP risk factors, baseline B symptoms, baseline ECOG status and gender. The\r analyses showed a consistent trend towards benefit for patients who received\r ADCETRIS + AVD compared with patients who received ABVD in most subgroups.\r P</span><span lang=\"EN-GB\" style=\"color:windowtext\">atients with Stage IV disease\r for whom extranodal disease was reported ([n = 722] [HR = 0.69,\r 95% CI (0.50, 0.94)]) showed an mPFS (per IRF) benefit. In patients with Stage\r IV disease for whom no extranodal disease was reported, n</span><span lang=\"EN-GB\" style=\"color:windowtext\">o benefit has been shown at time of\r analysis </span><span lang=\"EN-GB\" style=\"color:windowtext\">([n = 85]\r [HR = 1.49, 95% CI (0.51, 4.31)]). </span><span lang=\"EN-GB\" style=\"color:windowtext\">The significance of this finding in stage IV HL\r patients with no extranodal disease is not established due to small patient\r numbers and low event rates (14 events).</span><span lang=\"EN-GB\" style=\"color:windowtext\">The efficacy in elderly patients with Stage IV disease\r in the A + AVD arm (patients \u2265 60 years of age [n = 118]\r [HR = 0.80, 95% CI (0.42, 1.53)] and \u2265 65 years of age [n = 78]\r [HR = 0.78, 95% CI (0.36, 1.67)]) showed better benefit compared with\r elderly patients in ITT population.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><a name=\"_Hlk519587500\"><span lang=\"EN-GB\">In the ITT\r population, 33% fewer patients treated with ADCETRIS + AVD in the ITT\r population received subsequent salvage chemotherapy (n = 66) and\r high-dose chemotherapy and transplant (n = 36) compared with those\r treated with ABVD (n = 99 and n = 54, respectively). In the\r Stage IV population, 35% fewer patients treated with ADCETRIS + AVD received\r subsequent salvage chemotherapy (n = 45) compared with those treated\r with ABVD (n = 69) and 22% fewer patients treated with ADCETRIS + AVD\r received high-dose chemotherapy and transplant (n = 29) compared with\r those treated with ABVD (n = 37).</span></a></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The European\r Organization for Research and Treatment of Cancer Quality of Life 30\u2011Item\r Questionnaire (EORTC\u2011QLQ\u2011C30) showed no clinically meaningful\r difference between the two arms in both the ITT and Stage IV population.</span></p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\"></span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Study SGN35\u2011005</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy and safety of ADCETRIS were\r evaluated in a randomised, double\u2011blind, placebo\u2011controlled, 2\u2011arm\r multicenter trial in 329 patients with HL at risk of relapse or\r progression following ASCT. Patients with known cerebral/meningeal disease,\r including history of PML were excluded from the study. See Table 8 for\r patient characteristics. Of the 329 patients, 165 patients were\r randomised to the treatment arm and 164 patients were randomised to the\r placebo arm. In the study, patients were to receive their first dose after\r recovery from ASCT (between days 30\u201145 following ASCT). Patients were\r treated with 1.8 mg/kg of ADCETRIS or matching placebo intravenously over\r 30 minutes every 3 weeks for up to 16 cycles.</span></p> <p class=\"MsoNormal\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">Eligible patients were required to have at least one of the following\r risk factors: </span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt;font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">HL that was refractory\r to frontline treatment</span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt;font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Relapsed or progressive\r HL that occurred &lt;12 months from the end of frontline treatment</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">Extranodal involvement at time of pre\u2011ASCT\r relapse, including extranodal extension of nodal masses into adjacent vital\r organs.</span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in\"></p> <p class=\"MsoNormal\" style=\"page-break-before:always;page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 8: Summary of baseline patient and disease characteristics in\r the phase 3 HL post\u2011ASCT Study<br/> <br/> </span></b></p> <div align=\"center\"> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:444.45pt;border-collapse:collapse;border:none\" width=\"593\"> <tr style=\"height:15.1pt\"> <td style=\"width:215.95pt;border:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-bottom:3.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Patient characteristics</span></b></p> </td> <td style=\"width:112.5pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 165</span></b></p> </td> <td style=\"width:116.0pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Placebo</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 164</span></b></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:3.1pt;text-indent:5.5pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Median age, years (range)</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">33 years (18\u201171)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">32 years (18\u201176)</span></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt\"><span lang=\"EN-GB\">Gender</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">76M\r   (46%)/89F (54%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">97M\r   (59%)/67F (41%)</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt\"><span lang=\"EN-GB\">ECOG status</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> </tr> <tr style=\"height:12.75pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">87\r   (53%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">97\r   (59%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">1</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">77\r   (47%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">67\r   (41%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">2</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\r   (1%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:3.0pt;\r   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;\r   text-indent:-19.45pt\"><b><span lang=\"EN-GB\">Disease characteristics</span></b></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> </tr> <tr style=\"height:8.0pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median number of prior chemotherapy regimens (range)</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\r   (2\u20118)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\r   (2\u20117)</span></p> </td> </tr> <tr style=\"height:7.15pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median time from HL diagnosis to first dose (range)</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">18.7 mo\r   (6.1\u2011204.0)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">18.8 mo\r   (7.4\u2011180.8)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Disease stage at initial diagnosis of HL</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Stage I</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\r   (1%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5\r   (3%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Stage II</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">73\r   (44%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">61\r   (37%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Stage III</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">48\r   (29%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">45\r   (27%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Stage IV</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">43\r   (26%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">51\r   (31%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Unknown</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\r   (1%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">PET scan Status prior to ASCT</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">FDG\u2011AVID</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">64\r   (39%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">51\r   (31%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">FDG\u2011NEGATIVE</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">56\r   (34%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">57\r   (35%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">NOT DONE</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">45\r   (27%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">56\r   (34%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Extranodal involvement at time of pre\u2011ASCT relapse</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">54\r   (33%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">53\r   (32%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">B symptoms</span><sup><span lang=\"EN-GB\">a</span></sup></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">47\r   (28%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">40\r   (24%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Best response to salvage therapy pre\u2011ASCT<sup>b</sup></span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Complete\r   Response</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">61\r   (37%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">62\r   (38%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Partial\r   Response</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">57\r   (35%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">56\r   (34%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Stable Disease</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">47\r   (28%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">46\r   (28%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">HL Status after the end of frontline standard chemotherapy<sup>b</sup></span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Refractory</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">99\r   (60%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">97\r   (59%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Relapse\r   occurred &lt;12 months</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">53\r   (32%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">54\r   (33%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Relapse\r   occurred \u2265 12 months</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">13\r   (8%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">13\r   (8%)</span></p> </td> </tr> </table> </div> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in\"><sup><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">For refractory disease, or upon progression or relapse after frontline therapy.</span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in\"><sup><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">b.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Stratification\r factors at randomisation.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy results are shown in Table 9.\r The primary endpoint of PFS was met and showed a difference in median PFS of\r 18.8 months in favour of the treatment arm.</span></p> <p class=\"MsoNormal\" style=\"margin-left:43.1pt;text-indent:-43.1pt\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 9:\r Efficacy results in HL patients at increased risk of relapse or progression following\r ASCT treated with 1.8 mg/kg of ADCETRIS every 3 weeks<br/> <br/> </span></b></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:459.4pt;border-collapse:collapse;border:none\" width=\"613\"> <tr style=\"height:39.0pt\"> <td style=\"width:85.9pt;border:solid windowtext 1.0pt;padding:.7pt 4.9pt 0in 4.9pt;\r   height:39.0pt\" width=\"115\"></td> <td style=\"width:1.75in;border:solid windowtext 1.0pt;border-left:\r   none;padding:.7pt 4.9pt 0in 4.9pt;height:39.0pt\" width=\"168\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 165</span></b></p> </td> <td style=\"width:130.5pt;border:solid windowtext 1.0pt;border-left:\r   none;padding:.7pt 4.9pt 0in 4.9pt;height:39.0pt\" width=\"174\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Placebo</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 164</span></b></p> </td> <td style=\"width:117.0pt;border:solid windowtext 1.0pt;border-left:\r   none;padding:.7pt 4.9pt 0in 4.9pt;height:39.0pt\" width=\"156\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Stratified Hazard Ratio</span></b></p> </td> </tr> <tr style=\"height:19.3pt\"> <td rowspan=\"4\" style=\"width:85.9pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" width=\"115\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Progression\r   Free Survival<sup>a</sup> </span></b></p> </td> <td colspan=\"2\" style=\"width:256.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" width=\"342\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Median per IRF</span></b></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" valign=\"top\" width=\"156\"></td> </tr> <tr style=\"height:19.3pt\"> <td style=\"width:1.75in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" width=\"168\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">42.9 months</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [30.4, 42.9])</span></p> </td> <td style=\"width:130.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" width=\"174\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">24.1 months</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [11.5, -])</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" valign=\"top\" width=\"156\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">0.57</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [0.40, 0.81])</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Stratified log-rank test p=0.001</span></p> </td> </tr> <tr style=\"height:19.3pt\"> <td colspan=\"2\" style=\"width:256.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" width=\"342\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Median per Investigator </span></b></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" valign=\"top\" width=\"156\"></td> </tr> <tr style=\"height:19.3pt\"> <td style=\"width:1.75in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" width=\"168\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Not reached</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [26.4, -])</span></p> </td> <td style=\"width:130.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" width=\"174\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">15.8 months</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [8.5, -])</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" valign=\"top\" width=\"156\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">0.5</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [0.36, 0.70])<sup>b</sup></span></p> </td> </tr> <tr style=\"height:19.3pt\"> <td rowspan=\"2\" style=\"width:85.9pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" width=\"115\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Overall\r   Survival</span></b></p> </td> <td colspan=\"2\" style=\"width:256.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" width=\"342\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Number of deaths (%)</span></b></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" valign=\"top\" width=\"156\"></td> </tr> <tr style=\"height:25.75pt\"> <td style=\"width:1.75in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:25.75pt\" width=\"168\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">28 (17)</span></p> </td> <td style=\"width:130.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:25.75pt\" width=\"174\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">25 (15)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:25.75pt\" width=\"156\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">1.15</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [0.67, 1.97]</span></p> </td> </tr> </table> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">At the time of the\r primary analysis, the median follow-up time for both arms was 30 months (range,\r 0 to 50). </span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">b.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Stratified log\u2011rank\r test was not performed for PFS per Investigator.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Pre\u2011specified subgroup analyses of\r PFS per IRF were performed by patients\u2019 best response to pre\u2011ASCT\r salvage therapy, HL status after frontline therapy, age, gender, baseline\r weight, baseline ECOG performance status, number of treatments pre\u2011ASCT,\r geographic region, pre\u2011ASCT PET status, B symptom status after failure of\r frontline therapy, and pre\u2011ASCT extranodal disease status. The analyses\r showed a consistent trend towards benefit for patients who received ADCETRIS\r compared with patients who received placebo with the exception of patients\r \u226565 years of age (n = 8).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">No differences were observed in quality of\r life between the treatment and placebo arms. Medical resource utilization (MRU)\r analysis showed that hospitalizations and outpatient visits, as well as working\r days/other activities missed by patients and caregivers were lower with ADCETRIS\r compared with placebo in patients with HL at increased risk of relapse.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">An updated analysis conducted after\r 3 years of follow\u2011up showed a sustained PFS improvement per IRF\r (HR = 0.58 [95% CI (0.41, 0.81)]).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Post\u2011hoc\r Risk Factor Analyses</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Post\u2011hoc analyses were performed </span><span lang=\"EN-GB\">to evaluate the impact of increased</span><span lang=\"EN-GB\"> risk\r (number of risk factors) on clinical benefit (Table 10). </span><span lang=\"EN-GB\">Representative risk factors for these analyses were:</span></p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">HL that occurred &lt;12 months or HL that\r was refractory to frontline therapy</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">Best response of PR or SD to most recent salvage\r therapy as determined by CT and/or PET scanning </span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">Extranodal disease at pre\u2011ASCT relapse</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">B symptoms at pre\u2011ASCT relapse</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">Two or more prior salvage therapies. </span></p> <p class=\"MsoListParagraphCxSpLast\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The results of these post\u2011hoc\r analyses suggest increased clinical benefit for patients with two or more risk\r factors but no difference based on any of the individual risk factors. No benefit\r in terms of PFS or OS has been observed in patients with one risk factor for\r relapse or progression.</span></p> <p class=\"MsoNormal\" style=\"margin-left:41.05pt;text-indent:-41.05pt\"></p> <p class=\"MsoNormal\" style=\"margin-left:-4.5pt;text-indent:-.55pt;page-break-after:\r avoid\"><b><span lang=\"EN-GB\">Table 10: Summary of PFS per IRF and OS by number of\r risk factors in the phase 3 HL post\u2011ASCT Study <br/> <br/> </span></b></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"613\"> <tr> <td colspan=\"7\" style=\"width:459.9pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"613\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">                                               Progression\r   Free Survival per IRF</span></b></p> </td> </tr> <tr> <td rowspan=\"2\" style=\"width:.95in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"91\"></td> <td colspan=\"2\" style=\"width:128.85pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"172\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Number of Risk Factors</span></b><span lang=\"EN-GB\"> <b>= 1</b></span></p> </td> <td colspan=\"2\" style=\"width:136.65pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"182\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Number of Risk Factors \u2265 2</span></b></p> </td> <td colspan=\"2\" style=\"width:1.75in;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Number of Risk Factors \u2265 3</span></b></p> </td> </tr> <tr> <td style=\"width:76.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 21</span></b></p> </td> <td style=\"width:52.35pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"70\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Placebo</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 28</span></b></p> </td> <td style=\"width:83.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"112\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 144</span></b></p> </td> <td style=\"width:52.7pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"70\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Placebo</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 136</span></b></p> </td> <td style=\"width:76.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 82</span></b></p> </td> <td style=\"width:49.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Placebo</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 84</span></b></p> </td> </tr> <tr> <td style=\"width:.95in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"91\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number of\r   patients with disease progression or death<sup>a </sup></span><span lang=\"EN-GB\">(%)</span></p> </td> <td style=\"width:76.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">9 (43)</span></p> </td> <td style=\"width:52.35pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"70\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">7 (25)</span></p> </td> <td style=\"width:83.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"112\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">51 (35)</span></p> </td> <td style=\"width:52.7pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"70\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">68 (50)</span></p> </td> <td style=\"width:76.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">32 (39)</span></p> </td> <td style=\"width:49.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">49 (58)</span></p> </td> </tr> <tr> <td style=\"width:.95in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"91\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Stratified\r   Hazard Ratio </span></p> </td> <td colspan=\"2\" style=\"width:128.85pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"172\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">1.65</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [0.60, 4.55])<sup>b</sup></span></p> </td> <td colspan=\"2\" style=\"width:136.65pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"182\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">0.49</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [0.34, 0.71])</span></p> </td> <td colspan=\"2\" style=\"width:1.75in;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">0.43 </span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [0.27, 0.68])</span></p> </td> </tr> <tr> <td colspan=\"7\" style=\"width:459.9pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"613\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Overall Survival </span></b></p> </td> </tr> <tr> <td rowspan=\"2\" style=\"width:.95in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"91\"></td> <td colspan=\"2\" style=\"width:128.85pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"172\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Number of Risk Factors = 1</span></b></p> </td> <td colspan=\"2\" style=\"width:136.65pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"182\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Number of Risk Factors \u2265 2</span></b></p> </td> <td colspan=\"2\" style=\"width:1.75in;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Number of Risk Factors \u2265 3</span></b></p> </td> </tr> <tr> <td style=\"width:76.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 21</span></b></p> </td> <td style=\"width:52.35pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"70\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Placebo</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 28</span></b></p> </td> <td style=\"width:83.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"112\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 144</span></b></p> </td> <td style=\"width:52.7pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"70\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Placebo</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 136</span></b></p> </td> <td style=\"width:76.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 82</span></b></p> </td> <td style=\"width:49.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Placebo</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 84</span></b></p> </td> </tr> <tr> <td style=\"width:.95in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"91\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number of\r   deaths<sup>c </sup></span><span lang=\"EN-GB\">(%)</span></p> </td> <td style=\"width:76.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">5 (24)</span></p> </td> <td style=\"width:52.35pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"70\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">1 (4)</span></p> </td> <td style=\"width:83.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"112\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">23 (16)</span></p> </td> <td style=\"width:52.7pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"70\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">24 (18)</span></p> </td> <td style=\"width:76.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">15 (18)</span></p> </td> <td style=\"width:49.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">16 (19)</span></p> </td> </tr> <tr> <td style=\"width:.95in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"91\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Stratified\r   Hazard Ratio </span></p> </td> <td colspan=\"2\" style=\"width:128.85pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"172\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">7.94</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [0.93, 68.06])<sup>b</sup></span></p> </td> <td colspan=\"2\" style=\"width:136.65pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"182\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">0.94</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [0.53, 1.67])</span></p> </td> <td colspan=\"2\" style=\"width:1.75in;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">0.92</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [0.45, 1.88])</span></p> </td> </tr> </table> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Death without either prior progression or more than one missed assessment visit.</span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">b.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Indicates results\r from non-stratified analysis.</span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">c.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Events are death due to any cause.</span></p> <p class=\"MsoNormal\" style=\"margin-left:41.05pt;text-indent:-41.05pt;page-break-after:\r avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">At the time of the updated analysis\r (3 years of follow-up) for patients with 2 or more risk factors, the\r hazard ratio for PFS per IRF was 0.49 (95% CI [0.34, 0.71]) and the hazard\r ratio for PFS per investigator was 0.41 (95% CI [0.29, 0.58]) (see Figures 3\r and 4).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Figure 3:\r Kaplan-Meier Plot of PFS per IRF in Patients with \u2265 2 Risk Factors</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"><img border=\"0\" height=\"299\" id=\"Picture 38\" src=\"Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image004.gif\" width=\"605\"/></span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Figure 4:\r Kaplan-Meier Plot of PFS per Investigator in Patients with \u2265 2 Risk\r Factors</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"><img border=\"0\" height=\"299\" id=\"Picture 79\" src=\"Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image005.gif\" width=\"605\"/></span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Study SG035\u20110003</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">The efficacy and safety of </span><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">ADCETRIS</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> as a single\r agent was evaluated in a pivotal open-label, single\u2011arm, multicenter\r study in 102 patients with relapsed or refractory HL. See Table 11\r below for a summary of baseline patient and disease characteristics. </span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"></span></u></i></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Table 11: Summary of baseline patient and\r disease characteristics in the phase 2 relapsed or refractory HL study<br/> <br/> </span></b></p> <div align=\"center\"> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:444.45pt;border-collapse:collapse;border:none\" width=\"593\"> <tr style=\"height:15.1pt\"> <td style=\"width:309.65pt;border:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-bottom:3.0pt;page-break-after:avoid\"><a name=\"OLE_LINK4\"></a><a name=\"RANGE!A1\"></a><b><span lang=\"EN-GB\">Patient\r   characteristics</span></b></p> </td> <td style=\"width:134.8pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><a name=\"OLE_LINK3\"><b><span lang=\"EN-GB\">n = 102</span></b></a></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:3.1pt;text-indent:5.5pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Median age, years (range)</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">31 years (15\u201177)</span></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Gender</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">48M (47%)/54F (53%)</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">ECOG status</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:12.75pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">42 (41%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">1</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">60 (59%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Prior ASCT</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">102 (100%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Prior chemotherapy Regimens</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">3.5 (1\u201113)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Time from ASCT to first post-transplant relapse</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">6.7 mo (0\u2011131)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Histologically confirmed CD30\u2011expressing\r   disease</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">102 (100%)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:3.0pt;\r   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;\r   text-indent:-19.45pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\r   characteristics</span></b></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:8.0pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Primary Refractory to frontline therapy<sup>a</sup></span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">72 (71%)</span></p> </td> </tr> <tr style=\"height:7.15pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Refractory to most recent therapy</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">43 (42%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Baseline B symptoms</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">35 (33%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Stage III at initial diagnosis</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">27 (26%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Stage IV at initial diagnosis</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">20 (20%)</span></p> </td> </tr> </table> </div> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:22.5pt;text-indent:-.25in\"><sup><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Primary refractory\r HL is defined as a failure to achieve a complete remission to, or progressed\r within 3 months of completing frontline therapy.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">Eighteen (18) patients (18%) received 16 cycles of </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">ADCETRIS</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">; and the median number of cycles received was 9\r (ranging from 1 to 1</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">6).<sup> </sup></span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">Response to treatment with </span><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">ADCETRIS</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> was assessed\r by Independent Review Facility (IRF) using the Revised Response Criteria for\r Malignant Lymphoma (Cheson, 2007). Treatment response was assessed by spiral CT\r of chest, neck, abdomen and pelvis; PET scans and clinical data. Response\r assessments were performed at cycles 2, 4, 7, 10, 13, and 16 with PET at cycles\r 4 and 7.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">The objective response rate (ORR) per IRF assessment was 75% (76 of\r 102 patients in the intent\u2011to\u2011treat [ITT] set) and tumour\r reduction was achieved in 94% of patients. Complete remission (CR) was 33% (34\r of 102 patients in the ITT set). The median overall survival (OS) is\r 40.5 months (the median observation time (time to death or last contact)\r from first dose was 35.1 months (range 1.8 to 72.9+ months). The\r estimated overall survival rate at 5 years was 41% (95% CI [31%,\r 51%]).<a name=\"OLE_LINK8\"></a><a name=\"OLE_LINK9\"> The investigator assessments\r were generally consistent with the independent review of the scans.</a> </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Of the patients treated, 8 responding\r patients went on to receive an allogeneic SCT. </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">For further efficacy results see Table 12. </span></p> <p class=\"MsoNormal\" style=\"margin-left:131.75pt;text-indent:-131.75pt\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 12:\r Efficacy results in relapsed or refractory Hodgkin lymphoma patients treated\r with 1.8 mg/kg of </span></b><b><span lang=\"EN-GB\">ADCETRIS</span><span lang=\"EN-GB\"> every 3 weeks<br/> <br/> </span></b></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"600\"> <tr style=\"height:15.1pt\"> <td nowrap=\"\" style=\"width:188.1pt;border:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Best\r   clinical response</span></b><b><sup></sup></b><b><span lang=\"EN-GB\">(n = 102</span></b><sup></sup><b><span lang=\"EN-GB\">)</span></b></p> </td> <td nowrap=\"\" style=\"width:1.95in;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">IRF n (%)</span></b></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">95% CI</span></b></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:188.1pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">   \r   Objective response rate (CR + PR)</span></p> </td> <td nowrap=\"\" style=\"width:1.95in;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">76 (75)</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">64.9, 82.6</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:188.1pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">         \r   Complete remission (CR)</span></p> </td> <td nowrap=\"\" style=\"width:1.95in;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">34 (33)</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">24.3, 43.4</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:188.1pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">         \r   Partial remission (PR)</span></p> </td> <td nowrap=\"\" style=\"width:1.95in;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">42 (41)</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">NA</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:188.1pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">   \r   Disease control rate (CR + PR + SD)</span></p> </td> <td nowrap=\"\" style=\"width:1.95in;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">98 (96)</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">90.3, 98.9</span></p> </td> </tr> <tr style=\"height:14.8pt\"> <td nowrap=\"\" style=\"width:188.1pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.8pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Duration\r   of response </span></b></p> </td> <td style=\"width:1.95in;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.8pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Median per IRF </span></b></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.8pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">95% CI</span></b></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:188.1pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">   \r   Objective response rate (CR + PR)<sup>a</sup></span></p> </td> <td nowrap=\"\" style=\"width:1.95in;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">6.7 months </span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">3.6, 14.8</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:188.1pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">   \r   Complete remission (CR)</span></p> </td> <td nowrap=\"\" style=\"width:1.95in;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">27.9 months</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">10.8, NE<sup>b</sup> </span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:188.1pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Overall\r   survival </span></b></p> </td> <td style=\"width:1.95in;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td style=\"width:121.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">95% CI</span></b></p> </td> </tr> <tr style=\"height:7.5pt\"> <td style=\"width:188.1pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median</span></p> </td> <td style=\"width:1.95in;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">40.5 months</span><b><sup></sup></b></p> </td> <td style=\"width:121.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">28.7, 61.9</span></p> </td> </tr> <tr style=\"height:7.5pt\"> <td style=\"width:188.1pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Estimated 5\u2011year OS Rate</span></p> </td> <td style=\"width:1.95in;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">41%</span></p> </td> <td style=\"width:121.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">31%, 51%</span></p> </td> </tr> </table> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">The range of DOR\r was 1.2+ months to 43+ months and the median follow-up time from\r first dose for patients who achieved objective response (OR) per IRF was\r 9.0 months.</span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in\"><sup><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">b.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Not estimable.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">An exploratory intra\u2011patient analysis showed that approximately\r 64% of the HL patients treated with ADCETRIS as part of the SG035\u20110003\r clinical study experienced an improvement in clinical benefit as measured by\r longer progression free survival (PFS) compared with their most recent prior\r line of therapy. </span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">Of the 35 patients (33%) who had B symptoms at baseline,\r 27 patients (77%) experienced resolution of all B symptoms at a median\r time of 0.7 months from initiation of </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">ADCETRIS</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Data in HL\r Patients Who Are Not Stem Cell Transplant (SCT) Candidates</span></p> <p class=\"TableText\" style=\"margin-bottom:0in\"></p> <p class=\"TableText\" style=\"margin-bottom:0in;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Study\u2011C25007 </span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">A phase 4 single-arm study was\r conducted in patients with relapsed or refractory HL (n = 60) who had\r received at least one prior chemotherapeutic regimen and at the time of\r treatment initiation with ADCETRIS were not considered candidates for SCT or\r multiagent chemotherapy. The median number of cycles was 7 (range 1 to 16\r cycles). Patients were treated with 1.8 mg/kg of ADCETRIS every 3 weeks.\r Per IRF, the objective response rate (ORR) in the ITT population was 50% (95%\r CI, 37; 63%). A best overall response of CR was reported for 7 patients\r (12%); PR was reported for 23 patients (38%). Among these 30 patients,\r the median time to response, defined as the time from first dose to the soonest\r of PR or CR, was 6 weeks (range, 5 to 39 weeks). The median time to best\r overall response, defined as the time from first dose to the clinical best\r response of CR or PR, was 11 weeks (range, 5 to 60 weeks). Twenty\u2011eight\r patients (47%) went on to receive SCT after a median of 7 cycles (range, 4 to 16\r cycles) of ADCETRIS treatment. The 32 patients (53%) who did not receive\r subsequent SCT also received ADCETRIS for a median of 7 cycles (range, 1 to\r 16 cycles). </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Of the study\u2019s 60 patients, 49 patients\r (82%) received &gt; 1 prior cancer-related treatment and 11 patients\r (18%) received 1 prior cancer-related treatment. Per IRF, the ORR was 51% (95% CI [36%,\r 66%]) for the patients who had received &gt; 1 prior cancer-related\r treatment and 45% (95% CI [17%, 77%]) for the patients who had\r received 1 prior cancer-related treatment. For the patients who received\r &gt; 1 prior cancer-related treatment, a best overall response of CR was\r reported for 6 patients (12%); PR was reported for 19 patients (39%).\r For the patients who received 1 prior cancer-related treatment, CR was\r reported for 1 patient (9%) and PR was reported for 4 patients (36%).\r Out of the 49 patients receiving &gt; 1 line of prior treatment, 22 patients\r (45%) received subsequent SCT; of the 11 patients who had received 1 prior\r treatment, 6 patients (55%) received subsequent SCT.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Data were also collected from patients (n = 15)\r in phase 1 dose escalation and clinical pharmacology studies, and from\r patients (n = 26) in a NPP, with relapsed or refractory HL who had\r not received an ASCT, and who were treated with 1.8 mg/kg of ADCETRIS\r every 3 weeks.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Baseline patient characteristics showed\r failure from multiple prior chemotherapy regimens (median of 3 with a\r range of 1 to 7) before first administration with ADCETRIS. Fifty nine percent\r (59%) of patients had advanced stage disease (Stage III or IV) at initial\r diagnosis. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Results from these phase 1 studies and from\r the NPP experience showed, that in patients with relapsed or refractory HL\r without prior ASCT, clinically meaningful responses can be achieved as\r evidenced by an investigator-assessed, objective response rate of 54% and a\r complete remission rate of 22% after a median of 5 cycles of ADCETRIS. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Study SGN35\u2011006\r (Retreatment Study)</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"></span></u></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">The efficacy of retreatment in patients who had previously responded\r (CR or PR) to treatment with ADCETRIS was evaluated in a phase 2,\r open-label, multicenter trial. Twenty patients with relapsed or refractory HL\r received a starting dose of 1.8 mg/kg and one patient received a starting\r dose of 1.2 mg/kg of ADCETRIS administered intravenously over\r 30 minutes every 3 weeks. The median number of cycles was 7 (range, 2\r to 37 cycles).</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Of the 20 evaluable patients with HL,\r 6 patients (30%) achieved a CR and 6 patients (30%) achieved a PR\r with ADCETRIS retreatment, for an ORR of 60%. </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The median duration of response was 9.2 and\r 9.4 months in patients who achieved OR (CR+PR) and CR, respectively.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Systemic anaplastic large cell lymphoma</span></i></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Study SGN35\u2011014</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">The efficacy and safety of ADCETRIS were evaluated in a randomised,\r double-blind, double-dummy, active-controlled, multicenter trial of 452 patients\r with previously untreated CD30+ PTCL in combination with cyclophosphamide [C],\r doxorubicin [H] and prednisone [P] (CHP). </span><span style=\"font-size:11.0pt\">For\r enrollment, the trial required CD30 expression \u226510% per\r immunohistochemistry. </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Only\r patients with CD30+ PTCLs who were eligible for a </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">cyclophosphamide [C], doxorubicin [H], vincristine [O]\r and prednisone [P]</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> (CHOP)-based\r regimen were included.</span><span style=\"font-size:11.0pt\"> The combination of\r ADCETRIS + CHP has not been studied in all PTCL subtypes. See Table\r 13 for enrolled PTCL subtypes. </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Of\r the 452 patients, 226 were randomised to treatment with ADCETRIS + CHP\r and 226 patients were randomised to treatment with CHOP. Randomisation was\r stratified by ALK-positive sALCL versus all other subtypes and by the\r International Prognostic Index (IPI) score. Patients were treated with ADCETRIS\r administered as an intravenous infusion over 30 minutes on day 1 of\r each 21\u2011day cycle for 6 to 8 cycles + CHP. The median number of\r cycles received was 6 (range, 1 to 8 cycles); 70% of patients\r received 6 cycles of treatment, and 18% received 8 cycles of\r treatment. Table 13 provides a summary of baseline patient and disease\r characteristics.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><a name=\"_Ref525816436\"><b><span lang=\"EN-GB\">Table </span></b></a><b><span lang=\"EN-GB\">13: Summary of baseline\r patient and disease characteristics in the phase 3 previously untreated PTCL\r study (ITT and sALCL)</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:459.4pt;border-collapse:collapse;border:none\" width=\"613\"> <thead> <tr> <td style=\"width:189.45pt;border:solid windowtext 1.0pt;\r    border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> </td> <td colspan=\"2\" style=\"width:133.95pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"179\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">ITT Population </span></b></p> </td> <td colspan=\"2\" style=\"width:136.0pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"181\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">sALCL Population<sup>b</sup></span></b></p> </td> </tr> <tr> <td style=\"width:189.45pt;border-top:none;border-left:\r    solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r    none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Patient\r    characteristics</span></b></p> </td> <td style=\"width:67.65pt;border:none;border-bottom:\r    solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">ADCETRIS + CHP</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">n=226</span></b></p> </td> <td style=\"width:66.3pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">CHOP</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">n=226</span></b></p> </td> <td style=\"width:69.55pt;border:none;border-bottom:\r    solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">ADCETRIS + CHP</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">n=162</span></b></p> </td> <td style=\"width:66.45pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">CHOP</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">n=154</span></b></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\r    age (range)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">58.0 (18\u201185)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">58.0 (18\u201183)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">55.0 (18-85)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">54.0 (18-83)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Patients\r    \u2265 65 years old (%)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">69 (31)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">70 (31)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">38 (23)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">36 (23)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Male sex,\r    n (%)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">133 (59)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">151 (67)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">95 (59)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">110 (71)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">ECOG\r    status, n (%)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">84 (37)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">93 (41)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">58 (36)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">53 (34)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">1</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">90 (40)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">86 (38)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">62 (38)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">61 (40)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border-top:none;border-left:\r    solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r    none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">2</span></p> </td> <td style=\"width:67.65pt;border:none;border-bottom:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">51 (23)</span></p> </td> <td style=\"width:66.3pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">47 (21)</span></p> </td> <td style=\"width:69.55pt;border:none;border-bottom:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">41 (25)</span></p> </td> <td style=\"width:66.45pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">40 (26)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border-top:none;border-left:\r    solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r    none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\r    characteristics</span></b></p> </td> <td style=\"width:67.65pt;border:none;border-bottom:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.3pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:69.55pt;border:none;border-bottom:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.45pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">Diagnosis, per local assessment, n (%)<sup>a</sup></span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">sALCL</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">162 (72)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">154 (68)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">162 (100)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">154 (100)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.4in;page-break-after:avoid\"><span lang=\"EN-GB\">ALK-positive</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">49 (22)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">49 (22)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">49 (30)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">49 (32)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.4in;page-break-after:avoid\"><span lang=\"EN-GB\">ALK-negative</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">113 (50)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">105 (46)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">113 (70)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">105 (68)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"FR\">Peripheral T-cell lymphoma (PTCL-NOS)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">29 (13)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">43 (19)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">NA</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">NA</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">Angioimmunoblastic T-cell lymphoma (AITL)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">30 (13)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">24 (11)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">NA</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">NA</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">Adult T-cell leukemia/lymphoma (ATLL)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">4 (2)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">3 (1)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">NA</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">NA</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">Enteropathy-associated T-cell lymphoma (EATL)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">1 (0)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">2 (1)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">NA</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">NA</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">Median time from diagnosis to first dose, months (range)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">0.8 (0, 19)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">0.9 (0, 10)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">0.8 (0, 19)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">0.9 (0, 10)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">Disease stage at initial diagnosis of PTCL, n (%)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">Stage I</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">12 (5)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">9 (4)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">12 (7)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">7 (5)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">Stage II</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">30 (13)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">37 (16)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">22 (14)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">27 (18)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">Stage III</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">57 (25)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">67 (30)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">29 (18)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">46 (30)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">Stage IV</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">127 (56)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">113 (50)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">99 (61)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">74 (48)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">IPI score </span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">8 (4)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">16 (7)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">7 (4)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">14 (9)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">1</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">45 (20)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">32 (14)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">34 (21)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">18 (12)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">2</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">74 (33)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">78 (35)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">58 (36)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">60 (39)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">3</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">66 (29)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">66 (29)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">37 (23)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">40 (26)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">4</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">29 (13)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">25 (11)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">22 (14)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">16 (10)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">5</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">4 (2)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">9 (4)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">4 (2)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">6 (4)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">Extranodal involvement at time of diagnosis, n (%)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:.2in;margin-bottom:\r    0in;margin-left:.2in;margin-bottom:.0001pt;page-break-after:avoid\"><span lang=\"EN-GB\">\u2264 1 site</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">142 (63)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">146 (65)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">94 (58)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">95 (62)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">&gt;1 site</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">84 (37)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">80 (35)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">68 (42)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">59 (38)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">Baseline bone marrow biopsy-lymphoma involvement, n (%)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">Yes</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">30 (13)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">34 (15)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">15 (9)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">13 (8)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border-top:none;border-left:\r    solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r    none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">No</span></p> </td> <td style=\"width:67.65pt;border:none;border-bottom:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">196 (87)</span></p> </td> <td style=\"width:66.3pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">192 (85)</span></p> </td> <td style=\"width:69.55pt;border:none;border-bottom:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">147 (91)</span></p> </td> <td style=\"width:66.45pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">141 (92)</span></p> </td> </tr> </thead> </table> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:17.85pt;text-indent:-17.85pt\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">      As\r per the 2008 WHO classification.</span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:17.85pt;text-indent:-17.85pt\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">b.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">      For\r patients with locally-diagnosed sALCL.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The primary endpoint in SGN35\u2011014 was\r PFS per IRF, defined as the time from the date of randomisation to the date of\r first documentation of progressive disease, death due to any cause, or receipt\r of subsequent anticancer chemotherapy to treat residual or progressive disease,\r whichever occurs first. Receipt of post\u2011treatment consolidative\r radiotherapy, post-treatment chemotherapy for the purpose of mobilising\r peripheral blood stem cells, or consolidative autologous or allogeneic stem\r cell transplant were not considered as disease progression or as having started\r new anticancer therapy.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"Default\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Key secondary\r endpoints included PFS per IRF for patients with centrally-confirmed sALCL, CR\r rate per IRF </span><span style=\"font-size:11.0pt\">following the completion of\r study treatment</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">, OS and ORR\r per IRF </span><span style=\"font-size:11.0pt\">following the completion of study\r treatment</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> which were tested by\r a fixed sequence testing procedure following the statistical significance of\r PFS per IRF. </span></p> <p class=\"Default\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The primary\r endpoint and alpha-protected, key secondary endpoints, which were evaluated\r hierarchically, were met. The median PFS per IRF for the ITT population was\r 48.2 months on the ADCETRIS + CHP arm versus 20.8 months on\r the CHOP arm. The stratified hazard ratio was 0.71 (95% CI: 0.54;\r 0.93, p=0.011), indicating a 29% reduction in the risk of PFS events for ADCETRIS + CHP\r versus CHOP. </span><span lang=\"EN-GB\">For overall survival, the stratified\r hazard ratio was </span><span lang=\"EN-GB\" style=\"color:windowtext\">0.66</span><span lang=\"EN-GB\"> (95% CI: </span><span lang=\"EN-GB\" style=\"color:windowtext\">0.46;\r 0.95, p=0.024),</span><span lang=\"EN-GB\"> a 34% reduction in the risk of OS\r events for ADCETRIS + CHP versus CHOP. </span></p> <p class=\"MsoCaption\" style=\"margin:0in;text-indent:0in;page-break-after:auto\"><a name=\"_Hlk7682306\"></a></p> <p class=\"MsoCaption\" style=\"margin:0in;text-indent:0in;page-break-after:auto\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r font-weight:normal'>PFS per IRF for patients with centrally-confirmed sALCL was\r a pre-specified key secondary endpoint. The median PFS per IRF was\r 55.7 months on the ADCETRIS + CHP arm versus 54.2 months on\r the CHOP arm</span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r font-weight:normal'>. The stratified hazard ratio was 0.59 (95% CI:\r 0.42; 0.84), compatible with a statistically significant 41% reduction in the\r risk of PFS events for ADCETRIS + CHP versus CHOP (p\u2011value=0.003),\r see Figure 5 and Table 14.</span></p> <p class=\"MsoCaption\" style=\"margin:0in;text-indent:0in;page-break-after:auto\"></p> <p class=\"MsoCaption\" style=\"margin:0in;text-indent:0in;page-break-after:auto\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;font-weight:normal'>Subgroup\r analyses were performed for patients with locally-diagnosed sALCL. For overall\r survival, the stratified hazard ratio was </span><span style='font-size:11.0pt;\r font-family:\"Times New Roman\",serif;color:windowtext;font-weight:normal'>0.54</span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;font-weight:normal'>\r (95% CI: </span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext;font-weight:normal'>0.34; 0.87),</span><span style='font-size:\r 11.0pt;font-family:\"Times New Roman\",serif;font-weight:normal'> a 46% reduction\r in the risk of OS events for ADCETRIS + CHP versus CHOP, see Figure 6.\r At the end of treatment, the CR rate by IRF assessment was 71.0% for patients on\r the ADCETRIS + CHP arm compared with 53.2% for patients on the CHOP\r arm with a difference of 17.7% (95% CI: 7.2%; 28.3%). At the end of treatment,\r the ORR rate by IRF assessment was 87.7% for patients on the ADCETRIS + CHP\r arm compared with 70.8% for patients on the CHOP arm with a difference of 16.9%\r (95% CI: 8.1%; 25.7%). In the subgroup of patients with ALK+ sALCL and ALK-\r sALCL the stratified hazard ratio for PFS per IRF was </span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:windowtext;\r font-weight:normal'>0.29</span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r font-weight:normal'> (95% CI: </span><span style='font-size:11.0pt;font-family:\r \"Times New Roman\",serif;color:windowtext;font-weight:normal'>0.11; 0.79) and 0.65</span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;font-weight:normal'>\r (95% CI: </span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext;font-weight:normal'>0.44; 0.95), respectively. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 14:\r Efficacy results in patients with previously untreated sALCL with\r 1.8 mg/kg of ADCETRIS on day 1 of a 3\u2011week cycle </span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.35pt;border-collapse:collapse;border:none\" width=\"587\"> <tr style=\"height:30.35pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:30.35pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:5.1pt;text-align:left;\r   line-height:normal;page-break-after:avoid\"></p> </td> <td colspan=\"2\" style=\"width:112.5pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:30.35pt\" valign=\"top\" width=\"150\"> <p class=\"TableParagraph\" style=\"margin-top:0in;margin-right:15.35pt;\r   margin-bottom:0in;margin-left:9.0pt;margin-bottom:.0001pt;text-indent:-4.5pt;\r   line-height:125%;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>ADCETRIS + CHP</span></b></p> <p class=\"TableParagraph\" style=\"margin-top:0in;margin-right:15.35pt;\r   margin-bottom:0in;margin-left:9.0pt;margin-bottom:.0001pt;text-indent:-4.5pt;\r   line-height:125%;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>n=162<sup>a</sup></span></b></p> </td> <td style=\"width:1.5in;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:30.35pt\" valign=\"top\" width=\"144\"> <p class=\"TableParagraph\" style=\"margin-top:0in;margin-right:15.35pt;\r   margin-bottom:0in;margin-left:9.0pt;margin-bottom:.0001pt;text-indent:-4.5pt;\r   line-height:125%;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>CHOP</span></b></p> <p class=\"TableParagraph\" style=\"margin-top:0in;margin-right:15.35pt;\r   margin-bottom:0in;margin-left:9.0pt;margin-bottom:.0001pt;text-indent:-4.5pt;\r   line-height:125%;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>n=154<sup>a</sup></span></b></p> </td> </tr> <tr style=\"height:15.1pt\"> <td colspan=\"4\" style=\"width:440.4pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"bottom\" width=\"587\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:7.25pt;text-align:left;\r   text-indent:5.75pt;line-height:normal;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>PFS per IRF</span></b></p> </td> </tr> <tr style=\"height:15.8pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.8pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:26.5pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>Number\r   of patients with a PFS event, n (%)</span></p> </td> <td colspan=\"2\" style=\"width:112.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.8pt\" valign=\"top\" width=\"150\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>56 (34)</span></p> </td> <td style=\"width:1.5in;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;\r   height:15.8pt\" valign=\"top\" width=\"144\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>73 (48)</span></p> </td> </tr> <tr style=\"height:17.6pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:17.6pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:26.5pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>Median\r   PFS, months (95% CI)</span></p> </td> <td colspan=\"2\" style=\"width:112.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:17.6pt\" valign=\"top\" width=\"150\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>55.66 (48.20, NE)</span></p> </td> <td style=\"width:1.5in;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;\r   height:17.6pt\" valign=\"top\" width=\"144\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>54.18 (13.44, NE)</span></p> </td> </tr> <tr style=\"height:15.8pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.8pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:26.5pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>Hazard\r   ratio (95% CI)<sup>b</sup></span></p> </td> <td colspan=\"3\" style=\"width:220.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.8pt\" valign=\"top\" width=\"294\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>0.59 (0.42, 0.84)</span></p> </td> </tr> <tr style=\"height:15.0pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.0pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:26.5pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>p-value<sup>c</sup></span></p> </td> <td colspan=\"3\" style=\"width:220.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.0pt\" valign=\"top\" width=\"294\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>0.0031</span></p> </td> </tr> <tr style=\"height:15.0pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.0pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:13.0pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>Estimated\r   PFS (95% CI)</span></b><sup><span style='font-family:\"Times New Roman\",serif'>d</span></sup><b><span style='font-family:\"Times New Roman\",serif'> at:</span></b></p> </td> <td style=\"width:110.25pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.0pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"></p> </td> <td colspan=\"2\" style=\"width:110.25pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.0pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"></p> </td> </tr> <tr style=\"height:29.75pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:29.75pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:26.5pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>6\r   months</span></p> </td> <td style=\"width:110.25pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:29.75pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>88.0% </span></p> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>(81.8%, 92.2%)</span></p> </td> <td colspan=\"2\" style=\"width:110.25pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:29.75pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>68.4% </span></p> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>(60.3%, 75.2%)</span></p> </td> </tr> <tr style=\"height:26.6pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:26.6pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:26.5pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>12\r   months</span></p> </td> <td style=\"width:110.25pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:26.6pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>78.7% </span></p> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>(71.4%, 84.4%)</span></p> </td> <td colspan=\"2\" style=\"width:110.25pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:26.6pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>60.3% </span></p> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>(51.9%, 67.6%)</span></p> </td> </tr> <tr style=\"height:27.05pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:27.05pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:26.5pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>24\r   months</span></p> </td> <td style=\"width:110.25pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:27.05pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>68.4% </span></p> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>(60.4%, 75.2%)</span></p> </td> <td colspan=\"2\" style=\"width:110.25pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:27.05pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>53.9% </span></p> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>(45.5%, 61.5%)</span></p> </td> </tr> <tr style=\"height:27.05pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:27.05pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:26.5pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>36\r   months</span></p> </td> <td style=\"width:110.25pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:27.05pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>65.5% </span></p> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>(57.1%, 72.7%)</span></p> </td> <td colspan=\"2\" style=\"width:110.25pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:27.05pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>50.2% </span></p> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>(41.6%, 58.1%)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td colspan=\"4\" style=\"width:440.4pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"bottom\" width=\"587\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-top:0in;margin-right:38.55pt;\r   margin-bottom:0in;margin-left:13.0pt;margin-bottom:.0001pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>OS</span></b><sup><span style='font-family:\"Times New Roman\",serif'>e</span></sup></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:.2in;text-align:left;\r   text-indent:12.1pt;line-height:normal;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>Number of deaths (%)</span></p> </td> <td colspan=\"2\" style=\"width:112.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"150\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>29 (18)</span></p> </td> <td style=\"width:1.5in;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;\r   height:15.1pt\" valign=\"top\" width=\"144\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>44 (29)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:.2in;text-align:left;\r   text-indent:12.1pt;line-height:normal;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>Median OS, months (95% CI)</span></p> </td> <td colspan=\"2\" style=\"width:112.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"150\"> <p class=\"TableParagraph\" style=\"margin-left:.25in;line-height:11.5pt;\r   page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>NE\r   (NE, NE)</span></p> </td> <td style=\"width:1.5in;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;\r   height:15.1pt\" valign=\"top\" width=\"144\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>NE (NE, NE)</span></p> </td> </tr> <tr style=\"height:17.6pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:17.6pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:.2in;text-align:left;\r   text-indent:12.1pt;line-height:normal;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>Hazard ratio (95% CI)<sup>b</sup></span></p> </td> <td colspan=\"3\" style=\"width:220.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:17.6pt\" valign=\"top\" width=\"294\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>0.54 (0.34, 0.87)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:.2in;text-align:left;\r   text-indent:12.1pt;line-height:normal;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>p-value<sup>c, f</sup></span></p> </td> <td colspan=\"3\" style=\"width:220.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"294\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>0.0096</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td colspan=\"4\" style=\"width:440.4pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"bottom\" width=\"587\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:13.0pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>CR\r   Rate</span></b><sup><span style='font-family:\"Times New Roman\",serif'>g</span></sup></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:.2in;text-align:left;\r   text-indent:12.1pt;line-height:normal;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>% (95% CI)</span></p> </td> <td colspan=\"2\" style=\"width:112.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"150\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>71% (63.3%, 77.8%)</span></p> </td> <td style=\"width:1.5in;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;\r   height:15.1pt\" valign=\"top\" width=\"144\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>53% (45.0%, 61.3%)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:.2in;text-align:left;\r   text-indent:12.1pt;line-height:normal;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>p-value<sup>f, h</sup></span></p> </td> <td colspan=\"3\" style=\"width:220.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"294\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>0.0004</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td colspan=\"4\" style=\"width:440.4pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"587\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:13.0pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>ORR</span></b><sup><span style='font-family:\"Times New Roman\",serif'>g</span></sup></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:.2in;text-align:left;\r   text-indent:12.1pt;line-height:normal;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>% (95% CI)</span></p> </td> <td colspan=\"2\" style=\"width:112.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"150\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>88% (81.6%, 92.3%)</span></p> </td> <td style=\"width:1.5in;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;\r   height:15.1pt\" valign=\"top\" width=\"144\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>71% (62.9%, 77.8%)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:.2in;text-align:left;\r   text-indent:12.1pt;line-height:normal;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>p-value<sup>f, h</sup></span></p> </td> <td colspan=\"3\" style=\"width:220.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"294\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>&lt;0.0001</span></p> </td> </tr> <tr height=\"0\"> <td style=\"border:none\" width=\"293\"></td> <td style=\"border:none\" width=\"147\"></td> <td style=\"border:none\" width=\"3\"></td> <td style=\"border:none\" width=\"144\"></td> </tr> </table> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">CR=complete remission; IRF=Independent Review Facility;\r NE: Not estimable; ORR=objective response rate; PFS=progression-free survival.</span></p> <p class=\"TableFootnoteLetter\" style=\"margin-left:17.85pt;text-indent:-17.85pt;\r page-break-after:avoid\"><span style=\"color:black\">a</span>PFS per IRF is calculated using patients with centrally-confirmed\r sALCL, with n=163 patients in A+CHP arm and n=151 in CHOP arm. OS, CR, and ORR\r are calculated using patients with locally-diagnosed sALCL</p> <p class=\"TableFootnoteLetter\" style=\"margin-left:17.85pt;text-indent:-17.85pt;\r page-break-after:avoid\"><span style=\"color:black\">b</span>Hazard ratio (A+CHP/CHOP) and 95% confidence intervals are based\r on a stratified Cox\u2019s proportional hazard regression model with\r stratification factors (ALK-positive sALCL versus all others and International\r Prognostic Index [IPI] score at baseline). Hazard ratio &lt;1 favours A+CHP\r arm.</p> <p class=\"TableFootnoteLetter\" style=\"margin-left:17.85pt;text-indent:-17.85pt;\r page-break-after:avoid\"><span style=\"color:black\">c</span>p-value is calculated using a stratified log-rank test.</p> <p class=\"TableFootnoteLetter\"><span style=\"color:black\">d</span>PFS rate is estimated using Kaplan-Meier methods and 95% CI is\r calculated using the complementary log-log</p> <p class=\"TableFootnoteLetter\" style=\"margin-left:0in;text-indent:17.85pt\">transformation\r method.</p> <p class=\"TableFootnoteLetter\" style=\"margin-left:17.85pt;text-indent:-17.85pt;\r page-break-after:avoid\"><span style=\"color:black\">e</span>Median OS follow-up in the A+CHP arm was 38.5 months; in the CHOP\r arm was 41.0 months.</p> <p class=\"TableFootnoteLetter\" style=\"margin-left:17.85pt;text-indent:-17.85pt;\r page-break-after:avoid\"><span style=\"color:black\">f</span>p-value is not adjusted for multiplicity. </p> <p class=\"TableFootnoteLetter\" style=\"margin-left:17.85pt;text-indent:-17.85pt;\r page-break-after:avoid\"><span style=\"color:black\">g</span>Response per 2007 International Working Group Criteria at end of\r treatment.</p> <p class=\"TableFootnoteLetter\" style=\"margin-left:17.85pt;text-indent:-17.85pt;\r page-break-after:avoid\"><span style=\"color:black\">h</span>p-value is calculated using a stratified Cochran-Mantel-Haenszel\r test.</p> <p class=\"MsoNormal\"> </p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Figure 5: </span></b><b><span style=\"font-size:11.0pt\">Progression-free\r survival per IRF in the sALCL population (ADCETRIS + CHP vs. CHOP)</span></b></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span style=\"font-size:11.0pt\"><img border=\"0\" height=\"416\" src=\"Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image006.jpg\" width=\"605\"/></span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Figure 6: </span></b><b><span style=\"font-size:11.0pt\">Overall\r survival in the sALCL population (ADCETRIS + CHP vs. CHOP)</span></b></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"MsoNormal\"><img border=\"0\" height=\"340\" src=\"Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image007.jpg\" width=\"604\"/></p> <p class=\"MsoCaption\" style=\"margin:0in;text-indent:0in;page-break-after:auto\"><span style='font-size:9.0pt;font-family:\"Times New Roman\",serif;font-weight:normal'>*p-value\r for overall survival is not adjusted for multiplicity.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Study SG035\u20110004</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The efficacy and safety of </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">ADCETRIS</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> as a single agent was evaluated in an open-label,\r single\u2011arm, multicenter study in 58 patients with relapsed or\r refractory sALCL. See Table 15 below for a summary of baseline patient and\r disease characteristics. </span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Table 15: Summary of baseline patient and\r disease characteristics in the phase 2 relapsed or refractory sALCL study<br/> <br/> </span></b></p> <div align=\"center\"> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:6.25in;border-collapse:collapse;border:none\" width=\"600\"> <tr style=\"height:23.65pt\"> <td style=\"width:288.05pt;border:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:23.65pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-bottom:3.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Patient characteristics</span></b></p> </td> <td style=\"width:161.95pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.65pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 58</span></b></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:3.1pt;text-indent:5.5pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Median age, years (range)</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">52 years (14\u201176)</span></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Gender</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">33M (57%)/25F (43%)</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">ECOG status<sup>a</sup></span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:12.75pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">19 (33%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">1</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">38 (66%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Prior ASCT</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">15 (26%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Prior chemotherapy Regimens (range)</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">2 (1\u20116)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Histologically confirmed CD30\u2011expressing\r   disease</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">57 (98%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Anaplastic lymphoma kinase (ALK)-negative disease</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">42 (72%)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:3.0pt;\r   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;\r   text-indent:-19.45pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\r   characteristics</span></b></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:8.0pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Primary Refractory to frontline therapy<sup>b</sup></span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">36 (62%)</span></p> </td> </tr> <tr style=\"height:7.15pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Refractory to most recent therapy</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">29 (50%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Relapsed to most recent therapy</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">29 (50%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Baseline B symptoms</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">17 (29%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Stage III at initial diagnosis</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">8 (14%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Stage IV at initial diagnosis</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">21 (36%)</span></p> </td> </tr> </table> </div> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">a.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">One patient had a\r baseline ECOG status of 2, which was prohibited by protocol and is captured as\r Inclusion Criteria Not Met.</span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">b.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Primary refractory sALCL\r is defined as a failure to achieve a complete remission to, or progressed\r within 3 months of completing frontline therapy.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">The median time from initial sALCL diagnosis to first dose with ADCETRIS\r was 16.8 months. </span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">Ten (10) patients (17%) received 16 cycles of </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">ADCETRIS</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">; the median number of cycles received was 7 (range,\r 1 to 16). </span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Response to\r treatment with </span><span lang=\"EN-GB\">ADCETRIS</span><span lang=\"EN-GB\"> was\r assessed by Independent Review Facility (IRF) using the Revised Response\r Criteria for Malignant Lymphoma (Cheson, 2007). Treatment response was assessed\r by spiral CT of chest, neck, abdomen and pelvis; PET scans and clinical data.\r Response assessments were performed at cycles 2, 4, 7, 10, 13 and 16 with\r PET at cycles 4 and 7. </span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The ORR per IRF assessment was 86% (50 of\r 58 patients in the ITT set). CR was 59% (34 of 58 patients in the ITT\r set) and tumour reduction (of any degree) was achieved in 97% of patients. The\r estimated overall survival at 5 years was 60% (95% CI [47%,73%]). The\r median observation time (time to death or last contact) from first dose was\r 71.4 months. The investigator assessments were generally consistent with\r the independent review of the scans. Of the patients treated, 9 responding\r patients went on to receive an allogeneic stem cell transplant (SCT) and 9 responding\r patients went on to autologous SCT. For further efficacy results, see Table 16\r and Figure 7.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 16:\r Efficacy results in relapsed or refractory sALCL patients treated with\r 1.8 mg/kg of </span></b><b><span lang=\"EN-GB\">ADCETRIS</span><span lang=\"EN-GB\"> every 3 weeks<br/> <br/> </span></b></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"600\"> <tr style=\"height:15.1pt\"> <td nowrap=\"\" style=\"width:189.0pt;border:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Best\r   clinical response</span></b><b><sup></sup></b><b><span lang=\"EN-GB\">(n = 58</span></b><sup></sup><b><span lang=\"EN-GB\">)</span></b></p> </td> <td nowrap=\"\" style=\"width:139.5pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">IRF n (%)</span></b></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">95% CI</span></b></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:189.0pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">   \r   Objective response rate (CR + PR)</span></p> </td> <td nowrap=\"\" style=\"width:139.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">50 (86)</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">74.6, 93.9</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:189.0pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">         \r   Complete remission (CR)</span></p> </td> <td nowrap=\"\" style=\"width:139.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">34 (59)</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">44.9, 71.4</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:189.0pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">         \r   Partial remission (PR)</span></p> </td> <td nowrap=\"\" style=\"width:139.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">16 (28)</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">NA</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:189.0pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">   \r   Disease control rate (CR + PR + SD)</span></p> </td> <td nowrap=\"\" style=\"width:139.5pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">52 (90)</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">78.8, 96.1</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td nowrap=\"\" style=\"width:189.0pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Duration\r   of response</span></b><sup></sup></p> </td> <td style=\"width:139.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Median per IRF </span></b></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">95% CI</span></b></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:189.0pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">   \r   Objective response (CR + PR)<sup>a</sup></span></p> </td> <td nowrap=\"\" style=\"width:139.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">13.2 </span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">5.7, 26.3 </span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:189.0pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">   \r   Complete remission (CR)</span></p> </td> <td nowrap=\"\" style=\"width:139.5pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">26.3</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">13.2, NE<sup>b</sup></span></p> </td> </tr> <tr style=\"height:14.75pt\"> <td style=\"width:189.0pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.75pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Progression\r   Free Survival</span></b></p> </td> <td style=\"width:139.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.75pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Median per IRF</span></b></p> </td> <td style=\"width:121.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">95% CI</span></b></p> </td> </tr> <tr style=\"height:14.75pt\"> <td style=\"width:189.0pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.75pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"text-indent:9.05pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median</span></p> </td> <td style=\"width:139.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.75pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">14.6</span></p> </td> <td style=\"width:121.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">6.9, 20.6</span></p> </td> </tr> <tr style=\"height:14.75pt\"> <td style=\"width:189.0pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.75pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Overall\r   survival</span></b><sup></sup></p> </td> <td style=\"width:139.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.75pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Median</span></b></p> </td> <td style=\"width:121.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">95% CI</span></b></p> </td> </tr> <tr style=\"height:17.45pt\"> <td style=\"width:189.0pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:17.45pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"text-indent:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median</span></p> </td> <td style=\"width:139.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:17.45pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Not reached<sup> </sup></span></p> </td> <td style=\"width:121.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:17.45pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">21.3, NE<sup>b</sup></span></p> </td> </tr> </table> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">The range of DOR\r was 0.1 months to 39.1+ months and the median follow\u2011up time\r from first dose for patients who achieved objective response (OR) per IRF was\r 15.5 months. </span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">b.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Not estimable.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Figure 7: Kaplan-Meier Plot of OS</span></b></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\"><img border=\"0\" height=\"302\" src=\"Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image008.gif\" width=\"605\"/></span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">An exploratory intra-patient analysis showed that approximately 69% of\r the sALCL patients treated with ADCETRIS as part of the SG035\u20110004\r clinical study experienced an improvement in clinical benefit as measured by\r longer progression free survival (PFS) compared with their most recent prior\r line of therapy.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt;color:black\">Of the 17 patients (29%) who had B symptoms at\r baseline, 14 patients (82%) experienced resolution of all B symptoms in a\r median time from initiation of </span><span lang=\"EN-GB\" style=\"font-size:11.0pt;\r color:black\">ADCETRIS</span><span lang=\"EN-GB\" style=\"font-size:11.0pt;\r color:black\"> of 0.7 months.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Study SGN35\u2011006\r (Retreatment study)</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">The efficacy of\r retreatment in patients who had previously responded (CR or PR) to treatment\r with ADCETRIS was evaluated in a phase 2, open\u2011label, multicenter trial.\r Seven patients with relapsed sALCL received a starting dose of 1.8 mg/kg\r and one patient received a starting dose of 1.2 mg/kg of ADCETRIS\r administered intravenously over 30 minutes every 3 weeks. The median\r number of cycles was 8.5 (range, 2 to 30 cycles).</span><span lang=\"EN-GB\" style=\"color:windowtext\">Of\r the 8 sALCL patients, 3 were retreated twice for a total of\r 11 retreatment experiences. Retreatment with ADCETRIS resulted in\r 6 CRs (55%) and 4 PRs (36%), for an ORR of 91%. </span><span lang=\"EN-GB\" style=\"color:windowtext\">The median duration of response was 8.8 and\r 12.3 months in patients who achieved OR (CR+PR) and CR, respectively.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Cutaneous\r T\u2011cell lymphoma</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"letter-spacing:-.1pt\"></span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Study C25001\r </span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoBodyText\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The efficacy and\r safety of ADCETRIS as a single agent was evaluated in a pivotal phase 3,\r open-label, randomised, multicentre study in 128 patients with\r histologically confirmed CD30+ CTCL. </span><span style=\"font-size:11.0pt\">CD30\r positivity was defined as \u226510% target lymphoid cells demonstrating\r membrane, cytoplasmic, and/or Golgi staining pattern based on an\r immunohistochemistry assay (Ventana anti\u2011CD30 [Ber\u2011H2]). </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Patients with a diagnosis of mycosis\r fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]\r were considered eligible for the study. Patients were stratified by these\r disease types and randomised 1:1 to receive either ADCETRIS or the\r physician\u2019s choice of either methotrexate or bexarotene. Patients with\r pcALCL received either prior radiation therapy or at least 1 prior systemic\r therapy and patients with MF received at least 1 prior systemic therapy.\r Patients with a concurrent diagnosis of systemic ALCL, Sezary syndrome and\r other non\u2011Hodgkin lymphoma (except for lymphomatoid papulosis [LyP]) were\r excluded from this study. Patients were treated with 1.8 mg/kg of ADCETRIS\r intravenously over 30 minutes every 3 weeks for up to 16 cycles\r or physician\u2019s choice for up to 48 weeks. The median number of\r cycles was approximately 12 cycles in the ADCETRIS arm. In the\r physician\u2019s choice arm, the median duration of treatment (number of\r cycles) for patients receiving bexarotene was approximately 16 weeks (5.5 cycles)\r and 11 weeks (3 cycles) for patients receiving methotrexate. Table 17\r provides a summary of the baseline patient and disease characteristics.</span></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 17:\r Summary of baseline patient and disease characteristics in the phase 3 CTCL\r Study (ITT Population)<br/> <br/> </span></b></p> <div align=\"center\"> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:455.6pt;border-collapse:collapse;border:none\" width=\"607\"> <tr style=\"height:15.1pt\"> <td colspan=\"2\" style=\"width:178.15pt;border:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-bottom:3.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Patient characteristics</span></b></p> </td> <td style=\"width:155.9pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 64</span></b></p> </td> <td style=\"width:121.55pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Physician\u2019s Choice (Methotrexate or Bexarotene)</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 64</span></b></p> </td> </tr> <tr style=\"height:13.5pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:3.1pt;text-indent:5.5pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Median age (range)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">62 years (22\u201183)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">58.5 years (22\u201183)</span></p> </td> </tr> <tr style=\"height:13.5pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Patients \u2265 65 years old n (%)</span></p> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Gender n (%)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">28 (44%)</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">33M (52%)/31F (48%)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">24 (38%)</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">37M (58%)/27F (42%)</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">ECOG status n (%)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:12.75pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">43 (67)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">46 (72)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">1</span></p> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">2</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">18 (28)</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">3 (5)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">16 (25)</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">2 (3)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:3.0pt;\r   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;\r   text-indent:-19.45pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\r   characteristics</span></b></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:8.0pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median number of prior therapies (range)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">4 (0\u201113)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">3.5 (1\u201115)</span></p> </td> </tr> <tr style=\"height:7.15pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median number of skin-directed therapies (range)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">1 (0\u20116)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">1 (0\u20119)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median number of systemic therapies (range)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">2 (0\u201111)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">2 (1\u20118)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:176.5pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   none;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"235\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">MF, n (%)</span></p> </td> <td colspan=\"2\" style=\"width:157.55pt;border:none;\r   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"210\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:-.85pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">48 (75)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:-.85pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">49 (77)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Early (IA\u2011IIA)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">15 (31)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">18 (37)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Advanced (IIB\u2011IVB<sup>a</sup>)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">32 (67)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">30 (61)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:176.5pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   none;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"235\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">pcALCL, n (%)</span></p> </td> <td colspan=\"2\" style=\"width:157.55pt;border:none;\r   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"210\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:-.85pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">16 (25)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:-.85pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">15 (23)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Skin only </span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">9 (56)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">11 (73)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Extracutaneous disease</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">7 (44)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">4 (27)</span></p> </td> </tr> <tr height=\"0\"> <td style=\"border:none\" width=\"235\"></td> <td style=\"border:none\" width=\"2\"></td> <td style=\"border:none\" width=\"208\"></td> <td style=\"border:none\" width=\"162\"></td> </tr> </table> </div> <p class=\"MsoNormal\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">One patient in each arm had incomplete\r staging data and are not included in the table.</span></p> <p class=\"MsoNormal\"><b></b></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The most common prior skin directed\r therapies in the ITT population were radiotherapy (64%), phototherapy (48%) and\r topical steroids (17%). The most common prior systemic therapies in the ITT\r population were chemotherapy (71%), immunotherapy (43%) and bexarotene (38%).</span></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The primary\r endpoint was objective response rate that lasts at least 4 months (ORR4)\r (duration from first response to last response \u2265 4 months), as\r determined by an independent review of the Global Response Score (GRS)\r consisting of skin evaluations (modified severity weighted assessment tool\r [mSWAT] as assessed per investigator), nodal and visceral radiographic\r assessment, and detection of circulating S\u00e9zary cells (Olsen 2011).\r Table 18 includes the results for ORR4 and other key secondary endpoints.</span></p> <p class=\"MsoNormal\"><b></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 18:\r Efficacy results in CTCL patients treated with 1.8 mg/kg of ADCETRIS every\r 3 weeks (ITT population)<br/> <br/> </span></b></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:168.45pt;border:solid windowtext 1.0pt;\r   border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> </td> <td style=\"width:92.1pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS      (n = 64)</span></b></p> </td> <td style=\"width:87.7pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"117\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> </td> <td colspan=\"2\" style=\"width:116.1pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Physician\u2019s Choice (Methotrexate or\r   Bexarotene) </span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 64</span></b></p> </td> </tr> <tr> <td colspan=\"5\" style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Objective\r   Response Rate lasting at least 4 months (ORR4) per IRF</span></b></p> </td> </tr> <tr> <td style=\"width:168.45pt;border:none;border-left:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">n (%)</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Percent\r   Difference (95% CI)</span></p> </td> <td style=\"width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">36 (56.3)</span></p> </td> <td colspan=\"2\" style=\"width:99.25pt;border:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"132\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">43.8 (29.1, 58.4)</span></p> </td> <td style=\"width:104.55pt;border:none;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"139\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">8 (12.5)</span></p> </td> </tr> <tr> <td style=\"width:168.45pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value</span></p> </td> <td style=\"width:92.1pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td colspan=\"2\" style=\"width:99.25pt;border:none;\r   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"132\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">&lt;0.001</span></p> </td> <td style=\"width:104.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"139\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr> <td colspan=\"5\" style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"IT\">Complete\r   Response (CR) per IRF</span></b></p> </td> </tr> <tr> <td style=\"width:168.45pt;border:none;border-left:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">n (%)</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Percent\r   Difference (95% CI)</span></p> </td> <td style=\"width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">10 (15.6)</span></p> </td> <td style=\"width:87.7pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"117\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">14.1 (-4.0, 31.5)</span></p> </td> <td colspan=\"2\" style=\"width:116.1pt;border:none;\r   border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">1 (1.6)</span></p> </td> </tr> <tr style=\"height:4.0pt\"> <td style=\"width:168.45pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   none;padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"225\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Adjusted\r   p-value<sup>a</sup></span></p> </td> <td style=\"width:92.1pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"123\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td style=\"width:87.7pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"117\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">0.0046</span></p> </td> <td colspan=\"2\" style=\"width:116.1pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:4.0pt\"> <td colspan=\"5\" style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Progression\r   Free Survival (PFS) per IRF</span></b></p> </td> </tr> <tr style=\"height:4.0pt\"> <td style=\"width:168.45pt;border:none;border-left:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"225\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\r   (months)</span></p> </td> <td style=\"width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:4.0pt\" valign=\"top\" width=\"123\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">16.7</span></p> </td> <td style=\"width:87.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:4.0pt\" valign=\"top\" width=\"117\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td colspan=\"2\" style=\"width:116.1pt;border:none;\r   border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">3.5</span></p> </td> </tr> <tr style=\"height:4.0pt\"> <td style=\"width:168.45pt;border:none;border-left:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"225\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hazard\r   Ratio</span></p> </td> <td style=\"width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:4.0pt\" valign=\"top\" width=\"123\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td style=\"width:87.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:4.0pt\" valign=\"top\" width=\"117\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">0.270</span></p> </td> <td colspan=\"2\" style=\"width:116.1pt;border:none;\r   border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:4.0pt\"> <td style=\"width:168.45pt;border:none;border-left:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"225\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p> </td> <td style=\"width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:4.0pt\" valign=\"top\" width=\"123\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td style=\"width:87.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:4.0pt\" valign=\"top\" width=\"117\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(0.17, 0.43)</span></p> </td> <td colspan=\"2\" style=\"width:116.1pt;border:none;\r   border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:4.0pt\"> <td style=\"width:168.45pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   none;padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"225\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Adjusted\r   p-value<sup>a</sup></span></p> </td> <td style=\"width:92.1pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"123\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td style=\"width:87.7pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"117\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">&lt;0.001</span></p> </td> <td colspan=\"2\" style=\"width:116.1pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr height=\"0\"> <td style=\"border:none\" width=\"225\"></td> <td style=\"border:none\" width=\"123\"></td> <td style=\"border:none\" width=\"117\"></td> <td style=\"border:none\" width=\"15\"></td> <td style=\"border:none\" width=\"139\"></td> </tr> </table> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">   Calculated from a weighted\r Holm\u2019s procedure.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Pre-specified\r subgroup analyses of ORR4 per IRF were performed by patients\u2019 CTCL\r subtype, physicians\u2019 choice of treatment, baseline ECOG status, age,\r gender, and geographic region. The analyses showed a consistent trend towards\r benefit for patients who received ADCETRIS compared with patients who received\r physician\u2019s choice. ORR4 was 50% and 75% in the ADCETRIS arm versus 10.2%\r and 20% in the physician\u2019s choice arm for MF and pcALCL, respectively.</span></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">No meaningful differences in quality of\r life (assessed by the EuroQol five dimensions questionnaire [EQ-5D] and\r Functional Assessment of Cancer Therapy-General [FACT-G]) were observed between\r the treatment arms.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy and safety of ADCETRIS were\r evaluated in two additional open-label studies in 108 patients with\r relapsed CD30+ CTCL (including MF and pcALCL as well as SS, LyP and mixed CTCL\r histology), <span style=\"background:white\">regardless of CD30 expression level.\r Patients</span> were treated with ADCETRIS 1.8 mg/kg intravenously over 30 minutes\r every 3 weeks for up to 16 cycles. The safety and efficacy results in\r these studies were consistent with results in Study C25001. Overall response\r rates for MF were 54\u201166%; pcALCL, 67%; SS, 50%; LyP, 92%; and mixed CTCL\r histology, 82\u201185%.</span></p> <p class=\"MsoNormal\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Paediatric population</span></i></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">The safety, pharmacokinetics and anti-tumour activity\r of ADCETRIS in 36 paediatric patients (7\u201117 years of age) with\r r/r HL and sALCL (children aged 7\u201111 years, n = 12 and\r adolescents aged 12 to 17 years, n = 24) were evaluated in\r a phase 1/2 open-label, single-agent, multicentre dose-escalation study\r (C25002). Phase 1 of the study assessed the safety profile (see\r section 4.8), determined the paediatric maximum tolerated dose (MTD)\r and/or recommended phase 2 dose (RP2D), and assessed the pharmacokinetics\r of ADCETRIS (see section 5.2). Phase 1 included 3 r/r HL\r patients treated at 1.4 mg/kg and 9 patients (7 r/r HL and\r 2 sALCL) treated at 1.8 mg/kg. The MTD was not reached. The RP2D was\r determined to be 1.8 mg/kg. Across the study, a total of 16 patients\r with r/r HL and 17 patients with r/r sALCL, of whom 10 were in first\r relapse, were treated with 1.8 mg/kg of ADCETRIS. The best overall\r response rate (ORR) per independent review facility (IRF) was analysed across\r both study phases at the RP2D. Of these 33 patients who received the RP2D,\r 32 were evaluable for response. The ORR was 47% in response-evaluable\r patients with r/r HL, 53% in patients with r/r sALCL and 60% in sALCL patients\r in first relapse. Eight HL patients and 9 sALCL patients went on to\r receive SCT following treatment with ADCETRIS. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The European\r Medicines Agency has deferred the obligation to submit the results of studies\r with </span><span lang=\"EN-GB\">ADCETRIS</span><span lang=\"EN-GB\"> in one or more\r subsets of the paediatric population in the treatment of Hodgkin lymphoma and\r treatment of anaplastic large cell lymphoma (see section 4.2 for\r information on paediatric use).</span></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">This medicinal\r product has been authorised under a so-called \u2018conditional\r approval\u2019 scheme. This means that further evidence on this medicinal\r product is awaited.</span></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The European\r Medicines Agency will review new information on this medicinal product at least\r every year and this SmPC will be updated as necessary.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <h3><span lang=\"EN-GB\">5.2     Pharmacokinetic properties</span></h3> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Monotherapy</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"></span></u></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The\r pharmacokinetics of </span><span lang=\"EN-GB\">brentuximab vedotin</span><span lang=\"EN-GB\"> were evaluated in phase 1 studies and in a population\r pharmacokinetic analysis of data from 314 patients. In all clinical\r trials, brentuximab vedotin was administered as an intravenous infusion. </span></p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">Maximum concentrations of brentuximab vedotin ADC were typically\r observed at the end of infusion or the sampling timepoint closest to the end of\r infusion. A multiexponential decline in ADC serum concentrations was observed\r with a terminal half-life of approximately 4 to 6 days.\r Exposures were approximately dose proportional. Minimal to no accumulation of\r ADC was observed with multiple doses at the every 3\u2011week schedule,\r consistent with the terminal half-life estimate. Typical C<sub>max</sub> and\r AUC of ADC after a single 1.8 mg/kg in a phase 1 study was\r approximately </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">31.98 \u03bcg/ mL\r and 79.41 \u03bcg/ mL x day respectively.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">MMAE is the major metabolite of brentuximab vedotin. Median C<sub>max</sub>,\r AUC and T<sub>max</sub> of MMAE after a single 1.8 mg/kg of the ADC in a\r phase 1 study was approximately 4.97 ng/ mL, 37.03 ng/ mL x\r day and 2.09 days respectively. MMAE exposures decreased after multiple\r doses of brentuximab vedotin with approximately 50% to 80% of the exposure of\r the first dose being observed at subsequent doses. MMAE is further metabolised\r mainly to an equally potent metabolite; however, its exposure is an order of\r magnitude lower than that of MMAE. Thus, it is not likely to have any\r substantial contribution to the systemic effects of MMAE.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In the first cycle, higher MMAE exposure\r was associated with an absolute decrease in neutrophil count.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Combination\r therapy</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"></span></u></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The pharmacokinetics of ADCETRIS in\r combination with AVD were evaluated in a single phase 3 study in 661 patients.\r Population pharmacokinetic analysis indicated that the pharmacokinetics of\r ADCETRIS in combination with AVD were consistent to that in monotherapy. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">After multiple\u2011dose, IV infusion of\r 1.2 mg/kg brentuximab vedotin every two weeks, maximal serum\r concentrations of ADC were observed near the end of the infusion and\r elimination exhibited a multi\u2011exponential decline with a t<sub>1/2z</sub>\r of approximately 4 to 5 days. Maximal plasma concentrations of MMAE\r were observed approximately 2 days after the end of infusion, and\r exhibited a mono\u2011exponential decline with a t<sub>1/2z </sub>of\r approximately 3 to 4 days.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">After multiple\u2011dose, IV infusion of\r 1.2 mg/kg brentuximab vedotin every two weeks, steady\u2011state trough\r concentrations of ADC and MMAE were achieved by Cycle 3. Once steady-state\r was achieved, the PK of ADC did not appear to change with time. ADC\r accumulation (as assessed by AUC<sub>14D</sub> between Cycle 1 and\r Cycle 3) was 1.27\u2011fold. The exposure of MMAE (as assessed by AUC<sub>14D</sub>\r between Cycle 1 and Cycle 3) appeared to decrease with time by\r approximately 50%.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The pharmacokinetics of ADCETRIS in\r combination with CHP were evaluated in a single phase 3 study in 223 patients\r (SGN35\u2011014). After multiple-dose IV infusion of 1.8 mg/kg ADCETRIS\r every 3 weeks, the pharmacokinetics of ADC and MMAE were similar to those\r of monotherapy.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Distribution</span></u></p> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In vitro</span></i><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">, </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">the binding of MMAE\r to human serum plasma proteins ranged from 68\u201182%. MMAE is not likely to\r displace or to be displaced by highly protein-bound medicines. <i>In vitro</i>,\r MMAE was a substrate of P\u2011gp and was not an inhibitor of P\u2011gp at\r clinical concentrations.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">In humans, the mean steady state volume of distribution was\r approximately 6\u201110 L for ADC. Based on population PK estimation the\r typical apparent central volume of distribution of MMAE was 35.5 L.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Metabolism</span></u></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The ADC is\r expected to be catabolised as a protein with component amino acids recycled or\r eliminated.</span></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><i><span lang=\"EN-GB\">In</span></i><span lang=\"EN-GB\"> <i>vivo</i> data in animals and humans suggest that only a small\r fraction of MMAE released from </span><span lang=\"EN-GB\">brentuximab vedotin is metabolised.\r The levels of MMAE metabolites have not been measured in human plasma. At least\r one metabolite of MMAE has been shown to be active <i>in vitro.</i> </span></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">MMAE is a\r substrate of CYP3A4 and possibly CYP2D6. <i>In vitro</i> data indicate that the\r MMAE metabolism that occurs is primarily via oxidation by CYP3A4/5. <i>In vitro</i>\r studies using human liver microsomes indicate that MMAE inhibits only CYP3A4/5\r at concentrations much higher than was achieved during clinical application.\r MMAE does not inhibit other isoforms. </span></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">MMAE did not\r induce any major CYP450 enzymes in primary cultures of human hepatocytes.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Elimination</span></u></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><u><span lang=\"EN-GB\"></span></u></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The ADC is\r eliminated by catabolism with a typical estimated CL and half life of 1.5 L/day\r and 4\u20116 days respectively. </span></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The elimination\r of MMAE was limited by its rate of release from ADC, typical apparent CL and\r half life of MMAE was 19.99 L/day and 3\u20114 days respectively. </span></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">An excretion\r study was undertaken in patients who received a dose of 1.8 mg/kg of\r brentuximab vedotin. Approximately 24% of the total MMAE administered as part\r of the ADC during a brentuximab vedotin infusion was recovered in both urine\r and faeces over a 1\u2011week period. Of the recovered MMAE, approximately 72%\r was recovered in the faeces. A lesser amount of MMAE (28%) was excreted in the\r urine.</span></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><u><span lang=\"EN-GB\"></span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pharmacokinetics\r in special populations</span></u></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Population PK analysis showed that baseline\r serum albumin concentration was a significant covariate of MMAE clearance. The\r analysis indicated that MMAE clearance was 2\u2011fold lower in patients with\r low serum albumin concentrations &lt;3.0 g/dL compared with patients with\r serum albumin concentrations within the normal range.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hepatic\r impairment</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">A study\r evaluated the PK of brentuximab vedotin and MMAE after the administration of\r 1.2 mg/kg of ADCETRIS to patients with mild (Child-Pugh A; n = 1),\r moderate (Child-Pugh B; n = 5) and severe (Child-Pugh C; n = 1)\r hepatic impairment. Compared to patients with normal hepatic function, MMAE\r exposure increased approximately 2.3\u2011fold (90% CI 1.27\u20114.12\u2011fold)\r in patients with hepatic impairment.</span></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Renal\r impairment</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">A study\r evaluated the PK of brentuximab vedotin and MMAE after the administration of\r 1.2 mg/kg of ADCETRIS to patients with mild (n = 4), moderate (n = 3)\r and severe (n = 3) renal impairment. Compared to patients with normal\r renal function, MMAE exposure increased approximately 1.9\u2011fold (90% CI\r 0.85\u20114.21\u2011fold) in patients with severe renal impairment\r (creatinine clearance &lt; 30 mL/min). No effect was observed in\r patients with mild or moderate renal impairment.</span></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Elderly</span></i></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The population pharmacokinetics of\r brentuximab vedotin were examined from several studies, including data from 380 patients\r up to 87 years old (34 patients </span><span lang=\"EN-GB\">\u226565\u2011&lt; 75\r and 17 patients \u226575 years of age</span><span lang=\"EN-GB\">). Additionally,\r the population pharmacokinetics of brentuximab vedotin in combination with AVD\r were examined, including data from 661 patients up to 82 years old (</span><span lang=\"EN-GB\">42 patients \u2265 65\u2011&lt; 75 and 17 patients \u2265 75 years\r of age). The influence of age on pharmacokinetics was investigated in each\r analysis and it was not a significant covariate.</span></p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><u><span lang=\"EN-GB\" style=\"background:yellow\"></span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Paediatric\r population</span></i></p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The pharmacokinetics of brentuximab vedotin\r ADC and MMAE following a 30\u2011minute intravenous infusion of BV administered\r at 1.4 mg/kg or 1.8 mg/kg given every 3 weeks were evaluated in\r a phase 1/2 clinical trial of 36 paediatric patients (7\u201117 years\r of age) with r/r HL and sALCL (children aged 7\u201111 years, n = 12\r and adolescents aged 12 to 17 years, n = 24) (see section 5.1).\r The C<sub>max</sub> of ADC was typically observed at the end of infusion or the\r sampling closest to the end of infusion. A multi-exponential decline in ADC\r serum concentrations was observed with a terminal half-life of approximately 4\r to 5 days. Exposures were approximately dose proportional with a trend\r observed for lower ADC exposures at lower ages/ body weights in the study\r population. </span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Median ADC AUC in\r children and adolescents from this study was approx. 14% and 3% lower than in\r adult patients, respectively, while MMAE exposures were 53% lower and 13%\r higher, respectively, than in adult patients.</span><span lang=\"EN-GB\" style=\"color:windowtext\"> Median C<sub>max</sub> and AUC of ADC after a single\r 1.8 mg/kg dose were 29.8 \u00b5g/ mL and\r 67.9 \u00b5g*day/ mL, respectively, in patients &lt; 12 years\r of age and 34.4 \u00b5g/mL and 77.8 \u00b5g*day/mL, respectively,\r in patients \u2265 12 years of age. Median C<sub>max</sub>, AUC, and\r T<sub>max</sub> of MMAE after a single 1.8 mg/kg dose were\r 3.73 ng/mL, 17.3 ng*day/mL, and 1.92 days, respectively, in patients\r &lt; 12 years of age and 6.33 ng/mL, 42.3 ng*day/mL, and\r 1.82 days, respectively, in patients \u2265 12 years of age. </span><span lang=\"EN-GB\" style=\"color:windowtext\">There was a trend of increased clearance of\r brentuximab vedotin in paediatric patients confirmed positive for ADAs. No\r patients aged &lt; 12 years (0 of 11) and 2 patients aged\r \u2265 12 years (2 of 23) became persistently ADA positive.</span></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><u><span lang=\"EN-GB\"></span></u></p> <h3><span lang=\"EN-GB\">5.3     Preclinical safety data</span></h3> <p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p> <p class=\"Default\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">MMAE has been shown\r to have aneugenic properties in an <i>in vivo</i> rat bone marrow micronucleus\r study. These results were consistent with the pharmacological effect of MMAE on\r the mitotic apparatus (disruption of the microtubule network) in cells.</span></p> <p class=\"Default\"></p> <p class=\"Default\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The effects of </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">brentuximab vedotin on human male and\r female fertility have not been studied. However, results of repeat-dose\r toxicity studies in rats indicate the potential for brentuximab vedotin to\r impair male reproductive function and fertility. Testicular atrophy and\r degeneration were partially reversible following a 16\u2011week treatment-free\r period.</span></p> <p class=\"Default\"></p> <p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Brentuximab vedotin caused embryo-foetal\r lethality in pregnant female rats. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In nonclinical studies, lymphoid depletion\r and reduced thymic weight were observed, consistent with the pharmacologic\r disruption of microtubules caused by MMAE derived from brentuximab vedotin.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <h2><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>6.       PHARMACEUTICAL\r PARTICULARS</span></h2> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <h3><span lang=\"EN-GB\">6.1     List of excipients</span></h3> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:windowtext\">Citric acid monohydrate </span><span style=\"color:windowtext\">(for pH-adjustment)</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:windowtext\">Sodium citrate dihydrate </span><span style=\"color:windowtext\">(for pH-adjustment)</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">\u03b1,\u03b1\u2011Trehalose dihydrate</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Polysorbate 80</span></p> <p class=\"MsoNormal\"></p> <h3><span lang=\"EN-GB\">6.2     Incompatibilities</span></h3> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In the absence of compatibility studies,\r this medicinal product must not be mixed with other medicinal products except\r those mentioned in section 6.6.</span></p> <p class=\"MsoNormal\"></p> <h3><span lang=\"EN-GB\">6.3     Shelf life</span></h3> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">4 years.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">After reconstitution/dilution, from a\r microbiological point of view, the product should be used immediately. However,\r chemical and physical in\u2011use stability has been demonstrated for\r 24 hours at 2 </span><span lang=\"EN-GB\">\u00b0</span><span lang=\"EN-GB\">C\u20118 </span><span lang=\"EN-GB\">\u00b0</span><span lang=\"EN-GB\">C.</span></p> <p class=\"MsoNormal\"></p> <h3><span lang=\"EN-GB\">6.4     Special precautions for\r storage</span></h3> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Store in a\r refrigerator (2 \u00b0C\u20118 \u00b0C). </span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Do not freeze. </span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Keep the vial\r in the original carton in order to protect from light.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">For storage\r conditions after reconstitution and dilution of the medicinal product, see\r section 6.3.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <h3><span lang=\"EN-GB\">6.5     Nature and contents of\r container </span></h3> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Type I glass vial with a butyl rubber\r stopper and an aluminium/plastic flip-off seal, containing 50 mg powder.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Pack of 1 vial. </span></p> <p class=\"MsoNormal\"></p> <h3><a name=\"OLE_LINK1\"><span lang=\"EN-GB\">6.6     Special\r precautions for disposal and other handling</span></a></h3> <p class=\"Default\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"></span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">General\r precautions</span></u></p> <p class=\"Default\" style=\"page-break-after:avoid\"></p> <p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">Procedures for proper handling and disposal of anticancer medicinal\r products should be considered. </span></p> <p class=\"Default\"></p> <p class=\"Default\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Proper aseptic\r technique throughout the handling of this medicinal product should be followed.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Instructions\r for reconstitution </span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Each single use vial must be reconstituted\r with 10.5 mL of water for injections to a final concentration of\r 5 mg/ mL. Each vial contains a 10% overfill giving 55 mg of\r ADCETRIS per vial and a total reconstituted volume of 11 mL.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">1.</span><span lang=\"EN-GB\">Direct the stream toward the wall of the vial\r and not directly at the cake or powder. </span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\">2.</span><span lang=\"EN-GB\">Gently swirl the vial to aid dissolution. DO NOT\r SHAKE.</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\">3.</span><span lang=\"EN-GB\">The reconstituted solution in the vial is a\r clear to slightly opalescent, colourless solution with a final pH of 6.6. </span></p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">4.</span><span lang=\"EN-GB\">The reconstituted solution should be inspected\r visually for any foreign particulate matter and/or discolouration. In the event\r of either being observed, discard the medicinal product. </span></p> <p class=\"Default\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"></span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Preparation\r of infusion solution</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The appropriate amount of reconstituted\r ADCETRIS must be withdrawn from the vial(s) and added to an infusion bag\r containing sodium chloride 9 mg/ mL (0.9%) solution for injection in\r order to achieve a final concentration of 0.4\u20111.2 mg/ mL\r ADCETRIS. The recommended diluent volume is 150 mL. The already\r reconstituted ADCETRIS can also be diluted into 5% dextrose for injection or\r Lactated Ringer's for injection. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Gently invert the bag to mix the solution\r containing ADCETRIS. DO NOT SHAKE. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Any portion left in the vial, after\r withdrawal of the volume to be diluted, must be disposed of in accordance with local\r requirements. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not add other medicinal products to the\r prepared ADCETRIS infusion solution or intravenous infusion set. The infusion\r line should be flushed following administration with sodium chloride 9 mg/ mL\r (0.9%) solution for injection, 5% dextrose for injection, or Lactated Ringer's\r for injection. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Following dilution, infuse the ADCETRIS\r solution immediately at the recommended infusion rate. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Total storage time of the solution from\r reconstitution to infusion should not exceed 24 hours. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Determining\r dosage amount:</span></u></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Calculation\r to determine the total ADCETRIS dose (mL) to be further diluted (see section 4.2):\r </span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:496.15pt;margin-left:5.4pt;border-collapse:collapse\" width=\"662\"> <tr> <td style=\"width:255.15pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"340\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">ADCETRIS\r   dose (mg/kg) x patient\u2019s body weight (kg)</span></p> </td> <td rowspan=\"2\" style=\"width:241.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"321\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> = Total ADCETRIS\r   dose (mL) to be further diluted</span></p> </td> </tr> <tr> <td style=\"width:255.15pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"340\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Reconstituted\r   vial concentration (5 mg/mL)</span></p> </td> </tr> </table> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Note: If patient\u2019s weight is more\r than 100 kg, the dose calculation should use 100 kg. The maximal\r recommended dose is 180 mg. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Calculation\r to determine the total number of ADCETRIS vials needed: </span></i></p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;page-break-after:\r avoid\"></p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:496.15pt;margin-left:5.4pt;border-collapse:collapse\" width=\"662\"> <tr> <td style=\"width:255.15pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"340\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Total\r   ADCETRIS dose (mL) to be administered</span></p> </td> <td rowspan=\"2\" style=\"width:241.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"321\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> = Number of ADCETRIS vials\r   needed</span></p> </td> </tr> <tr> <td style=\"width:255.15pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"340\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Total\r   volume per vial (10 mL/vial)</span></p> </td> </tr> </table> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 19:\r Sample calculations for patients receiving the recommended dose of\r 1.8 mg/kg of ADCETRIS for weights ranging from 60 kg to 120 kg<br/> <br/> </span></b></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\"> <tr> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Patient\r   weight (kg)</span></b></p> </td> <td style=\"width:126.45pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Total\r   dose = </span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">patient\r   weight multiplied by recommended dose [1.8 mg/kg<sup>a</sup>])</span></b></p> </td> <td style=\"width:148.8pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Total\r   volume to be diluted<sup>b</sup> = total dose divided by reconstituted\r   vial concentration [5 mg/ mL])</span></b></p> </td> <td style=\"width:136.95pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Number\r   of vials needed = </span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">total\r   volume to be diluted divided by total volume per vial [10 mL/vial])</span></b></p> </td> </tr> <tr> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">60 kg</span></p> </td> <td style=\"width:126.45pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">108 mg</span></p> </td> <td style=\"width:148.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">21.6 mL</span></p> </td> <td style=\"width:136.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">2.16 vials</span></p> </td> </tr> <tr> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">80 kg</span></p> </td> <td style=\"width:126.45pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">144 mg</span></p> </td> <td style=\"width:148.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28.8 mL</span></p> </td> <td style=\"width:136.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">2.88 vials</span></p> </td> </tr> <tr> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">100 kg</span></p> </td> <td style=\"width:126.45pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">180 mg</span></p> </td> <td style=\"width:148.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">36 mL</span></p> </td> <td style=\"width:136.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3.6 vials</span></p> </td> </tr> <tr> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">120 kg<sup>c</sup></span></p> </td> <td style=\"width:126.45pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">180 mg<sup>\r   d</sup></span></p> </td> <td style=\"width:148.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">36 mL</span></p> </td> <td style=\"width:136.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3.6 vials</span></p> </td> </tr> </table> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">a.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">For a reduced dose, use\r 1.2 mg/kg for the calculation.</span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">b.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">To be diluted in 150 mL\r of diluent and administered by intravenous infusion over 30 minutes every\r 3 weeks.</span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">c.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">If patient\u2019s\r weight is more than 100 kg, the dose calculation should use 100 kg.</span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">d.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">The maximal recommended\r dose is 180 mg.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"margin-left:4.5pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 20: Sample calculations for patients receiving the recommended\r dose of 1.2 mg/kg of ADCETRIS for weights ranging from 60 kg to\r 120 kg as combination therapy or when a reduced dose is required<br/> <br/> </span></b></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\"> <tr> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Patient\r   weight (kg)</span></b></p> </td> <td style=\"width:126.45pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Total\r   dose = </span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">patient\r   weight multiplied by recommended dose [1.2 mg/kg<sup>a</sup>])</span></b></p> </td> <td style=\"width:148.8pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Total\r   volume to be diluted<sup>b</sup> = total dose divided by reconstituted\r   vial concentration [5 mg/mL])</span></b></p> </td> <td style=\"width:136.95pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Number\r   of vials needed = </span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">total\r   volume to be diluted divided by total volume per vial [10 mL/vial])</span></b></p> </td> </tr> <tr> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">60 kg</span></p> </td> <td style=\"width:126.45pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">72 mg</span></p> </td> <td style=\"width:148.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">14.4 mL</span></p> </td> <td style=\"width:136.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">1.44 vials</span></p> </td> </tr> <tr> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">80 kg</span></p> </td> <td style=\"width:126.45pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">96 mg</span></p> </td> <td style=\"width:148.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">19.2 mL</span></p> </td> <td style=\"width:136.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">1.92 vials</span></p> </td> </tr> <tr style=\"height:20.4pt\"> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:20.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">100 kg</span></p> </td> <td style=\"width:126.45pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:20.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">120 mg</span></p> </td> <td style=\"width:148.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:20.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">24 mL</span></p> </td> <td style=\"width:136.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:20.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">2.4 vials</span></p> </td> </tr> <tr> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">120 kg<sup>c</sup></span></p> </td> <td style=\"width:126.45pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">120 mg<sup>\r   d</sup></span></p> </td> <td style=\"width:148.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">24 mL</span></p> </td> <td style=\"width:136.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">2.4 vials</span></p> </td> </tr> </table> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">a.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">For a reduced dose, use\r 0.9 mg/kg for the calculation.</span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">b.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">To be diluted in\r 150 mL of diluent and administered by intravenous infusion over\r 30 minutes every 2 weeks as combination therapy or every 3 weeks when a\r reduced dose of the monotherapy is required.</span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">c.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">If patient\u2019s\r weight is more than 100 kg, the dose calculation should use 100 kg.</span></p> <p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">d.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">The maximal recommended\r dose for combination therapy is 120 mg.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Disposal</span></u></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">ADCETRIS is for single use only. </span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Any unused product or waste material should\r be disposed of in accordance with local requirements.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <h1 align=\"left\" style=\"text-align:left;page-break-after:avoid\"><span lang=\"EN-GB\">7.   MARKETING\r AUTHORISATION HOLDER</span></h1> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Takeda\r Pharma A/S</span></p> <p class=\"MsoNormal\"><span lang=\"DA\">Dybendal Alle 10</span></p> <p class=\"MsoNormal\"><span lang=\"DA\">2630 Taastrup</span></p> <p class=\"MsoNormal\"><span lang=\"DA\">Denmark </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <h1 align=\"left\" style=\"text-align:left;page-break-after:avoid\"><span lang=\"DA\">8.   MARKETING\r AUTHORISATION NUMBER </span></h1> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"DA\">EU/1/12/794/001</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <h1 align=\"left\" style=\"margin-left:17.85pt;text-align:left;text-indent:-17.85pt;\r page-break-after:avoid\"><span lang=\"EN-GB\">9.   DATE OF FIRST\r AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></h1> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of first authorisation: 25 October\r 2012</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of latest renewal: 19 September 2019</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <h1 align=\"left\" style=\"text-align:left;page-break-after:avoid\"><span lang=\"EN-GB\">10. DATE\r OF REVISION OF THE TEXT</span></h1> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Detailed information on this medicinal\r product is available on the website of the European Medicines Agency <a href=\"http://www.ema.europa.eu/\">http://www.ema.europa.eu</a></span></p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"/> </span> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif;text-transform:uppercase'>Annex\r II</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">A.      MANUFACTURERS OF THE BIOLOGICAL\r ACTIVE SUBSTANCE AND <span style=\"text-transform:uppercase\">manufacturerS\r responsible for batch release </span></span></b></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">B.      Conditions\r or restrictions regarding supply and use</span></b></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">C.      Other\r conditions and requirements of the marketing authorisation</span></b></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">D.      CONDITIONS\r OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL\r PRODUCT</span></b></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">E.      SPECIFIC\r OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL\r MARKETING AUTHORISATION</span></b></p> <p class=\"MsoNormal\"></p> <p class=\"NormalAgency\"></p> <p class=\"NormalAgency\"></p> <p class=\"TitleB\" style=\"page-break-before:always\"><span lang=\"EN-GB\">A.      MANUFACTURERS\r OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH\r RELEASE</span></p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Name and address of the manufacturers of\r the biological active substance </span></u></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Piramal Healthcare UK Ltd.</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Earls Road, Grangemouth</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stirlingshire, Scotland FK3 8XG</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">United Kingdom</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Lonza AG</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Lonzastrasse</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">3930 Visp</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Switzerland</span></p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><u><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Name\r and address of the manufacturers responsible for batch release</span></u></p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Takeda Austria GmbH</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">St. Peter\u2011Stra\u03b2e 25</span></p> <p class=\"MsoNormal\"><span lang=\"PT\">A\u20114020 Linz</span></p> <p class=\"MsoNormal\"><span lang=\"PT\">Austria</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"PT\">Delpharm Novara S.r.l.</span></p> <p class=\"MsoNormal\">Via Crosa, 86</p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">28065 Cerano (NO)</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Italy</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The printed package leaflet of the\r medicinal product must state the name and address of the manufacturer\r responsible for the release of the concerned batch.</span></p> <p class=\"NormalAgency\"></p> <p class=\"NormalAgency\"></p> <p class=\"TitleB\"><span lang=\"EN-GB\">B.      CONDITIONS OR\r RESTRICTIONS REGARDING SUPPLY AND USE</span></p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Medicinal\r product subject to restricted medical prescription (see Annex I: Summary of\r Product Characteristics, section 4.2).</span></p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p> <p class=\"NormalAgency\"></p> <p class=\"TitleB\"><span lang=\"EN-GB\">C.      OTHER\r CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><b><span lang=\"EN-GB\">Periodic safety update reports (PSURs) </span></b></p> <p class=\"MsoListParagraphCxSpLast\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The\r requirements for submission of PSURs for this medicinal product are set out in\r the list of Union reference dates (EURD list) provided for under Article\r 107c(7) of Directive 2001/83/EC and any subsequent updates published on the\r European medicines web-portal.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"TitleB\"><span lang=\"EN-GB\">D.      CONDITIONS OR\r RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p> <p class=\"DraftingNotesAgency\" style=\"margin-bottom:0in;line-height:normal\"></p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><b><span lang=\"EN-GB\">Risk management plan (RMP)</span></b></p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>The marketing\r authorisation holder (MAH) shall perform the required pharmacovigilance\r activities and interventions detailed in the agreed RMP presented in Module\r 1.8.2 of the marketing authorisation and any agreed subsequent updates of the\r RMP.</span></p> <p class=\"NormalAgency\"></p> <p class=\"NormalAgency\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>An updated RMP\r should be submitted:</span></p> <p class=\"NormalAgency\" style=\"margin-left:27.5pt;text-indent:-27.5pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>At\r the request of the European Medicines Agency; </span></p> <p class=\"NormalAgency\" style=\"margin-left:27.5pt;text-indent:-27.5pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Whenever\r the risk management system is modified, especially as the result of new\r information being received that may lead to a significant change to the benefit/risk\r profile or as the result of an important (pharmacovigilance or risk\r minimisation) milestone being reached</span></p> <p class=\"NormalAgency\"></p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p> <p class=\"TitleB\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">E.      <span style=\"text-transform:uppercase\">Specific Obligation to complete\r post-authorisation measures for the conditional marketing authorisation</span> </span></p> <p class=\"NormalAgency\" style=\"page-break-after:avoid\"></p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>This\r being a conditional marketing authorisation and pursuant to Article 14a(4) of\r Regulation (EC) No<span style=\"layout-grid-mode:line\"> 726/2004, the MAH shall\r complete, within the stated timeframe, the following measure:</span></span></p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"98%\"> <thead> <tr> <td style=\"width:55.38%;border:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"55%\"> <p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><b><span lang=\"EN-GB\">Description</span></b></p> </td> <td style=\"width:44.62%;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"44%\"> <p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><b><span lang=\"EN-GB\">Due date</span></b></p> </td> </tr> </thead> <tr> <td style=\"width:55.38%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"55%\"> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r   color:black'>To perform a single\u2011arm study in a similar patient\r   population as the sALCL population investigating response rate, duration of\r   response, rate of (second) ASCT and data in subpopulations (including but not\r   necessarily restricted to ALK status and age) based on a CHMP agreed protocol\r   (Study C25006).</span></p> </td> <td style=\"width:44.62%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"44%\"> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r   color:black'>Final Study Report by: Q4 2021</span></p> </td> </tr> </table> <p class=\"MsoNormal\"></p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"/> </span> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <h1><span lang=\"EN-GB\">ANNEX III</span></h1> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <h1><span lang=\"EN-GB\">LABELLING AND PACKAGE LEAFLET</span></h1> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"/> </span> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p class=\"TitleA\"><span lang=\"EN-GB\">A. LABELLING</span></p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"/> </span> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS\r TO APPEAR ON THE OUTER PACKAGING</span></b></p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"></p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">OUTER\r CARTON</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME\r OF THE MEDICINAL PRODUCT</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">ADCETRIS 50 mg powder for concentrate\r for solution for infusion</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">brentuximab vedotin</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       STATEMENT\r OF ACTIVE SUBSTANCE(S)</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Each vial contains 50 mg of\r brentuximab vedotin</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">After reconstitution each vial contains\r 5 mg/ml of brentuximab vedotin</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       LIST\r OF EXCIPIENTS</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Excipients: Ci</span><span lang=\"EN-GB\">tric\r acid monohydrate</span><span lang=\"EN-GB\">, s</span><span lang=\"EN-GB\">odium\r citrate dihydrate</span><span lang=\"EN-GB\">, </span><span lang=\"EN-GB\">\u03b1,\u03b1\u2011</span><span lang=\"EN-GB\">t</span><span lang=\"EN-GB\">rehalose dihydrate,</span><span lang=\"EN-GB\">\r p</span><span lang=\"EN-GB\">olysorbate 80</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">See package\r leaflet for further information</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL\r FORM AND CONTENTS</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Powder for\r concentrate for solution for infusion</span></i></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">1 vial</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       METHOD\r AND ROUTE(S) OF ADMINISTRATION</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">For intravenous use after reconstitution\r and dilution </span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">6.      SPECIAL\r WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">7.       OTHER\r SPECIAL WARNING(S), IF NECESSARY</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">8.       EXPIRY\r DATE</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"page-break-before:always;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Store in a refrigerator </span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not freeze</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the vial in the outer carton in order\r to protect from light.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">10.    SPECIAL PRECAUTIONS FOR\r DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH\r MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">For single use only</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">11.    NAME AND ADDRESS OF THE\r MARKETING AUTHORISATION HOLDER</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"PT\">Takeda Pharma A/S</span></p> <p class=\"MsoNormal\"><span lang=\"PT\">Dybendal Alle 10</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2630 Taastrup</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Denmark </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">12.    MARKETING AUTHORISATION\r NUMBER(S) </span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/12/794/001</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">13.    BATCH NUMBER</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Lot</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">14.    GENERAL CLASSIFICATION\r FOR SUPPLY</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicinal product subject to medical\r prescription</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">15.    INSTRUCTIONS ON USE</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">16.    INFORMATION IN BRAILLE</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Justification\r for not including Braille accepted</span></i></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.       UNIQUE\r IDENTIFIER \u2013 2D BARCODE</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">2D barcode\r carrying the unique identifier included.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.       UNIQUE\r IDENTIFIER - HUMAN READABLE DATA</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">PC: </span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN: </span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">NN:</span></p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"/> </span> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON SMALL\r IMMEDIATE PACKAGING UNITS</span></b></p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"></p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">VIAL LABEL</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">1.      NAME OF THE\r MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">ADCETRIS 50 mg powder for concentrate\r for solution for infusion</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">brentuximab vedotin</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">IV use</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">2.      METHOD OF\r ADMINISTRATION</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">For intravenous use after reconstitution\r and dilution </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">3.      EXPIRY DATE</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">4.      BATCH NUMBER</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Lot</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">5.      CONTENTS BY\r WEIGHT, BY VOLUME OR BY UNIT</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">50 mg</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">6.      OTHER</span></b></p> </div> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"/> </span> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p class=\"TitleA\"><span lang=\"EN-GB\">B. PACKAGE LEAFLET</span></p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"/> </span></b> <p class=\"MsoNormal\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Package\r leaflet: Information for the patient</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Adcetris\r 50 mg powder for concentrate for solution for infusion</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">brentuximab\r vedotin</span></b></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"><img alt=\"Description: Description: Description: BT_1000x858px\" border=\"0\" height=\"18\" id=\"Picture 2\" src=\"Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image009.gif\" width=\"21\"/></span><span lang=\"EN-GB\">This medicine is subject to additional monitoring. This will allow\r quick identification of new safety information. You can help by reporting any\r side effects you may get. See the end of section 4 for how to report side\r effects.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Read all\r of this leaflet carefully before you start using this medicine because it\r contains important information for you.</span></b></p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r page-break-after:avoid\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it\r again.</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">If you have any further questions, ask your\r doctor.</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">If you get any side effects, talk to your\r doctor. This includes any possible side effects not listed</span></p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:0in;page-break-after:avoid\"><span lang=\"EN-GB\">           in this\r leaflet. See section 4.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What is\r in this leaflet</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">1.       What Adcetris is and what it\r is used for</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">2.       What you need to know before\r you are given Adcetris</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">3.       How Adcetris will be given</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">4.       Possible side effects</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">5.       How to store Adcetris</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">6.       Contents of the pack and\r other information</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <p class=\"MsoHeading7\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">1.       What\r Adcetris is and what it is used for</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Adcetris contains the active substance <b>brentuximab\r vedotin</b>, an anti-cancer agent, which is made up of a monoclonal antibody\r linked to a substance intended to kill cancer cells. This substance is\r delivered to cancer cells by the monoclonal antibody. A monoclonal antibody is\r a protein which recognises certain cancer cells. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Hodgkin lymphoma, systemic anaplastic large\r cell lymphoma and cutaneous T\u2011cell lymphoma are types of cancer of the\r white blood cells.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Classical Hodgkin lymphoma expresses\r specific proteins on the cell surface that are different from non-classical\r Hodgkin lymphoma. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Adcetris is used to treat patients with advanced\r classical Hodgkin lymphoma who have not had treatment before.</span><span lang=\"EN-GB\"> Adcetris will be given to you together with doxorubicin,\r vinblastine and dacarbazine which are other chemotherapy medicines used to\r treat Hodgkin lymphoma. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Adcetris is used alone to lower the\r likelihood of classical Hodgkin lymphoma coming back after an autologous stem\r cell transplant in patients with certain risk factors.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Adcetris is also used alone to treat\r classical Hodgkin lymphoma that has:</span></p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">come back after or not responded to an infusion\r of your own healthy stem cells into your body (autologous stem cell\r transplant), or</span></p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">come back after or never responded to at least\r two previous therapies, and where you cannot receive additional combination\r anti-cancer treatments or have an autologous stem cell transplant.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Systemic anaplastic large cell lymphoma is\r a type of non\u2011Hodgkin lymphoma found in your lymph nodes and/or\r throughout other parts of your body.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Adcetris is used to treat patients with systemic\r anaplastic large cell lymphoma who have not had treatment before.</span><span lang=\"EN-GB\"> Adcetris will be given to you together with </span><span lang=\"EN-GB\">cyclophosphamide, doxorubicin and prednisone</span><span lang=\"EN-GB\">\r which are other chemotherapy medicines used to treat these conditions.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Adcetris is also used to treat systemic\r anaplastic large cell lymphoma that has:</span></p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">not responded to other types of anti-cancer\r treatments, or </span></p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">come back after previous anti-cancer treatment.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span style=\"color:windowtext\">Cutaneous T\u2011cell\r lymphoma is a cancer of a certain type of white blood cell called a \u2018T\u2011cell\u2019\r that mainly affects the skin. </span><span lang=\"EN-GB\" style=\"color:windowtext\">Adcetris\r is used to treat cutaneous T\u2011cell lymphoma where a specific type of\r protein is present on the cells\u2019 surface.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Adcetris is used\r to treat cutaneous T\u2011cell lymphoma in patients who have previously\r received at least one anti-cancer medicine that travels through the\r bloodstream.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"margin-right:17.65pt\"></p> <p class=\"MsoHeading7\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">2.       What\r you need to know before you are given Adcetris</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Do NOT\r use Adcetris if you</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">are allergic to brentuximab vedotin or any of\r the other ingredients of this medicine (listed in section 6). </span></p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">are currently using bleomycin, an anti-cancer\r agent. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Warnings\r and precautions</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">When you\r first receive this medicine and during the course of treatment, tell your\r doctor if you:</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">have confusion, trouble thinking, memory loss,\r blurred or loss of vision, decreased strength, decreased control or sensation\r in one arm or leg, a change in the way of walking, or loss of balance, as these\r may be symptoms of a serious and potentially fatal brain condition known as\r progressive multifocal leukoencephalopathy (PML). If you have these symptoms\r prior to treatment with this medicine, tell your doctor immediately about any\r changes in these symptoms. You should also inform your partner or caregivers\r about your treatment, since they may notice symptoms that you are not aware of</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">have severe and persistent stomach pain, with or\r without nausea and vomiting, as these may be symptoms of a serious and\r potentially fatal condition known as pancreatitis (inflammation of the\r pancreas)</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">have new or worsening shortness of breath or\r cough as these may be symptoms of a serious and potentially fatal lung\r complication (pulmonary toxicity)</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">are taking, or have previously taken, medicines\r which may affect your immune system, such as chemotherapy or immunosuppressive\r agents </span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">have, or think you have, an infection. Some\r infections may be serious and can be due to viruses, bacteria, or other causes\r that may be life-threatening</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">experience a whistling sound during breathing\r (wheezing)/difficulty breathing, hives, itching, or swelling (signs of an\r infusion reaction). For more detailed information, see \u201cInfusion reactions\u201d\r in section 4</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">have any problems with a change in the\r sensitivity of the skin, especially in the hands or feet, such as numbness,\r tingling, a burning sensation, pain, discomfort or weakness (neuropathy)</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">have headaches, feel tired, experience dizziness,\r look pale (anaemia), or have unusual bleeding or bruising under the skin,\r longer than usual bleeding after your blood has been drawn, or bleeding from\r your gums (thrombocytopenia) </span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">develop chills or shivering, or feel warm; you\r should take your temperature as you may have a fever. A fever with a low white\r blood cell count may be a sign of serious infection </span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">experience dizziness, decreased urination,\r confusion, vomiting, nausea, swelling, shortness of breath, or heart rhythm\r disturbances (this may be a potentially life-threatening complication known as\r tumour lysis syndrome)</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">experience flu-like symptoms followed by a\r painful red or purplish rash that spreads and blisters including extensive\r detachment of the skin that may be life-threatening (this may be a serious skin\r reaction known as Stevens-Johnson syndrome and toxic epidermal necrolysis)</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">have new or worsening stomach pain, nausea,\r vomiting, constipation as these may be symptoms of a serious and potentially\r fatal stomach or intestinal complication (gastrointestinal complications)</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">have abnormal liver test results as this may be\r related to a serious and potentially fatal liver injury (hepatotoxicity). Liver\r disease and other medical conditions that may have been present before you\r start taking Adcetris and some medications that you are currently taking might\r increase the risk of liver injury</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">feel tired, have frequent urination, increased\r thirst, increased appetite with unintended weight loss, or irritability\r (hyperglycaemia)</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">have kidney or liver problems</span></p> <p class=\"MsoListParagraph\" style=\"margin-left:31.5pt\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Your doctor will perform regular blood\r tests to make sure that it is safe for you to receive this medicine.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Other\r medicines and Adcetris</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor if you are taking any\r other medicines, if you have taken any recently, or if you start taking new ones.\r This includes herbal medicines and other medicines you can obtain without a\r prescription. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Pregnancy,\r breast\u2011feeding and fertility</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">You and your partner must use two methods\r of effective contraception during your treatment with this medicine. Women must\r continue using contraception for 6 months following the last dose of\r Adcetris.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">You should not use this medicine if you are\r pregnant unless you and your doctor decide that the benefit to you outweighs\r the potential risk to the unborn baby. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">It is important to tell your doctor before\r and during treatment if you are pregnant, think you may be pregnant, or are\r planning to get pregnant.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you are breast\u2011feeding, you should\r discuss with your doctor whether you should receive this medicine.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Men being treated with this medicine are\r advised to have sperm samples frozen and stored before treatment. Men are\r advised not to father a child during treatment with this medicine and for up to\r 6 months following the last dose of this medicine. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Driving\r and using machines</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Your treatment may influence your ability\r to drive or operate machines. If you feel unwell during treatment then do not\r drive or operate machines.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Adcetris\r contains sodium</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">This medicine\r contains 13.2 mg sodium (main component of cooking/table salt) in each\r vial. This is equivalent to 0.7% of the recommended maximum daily dietary\r intake of sodium for an adult</span><span lang=\"EN-GB\">.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoHeading7\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3.       How\r Adcetris will be given</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you have any questions on the use of\r this medicine, ask the doctor or nurse who is giving you the infusion. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Dose and\r frequency</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The dose of\r this medicine depends on your body weight. </span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">The usual dose of Adcetris given in combination\r with </span><span lang=\"EN-GB\">doxorubicin, vinblastine and dacarbazine</span><span lang=\"EN-GB\"> is </span><span lang=\"EN-GB\">1.2 mg/kg given every 2 weeks\r for 6 months. </span></p> <p class=\"MsoNormal\" style=\"margin-left:.25in;text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">The usual dose of Adcetris given in combination\r with cyclophosphamide, doxorubicin and prednisone is </span><span lang=\"EN-GB\">1.8 mg/kg\r given every 3 weeks for approximately 4\u20116 months.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">See the package\r leaflets for these medicines given in combination with Adcetris for additional\r information on their use and effects. After the first dose of Adcetris in\r combination with chemotherapy, your doctor may also give you a medicine that\r will help prevent development or reduce the severity of neutropenia (decrease\r of white blood cell count) which can increase the risk of infection. Tell your\r doctor </span><span lang=\"EN-GB\">if you have kidney or liver problems as your\r doctor may lower your starting dose or may not recommend Adcetris.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"></p> <p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">The usual dose of Adcetris given alone is\r 1.8 mg/kg, given once every 3 weeks for no more than one year. Your\r doctor may lower your starting dose to 1.2 mg/kg if you have kidney or\r liver problems.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Adcetris is to be given to adults only. It\r is not for use in children. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">How\r Adcetris is given</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">This medicine is given to you into a vein\r (intravenously) as an infusion. It is given by your doctor or nurse over\r 30 minutes. Your doctor or nurse will also monitor you during and after\r the infusion. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you have any other questions on the use\r of this medicine, ask your doctor.</span></p> <p class=\"MsoNormal\" style=\"margin-right:17.65pt\"></p> <p class=\"MsoNormal\" style=\"margin-right:17.65pt\"></p> <p class=\"MsoHeading7\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">4.       Possible\r side effects </span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Like all medicines, this medicine may cause\r side effects, although not everybody gets them. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Infusion\r reactions</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Medicines of\r this type (monoclonal antibodies) can cause infusion reactions such as:</span></p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">a rash </span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">shortness of breath</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">difficulty breathing</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">cough</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">a tight chest </span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">fever</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">back pain</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">chills</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">headache</span></p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">feeling sick (nausea) or being sick (vomiting).</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infusion\r reactions to this medicine may affect more than 1 in 10 people. </span></p> <p class=\"MsoDate\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In general, these types of reactions occur\r within minutes to several hours following completion of the infusion. However,\r they may develop more than several hours after completion of the infusion but\r this is uncommon. These infusion reactions can be serious or even fatal (known\r as an anaphylactic reaction). It is not known how frequently infusion-related\r reactions to this medicine are serious or fatal. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">You may be given other medicines such as </span></p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">anti-histamines, corticosteroids or paracetamol </span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">to help reduce any of the reactions above\r if you have already experienced these when receiving this type of medicine. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you think you have previously had a\r similar reaction, tell your doctor BEFORE you are given this medicine. </span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you develop infusion reactions (as\r stated previously), your doctor may stop giving this medicine and start support\r treatment.</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If your infusion is restarted, your doctor\r may increase the time over which your infusion is given so that you may be able\r to tolerate it better. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Tell your\r doctor straight away if you notice any of the following symptoms because some\r of them may be signs of a serious or possibly fatal condition:</span></b></p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">progressive multifocal leukoencephalopathy (PML)\r symptoms such as confusion, trouble thinking, memory loss, blurred or loss of\r vision, decreased strength, decreased control or sensation in one arm or leg, a\r change in the way of walking, or loss of balance (for more detailed\r information, see section 2) (affects less than 1 in 100 people)</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">symptoms of inflammation of the pancreas\r (pancreatitis) such as severe and persistent stomach pain, with or without\r nausea and vomiting (may affect up to 1 in 100 people).</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">shortness of breath or cough (may affect more\r than 1 in 10 people)</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">flu-like symptoms followed by a painful red or\r purplish rash that spreads and blisters including extensive detachment of the\r skin (may affect up to 1 in 100 people)</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">a change in feeling or sensitivity, especially\r in the skin, numbness, tingling, discomfort, a burning sensation, weakness, or\r pain in the hands or feet (neuropathy; may affect more than 1 in\r 10 people)</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">a feeling of weakness (may affect more than 1 in\r 10 people)</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">constipation (may affect more than 1 in\r 10 people)</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">diarrhoea, vomiting (may affect more than 1 in\r 10 people)</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">chills or shivering (may affect up to 1 in\r 10 people)</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">feeling tired, frequent urination, increased\r thirst, increased appetite with unintended weight loss, and irritability (these\r may be signs of hyperglycaemia, which may affect up to 1 in 10 people)</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">unusual bleeding or bruising under the skin,\r longer than usual bleeding after your blood has been drawn, or bleeding from\r your gums (these may be signs of thrombocyopenia which may affect up to 1 in\r 10 people)</span></p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">headaches, experience dizziness, look pale\r (these may be signs of anaemia, which may affect more than 1 in 10 people)</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">You may\r experience the following side effects:</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The\r following side effects have been reported with Adcetris alone:</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"margin-left:.25in;page-break-after:avoid\"><b><span lang=\"EN-GB\">Very common side effects</span></b><span lang=\"EN-GB\"> (may affect\r more than 1 in 10 people)</span></p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">decreased level of white blood cells</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">upper respiratory tract infection</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">decrease in weight</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">infection</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">nausea</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">abdominal pain</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">itching</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">muscle pain</span></p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">joint pain or painful, swollen joints</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"margin-left:.25in;page-break-after:avoid\"><b><span lang=\"EN-GB\">Common side effects</span></b><span lang=\"EN-GB\"> (may affect up to 1\r in 10 people)</span></p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">pneumonia</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">sore, creamy-yellow, raised patches in the mouth\r (thrush)</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">decreased level of blood platelets</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">dizziness</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">blisters which may crust or scab</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">increased level of blood sugar</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">increased liver enzyme levels </span></p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">unusual hair loss or thinning</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"margin-left:21.3pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Uncommon side effects</span></b><span lang=\"EN-GB\"> (may affect up to\r 1 in 100 people)</span></p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">Tumour lysis syndrome \u2013 a potentially-life\r threatening condition in which you may experience dizziness, decreased\r urination, confusion, vomiting, nausea, swelling, shortness of breath, or heart\r rhythm disturbances. </span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">new or recurring cytomegalovirus (CMV) infection</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">an infection in the blood (sepsis) and/or septic\r shock (a life-threatening form of sepsis)</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">Stevens-Johnson syndrome and toxic epidermal\r necrolysis - a rare, serious disorder in which you may experience flu-like\r symptoms followed by a painful red or purplish rash that spreads and blisters\r including extensive detachment of the skin </span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">decreased level of white blood cells with a fever</span></p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">damage to the nerves and nerve coverings\r (demyelinating polyneuropathy)</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The\r following side effects have been reported with Adcetris in combination with\r chemotherapy medicines:</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"margin-left:.25in;page-break-after:avoid\"><b><span lang=\"EN-GB\">Very common side effects</span></b><span lang=\"EN-GB\"> (may affect\r more than 1 in 10 people)</span></p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">decreased level of white blood cells</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">decreased level of blood platelets</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">decreased level of white blood cells with a\r fever</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">upper respiratory tract infection</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">decrease in weight</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">infection</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">nausea</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">abdominal pain</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">unusual hair loss or thinning</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">muscle pain</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">joint pain or painful, swollen joints</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">dizziness</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">decreased appetite</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">not being able to sleep</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">bone pain</span></p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">blisters which may crust or scab</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"></p> <p class=\"MsoNormal\" style=\"margin-left:.25in;page-break-after:avoid\"><b><span lang=\"EN-GB\">Common side effects</span></b><span lang=\"EN-GB\"> (may affect up to 1\r in 10 people)</span></p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">an infection in the blood (sepsis) and/or septic\r shock (a life-threatening form of sepsis); pneumonia</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">sore or inflammation in the mouth</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">sore, creamy-yellow, raised patches in the mouth\r (thrush)</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">itching</span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">increased level of blood sugar</span></p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">increased liver enzyme levels</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"margin-left:21.3pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Uncommon side effects</span></b><span lang=\"EN-GB\"> (may affect up to\r 1 in 100 people)</span></p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">Tumour lysis syndrome \u2013 a potentially-life\r threatening condition in which you may experience dizziness, decreased\r urination, confusion, vomiting, nausea, swelling, shortness of breath, or heart\r rhythm disturbances </span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">Stevens\u2011Johnson syndrome - a rare, serious\r disorder in which you may experience flu\u2011like symptoms followed by a\r painful red or purplish rash that spreads and blisters including extensive\r detachment of the skin </span></p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">new or recurring cytomegalovirus (CMV) infection</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">If you are an\r older patient (\u2265 65 years of age) you may experience serious\r adverse events more frequently. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Reporting\r of side effects</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you get any side effects, talk to your\r doctor. This includes any possible side effects not listed in this leaflet.</span><span lang=\"EN-GB\"> You can also report side effects directly via <span style=\"background:silver\">the national reporting system listed in </span></span><span lang=\"EN-GB\"><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background:silver\">Appendix V</span></a><a name=\"_Hlt351112648\"></a><a name=\"_Hlt351112647\"></a></span><span lang=\"EN-GB\">. By reporting side effects\r you can help provide more information on the safety of this medicine.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <p class=\"MsoHeading7\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">5.       How\r to store Adcetris </span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Keep this\r medicine out of the sight and reach of children.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not use this medicine after the expiry\r date which is stated on the vial label and the carton after EXP. The expiry\r date refers to the last day of that month. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Unopened vial:</span></b><span lang=\"EN-GB\"> Store in a refrigerator (2 \u00b0C\u20118 \u00b0C). Do not\r freeze.</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the vial in the original carton in\r order to protect from light. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Reconstituted/diluted solution:</span></b><span lang=\"EN-GB\">Use immediately or </span><span lang=\"EN-GB\">store\r in a refrigerator (2 </span><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b0</span><span lang=\"EN-GB\">C\u20118 \u00b0C) and use within 24 hours.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not use this medicine if you notice any\r particulate matter or discolouration prior to administration. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not throw away any medicines via\r wastewater or household waste. The doctor or nurse will dispose of this\r medicine. These measures will help protect the environment. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <p class=\"MsoHeading7\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">6.       Contents\r of the pack and other information</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What\r Adcetris contains</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">The active substance is brentuximab vedotin.\r Each vial contains 50 mg of brentuximab vedotin. After reconstitution each mL\r of solution contains </span><span lang=\"EN-GB\">5 mg of Adcetris. </span></p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">The other ingredients are citric acid\r monohydrate, sodium citrate dihydrate, \u03b1,\u03b1\u2011trehalose dihydrate,\r and polysorbate 80 See section 2 for further information about sodium. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What\r Adcetris looks like and contents of the pack</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Adcetris is a white to off-white cake or\r powder for concentrate for solution for infusion provided in a glass vial. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Each pack of Adcetris consists of one vial.\r </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><a name=\"_Hlk19873870\"><b><span lang=\"EN-GB\">Marketing\r Authorisation Holder</span></b></a></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Takeda Pharma A/S</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Dybendal Alle 10</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2630 Taastrup</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Denmark </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Manufacturer</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:silver\">Takeda Austria GmbH</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:silver\">St. Peter\u2011Stra\u03b2e 25</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"PT\" style=\"background:silver\">A\u20114020 Linz</span></p> <p class=\"MsoNormal\"><span lang=\"PT\" style=\"background:silver\">Austria</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"PT\">Delpharm Novara S.r.l.</span></p> <p class=\"MsoNormal\"><span lang=\"IT\">Via Crosa, 86</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">28065 Cerano (NO) </span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Italy</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">For any\r information about this medicine, please contact the local representative of the\r Marketing Authorisation Holder:</span></p> <p class=\"MsoNormal\"></p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\"> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"DE\" style=\"color:windowtext\">Belgi\u00eb/Belgique/Belgien</span></b></p> <p class=\"MsoNormal\"><span lang=\"DE\" style=\"color:windowtext\">Takeda Belgium</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"DE\" style=\"color:windowtext\">T\u00e9l/Tel: +32 2 464 06 11</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">takeda-belgium@takeda.com</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"FI\" style=\"color:windowtext\">Lietuva</span></b></p> <p class=\"MsoNormal\"><span lang=\"FI\" style=\"color:windowtext\">Takeda, UAB</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"FI\" style=\"color:windowtext\">Tel: +370 521 09 070</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"FI\" style=\"color:windowtext\">lt-info@takeda.com</span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p> <p class=\"MsoPlainText\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\r   \"Times New Roman\",serif'>\u0422\u0430\u043a\u0435\u0434\u0430\r   \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></p> <p class=\"MsoPlainText\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\r   \"Times New Roman\",serif'>\u0422\u0435\u043b.: + 359 2 958 27 36</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"DE\" style=\"color:windowtext\">Luxembourg</span></b><b><span lang=\"DE\" style=\"color:windowtext\">/Luxemburg</span></b></p> <p class=\"MsoNormal\"><span lang=\"DE\" style=\"color:windowtext\">Takeda Belgium</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"DE\" style=\"color:windowtext\">T\u00e9l:/Tel: +32 2 464 06 11</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">takeda-belgium@takeda.com<span class=\"MsoHyperlink\"></span></span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">\u010cesk\u00e1 republika</span></b></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Takeda\r   Pharmaceuticals </span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Czech Republic\r   s.r.o.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:windowtext\">Tel: + 420 23<span style=\"letter-spacing:1.9pt\">4</span>72<span style=\"letter-spacing:1.9pt\">2</span>722 </span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">Magyarorsz\u00e1g</span></b></p> <p class=\"MsoPlainText\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\r   \"Times New Roman\",serif'>Takeda Pharma Kft.</span></p> <p class=\"MsoPlainText\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\r   \"Times New Roman\",serif'>Tel.: +361 2707030</span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">Danmark</span></b></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">Takeda Pharma A/S</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">Tlf: +45 46 77 11 11</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"FI\" style=\"color:windowtext\">Malta</span></b></p> <p class=\"MsoPlainText\"><span lang=\"FI\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Takeda\r   Italia S.p.A.</span></p> <p class=\"MsoPlainText\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\r   \"Times New Roman\",serif'>Tel: +39 06 502601</span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r   page-break-after:avoid\"><b><span lang=\"DE\" style=\"color:windowtext\">Deutschland</span></b></p> <p class=\"MsoPlainText\"><span lang=\"DE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Takeda\r   GmbH</span></p> <p class=\"MsoPlainText\"><span lang=\"DE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Tel:\r   +49 (0) 800 825 3325</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"DE\" style=\"color:windowtext\">medinfo@takeda.de</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"SV\" style=\"color:windowtext\">Nederland</span></b></p> <p class=\"MsoPlainText\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Takeda\r   Nederland bv</span></p> <p class=\"MsoPlainText\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Tel:\r   +31 23 56 68 777</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"SV\" style=\"color:windowtext\">nl.medical.info@takeda.com</span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"PT-BR\" style=\"color:windowtext\">Eesti</span></b></p> <p class=\"MsoNormal\"><span lang=\"PT-BR\" style=\"color:windowtext\">Takeda Pharma AS</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"PT-BR\" style=\"color:windowtext\">Tel: +372 6177 669</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"NO-NYN\" style=\"color:windowtext\">Norge</span></b></p> <p class=\"MsoNormal\"><span lang=\"NO-NYN\" style=\"color:windowtext\">Takeda AS</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"NO-NYN\" style=\"color:windowtext\">Tlf: +47 6676 3030</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"NO-NYN\" style=\"color:windowtext\">infonorge@takeda.com</span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p> <p class=\"MsoNormal\"><span lang=\"NO-NYN\" style=\"color:windowtext\">TAKEDA </span><span lang=\"EN-GB\" style=\"color:windowtext\">\u0395\u039b\u039b\u0391\u03a3</span><span lang=\"EN-GB\" style=\"color:windowtext\">\u0391</span><span lang=\"NO-NYN\" style=\"color:windowtext\">.</span><span lang=\"EN-GB\" style=\"color:windowtext\">\u0395</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"NO-NYN\" style=\"color:windowtext\">T</span><span lang=\"EL\" style=\"color:windowtext\">\u03b7\u03bb</span><span lang=\"EN-GB\" style=\"color:windowtext\">: +30 210 6387800</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"DE\" style=\"color:windowtext\">gr.info@takeda.com</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"DE\" style=\"color:windowtext\">\u00d6sterreich</span></b></p> <p class=\"Default\"><span lang=\"DE\" style=\"font-size:11.0pt;color:windowtext\">Takeda\r   Pharma Ges.m.b.H. </span></p> <p class=\"MsoPlainText\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\r   \"Times New Roman\",serif'>Tel: +43 (0) 800 20 80 50 </span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"ES\" style=\"color:windowtext\">Espa\u00f1a</span></b></p> <p class=\"MsoNormal\"><span lang=\"ES\" style=\"color:windowtext\">Takeda\r   Farmac\u00e9utica Espa\u00f1a S.A</span></p> <p class=\"MsoPlainText\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\r   \"Times New Roman\",serif'>Tel: +34 </span><span style='font-size:11.0pt;\r   font-family:\"Times New Roman\",serif'>917 90 42 22</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">spain@takeda.com</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"PL\" style=\"color:windowtext\">Polska</span></b></p> <p class=\"MsoNormal\"><span lang=\"PL\" style=\"color:windowtext\">Takeda Pharma sp. z\r   o.o.</span></p> <p class=\"MsoNormal\"><span lang=\"FR\" style=\"color:windowtext\">Tel.: + 48 22 608\r   13 00</span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"FR\" style=\"color:windowtext\">France</span></b></p> <p class=\"MsoNormal\"><span lang=\"FR\" style=\"color:windowtext\">Takeda France </span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l</span><span lang=\"EN-GB\">:</span><span lang=\"FR\" style=\"color:windowtext\"> +33 1 46 25 16 16</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"PT-BR\" style=\"color:windowtext\">Portugal</span></b></p> <p class=\"MsoPlainText\"><span lang=\"PT-BR\" style='font-size:11.0pt;font-family:\r   \"Times New Roman\",serif'>Takeda Farmac\u00eauticos Portugal, Lda.</span></p> <p class=\"MsoNormal\"><span lang=\"FR\" style=\"color:windowtext\">Tel: + 351 21 120\r   1457</span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span style=\"color:windowtext\">Hrvats</span></b><b><span lang=\"EN-GB\" style=\"color:windowtext\">ka</span></b></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">Takeda Pharmaceuticals Croatia d.o.o.</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">Tel: +385 1 377 88 96</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">Rom\u00e2nia\r   </span></b></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Takeda\r   Pharmaceuticals SRL</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">Tel: +40 21 335 03 91</span></p> <p class=\"MsoNormal\" style=\"text-indent:28.35pt\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">Ireland</span></b></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Takeda Products\r   Ireland Limited</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Tel: +44 (0)1628\r   537 900</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"NO-NYN\" style=\"color:windowtext\">Slovenija</span></b></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"NO-NYN\" style=\"color:windowtext\">Takeda GmbH, Podru\u017enica Slovenija</span></p> <p class=\"MsoNormal\"><span lang=\"NO-NYN\" style=\"color:windowtext\">Tel: + 386 (0)\r   59 082 480</span></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">\u00cdsland</span></b></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Vistor hf. </span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi:</span><span lang=\"EN-GB\" style=\"color:windowtext\"> +354 535 7000</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">vistor@vistor.is</span></p> <p class=\"MsoNormal\" style=\"text-indent:28.35pt\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">Slovensk\u00e1 republika</span></b></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Takeda\r   Pharmaceuticals Slovakia s.r.o.</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Tel: +421 (2) 20\r   602 600</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoPlainText\" style=\"page-break-after:avoid\"><b><span lang=\"ES\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Italia </span></b></p> <p class=\"MsoPlainText\"><span lang=\"ES\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Takeda\r   Italia S.p.A.</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Tel: +39 06\r   502601</span></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"SV\" style=\"color:windowtext\">Suomi/Finland</span></b></p> <p class=\"MsoNormal\"><span lang=\"SV\" style=\"color:windowtext\">Takeda Oy</span></p> <p class=\"MsoNormal\"><span lang=\"SV\">Puh/Tel:</span><span lang=\"SV\" style=\"color:windowtext\"> +358 20 746 5000</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">infoposti@takeda.com</span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:windowtext\">A. POTAMITIS MEDICARE LTD</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:windowtext\">T\u03b7\u03bb: +357 22583333</span></p> <p class=\"MsoNormal\"><span lang=\"LV\" style=\"color:windowtext\">info@potamitismedicare.com</span></p> <p class=\"MsoNormal\"><span lang=\"LV\" style=\"color:windowtext\"><a href=\"mailto:info@potamitismedicare.com\"></a></span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"SV\" style=\"color:windowtext\">Sverige</span></b></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"SV\" style=\"color:windowtext\">Takeda Pharma AB</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"SV\" style=\"color:windowtext\">Tel: +46 8 731 28 00</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">infosweden@takeda.com</span></p> <p class=\"MsoNormal\" style=\"text-indent:28.35pt\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r   page-break-after:avoid\"><b><span lang=\"FI\" style=\"color:windowtext\">Latvija</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FI\" style=\"color:windowtext\">Takeda Latvia SIA</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FI\" style=\"color:windowtext\">Tel: +371 67840082</span></p> <p class=\"MsoNormal\" style=\"text-indent:28.35pt;page-break-after:avoid\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">United\r   Kingdom</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">Takeda UK Ltd</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">Tel: +44 (0)1628 537 900</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> </td> </tr> </table> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">This\r leaflet was last revised in</span></b></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">This medicine\r has been given \u2018conditional approval\u2019. This means that there is\r more evidence to come about this medicine.</span></p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The European\r Medicines Agency will review new information on this medicine at least every\r year and this leaflet will be updated as necessary.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Detailed information on this medicine is\r available on the European Medicines Agency website: </span><u><span lang=\"EN-GB\" style=\"color:blue\">http://www.ema.europa.eu/</span></u></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">----------------------------------------------------------------------------------------------------------------------</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The following information is intended for\r healthcare professionals only:</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Traceability</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">In order to\r improve the traceability of biological medicinal products, the name and the\r batch number of the administered product should be clearly recorded.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Disposal </span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Adcetris is for single use only. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Any unused product or waste material should\r be disposed of in accordance with local requirements.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Instructions\r for reconstitution </span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Each single use vial must be reconstituted\r with 10.5 mL of water for injections to a final concentration of\r 5 mg/mL. Each vial contains a 10% overfill giving 55 mg of Adcetris\r per vial and a total reconstituted volume of 11 mL.</span></p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">1.</span><span lang=\"EN-GB\">Direct the stream toward the wall of the vial\r and not directly at the cake or powder. </span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\">2.</span><span lang=\"EN-GB\">Gently swirl the vial to aid dissolution. DO NOT\r SHAKE. </span></p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\">3.</span><span lang=\"EN-GB\">The reconstituted solution in the vial is a\r clear to slightly opalescent, colourless solution with a final pH of 6.6. </span></p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">4.</span><span lang=\"EN-GB\">The reconstituted solution should be inspected\r visually for any foreign particulate matter and/or discolouration. In the event\r of either being observed, discard the medicinal product.</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Preparation\r of Infusion Solution</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The appropriate amount of reconstituted\r Adcetris must be withdrawn from the vial(s) and added to an infusion bag\r containing sodium chloride 9 mg/mL (0.9%) solution for injection in order\r to achieve a final concentration of 0.4\u20111.2 mg/mL Adcetris. The\r recommended diluent volume is 150 mL. The already reconstituted Adcetris\r can also be diluted into 5% dextrose for injection or Lactated Ringer's for\r injection. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Gently invert the bag to mix the solution\r containing Adcetris. DO NOT SHAKE. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Any portion left in the vial, after\r withdrawal of the volume to be diluted, must be disposed of in accordance with\r local requirements. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not add other medicinal products to the\r prepared Adcetris infusion solution or intravenous infusion set. The infusion\r line should be flushed following administration with sodium chloride\r 9 mg/mL (0.9%) solution for injection, 5% dextrose for injection, or\r Lactated Ringer's for injection. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Following dilution, infuse the Adcetris\r solution immediately at the recommended infusion rate. </span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Total storage time of the solution from\r reconstitution to infusion should not exceed 24 hours.</span></p> </div>", "ID": "5e28ec10-a96d-47c4-ab03-42178b2c86a0", "Styles": "None", "Classes": "['WordSection1']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ", "ParentId": "de41543b-e580-42ab-9af7-b39256d1a2f5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "c27ca2ac-fccf-479b-9d1c-423295424271", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "bfba1ebf-c366-4d7e-af39-11866a8382c9", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "f2894aa4-c9cd-4f0f-b73e-1a870f556dba", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "e9bea67a-08a5-4c37-a09e-8d3863eee466", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "ade1882c-8191-4c64-b1d4-a21eea042d8b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "3b76dcb3-c272-4d49-80d5-f2ba994bd926", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "f2eaac15-e33e-48d1-a36f-855d8891633c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "f60422d2-112d-420b-9bd2-c1d36d96d951", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "20bb5ac4-9706-4fc5-9c92-b7a3084d0294", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "10ec9ace-ecd9-4466-955f-9d4ba945c0bb", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "98466f5a-7ceb-4d6b-9ca7-c4bea0db1af5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "8f80ee26-6c9e-4d27-982a-545e59b784b0", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "96f81efb-a8f9-4070-b363-0f76fc02ba17", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "87a8a641-6993-4a74-9546-cba1e6f16559", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "d6461806-7e4c-4a8d-9526-7ce8d4bc0b37", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "07463396-a697-4999-9b6f-6c4d0ea626f0", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "8d4b44ea-3ee0-4107-a610-c566baaeab7c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "dfa16ade-fd10-4682-a465-a28a312c68e4", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "abdc9d8f-2bd8-4dca-94f8-023446a08fc1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "c766d86f-e380-4e4c-911f-e5ffe52b285b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "657541bc-8c0d-4910-b3d0-93f930917e4a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "18d3849f-281b-47bb-93fb-30aad5299b0b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "998da1be-41f4-4c47-8892-f5b9c97f56b1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h1><span lang=\"EN-GB\">ANNEX I </span></h1>", "ID": "9255977e-8584-43df-92ed-4cdb1f5c78eb", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": null, "Text": "ANNEX I ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "95132385-44d7-4f95-9637-6a62cc61214c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TitleA\"><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS</span></p>", "ID": "49995fbe-e986-4df5-b68d-3e5eb994781b", "Styles": "None", "Classes": "['TitleA']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "SUMMARY OF PRODUCT CHARACTERISTICS", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:green'><br clear=\"all\" style=\"page-break-before:always\"/> </span>", "ID": "6a5e7956-fad5-45ad-919d-d8e041ae4198", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\r\ncolor:green", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": " ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "be54b3ff-fb0c-4de4-8b24-1ba149f593e5", "Styles": "page-break-before:always", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "6a5e7956-fad5-45ad-919d-d8e041ae4198"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\"><img alt=\"Description: Description: Description: BT_1000x858px\" height=\"18\" id=\"Picture 1\" src=\"Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image001.gif\" width=\"21\"/>This medicinal\r product is subject to additional monitoring. This will allow quick\r identification of new safety information. Healthcare professionals are asked to\r report any suspected adverse reactions. See section 4.8 for how to report\r adverse reactions.</span></p>", "ID": "cc8785fd-4271-43d4-9cf8-de75c12a83c8", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "This medicinal\r product is subject to additional monitoring. This will allow quick\r identification of new safety information. Healthcare professionals are asked to\r report any suspected adverse reactions. See section 4.8 for how to report\r adverse reactions.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "0c019d83-4fc4-4b4a-b393-1632244e0359", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "87f04047-2dff-4e86-8462-62dd875629a8", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h2 style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>1.</span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>NAME\r OF THE MEDICINAL PRODUCT</span></h2>", "ID": "ac4b35b3-84f2-4f88-a266-3d56c208f04f", "Styles": "margin-left:.5in;text-indent:-.5in", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "1.NAME\r OF THE MEDICINAL PRODUCT", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "6e516222-c246-46dc-817f-73b2173a4c0e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">ADCETRIS 50 mg powder for concentrate\r for solution for infusion.</span></p>", "ID": "3bdc62c2-8f10-47f9-b4dd-c2053224e9dd", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "ADCETRIS 50 mg powder for concentrate\r for solution for infusion.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"></p>", "ID": "6f923775-1afd-42f8-8059-c0e9f7402eff", "Styles": "text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"></p>", "ID": "d13c5d8e-0045-4369-88c5-f8afefaa7c10", "Styles": "text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h2><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>2.       QUALITATIVE\r AND QUANTITATIVE COMPOSITION</span></h2>", "ID": "3a7d64db-a350-4fe8-a729-585aa278f921", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "2.       QUALITATIVE\r AND QUANTITATIVE COMPOSITION", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "2a813ec1-52a2-461d-bbfd-3be957f53bba", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Each vial contains 50 mg of\r brentuximab vedotin. </span></p>", "ID": "f528fa9f-00d9-474e-bdd3-18849a91a512", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Each vial contains 50 mg of\r brentuximab vedotin. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "3027e3c5-7911-4bc4-8353-fefea4d41e30", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">After reconstitution (see section 6.6),\r each mL contains 5 mg of brentuximab vedotin.</span></p>", "ID": "3edb3896-f7b3-4922-ae25-96f852a31b4d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "After reconstitution (see section 6.6),\r each mL contains 5 mg of brentuximab vedotin.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "1d7dad85-94f1-4502-bcb0-a8bd9998de66", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">ADCETRIS is an antibody\u2011drug\r conjugate composed of a CD30\u2011directed monoclonal antibody (recombinant\r chimeric immunoglobulin G1 [IgG1], produced by recombinant DNA technology in\r Chinese Hamster ovary cells) that is covalently linked to the antimicrotubule\r agent monomethyl auristatin E (MMAE).</span></p>", "ID": "96c891ce-faee-4f20-86a1-680e4e041f2f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "ADCETRIS is an antibody\u2011drug\r conjugate composed of a CD30\u2011directed monoclonal antibody (recombinant\r chimeric immunoglobulin G1 [IgG1], produced by recombinant DNA technology in\r Chinese Hamster ovary cells) that is covalently linked to the antimicrotubule\r agent monomethyl auristatin E (MMAE).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "bf8e79f5-f0a0-4364-8191-abc14c6e03c8", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Excipient with known effect</span></u></p>", "ID": "8af11f14-c241-4432-9fd5-08c4faf0d3f4", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Excipient with known effect", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "89690839-b1c7-4769-a6be-d05792ef9759", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Each vial contains approximately\r 13.2 mg of sodium. </span></p>", "ID": "b1252965-9fff-46e9-a2e0-3420f199ba04", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Each vial contains approximately\r 13.2 mg of sodium. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "1d822f15-e1c1-4550-a2ba-0bc12e6b2abc", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For the full list of excipients, see section 6.1.</span></p>", "ID": "9ecd6c16-d916-4cb9-9b61-8db994d94ba9", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "For the full list of excipients, see section 6.1.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "c1f48685-ee74-45fd-a446-9216f735a9fe", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "4a82c1f3-c3e9-4a2d-863d-1a10f95aafc9", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h2><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>3.       PHARMACEUTICAL\r form</span></h2>", "ID": "9400b2a8-af7f-463b-8d42-99998b85ea0e", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "3.       PHARMACEUTICAL\r form", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r page-break-after:avoid;text-autospace:none\"></p>", "ID": "2cd9d883-be93-4fbb-b7ec-24aa6300dc6e", "Styles": "text-align:justify;text-justify:inter-ideograph;\r\npage-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\">Powder for concentrate for solution for\r infusion.</span></p>", "ID": "2ae98b87-a000-46d7-bfb8-095f2dc9161c", "Styles": "text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Powder for concentrate for solution for\r infusion.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"></p>", "ID": "0a1213c7-a338-46eb-80b4-aa07c0293e7c", "Styles": "text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><span lang=\"EN-GB\">White to off\u2011white cake or powder. </span></p>", "ID": "f4775641-6e54-48aa-bb9e-8ebbb6b28229", "Styles": "text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "White to off\u2011white cake or powder. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"></p>", "ID": "3aa1e0c0-e58d-41c5-9c76-e6fa2d156865", "Styles": "text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "781ec68b-c23b-4181-982b-892e8596fe8f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h2><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>4.       Clinical\r particulars</span></h2>", "ID": "9745c890-eb22-451b-922b-2214296f95c5", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "4.       Clinical\r particulars", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "aef77f13-11fa-4780-83e2-b634d518d8bb", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h3><span lang=\"EN-GB\">4.1     Therapeutic indications</span></h3>", "ID": "243ff1b6-e974-441b-89c8-320d6d265980", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "4.1     Therapeutic indications", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><a name=\"OLE_LINK2\"></a><a name=\"OLE_LINK5\"></a></p>", "ID": "0b676044-d14d-467d-8045-a5895c3c0b61", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hodgkin\r lymphoma</span></u></p>", "ID": "4bd5f52f-050d-4313-b363-9aa96b810995", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Hodgkin\r lymphoma", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "f9d15c8d-8eef-4de8-beee-bcf2f7dd76e0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">ADCETRIS is indicated for adult patients\r with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in\r combination with doxorubicin, vinblastine and dacarbazine (AVD) (see sections 4.2 and 5.1).</span></p>", "ID": "3766bff7-fe63-40c5-bd1b-126476b1c491", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "ADCETRIS is indicated for adult patients\r with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in\r combination with doxorubicin, vinblastine and dacarbazine (AVD) (see sections 4.2 and 5.1).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoPlainText\"></p>", "ID": "e12e7314-93ff-4b09-9173-62d2dc550506", "Styles": "None", "Classes": "['MsoPlainText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">ADCETRIS is indicated for the treatment of adult patients with CD30+ HL\r at increased risk of relapse or progression following </span><span style=\"font-size:11.0pt\">autologous stem cell transplant</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> (ASCT) (see section 5.1).</span></p>", "ID": "dde549f5-549d-4caf-8e53-5311ba377f22", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "ADCETRIS is indicated for the treatment of adult patients with CD30+ HL\r at increased risk of relapse or progression following autologous stem cell transplant (ASCT) (see section 5.1).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "c9065535-6535-41a7-b63f-56fcaea3e5ab", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoPlainText\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\r \"Times New Roman\",serif'>ADCETRIS is indicated for the treatment of adult\r patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): </span></p>", "ID": "ef37a948-0f6d-4e27-9ad5-caa050560504", "Styles": "None", "Classes": "['MsoPlainText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "ADCETRIS is indicated for the treatment of adult\r patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoPlainText\" style=\"margin-left:66.55pt;text-indent:-.25in\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1.</span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>following\r ASCT, or</span></p>", "ID": "b49de249-9d06-454d-b605-e66c670c32ae", "Styles": "margin-left:66.55pt;text-indent:-.25in", "Classes": "['MsoPlainText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "1.following\r ASCT, or", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoPlainText\" style=\"margin-left:66.55pt;text-indent:-.25in\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>2.</span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>following\r at least two prior therapies when ASCT or multi-agent chemotherapy is not a\r treatment option.</span></p>", "ID": "c591880e-232d-4347-a436-68d7ab4e3182", "Styles": "margin-left:66.55pt;text-indent:-.25in", "Classes": "['MsoPlainText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "2.following\r at least two prior therapies when ASCT or multi-agent chemotherapy is not a\r treatment option.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "9c2aa06f-6872-401a-9d44-5b35a3f67da6", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Systemic anaplastic large cell lymphoma</span></u></p>", "ID": "04f488c3-fb70-45c2-b001-5e9225ccfc5b", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Systemic anaplastic large cell lymphoma", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "4ea0b069-d1d0-4425-991f-c091aa5583e5", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">ADCETRIS in combination with cyclophosphamide, doxorubicin and\r prednisone (CHP) is indicated for adult patients with previously untreated systemic\r anaplastic large cell lymphoma (sALCL) (see section 5.1).</span></p>", "ID": "9aab0b17-2a0b-44dc-b297-8ace7ab79cde", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "ADCETRIS in combination with cyclophosphamide, doxorubicin and\r prednisone (CHP) is indicated for adult patients with previously untreated systemic\r anaplastic large cell lymphoma (sALCL) (see section 5.1).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "0cc812e5-89f3-4a02-9398-266c5e38c15e", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">ADCETRIS is indicated for the treatment of adult patients with relapsed\r or refractory sALCL.</span></p>", "ID": "1904b61a-1e38-4a78-b0a6-d18ff03530dc", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "ADCETRIS is indicated for the treatment of adult patients with relapsed\r or refractory sALCL.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "d58be319-1ced-4f67-af7b-238fe23ddea0", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Cutaneous T\u2011cell lymphoma </span></u></p>", "ID": "5e0fea58-8fb2-4e44-9ef7-a7d5a4be28e9", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Cutaneous T\u2011cell lymphoma ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "4637b6b9-6513-4027-8395-bf6a3d1f0763", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">ADCETRIS is indicated for the treatment of adult patients with CD30+\r cutaneous T\u2011cell lymphoma (CTCL) after at least 1 prior systemic therapy (see\r section 5.1).</span></p>", "ID": "7d06b77e-3171-490d-b1d9-ae04407dd260", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "ADCETRIS is indicated for the treatment of adult patients with CD30+\r cutaneous T\u2011cell lymphoma (CTCL) after at least 1 prior systemic therapy (see\r section 5.1).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "6af436c5-004c-421a-8d6a-80f965fe38b9", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h3><span lang=\"EN-GB\">4.2     Posology and method of\r administration</span></h3>", "ID": "58f1c89f-9ebe-48b1-bd33-3f6c3512bad8", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "4.2     Posology and method of\r administration", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "9784a71d-4757-4e63-8c9a-cf82dc49ada5", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">ADCETRIS should\r be administered under the supervision of a physician experienced in the use of\r anti\u2011cancer agents.</span></p>", "ID": "32435789-c537-4d77-ac26-addc597d2cd3", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "ADCETRIS should\r be administered under the supervision of a physician experienced in the use of\r anti\u2011cancer agents.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "79153193-5b32-4e9c-8355-658ff0c96dba", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology</span></u></p>", "ID": "98ab6a7b-5244-4e45-8c61-a4ce3bdaebea", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Posology", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span lang=\"EN-GB\"></span></u></b></p>", "ID": "2ae3a4f6-63da-4d5f-bd21-5ab602505cd5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Previously\r Untreated HL</span></i></p>", "ID": "785f6f77-d6ab-4d2b-9222-5dbf7883d7b4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Previously\r Untreated HL", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "c960b3ec-316f-4351-a4eb-db4d28bec6e0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended dose in combination with\r chemotherapy (doxorubicin [A], vinblastine [V] and dacarbazine [D] [AVD]) is\r 1.2 mg/kg administered as an intravenous infusion over 30 minutes on\r days 1 and 15 of each 28\u2011day cycle for 6 cycles (see section 5.1).</span></p>", "ID": "72ce46b5-13e2-4207-94dc-b41a48e4201b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The recommended dose in combination with\r chemotherapy (doxorubicin [A], vinblastine [V] and dacarbazine [D] [AVD]) is\r 1.2 mg/kg administered as an intravenous infusion over 30 minutes on\r days 1 and 15 of each 28\u2011day cycle for 6 cycles (see section 5.1).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "1e5ea776-359e-4a05-ad19-04423143d9d0", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Primary prophylaxis with growth factor\r support (G-CSF), beginning with the first dose, is recommended for all patients\r with previously untreated HL receiving combination therapy (see section 4.4).</span></p>", "ID": "7dd55980-db9c-45aa-8353-205a70edf9b5", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Primary prophylaxis with growth factor\r support (G-CSF), beginning with the first dose, is recommended for all patients\r with previously untreated HL receiving combination therapy (see section 4.4).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "7fe829a0-9b98-4a68-83cd-f68b59b7e0cd", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Refer to the summary of product\r characteristics (SmPC) of chemotherapy agents given in combination with\r ADCETRIS for patients with previously untreated HL. </span></p>", "ID": "8f11e168-5581-4809-8d26-9f45b9ca093a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Refer to the summary of product\r characteristics (SmPC) of chemotherapy agents given in combination with\r ADCETRIS for patients with previously untreated HL. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "c8929ed2-4e07-4011-8c42-798d80af27d4", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">HL at\r increased risk of relapse or progression </span></i></p>", "ID": "9d28bec7-c658-42cc-9d52-1bb8730cb5d5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "HL at\r increased risk of relapse or progression ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"></span></u></i></p>", "ID": "b14fd12c-0df2-4ebc-adf8-cb0f4f5586ea", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended dose is 1.8 mg/kg\r administered as an intravenous infusion over 30 minutes every 3 weeks.</span></p>", "ID": "60249187-2e89-4aa4-a221-d28926b4c55a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The recommended dose is 1.8 mg/kg\r administered as an intravenous infusion over 30 minutes every 3 weeks.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "860aeca6-0f55-403a-b44c-e9523a8e8749", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">ADCETRIS treatment should start following\r recovery from ASCT based on clinical judgment. These patients should receive up\r to 16 cycles (see section 5.1).</span></p>", "ID": "2c2c6674-70e4-421c-9d64-3602e937e8c3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "ADCETRIS treatment should start following\r recovery from ASCT based on clinical judgment. These patients should receive up\r to 16 cycles (see section 5.1).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "f7857e6d-16b9-421f-bb73-0f4e1851c715", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Relapsed\r or refractory HL</span></i></p>", "ID": "5d7a8180-e4bc-4c84-b4f6-40318ea02881", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Relapsed\r or refractory HL", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "fc8f2412-6f40-4d14-b4c8-ca107c55513a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended dose is 1.8 mg/kg\r administered as an intravenous infusion over 30 minutes every\r 3 weeks.</span></p>", "ID": "e34f9b43-b67a-46f2-959f-5d13d0f40fe8", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The recommended dose is 1.8 mg/kg\r administered as an intravenous infusion over 30 minutes every\r 3 weeks.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "f5fd3564-92c5-4f7d-893a-e2866aa631e3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended starting dose for the\r retreatment of patients who have previously responded to treatment with\r ADCETRIS is 1.8 mg/kg administered as an intravenous infusion over\r 30 minutes every 3 weeks. Alternatively, treatment may be started at\r the last tolerated dose (see section 5.1).</span></p>", "ID": "02f367ab-66b2-4187-8a99-47caf1097591", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The recommended starting dose for the\r retreatment of patients who have previously responded to treatment with\r ADCETRIS is 1.8 mg/kg administered as an intravenous infusion over\r 30 minutes every 3 weeks. Alternatively, treatment may be started at\r the last tolerated dose (see section 5.1).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "4f821a9c-175b-41e9-b572-033a8252d0e5", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><a name=\"OLE_LINK6\"></a><a name=\"OLE_LINK7\"><span lang=\"EN-GB\">Treatment should be continued until disease progression or\r unacceptable toxicity<sup> </sup>(see section 4.4).</span></a></p>", "ID": "8b7c46ee-eee4-47f1-9d73-8ae1738f5bb6", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Treatment should be continued until disease progression or\r unacceptable toxicity (see section 4.4).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "eef3a202-be7e-493a-bf33-df99d7da0310", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients who achieve stable disease or\r better should receive a minimum of 8 cycles and </span><span lang=\"EN-GB\">up\r to a maximum of 16 cycles (approximately 1 year) (see section 5.1).\r </span></p>", "ID": "cd8d8a5f-56db-40eb-a192-40dedc5224dc", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Patients who achieve stable disease or\r better should receive a minimum of 8 cycles and up\r to a maximum of 16 cycles (approximately 1 year) (see section 5.1).\r ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "ed4db7bd-4421-4c96-8acc-64efa23321fe", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Previously\r untreated sALCL</span></i></p>", "ID": "2b1b2b7c-c546-4e4c-ae4f-af611e9d8000", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Previously\r untreated sALCL", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "ed416b56-b60e-47de-b2db-8da50e751974", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended dose in combination with\r chemotherapy (cyclophosphamide [C], doxorubicin [H] and prednisone [P] [CHP])\r is 1.8 mg/kg administered as an intravenous infusion over 30 minutes\r every 3 weeks for 6 to 8 cycles </span><span lang=\"EN-GB\">(see\r section 5.1). </span></p>", "ID": "edc22157-e38a-450e-b479-96cd33546d8d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The recommended dose in combination with\r chemotherapy (cyclophosphamide [C], doxorubicin [H] and prednisone [P] [CHP])\r is 1.8 mg/kg administered as an intravenous infusion over 30 minutes\r every 3 weeks for 6 to 8 cycles (see\r section 5.1). ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "ddcd41f4-62bb-4f60-a20d-e8265c1fe965", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Primary prophylaxis with G-CSF, beginning\r with the first dose, is recommended for all patients </span><span lang=\"EN-GB\">with\r previously untreated sALCL receiving combination therapy (see\r section 4.4).</span></p>", "ID": "da1ff342-5d7a-45e3-b0a6-04610a22ecb5", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Primary prophylaxis with G-CSF, beginning\r with the first dose, is recommended for all patients with\r previously untreated sALCL receiving combination therapy (see\r section 4.4).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "802d8773-1431-4f4c-bca9-bfaea12e4393", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Refer to the SmPCs of chemotherapy agents\r given in combination with ADCETRIS for patients with previously untreated sALCL.\r </span></p>", "ID": "97ef4c2c-3907-4f96-b223-a0c9a135ec54", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Refer to the SmPCs of chemotherapy agents\r given in combination with ADCETRIS for patients with previously untreated sALCL.\r ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "4e6744c8-48bb-4228-9319-88e1d3384576", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Relapsed\r or refractory sALCL</span></i></p>", "ID": "6138446f-fb63-4598-9cc6-30b32de6bae5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Relapsed\r or refractory sALCL", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "7009de69-f6c6-4c8b-81b3-c6e8d3937c7d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended dose is 1.8 mg/kg\r administered as an intravenous infusion over 30 minutes every\r 3 weeks.</span></p>", "ID": "fd8163e4-9822-4199-b3d5-b7bb2b149627", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The recommended dose is 1.8 mg/kg\r administered as an intravenous infusion over 30 minutes every\r 3 weeks.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "9af8f7f8-4c59-4cf6-bbd0-59981e27c5cc", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended starting dose for the\r retreatment of patients who have previously responded to treatment with\r ADCETRIS is 1.8 mg/kg administered as an intravenous infusion over\r 30 minutes every 3 weeks. Alternatively, treatment may be started at\r the last tolerated dose (see section 5.1).</span></p>", "ID": "5d8ba817-90db-4916-9b20-c8e0f8c4ad07", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The recommended starting dose for the\r retreatment of patients who have previously responded to treatment with\r ADCETRIS is 1.8 mg/kg administered as an intravenous infusion over\r 30 minutes every 3 weeks. Alternatively, treatment may be started at\r the last tolerated dose (see section 5.1).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "7af5d51c-606f-48ef-929e-0cd83025fbcd", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Treatment should be continued until disease\r progression or unacceptable toxicity<sup> </sup>(see section 4.4).</span></p>", "ID": "57203674-bcc0-4606-9953-332584abebe5", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Treatment should be continued until disease\r progression or unacceptable toxicity (see section 4.4).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "35d583a5-2d21-45d0-855b-0bb379f82df9", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients who achieve stable disease or\r better should receive a minimum of 8 cycles and up to a maximum of\r 16 cycles (approximately 1 year) (see section 5.1). </span></p>", "ID": "0fd14056-9632-4dac-a1d7-2b135b10e94f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Patients who achieve stable disease or\r better should receive a minimum of 8 cycles and up to a maximum of\r 16 cycles (approximately 1 year) (see section 5.1). ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "8b1c5d09-dd1b-4ac9-a4e0-95517725254e", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">CTCL</span></i></p>", "ID": "d97e4395-dd8d-4213-b860-2c9e2a845ee4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "CTCL", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "cf7b35a6-9e89-4a8e-89e6-0b5ac8fe42ac", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The recommended dose is 1.8 mg/kg\r administered as an intravenous infusion over 30 minutes every\r 3 weeks.</span></p>", "ID": "02ec8b5e-b88b-4c83-8487-aa19a6afa7e4", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The recommended dose is 1.8 mg/kg\r administered as an intravenous infusion over 30 minutes every\r 3 weeks.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "47c3b801-97d3-40db-a171-3bc90e2d63ea", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients with CTCL should receive up to 16\r cycles (see section 5.1).</span></p>", "ID": "04ca98b3-1d79-4c3b-9e6f-c84c6e57c0d8", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Patients with CTCL should receive up to 16\r cycles (see section 5.1).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "f0572f26-e42c-4590-97e6-e0392ca9114d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">General</span></i></p>", "ID": "15b16068-3fb6-4ca8-bfcb-1d2bdbb12d69", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "General", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "1cca410e-a3f9-453c-9a23-51a602e9f63c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">If the\r patient\u2019s weight is more than 100 kg, the dose calculation should\r use 100 kg (see section 6.6).</span></p>", "ID": "b6699be6-5103-403b-bc85-9511488e2eb2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "If the\r patient\u2019s weight is more than 100 kg, the dose calculation should\r use 100 kg (see section 6.6).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "dd02c42c-7f75-4b1f-a458-b5c785854881", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Complete blood\r counts should be monitored prior to administration of each dose of this\r treatment (see section 4.4). </span></p>", "ID": "338efed6-7ace-4f3c-855d-e3893cc0fcdf", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Complete blood\r counts should be monitored prior to administration of each dose of this\r treatment (see section 4.4). ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "7a760168-ed06-409c-a794-8bc32fcebea0", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Patients should\r be monitored during and after infusion (see section 4.4). </span></p>", "ID": "b9d8c666-4e75-440d-9106-66aa26724eb2", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Patients should\r be monitored during and after infusion (see section 4.4). ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "6289a1b7-a523-4103-9c28-b5f76de5cbde", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Dose\r adjustments</span></u></p>", "ID": "eeca2037-ce79-4dbc-808d-65a558fd4f59", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Dose\r adjustments", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"></p>", "ID": "1a9e9716-2fbd-45b0-beb0-2ffe51855b18", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Neutropenia</span></i></p>", "ID": "715c0f8d-d4b6-40ec-8872-f587d349d651", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Neutropenia", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "c10881de-284b-478f-b328-7a8ccd562a75", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">If\r neutropenia develops during treatment it should be managed by dose delays. See\r Table 1 and Table 2 for appropriate dosing recommendations for\r monotherapy and combination therapy, respectively (see also section 4.4). </span></p>", "ID": "f5ef3b4c-a0c1-4b7a-98c6-554aaacf4707", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "If\r neutropenia develops during treatment it should be managed by dose delays. See\r Table 1 and Table 2 for appropriate dosing recommendations for\r monotherapy and combination therapy, respectively (see also section 4.4). ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "bfaaf740-e617-410b-972b-0c4d9e426ede", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 1:\r Dosing recommendations for neutropenia with monotherapy<br/> <br/> </span></b></p>", "ID": "cbd7edc0-8b81-4e42-ae95-f56270619270", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 1:\r Dosing recommendations for neutropenia with monotherapy  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:99.22%;margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"99%\"> <tr> <td style=\"width:37.12%;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"37%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><a name=\"_Hlk8891520\"><b><span lang=\"EN-GB\">Severity grade of\r   neutropenia</span></b></a></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">(signs and symptoms </span></b><span lang=\"EN-GB\">[abbreviated\r   description of CTCAE<sup>a</sup>])</span></p> </td> <td style=\"width:62.88%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"62%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Modification of dosing schedule</span></b></p> </td> </tr> <tr> <td style=\"width:37.12%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"37%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"SV\">Grade 1\r   (&lt; LLN\u20111500/mm<sup>3</sup></span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"SV\">           \r      &lt; LLN\u20111.5 x 10<sup>9</sup>/L) or</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Grade 2\r   (&lt; 1500\u20111000/mm<sup>3</sup></span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup></sup><span lang=\"EN-GB\">&lt; 1.5\u20111.0 x 10<sup>9</sup>/L)</span></p> </td> <td style=\"width:62.88%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"62%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Continue\r   with the same dose and schedule.</span></p> </td> </tr> <tr> <td style=\"width:37.12%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"37%\"> <p class=\"MsoNormal\" style=\"margin-left:41.3pt;text-indent:-41.3pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 3 (&lt; 1,000\u2011500/mm<sup>3</sup></span></p> <p class=\"MsoNormal\" style=\"margin-left:41.3pt;text-indent:-41.3pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">               \r   &lt; 1.0\u20110.5 x 10<sup>9</sup>/L) or</span></p> <p class=\"MsoNormal\" style=\"margin-left:41.3pt;text-indent:-41.3pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 4 (&lt; 500/mm<sup>3</sup></span></p> <p class=\"MsoNormal\" style=\"margin-left:41.3pt;text-indent:-41.3pt;page-break-after:\r   avoid\"><sup></sup><span lang=\"EN-GB\">&lt; 0.5 x 10<sup>9</sup>/L)</span></p> </td> <td style=\"width:62.88%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"62%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Withhold\r   dose until toxicity returns to \u2264 Grade 2 or baseline then\r   resume treatment at the same dose and schedule<sup>b</sup>. Consider G\u2011CSF\r   or GM\u2011CSF in subsequent cycles for patients who develop Grade 3 or\r   Grade 4 neutropenia.</span></p> </td> </tr> </table>", "ID": "1bc3ac36-18d4-4d39-97dd-c188f418a5e8", "Styles": "width:99.22%;margin-left:5.4pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "   Severity grade of\r   neutropenia (signs and symptoms [abbreviated\r   description of CTCAEa])   Modification of dosing schedule     Grade 1\r   (< LLN\u20111500/mm3            \r      < LLN\u20111.5 x 109/L) or Grade 2\r   (< 1500\u20111000/mm3 < 1.5\u20111.0 x 109/L)   Continue\r   with the same dose and schedule.     Grade 3 (< 1,000\u2011500/mm3                \r   < 1.0\u20110.5 x 109/L) or Grade 4 (< 500/mm3 < 0.5 x 109/L)   Withhold\r   dose until toxicity returns to \u2264 Grade 2 or baseline then\r   resume treatment at the same dose and scheduleb. Consider G\u2011CSF\r   or GM\u2011CSF in subsequent cycles for patients who develop Grade 3 or\r   Grade 4 neutropenia.   ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Grading based on\r National Cancer Institute (NCI) Common Terminology Criteria for Adverse\r Events (CTCAE) v3.0; see Neutrophils/granulocytes; LLN = lower limit\r of normal.</span></p>", "ID": "a0342340-5f98-480a-a2eb-d5ea39782db2", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "a.Grading based on\r National Cancer Institute (NCI) Common Terminology Criteria for Adverse\r Events (CTCAE) v3.0; see Neutrophils/granulocytes; LLN = lower limit\r of normal.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:17.85pt;text-indent:-17.85pt\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">b.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Patients who\r develop Grade 3 or Grade 4 lymphopenia may continue treatment without\r interruption.</span></p>", "ID": "3310f7cc-3fd3-4d6d-a621-4f1936e9bcff", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:17.85pt;text-indent:-17.85pt", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "b.Patients who\r develop Grade 3 or Grade 4 lymphopenia may continue treatment without\r interruption.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "989e49b9-2bed-4f76-9fc9-75d89bd4d3b2", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Table 2: Dosing recommendations for\r neutropenia during combination therapy </span></b></p>", "ID": "bf92dd63-42fe-4969-b9df-8f7e0c15b515", "Styles": "None", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 2: Dosing recommendations for\r neutropenia during combination therapy ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "67c19bde-9efd-4665-8427-f9f8a08a2fd0", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:98.84%;margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"98%\"> <tr> <td style=\"width:36.54%;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"36%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Severity grade of neutropenia</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">(signs and symptoms </span></b><span lang=\"EN-GB\">[abbreviated\r   description of CTCAE<sup>a</sup>])</span></p> </td> <td style=\"width:63.46%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"63%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Modification of dosing schedule</span></b></p> </td> </tr> <tr style=\"height:101.7pt\"> <td style=\"width:36.54%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:101.7pt\" valign=\"top\" width=\"36%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"SV\">Grade 1\r   (&lt; LLN\u20111500/mm<sup>3</sup></span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"SV\">              \r   &lt; LLN\u20111.5 x 10<sup>9</sup>/L) or</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"SV\">Grade 2\r   (&lt; 1500\u20111000/mm<sup>3</sup></span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup></sup><span lang=\"SV\">&lt; 1.5\u20111.0 x 10<sup>9</sup>/L)</span></p> <p class=\"MsoNormal\" style=\"margin-left:41.3pt;text-indent:-41.3pt;page-break-after:\r   avoid\"><span lang=\"SV\">Grade 3 (&lt; 1,000\u2011500/mm<sup>3</sup></span></p> <p class=\"MsoNormal\" style=\"margin-left:41.3pt;text-indent:-41.3pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">&lt; 1.0\u20110.5 x 10<sup>9</sup>/L) or</span></p> <p class=\"MsoNormal\" style=\"margin-left:41.3pt;text-indent:-41.3pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 4 (&lt; 500/mm<sup>3</sup></span></p> <p class=\"MsoNormal\" style=\"margin-left:41.3pt;text-indent:-41.3pt;page-break-after:\r   avoid\"><sup></sup><span lang=\"EN-GB\">&lt; 0.5 x 10<sup>9</sup>/L)</span></p> </td> <td style=\"width:63.46%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:101.7pt\" valign=\"top\" width=\"63%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Primary\r   prophylaxis with G-CSF, beginning with the first dose, is recommended for all\r   patients receiving combination therapy. </span><span lang=\"EN-GB\">Continue with\r   the same dose and schedule.</span></p> </td> </tr> </table>", "ID": "9057c640-0d7a-4849-b354-f7534ed666f0", "Styles": "width:98.84%;margin-left:5.4pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "   Severity grade of neutropenia (signs and symptoms [abbreviated\r   description of CTCAEa])   Modification of dosing schedule     Grade 1\r   (< LLN\u20111500/mm3               \r   < LLN\u20111.5 x 109/L) or Grade 2\r   (< 1500\u20111000/mm3 < 1.5\u20111.0 x 109/L) Grade 3 (< 1,000\u2011500/mm3 < 1.0\u20110.5 x 109/L) or Grade 4 (< 500/mm3 < 0.5 x 109/L)   Primary\r   prophylaxis with G-CSF, beginning with the first dose, is recommended for all\r   patients receiving combination therapy. Continue with\r   the same dose and schedule.   ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Grading based on\r National Cancer Institute (NCI) Common Terminology Criteria for Adverse\r Events (CTCAE) v4.03; see Neutrophils/granulocytes; LLN = lower limit\r of normal.</span></p>", "ID": "40c3ee18-f23b-432c-affa-7d32f1363fc6", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "a.Grading based on\r National Cancer Institute (NCI) Common Terminology Criteria for Adverse\r Events (CTCAE) v4.03; see Neutrophils/granulocytes; LLN = lower limit\r of normal.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "00fccb04-f26d-4339-8581-1bc70860d7b3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Peripheral\r neuropathy</span></i></p>", "ID": "312872fc-35f1-4ec0-9e8a-12a26ee7a038", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Peripheral\r neuropathy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "a67db270-20cb-4169-8d29-7bd998964543", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">If\r peripheral sensory or motor neuropathy emerges or worsens during treatment see\r Table 3 and 4 for appropriate dosing recommendations for monotherapy\r and combination therapy, respectively (see section 4.4).</span></p>", "ID": "ccc5f921-8348-4316-9f5a-6434bd58c222", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "If\r peripheral sensory or motor neuropathy emerges or worsens during treatment see\r Table 3 and 4 for appropriate dosing recommendations for monotherapy\r and combination therapy, respectively (see section 4.4).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r page-break-after:avoid;text-autospace:none\"></p>", "ID": "d2a97fc1-2576-42c9-97d2-07f34d92a354", "Styles": "text-align:justify;text-justify:inter-ideograph;\r\npage-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Table 3: Dosing recommendations for new or worsening peripheral\r sensory or motor neuropathy with monotherapy</span></b></p>", "ID": "5c5d3b8f-5ad3-4eba-9e00-f43950d6adef", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 3: Dosing recommendations for new or worsening peripheral\r sensory or motor neuropathy with monotherapy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:99.22%;margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"99%\"> <tr> <td style=\"width:43.98%;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"43%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Severity of peripheral sensory or motor neuropathy\r   </span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">(signs and symptoms </span></b><span lang=\"EN-GB\">[abbreviated\r   description of CTCAE<sup>a</sup>])</span></p> </td> <td style=\"width:56.02%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"56%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Modification of dose and schedule</span></b></p> </td> </tr> <tr> <td style=\"width:43.98%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"43%\"> <p class=\"MsoNormal\" style=\"margin-left:39.7pt;text-indent:-39.7pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 1 (paraesthesia and/or loss of reflexes,\r   with no loss of function)</span></p> </td> <td style=\"width:56.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Continue\r   with the same dose and schedule. </span></p> </td> </tr> <tr> <td style=\"width:43.98%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"43%\"> <p class=\"MsoNormal\" style=\"margin-left:39.7pt;text-indent:-39.7pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 2 (interfering with function but not with\r   activities of daily living) </span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> </td> <td style=\"width:56.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Withhold\r   dose until toxicity returns to \u2264 Grade 1 or baseline,\r   then restart treatment at a reduced dose of 1.2 mg/kg </span><span lang=\"EN-GB\">up to a maximum of 120 mg</span><span lang=\"EN-GB\"> every\r   3 weeks.</span></p> </td> </tr> <tr> <td style=\"width:43.98%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"43%\"> <p class=\"MsoNormal\" style=\"margin-left:39.7pt;text-indent:-39.7pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 3 (interfering with activities of daily\r   living)</span></p> </td> <td style=\"width:56.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Withhold\r   dose until toxicity returns to \u2264 Grade 1 or baseline, then\r   restart treatment at a reduced dose of 1.2 mg/kg </span><span lang=\"EN-GB\">up to a maximum of 120 mg</span><span lang=\"EN-GB\"> every\r   3 weeks.</span></p> </td> </tr> <tr> <td style=\"width:43.98%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"43%\"> <p class=\"MsoNormal\" style=\"margin-left:39.7pt;text-indent:-39.7pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 4 (sensory neuropathy that is disabling or\r   motor neuropathy that is life threatening or leads to paralysis)</span></p> </td> <td style=\"width:56.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Discontinue\r   treatment.</span></p> </td> </tr> </table>", "ID": "3233e1b0-ed93-4ba9-9418-77ec718e585d", "Styles": "width:99.22%;margin-left:5.4pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "   Severity of peripheral sensory or motor neuropathy\r    (signs and symptoms [abbreviated\r   description of CTCAEa])   Modification of dose and schedule     Grade 1 (paraesthesia and/or loss of reflexes,\r   with no loss of function)   Continue\r   with the same dose and schedule.      Grade 2 (interfering with function but not with\r   activities of daily living)     Withhold\r   dose until toxicity returns to \u2264 Grade 1 or baseline,\r   then restart treatment at a reduced dose of 1.2 mg/kg up to a maximum of 120 mg every\r   3 weeks.     Grade 3 (interfering with activities of daily\r   living)   Withhold\r   dose until toxicity returns to \u2264 Grade 1 or baseline, then\r   restart treatment at a reduced dose of 1.2 mg/kg up to a maximum of 120 mg every\r   3 weeks.     Grade 4 (sensory neuropathy that is disabling or\r   motor neuropathy that is life threatening or leads to paralysis)   Discontinue\r   treatment.   ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in\"><sup><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Grading based on\r National Cancer Institute (NCI) Common Terminology Criteria for Adverse\r Events (CTCAE) v3.0; see neuropathy: motor; neuropathy: sensory; and\r neuropathic pain. </span></p>", "ID": "87bbc5d0-b445-4bba-a2d1-0d534d027947", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "a.Grading based on\r National Cancer Institute (NCI) Common Terminology Criteria for Adverse\r Events (CTCAE) v3.0; see neuropathy: motor; neuropathy: sensory; and\r neuropathic pain. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "912cfa2f-ac79-4ff8-821b-bb9e41435679", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Table 4: Dosing recommendations for new or worsening peripheral\r sensory or motor neuropathy during combination therapy</span></b></p>", "ID": "f6fa84e7-63df-434a-9499-21ec936fc472", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 4: Dosing recommendations for new or worsening peripheral\r sensory or motor neuropathy during combination therapy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:102.58%;margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"102%\"> <tr> <td style=\"width:42.54%;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td style=\"width:28.74%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Combination therapy with AVD</span></b></p> </td> <td style=\"width:28.74%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Combination therapy with CHP</span></b></p> </td> </tr> <tr> <td style=\"width:42.54%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Severity of peripheral sensory or motor neuropathy\r   </span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">(signs and symptoms </span></b><span lang=\"EN-GB\">[abbreviated\r   description of CTCAE<sup>a</sup>])</span></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Modification of dose and schedule </span></b></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Modification of dose and schedule </span></b></p> </td> </tr> <tr> <td style=\"width:42.54%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\"> <p class=\"MsoNormal\" style=\"margin-left:39.7pt;text-indent:-39.7pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 1 (paraesthesia and/or loss of reflexes,\r   with no loss of function)</span></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Continue\r   with the same dose and schedule.</span></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Continue\r   with the same dose and schedule.</span></p> </td> </tr> <tr> <td style=\"width:42.54%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\"> <p class=\"MsoNormal\" style=\"margin-left:41.1pt;text-indent:-39.7pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 2 (interfering with function but not with\r   activities of daily living)</span></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Reduce\r   dose to 0.9 mg/kg up </span><span lang=\"EN-GB\">to a maximum of 90 mg</span><span lang=\"EN-GB\"> every 2 weeks.</span></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p class=\"MsoNormal\" style=\"margin-bottom:3.0pt\"><u><span lang=\"EN-GB\">Sensory\r   neuropathy</span></u><span lang=\"EN-GB\">: Continue treatment at same dose level.</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Motor\r   neuropathy</span></u><span lang=\"EN-GB\">: Reduce dose to 1.2 mg/kg, up to\r   a maximum of 120 mg every 3 weeks.</span></p> </td> </tr> <tr> <td style=\"width:42.54%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\"> <p class=\"MsoNormal\" style=\"margin-left:39.7pt;text-indent:-39.7pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 3 (interfering with activities of daily\r   living)</span></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Withhold\r   treatment with ADCETRIS until toxicity is \u2264 Grade 2, then\r   restart treatment at a reduced dose to 0.9 mg/kg up </span><span lang=\"EN-GB\">to a maximum of 90 mg</span><span lang=\"EN-GB\">every 2 weeks.</span></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p class=\"MsoNormal\" style=\"margin-bottom:3.0pt\"><u><span lang=\"EN-GB\">Sensory\r   neuropathy</span></u><span lang=\"EN-GB\">: Reduce dose to 1.2 mg/kg up to a\r   maximum of 120 mg every 3 weeks.</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Motor\r   neuropathy</span></u><span lang=\"EN-GB\">: Discontinue treatment.</span></p> </td> </tr> <tr> <td style=\"width:42.54%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"42%\"> <p class=\"MsoNormal\" style=\"margin-left:39.7pt;text-indent:-39.7pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Grade 4 (sensory neuropathy which is disabling or\r   motor neuropathy that is life threatening or leads to paralysis)</span></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Discontinue\r   treatment.</span></p> </td> <td style=\"width:28.74%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"28%\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Discontinue\r   treatment.</span></p> </td> </tr> </table>", "ID": "25882f7f-6787-4172-9ec7-f100627d0159", "Styles": "width:102.58%;margin-left:5.4pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "      Combination therapy with AVD   Combination therapy with CHP     Severity of peripheral sensory or motor neuropathy\r    (signs and symptoms [abbreviated\r   description of CTCAEa])   Modification of dose and schedule    Modification of dose and schedule      Grade 1 (paraesthesia and/or loss of reflexes,\r   with no loss of function)   Continue\r   with the same dose and schedule.   Continue\r   with the same dose and schedule.     Grade 2 (interfering with function but not with\r   activities of daily living)   Reduce\r   dose to 0.9 mg/kg up to a maximum of 90 mg every 2 weeks.   Sensory\r   neuropathy: Continue treatment at same dose level. Motor\r   neuropathy: Reduce dose to 1.2 mg/kg, up to\r   a maximum of 120 mg every 3 weeks.     Grade 3 (interfering with activities of daily\r   living)   Withhold\r   treatment with ADCETRIS until toxicity is \u2264 Grade 2, then\r   restart treatment at a reduced dose to 0.9 mg/kg up to a maximum of 90 mgevery 2 weeks.   Sensory\r   neuropathy: Reduce dose to 1.2 mg/kg up to a\r   maximum of 120 mg every 3 weeks. Motor\r   neuropathy: Discontinue treatment.     Grade 4 (sensory neuropathy which is disabling or\r   motor neuropathy that is life threatening or leads to paralysis)   Discontinue\r   treatment.   Discontinue\r   treatment.   ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:4.5pt\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\"> Grading based on National Cancer Institute\r (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03; see\r neuropathy: motor; neuropathy: sensory; and neuropathic pain. </span></p>", "ID": "e665a371-4b86-4079-a0a9-84935c2ee0b4", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:4.5pt", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "a. Grading based on National Cancer Institute\r (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03; see\r neuropathy: motor; neuropathy: sensory; and neuropathic pain. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "424195b1-aac2-4582-999b-c47c79090ab2", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Special\r patient populations</span></u></p>", "ID": "c7ff2636-dfc4-4574-9de7-596f279d2476", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Special\r patient populations", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "a838525e-37dc-4923-955c-acb43b2dc34b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Renal and\r hepatic impairment</span></i></p>", "ID": "d631f352-64d7-49d9-95ad-14b64155e67f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Renal and\r hepatic impairment", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "f371e83a-3a6a-48a0-9b1e-1e85fa3e8939", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Combination\r therapy</span></p>", "ID": "9e7a9f11-f0cb-43dc-964b-16eff4fc6bbc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Combination\r therapy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "417dc40d-64ad-4597-98fe-636319aa0586", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Patients with\r renal impairment should be closely monitored for adverse events. </span><span lang=\"EN-GB\">There is no clinical trial experience using ADCETRIS in combination\r with chemotherapy in patients with renal impairment, where serum creatinine is\r \u2265 2.0 mg/dL and/or creatinine clearance or calculated\r creatinine clearance is \u2264 40 mL/minute. Use of ADCETRIS in\r combination with chemotherapy should be avoided in patients with severe renal\r impairment. </span></p>", "ID": "cb9991d9-1cce-4a3b-ac39-0c7f29aa69c0", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Patients with\r renal impairment should be closely monitored for adverse events. There is no clinical trial experience using ADCETRIS in combination\r with chemotherapy in patients with renal impairment, where serum creatinine is\r \u2265 2.0 mg/dL and/or creatinine clearance or calculated\r creatinine clearance is \u2264 40 mL/minute. Use of ADCETRIS in\r combination with chemotherapy should be avoided in patients with severe renal\r impairment. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h5 align=\"left\" style=\"text-align:left;page-break-after:auto\"></h5>", "ID": "c017c766-5a32-4790-87ef-c067fafb09db", "Styles": "text-align:left;page-break-after:auto", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients with hepatic impairment should be\r closely monitored for adverse events. The recommended starting dose in patients\r with mild hepatic impairment receiving ADCETRIS in combination with AVD is\r 0.9 mg/kg administered as an intravenous infusion over 30 minutes\r every 2 weeks. The recommended starting dose in patients with mild hepatic\r impairment receiving ADCETRIS in combination with CHP is 1.2 mg/kg\r administered as an intravenous infusion over 30 minutes every\r 3 weeks. There is no clinical trial experience using ADCETRIS in\r combination with chemotherapy in patients with hepatic impairment, where total\r bilirubin is &gt; 1.5 times the upper limit of normal (ULN) (unless due to\r Gilbert syndrome), or aspartate aminotransferase (AST) or alanine\r aminotransferase (ALT) are &gt; 3 times the ULN, or &gt; 5 times the\r ULN if their elevation may be reasonably ascribed to the presence of HL in the\r liver. Use of ADCETRIS in combination with chemotherapy should be avoided in patients\r with moderate and severe hepatic impairment.</span></p>", "ID": "7b762fbd-6b6f-423a-9b77-80e2e91a6b8c", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Patients with hepatic impairment should be\r closely monitored for adverse events. The recommended starting dose in patients\r with mild hepatic impairment receiving ADCETRIS in combination with AVD is\r 0.9 mg/kg administered as an intravenous infusion over 30 minutes\r every 2 weeks. The recommended starting dose in patients with mild hepatic\r impairment receiving ADCETRIS in combination with CHP is 1.2 mg/kg\r administered as an intravenous infusion over 30 minutes every\r 3 weeks. There is no clinical trial experience using ADCETRIS in\r combination with chemotherapy in patients with hepatic impairment, where total\r bilirubin is > 1.5 times the upper limit of normal (ULN) (unless due to\r Gilbert syndrome), or aspartate aminotransferase (AST) or alanine\r aminotransferase (ALT) are > 3 times the ULN, or > 5 times the\r ULN if their elevation may be reasonably ascribed to the presence of HL in the\r liver. Use of ADCETRIS in combination with chemotherapy should be avoided in patients\r with moderate and severe hepatic impairment.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "f0cf2c8e-1cf9-414b-8de7-2a6044e743c6", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Monotherapy</span></p>", "ID": "9ce9c15f-ccd3-45a1-b799-77ee89725771", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Monotherapy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "b59b2587-728f-4ead-967c-c99951cf4c41", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">The recommended starting dose in patients with severe renal\r impairment is 1.2 mg/kg administered as an intravenous infusion over\r 30 minutes every 3 weeks. Patients with renal impairment should be\r closely monitored for adverse events (see section 5.2).</span></p>", "ID": "1ccce3ff-f1be-402f-82b1-896d663d50ce", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The recommended starting dose in patients with severe renal\r impairment is 1.2 mg/kg administered as an intravenous infusion over\r 30 minutes every 3 weeks. Patients with renal impairment should be\r closely monitored for adverse events (see section 5.2).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "e54a0313-cf8f-4aa1-9cb9-6f88b58ee28a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The recommended\r starting dose in patients with hepatic impairment is 1.2 mg/kg\r administered as an intravenous infusion over 30 minutes every\r 3 weeks. Patients with hepatic impairment should be closely monitored for\r adverse events (see section 5.2).</span></p>", "ID": "2db8af71-229b-46c4-a525-49679015d031", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The recommended\r starting dose in patients with hepatic impairment is 1.2 mg/kg\r administered as an intravenous infusion over 30 minutes every\r 3 weeks. Patients with hepatic impairment should be closely monitored for\r adverse events (see section 5.2).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "c1e77acf-c2fd-4259-8d9f-5933e4c26308", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Elderly</span></i></p>", "ID": "78174ab3-6039-4928-ad55-ded31f98ee85", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Elderly", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "ef4f41c3-6ac3-4767-af7d-6c7f7786d609", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">The dosing\r recommendations for patients aged 65 and older are the same as for adults.</span><span style=\"color:windowtext\"> Currently available data are described in sections 4.8,\r 5.1 and 5.2.</span></p>", "ID": "7c779fa3-f1c8-45f8-b747-3fd0271d6e8a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The dosing\r recommendations for patients aged 65 and older are the same as for adults. Currently available data are described in sections 4.8,\r 5.1 and 5.2.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "f4f74e5c-69f7-4427-ae0b-4bc0752de665", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Paediatric\r population </span></i></p>", "ID": "fc8bd3dc-617d-4592-94ac-2447495c07dc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Paediatric\r population ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "4a1152f1-af1f-48ed-bd80-776d80659f42", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of</span><span lang=\"EN-GB\"> ADCETRIS in</span><span lang=\"EN-GB\"> children less than\r 18 years have not yet been established. </span>Currently available data\r are described in sections 4.8, 5.1 and 5.2 but no recommendation on a\r posology can be made.</p>", "ID": "ef63b900-470e-48e8-b494-6dfd15f939bf", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The safety and efficacy of ADCETRIS in children less than\r 18 years have not yet been established. Currently available data\r are described in sections 4.8, 5.1 and 5.2 but no recommendation on a\r posology can be made.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "855954dc-68a3-4e33-8269-9bf67750e4e9", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In nonclinical studies, thymus depletion\r has been observed (see section 5.3).</span></p>", "ID": "97e32c96-6f30-4fda-bde9-a4edb5e3f9cd", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In nonclinical studies, thymus depletion\r has been observed (see section 5.3).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"><b></b></p>", "ID": "dc01fc3a-2103-4dc2-aaf4-de5c020d7e96", "Styles": "text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Method of\r administration </span></u></p>", "ID": "699e453d-5bdc-4e35-8051-171c515f6484", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Method of\r administration ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"default0\" style=\"page-break-after:avoid\"></p>", "ID": "af3e4f35-e16d-4fb6-bd07-61cb01442259", "Styles": "page-break-after:avoid", "Classes": "['default0']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"default0\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The recommended\r dose of ADCETRIS is infused over 30 minutes. </span></p>", "ID": "421078b5-c2dc-46a1-8b97-4f0a41e6a7d8", "Styles": "None", "Classes": "['default0']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The recommended\r dose of ADCETRIS is infused over 30 minutes. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"default0\"></p>", "ID": "d702fcd9-bc13-4124-afbe-22338cc3347e", "Styles": "None", "Classes": "['default0']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"default0\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">For instructions on\r reconstitution and dilution of the medicinal product before administration, see\r section 6.6.</span></p>", "ID": "3782572a-1948-4cf8-914d-d249a849c1cc", "Styles": "None", "Classes": "['default0']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "For instructions on\r reconstitution and dilution of the medicinal product before administration, see\r section 6.6.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><b><u><span lang=\"EN-GB\"></span></u></b></p>", "ID": "64178ddf-c6d8-4291-b04d-40017b48dd91", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">ADCETRIS must not be administered as an\r intravenous push or bolus. ADCETRIS should be administered through a dedicated\r intravenous line and it must not be mixed with other medicinal products (see\r section 6.2).</span></p>", "ID": "79dc1dfb-cade-4d56-b94f-4a06d4883211", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "ADCETRIS must not be administered as an\r intravenous push or bolus. ADCETRIS should be administered through a dedicated\r intravenous line and it must not be mixed with other medicinal products (see\r section 6.2).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"default0\"></p>", "ID": "08d5333f-76af-4a47-bbc1-9fbe63a21ab7", "Styles": "None", "Classes": "['default0']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h3><span lang=\"EN-GB\">4.3     Contraindications</span></h3>", "ID": "eb31e37d-53a6-4d43-889c-6c9376bef4fe", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "4.3     Contraindications", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "86aaba37-79b6-4afe-ab3a-e3061909a169", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hypersensitivity to the active substance or\r to any of the excipients listed in section 6.1. </span></p>", "ID": "5a3ced8f-a21b-4025-9fb1-4aa41d202904", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Hypersensitivity to the active substance or\r to any of the excipients listed in section 6.1. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "d44fc5b6-a643-4880-8938-271e3e46eeaf", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Combined use of bleomycin and ADCETRIS\r causes pulmonary toxicity (see section 4.5). </span></p>", "ID": "1e981388-ddfb-4663-ae08-014256b8565a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Combined use of bleomycin and ADCETRIS\r causes pulmonary toxicity (see section 4.5). ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "76e5583a-8281-46bb-8736-99af69aeab38", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h3><span lang=\"EN-GB\">4.4     Special warnings and\r precautions for use</span></h3>", "ID": "ecdb387d-04b3-44c9-aed0-28ff5bd2b495", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "4.4     Special warnings and\r precautions for use", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"></p>", "ID": "dbb45823-05a4-4385-b4fe-d84dc2bf0638", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Progressive\r multifocal leukoencephalopathy</span></u></p>", "ID": "6fbae6e9-dcc6-4a71-817f-82f5f2cecfb4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Progressive\r multifocal leukoencephalopathy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r avoid\"><u><span lang=\"EN-GB\"></span></u></p>", "ID": "1b302a97-ef1f-4bec-bc28-b19b8bf67835", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\r\navoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">John Cunningham virus (JCV) reactivation\r resulting in progressive multifocal leukoencephalopathy (PML) and death can\r occur in ADCETRIS\u2011treated patients. PML has been reported in patients who\r received this treatment after receiving multiple prior chemotherapy regimens.\r PML is a rare demyelinating disease of the central nervous system that results\r from reactivation of latent JCV and is often fatal. </span></p>", "ID": "19172404-f3ed-4f56-889e-b1910e5e2ba6", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "John Cunningham virus (JCV) reactivation\r resulting in progressive multifocal leukoencephalopathy (PML) and death can\r occur in ADCETRIS\u2011treated patients. PML has been reported in patients who\r received this treatment after receiving multiple prior chemotherapy regimens.\r PML is a rare demyelinating disease of the central nervous system that results\r from reactivation of latent JCV and is often fatal. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "703422b9-e64d-4128-a76a-7be20a474caa", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients should be closely monitored for\r new or worsening neurological, cognitive, or behavioural signs or symptoms,\r which may be suggestive of PML. ADCETRIS should be held for any suspected case\r of PML. Suggested evaluation of PML includes neurology consultation, gadolinium\u2011enhanced\r magnetic resonance imaging of the brain and cerebrospinal fluid analysis for\r JCV DNA by polymerase chain reaction or a brain biopsy with evidence of JCV. A\r negative JCV PCR does not exclude PML. Additional follow up and evaluation may\r be warranted if no alternative diagnosis can be established. ADCETRIS dosing should\r be permanently discontinued if a diagnosis of PML is confirmed.</span></p>", "ID": "56d15036-76a9-4071-898a-8085b790b42b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Patients should be closely monitored for\r new or worsening neurological, cognitive, or behavioural signs or symptoms,\r which may be suggestive of PML. ADCETRIS should be held for any suspected case\r of PML. Suggested evaluation of PML includes neurology consultation, gadolinium\u2011enhanced\r magnetic resonance imaging of the brain and cerebrospinal fluid analysis for\r JCV DNA by polymerase chain reaction or a brain biopsy with evidence of JCV. A\r negative JCV PCR does not exclude PML. Additional follow up and evaluation may\r be warranted if no alternative diagnosis can be established. ADCETRIS dosing should\r be permanently discontinued if a diagnosis of PML is confirmed.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "3fa04d29-e458-4625-9c3e-a7d119934bf5", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The physician should be particularly alert\r to symptoms suggestive of PML that the patient may not notice (e.g., cognitive,\r neurological, or psychiatric symptoms).</span></p>", "ID": "ac826158-c6db-41a8-8b0b-99e427cf984d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The physician should be particularly alert\r to symptoms suggestive of PML that the patient may not notice (e.g., cognitive,\r neurological, or psychiatric symptoms).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "324aabdd-e4a5-42ec-b7fc-d9618f301c79", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:0in;page-break-after:\r avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Pancreatitis</span></u></p>", "ID": "3d55629d-b1b0-4032-b1df-c8b2f184ce3c", "Styles": "margin-left:0in;page-break-after:\r\navoid;text-autospace:none", "Classes": "['MsoListParagraphCxSpFirst']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Pancreatitis", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:0in;page-break-after:\r avoid;text-autospace:none\"><u><span lang=\"EN-GB\"></span></u></p>", "ID": "ff3f9b2e-0a75-4220-b151-049868cb86e0", "Styles": "margin-left:0in;page-break-after:\r\navoid;text-autospace:none", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:0in;text-autospace:none\"><span lang=\"EN-GB\">Acute pancreatitis has been observed in patients treated with ADCETRIS.\r Fatal outcomes have been reported.</span></p>", "ID": "33733342-a33a-4435-8b8c-f5e08aafcf86", "Styles": "margin-left:0in;text-autospace:none", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Acute pancreatitis has been observed in patients treated with ADCETRIS.\r Fatal outcomes have been reported.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:0in;text-autospace:none\"></p>", "ID": "723f4985-a937-45c4-ab7e-38bc1716a423", "Styles": "margin-left:0in;text-autospace:none", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:0in;text-autospace:none\"><span lang=\"EN-GB\">Patients should be closely monitored for new or worsening abdominal\r pain, which may be suggestive of acute pancreatitis. Patient evaluation may\r include physical examination, laboratory evaluation for serum amylase and serum\r lipase, and abdominal imaging, such as ultrasound and other appropriate\r diagnostic measures. ADCETRIS should be held for any suspected case of acute\r pancreatitis. ADCETRIS should be discontinued if a diagnosis of acute\r pancreatitis is confirmed. </span></p>", "ID": "d2897b21-05dc-4b8a-83a7-41dd5d2a4609", "Styles": "margin-left:0in;text-autospace:none", "Classes": "['MsoListParagraphCxSpLast']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Patients should be closely monitored for new or worsening abdominal\r pain, which may be suggestive of acute pancreatitis. Patient evaluation may\r include physical examination, laboratory evaluation for serum amylase and serum\r lipase, and abdominal imaging, such as ultrasound and other appropriate\r diagnostic measures. ADCETRIS should be held for any suspected case of acute\r pancreatitis. ADCETRIS should be discontinued if a diagnosis of acute\r pancreatitis is confirmed. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "7264105a-0f12-4872-a99c-14b78a0e4c58", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pulmonary\r toxicity</span></u></p>", "ID": "7de9ddb0-f881-4ccd-92d4-213adb079122", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Pulmonary\r toxicity", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "37f4f310-1b91-4062-9df3-bf30126e45dd", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cases of pulmonary toxicity</span><span lang=\"EN-GB\">, including pneumonitis, interstitial lung disease, and acute\r respiratory distress syndrome (ARDS), some with fatal outcomes,</span><span lang=\"EN-GB\"> have </span><span lang=\"EN-GB\">been </span><span lang=\"EN-GB\">reported </span><span lang=\"EN-GB\">in patients </span><span lang=\"EN-GB\">receiving ADCETRIS. Although a\r causal association </span><span lang=\"EN-GB\">with ADCETRIS</span><span lang=\"EN-GB\"> has not been established, the risk of pulmonary toxicity cannot be\r ruled out. In the event of new or worsening pulmonary symptoms (e.g. cough,\r dyspnoea), a prompt diagnostic evaluation should be performed and patients\r should be treated appropriately.</span><span lang=\"EN-GB\">Consider holding ADCETRIS dosing during evaluation and until\r symptomatic improvement.</span></p>", "ID": "d489922f-f223-4c39-bcd0-4880e4e42332", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Cases of pulmonary toxicity, including pneumonitis, interstitial lung disease, and acute\r respiratory distress syndrome (ARDS), some with fatal outcomes, have been reported in patients receiving ADCETRIS. Although a\r causal association with ADCETRIS has not been established, the risk of pulmonary toxicity cannot be\r ruled out. In the event of new or worsening pulmonary symptoms (e.g. cough,\r dyspnoea), a prompt diagnostic evaluation should be performed and patients\r should be treated appropriately.Consider holding ADCETRIS dosing during evaluation and until\r symptomatic improvement.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-left:0in;text-autospace:none\"></p>", "ID": "99a607b4-e6fb-4a2a-9d2d-0f7773ce6603", "Styles": "margin-left:0in;text-autospace:none", "Classes": "['MsoListParagraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Serious\r infections and opportunistic infections</span></u></p>", "ID": "a32e80fe-c34b-45a7-bc64-9363a90cdb60", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Serious\r infections and opportunistic infections", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "6e55867e-18f8-4b8c-99ef-09cb2357a4ea", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Serious infections such as pneumonia,\r staphylococcal bacteraemia, sepsis/septic shock (including fatal outcomes) and\r herpes zoster, cytomegalovirus (CMV) (reactivation) and opportunistic\r infections such as Pneumocystis jiroveci pneumonia and oral candidiasis have\r been reported in patients treated with ADCETRIS. Patients should be carefully\r monitored during treatment for the emergence of possible serious and\r opportunistic infections.</span></p>", "ID": "af628dce-2536-4b25-83d6-a9e323a332b3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Serious infections such as pneumonia,\r staphylococcal bacteraemia, sepsis/septic shock (including fatal outcomes) and\r herpes zoster, cytomegalovirus (CMV) (reactivation) and opportunistic\r infections such as Pneumocystis jiroveci pneumonia and oral candidiasis have\r been reported in patients treated with ADCETRIS. Patients should be carefully\r monitored during treatment for the emergence of possible serious and\r opportunistic infections.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "5b2a1cae-2ddc-4136-890b-35196159ab1b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Infusion\u2011related\r reactions</span></u></p>", "ID": "51e09c5b-2d67-4631-a5e8-171b22f712ef", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Infusion\u2011related\r reactions", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "e4deeb06-5059-470e-b0cb-d9229fe4fbf9", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">Immediate and delayed infusion\u2011related reactions (IRR), as well\r as anaphylactic reactions, have been reported. </span></p>", "ID": "60f9d415-7fd7-4410-bbb0-695fdeaa7265", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Immediate and delayed infusion\u2011related reactions (IRR), as well\r as anaphylactic reactions, have been reported. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "a9d22e2d-ef1f-47ac-8bb5-934498167023", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt;color:black\">Patients should be carefully monitored during and after\r infusion.</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <span style=\"color:black\">If an anaphylactic reaction occurs, administration of ADCETRIS\r should be immediately and permanently discontinued and appropriate medical\r therapy should be administered.</span></span></p>", "ID": "0f05f076-8bd7-4d50-aa05-b126a7ee2a1c", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Patients should be carefully monitored during and after\r infusion. If an anaphylactic reaction occurs, administration of ADCETRIS\r should be immediately and permanently discontinued and appropriate medical\r therapy should be administered.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "35b9d83a-6246-400e-b692-0dcebb720377", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">If an IRR occurs, the infusion should be interrupted and appropriate\r medical management instituted. The infusion may be restarted at a slower rate\r after symptom resolution. Patients who have experienced a prior IRR should be\r premedicated for subsequent infusions. Premedication may include paracetamol,\r an antihistamine and a corticosteroid. </span></p>", "ID": "b115a6b0-b38f-4962-ae7f-bb5252633dd6", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "If an IRR occurs, the infusion should be interrupted and appropriate\r medical management instituted. The infusion may be restarted at a slower rate\r after symptom resolution. Patients who have experienced a prior IRR should be\r premedicated for subsequent infusions. Premedication may include paracetamol,\r an antihistamine and a corticosteroid. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "409b0554-a001-4962-a2de-746d620498b0", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">IRRs are more\r frequent and more severe in patients with antibodies to brentuximab vedotin\r (see section 4.8).</span></p>", "ID": "587ea828-03ba-4682-9d8c-3ad777ae7934", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "IRRs are more\r frequent and more severe in patients with antibodies to brentuximab vedotin\r (see section 4.8).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "9693f945-6bbd-47ed-897f-e8c63a3cd645", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Tumour\r lysis syndrome</span></u></p>", "ID": "8f539862-9a73-4a57-b489-954fff0f4dae", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Tumour\r lysis syndrome", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in;page-break-after:\r avoid\"></p>", "ID": "07351be4-a44e-491f-9393-94c1b00d9b3f", "Styles": "margin-left:0in;text-indent:0in;page-break-after:\r\navoid", "Classes": "['MsoListBullet']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Tumour lysis syndrome (TLS) has been\r reported with ADCETRIS. Patients with rapidly proliferating tumour and high\r tumour burden are at risk of tumour lysis syndrome. These patients should be\r monitored closely and managed according to best medical practice. Management of\r TLS may include aggressive hydration, monitoring of renal function, correction\r of electrolyte abnormalities, anti\u2011hyperuricaemic therapy, and supportive\r care.</span></p>", "ID": "ac874429-0c85-4807-8292-d1151c0c9b2e", "Styles": "margin-left:0in;text-indent:0in", "Classes": "['MsoListBullet']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Tumour lysis syndrome (TLS) has been\r reported with ADCETRIS. Patients with rapidly proliferating tumour and high\r tumour burden are at risk of tumour lysis syndrome. These patients should be\r monitored closely and managed according to best medical practice. Management of\r TLS may include aggressive hydration, monitoring of renal function, correction\r of electrolyte abnormalities, anti\u2011hyperuricaemic therapy, and supportive\r care.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in\"></p>", "ID": "d0105daf-910c-4d9f-ba21-66d6ede2d308", "Styles": "margin-left:0in;text-indent:0in", "Classes": "['MsoListBullet']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Peripheral\r neuropathy</span></u></p>", "ID": "79ca3def-f5e3-4a25-8973-df178705bda3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Peripheral\r neuropathy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"></p>", "ID": "024efcc9-e996-4d08-a1e4-8641eb4b1a63", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\"><a name=\"_Hlk519675029\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">ADCETRIS may cause peripheral neuropathy, both sensory and motor. ADCETRIS\u2011induced\r peripheral neuropathy is typically an effect of cumulative exposure to this\r medicinal product and is reversible in most cases. In clinical trials, the\r majority of patients had resolution or improvement of their symptoms (see\r section 4.8). Patients should be monitored for symptoms of neuropathy,\r such as hypoesthesia, hyperesthesia, paraesthesia, discomfort, a burning\r sensation, neuropathic pain or weakness. Patients experiencing new or worsening\r peripheral neuropathy may require a delay and a dose </span></a><span lang=\"EN-GB\" style=\"font-size:11.0pt\">reduction of ADCETRIS or discontinuation of\r treatment (see section 4.2). </span></p>", "ID": "75d1844c-6a83-45f7-9b5e-cfe1ef9a1661", "Styles": "None", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "ADCETRIS may cause peripheral neuropathy, both sensory and motor. ADCETRIS\u2011induced\r peripheral neuropathy is typically an effect of cumulative exposure to this\r medicinal product and is reversible in most cases. In clinical trials, the\r majority of patients had resolution or improvement of their symptoms (see\r section 4.8). Patients should be monitored for symptoms of neuropathy,\r such as hypoesthesia, hyperesthesia, paraesthesia, discomfort, a burning\r sensation, neuropathic pain or weakness. Patients experiencing new or worsening\r peripheral neuropathy may require a delay and a dose reduction of ADCETRIS or discontinuation of\r treatment (see section 4.2). ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in\"></p>", "ID": "46bb2da1-c13b-4551-a6aa-659688b3a452", "Styles": "margin-left:0in;text-indent:0in", "Classes": "['MsoListBullet']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Haematological\r toxicities</span></u></p>", "ID": "b81de941-835c-4568-805a-2a8247a69536", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Haematological\r toxicities", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"></p>", "ID": "14c9a857-3108-40af-b0d2-961ab1ef7070", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Grade 3 or\r Grade 4 anaemia, thrombocytopenia, and prolonged (\u2265 1 week)\r Grade 3 or Grade 4 neutropenia can occur with ADCETRIS. Complete\r blood counts should be monitored prior to administration of each dose. If\r Grade 3 or Grade 4 neutropenia develops, refer to section 4.2.</span></p>", "ID": "85f5cf45-84b8-460b-9b66-ee944db5aab2", "Styles": "None", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Grade 3 or\r Grade 4 anaemia, thrombocytopenia, and prolonged (\u2265 1 week)\r Grade 3 or Grade 4 neutropenia can occur with ADCETRIS. Complete\r blood counts should be monitored prior to administration of each dose. If\r Grade 3 or Grade 4 neutropenia develops, refer to section 4.2.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in\"></p>", "ID": "51167f36-cfd7-4c50-8139-d5f3a5f535f7", "Styles": "margin-left:0in;text-indent:0in", "Classes": "['MsoListBullet']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Febrile\r neutropenia</span></u></p>", "ID": "29156b76-28a0-4e5b-8144-db5aad6b6b5d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Febrile\r neutropenia", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"></span></u></p>", "ID": "000b8aaf-65ff-4b4c-acd7-fb406afa00d0", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Febrile neutropenia\r (fever of unknown origin without clinically or microbiologically documented\r infection with an absolute neutrophil count &lt; 1.0 x 10<sup>9</sup>/L,\r fever \u2265 38.5 <sup>0</sup>C; ref CTCAE v3) has been reported\r with treatment with ADCETRIS. Complete blood counts should be monitored prior\r to administration of each dose of treatment. Patients should be monitored\r closely for fever and managed according to best medical practice if febrile\r neutropenia develops.</span></p>", "ID": "a97f54be-6804-48a2-b1ab-725ccfea60ab", "Styles": "None", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Febrile neutropenia\r (fever of unknown origin without clinically or microbiologically documented\r infection with an absolute neutrophil count < 1.0 x 109/L,\r fever \u2265 38.5 0C; ref CTCAE v3) has been reported\r with treatment with ADCETRIS. Complete blood counts should be monitored prior\r to administration of each dose of treatment. Patients should be monitored\r closely for fever and managed according to best medical practice if febrile\r neutropenia develops.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\"></p>", "ID": "50ed4709-1b38-487e-ba91-ded8a2ccfd09", "Styles": "None", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\"><span style=\"font-size:11.0pt\">In combination therapy with AVD\r or CHP, advanced age was a risk factor for febrile neutropenia. </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">When ADCETRIS is administered in\r combination with AVD or CHP, primary prophylaxis with G\u2011CSF, beginning\r with the first dose, is recommended for all patients regardless of age.</span></p>", "ID": "14fe60a0-8748-45b3-831e-240ed68c1a8e", "Styles": "None", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In combination therapy with AVD\r or CHP, advanced age was a risk factor for febrile neutropenia. When ADCETRIS is administered in\r combination with AVD or CHP, primary prophylaxis with G\u2011CSF, beginning\r with the first dose, is recommended for all patients regardless of age.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"ListEnd\"></p>", "ID": "c33d3781-d6c1-4b46-a8b0-b29135f5ceeb", "Styles": "None", "Classes": "['ListEnd']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Stevens\u2011Johnson\r syndrome and toxic epidermal necrolysis</span></u></p>", "ID": "2d36accc-bd02-4b3f-84f2-fc17847dcbdb", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Stevens\u2011Johnson\r syndrome and toxic epidermal necrolysis", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "2996ddd5-afdd-46f3-b67c-fccc0be2b0fa", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Stevens\u2011Johnson syndrome (SJS) and\r toxic epidermal necrolysis (TEN) have been reported with ADCETRIS. Fatal\r outcomes have been reported. If SJS or TEN occur, ADCETRIS should be\r discontinued and appropriate medical therapy should be administered.</span></p>", "ID": "9a1042ac-c80a-4364-8844-24f493483497", "Styles": "margin-left:0in;text-indent:0in", "Classes": "['MsoListBullet']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Stevens\u2011Johnson syndrome (SJS) and\r toxic epidermal necrolysis (TEN) have been reported with ADCETRIS. Fatal\r outcomes have been reported. If SJS or TEN occur, ADCETRIS should be\r discontinued and appropriate medical therapy should be administered.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "c8f8eddb-aaf8-4243-bd92-c2fddc7b1b73", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"ListEnd\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">Gastrointestinal complications</span></u></p>", "ID": "787c3cbf-3450-48a6-b547-851fcbb69244", "Styles": "page-break-after:avoid", "Classes": "['ListEnd']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Gastrointestinal complications", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "85596720-cdd9-404f-90b2-4f78ffd2139c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in;page-break-after:\r avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Gastrointestinal (GI)\r complications including intestinal obstruction, ileus, enterocolitis,\r neutropenic colitis, erosion, ulcer, perforation and haemorrhage, some with\r fatal outcomes, have been reported in patients treated with ADCETRIS. In the\r event of new or worsening GI symptoms, perform a prompt diagnostic evaluation\r and treat appropriately.</span></p>", "ID": "74ad16c8-dacb-457a-9813-165503631802", "Styles": "margin-left:0in;text-indent:0in;page-break-after:\r\navoid", "Classes": "['MsoListBullet']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Gastrointestinal (GI)\r complications including intestinal obstruction, ileus, enterocolitis,\r neutropenic colitis, erosion, ulcer, perforation and haemorrhage, some with\r fatal outcomes, have been reported in patients treated with ADCETRIS. In the\r event of new or worsening GI symptoms, perform a prompt diagnostic evaluation\r and treat appropriately.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in;page-break-after:\r avoid\"></p>", "ID": "de642984-248e-4b97-aeef-90bb23faccab", "Styles": "margin-left:0in;text-indent:0in;page-break-after:\r\navoid", "Classes": "['MsoListBullet']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatotoxicity</span></u></p>", "ID": "5e45a9de-73b1-4dee-95e4-3313fdacf4a4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Hepatotoxicity", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"></span></u></p>", "ID": "3f7a40f6-253b-4632-8cf1-eac962e6bedd", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:windowtext\">Hepatotoxicity in the form of elevations in\r alanine aminotransferase (ALT) and aspartate aminotransferase (AST) has been\r reported with ADCETRIS. </span><span lang=\"EN-GB\" style=\"color:windowtext\">Serious\r cases of hepatotoxicity, including fatal outcomes, have also occurred. Pre\u2011existing\r liver disease, comorbidities, and concomitant medications may also increase the\r risk. </span><span lang=\"EN-GB\" style=\"color:windowtext\">Liver function </span><span lang=\"EN-GB\" style=\"color:windowtext\">should be </span><span lang=\"EN-GB\" style=\"color:windowtext\">tested before initiating the treatment and </span><span lang=\"EN-GB\" style=\"color:windowtext\">routinely</span><span lang=\"EN-GB\" style=\"color:windowtext\"> monitored in patients receiving ADCETRIS. </span><span lang=\"EN-GB\" style=\"color:windowtext\">Patients experiencing hepatotoxicity may\r require a delay, change in dose or discontinuation of ADCETRIS.</span></p>", "ID": "1e2697c9-3f6c-421c-9877-a41e8c80d82e", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Hepatotoxicity in the form of elevations in\r alanine aminotransferase (ALT) and aspartate aminotransferase (AST) has been\r reported with ADCETRIS. Serious\r cases of hepatotoxicity, including fatal outcomes, have also occurred. Pre\u2011existing\r liver disease, comorbidities, and concomitant medications may also increase the\r risk. Liver function should be tested before initiating the treatment and routinely monitored in patients receiving ADCETRIS. Patients experiencing hepatotoxicity may\r require a delay, change in dose or discontinuation of ADCETRIS.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "0f348f45-17de-4fcc-96e5-86d46ade93db", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hyperglycaemia</span></u></p>", "ID": "3b3b0a6e-caa3-4214-b88c-d1177fb8bc39", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Hyperglycaemia", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "2dac21eb-e8ed-4f8c-b68f-6cd9bae76eef", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hyperglycaemia has been reported during\r clinical trials in patients with an elevated Body Mass Index (BMI) with or\r without a history of diabetes mellitus. However, any patient who experiences an\r event of hyperglycaemia should have their serum glucose closely monitored. Anti\u2011diabetic\r treatment should be administered as appropriate. </span></p>", "ID": "059f3957-a522-461d-96e9-efb9f87445a5", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Hyperglycaemia has been reported during\r clinical trials in patients with an elevated Body Mass Index (BMI) with or\r without a history of diabetes mellitus. However, any patient who experiences an\r event of hyperglycaemia should have their serum glucose closely monitored. Anti\u2011diabetic\r treatment should be administered as appropriate. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "4be48c6f-1218-4d23-b2d0-9f8930dad9af", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Renal and\r hepatic impairment</span></u></p>", "ID": "3af2e675-e90e-453b-a866-ad9e37d76d1d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Renal and\r hepatic impairment", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "c6fee747-e33c-44c2-8e92-ae771d4e0770", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">There is limited experience in patients\r with renal and hepatic impairment. Available data indicate that MMAE clearance\r might be affected by severe renal impairment, hepatic impairment, and by low\r serum albumin concentrations (see section 5.2). </span></p>", "ID": "25b3cb13-e157-47be-930f-f3f921a4a1cf", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "There is limited experience in patients\r with renal and hepatic impairment. Available data indicate that MMAE clearance\r might be affected by severe renal impairment, hepatic impairment, and by low\r serum albumin concentrations (see section 5.2). ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "3c1cd80d-f47c-4d22-bb9a-dacaddd81a43", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">CD30+\r CTCL</span></u></p>", "ID": "98f266eb-d60f-4f0c-b6d1-ce8f40cd4f95", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": true, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "CD30+\r CTCL", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "64437a37-ac39-4cab-a704-a35b5c1932f1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The size of the treatment effect in CD30 +\r CTCL subtypes other than mycosis fungoides (MF) and primary cutaneous\r anaplastic large cell lymphoma (pcALCL) is not clear due to lack of high level\r evidence. In two single arm phase II studies of ADCETRIS, disease activity has\r been shown in the subtypes S\u00e9zary syndrome (SS), lymphomatoid papulosis\r (LyP) and mixed CTCL histology. These data suggest that efficacy and safety can\r be extrapolated to other CTCL CD30+ subtypes. Nevertheless, ADCETRIS should be\r used with caution in other CD30+ CTCL patients after careful consideration of\r the potential benefit\u2011risk on an individual basis (see section 5.1).</span></p>", "ID": "814afaee-2da0-4d42-9a4f-9a6c201d5f45", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The size of the treatment effect in CD30 +\r CTCL subtypes other than mycosis fungoides (MF) and primary cutaneous\r anaplastic large cell lymphoma (pcALCL) is not clear due to lack of high level\r evidence. In two single arm phase II studies of ADCETRIS, disease activity has\r been shown in the subtypes S\u00e9zary syndrome (SS), lymphomatoid papulosis\r (LyP) and mixed CTCL histology. These data suggest that efficacy and safety can\r be extrapolated to other CTCL CD30+ subtypes. Nevertheless, ADCETRIS should be\r used with caution in other CD30+ CTCL patients after careful consideration of\r the potential benefit\u2011risk on an individual basis (see section 5.1).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "4569ffc0-c080-4f46-ac86-f98b15aebd8b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Sodium\r content in excipients</span></u></p>", "ID": "66b5fc9d-2a58-460f-b3ab-8214e9d3b84a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Sodium\r content in excipients", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in;page-break-after:\r avoid\"></p>", "ID": "0a0b2f61-0642-455f-a7c0-a1d8e8867e2b", "Styles": "margin-left:0in;text-indent:0in;page-break-after:\r\navoid", "Classes": "['MsoListBullet']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">This medicinal product contains 13.2 mg\r sodium per vial, equivalent to 0.7% of the WHO recommended maximum daily intake\r of 2 g sodium for an adult. </span></p>", "ID": "22868ab8-8c60-4c66-a7f6-1b5a5d0c9334", "Styles": "margin-left:0in;text-indent:0in", "Classes": "['MsoListBullet']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "This medicinal product contains 13.2 mg\r sodium per vial, equivalent to 0.7% of the WHO recommended maximum daily intake\r of 2 g sodium for an adult. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in\"></p>", "ID": "2ced8f6b-eb31-43bf-aa9f-83cc245f3d5f", "Styles": "margin-left:0in;text-indent:0in", "Classes": "['MsoListBullet']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Traceability</span></u></p>", "ID": "a3e1b030-933d-4783-865f-dd69568e702a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Traceability", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"></span></u></p>", "ID": "ac48fb6e-22ce-4551-8d82-545d5161b1b3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In order to improve the traceability of\r biological medicinal products, the name and the batch number of the\r administered product should be clearly recorded.</span></p>", "ID": "83926a49-ab22-4e2d-9892-27ea3b7e7bc2", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In order to improve the traceability of\r biological medicinal products, the name and the batch number of the\r administered product should be clearly recorded.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "4409ecf0-fa96-48cb-af6e-1675a4a8eec3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h3><span lang=\"EN-GB\">4.5     Interaction with other\r medicinal products and other forms of interaction</span></h3>", "ID": "fcc11e6a-0bff-4081-9abd-a05c4153c357", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "4.5     Interaction with other\r medicinal products and other forms of interaction", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"></p>", "ID": "4fd83442-6e0b-4292-b80a-3f1138cb4a35", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Interaction\r with medicinal products metabolised through CYP3A4 route (CYP3A4\r inhibitors/inducers)</span></u></p>", "ID": "89953861-aa28-4b63-b318-33f9cc5fb6d6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Interaction\r with medicinal products metabolised through CYP3A4 route (CYP3A4\r inhibitors/inducers)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "a4cde8b4-7c55-402e-85ae-caec750217e3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Co\u2011administration of brentuximab\r vedotin with ketoconazole, a strong CYP3A4 and P\u2011gp inhibitor, increased\r the exposure to the antimicrotubule agent MMAE by approximately 73%, and did\r not alter the plasma exposure to brentuximab vedotin. Therefore, co\u2011administration\r of brentuximab vedotin with strong CYP3A4 and P\u2011gp inhibitors may\r increase the incidence of neutropenia. If neutropenia develops, refer to </span><span lang=\"EN-GB\">Tables 1 and 2 for dosing recommendations for neutropenia\r (see section 4.2). </span></p>", "ID": "7105239f-b534-4532-bc09-e45bc14b823a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Co\u2011administration of brentuximab\r vedotin with ketoconazole, a strong CYP3A4 and P\u2011gp inhibitor, increased\r the exposure to the antimicrotubule agent MMAE by approximately 73%, and did\r not alter the plasma exposure to brentuximab vedotin. Therefore, co\u2011administration\r of brentuximab vedotin with strong CYP3A4 and P\u2011gp inhibitors may\r increase the incidence of neutropenia. If neutropenia develops, refer to Tables 1 and 2 for dosing recommendations for neutropenia\r (see section 4.2). ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "3161d9a9-04ac-4fe6-ba4c-bdd4dee0a0d3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Co\u2011administration of </span><span lang=\"EN-GB\">brentuximab vedotin</span><span lang=\"EN-GB\"> with rifampicin, a\r strong CYP3A4 inducer, did not alter the plasma exposure to </span><span lang=\"EN-GB\">brentuximab vedotin</span><span lang=\"EN-GB\">. Though PK data are\r limited, co-administration of rifampicin appeared to reduce plasma\r concentrations of MMAE metabolites that could be assayed. </span></p>", "ID": "c8cc4dd1-6e36-4829-a78e-217398690e20", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Co\u2011administration of brentuximab vedotin with rifampicin, a\r strong CYP3A4 inducer, did not alter the plasma exposure to brentuximab vedotin. Though PK data are\r limited, co-administration of rifampicin appeared to reduce plasma\r concentrations of MMAE metabolites that could be assayed. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "48d45127-76ae-4dbc-9c4c-ad681d923fd2", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Co</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration of midazolam, a CYP3A4 substrate, with brentuximab\r vedotin did not alter the metabolism of midazolam; therefore brentuximab\r vedotin is not expected to alter the exposure to medicines that are metabolised\r by CYP3A4 enzymes.</span></p>", "ID": "3120d498-58ba-479a-9da5-1ec09b245500", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Co\u2011administration of midazolam, a CYP3A4 substrate, with brentuximab\r vedotin did not alter the metabolism of midazolam; therefore brentuximab\r vedotin is not expected to alter the exposure to medicines that are metabolised\r by CYP3A4 enzymes.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"></span></u></p>", "ID": "7d743a1e-1e24-403b-8fdb-05f3794af590", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Doxorubicin,\r vinblastine and dacarbazine (AVD) </span></u></p>", "ID": "62319bca-d8af-438b-a20c-05e5778cf814", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Doxorubicin,\r vinblastine and dacarbazine (AVD) ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "dabcd76a-9514-4795-9557-9c9b241db18c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The serum\r and plasma pharmacokinetic characteristics of </span><span lang=\"EN-GB\">antibody\r drug conjugate (</span><span lang=\"EN-GB\">ADC) and MMAE respectively following\r administration of brentuximab vedotin in combination with AVD were similar to\r that in monotherapy.</span></p>", "ID": "003810e6-cf73-4022-942a-ba8604bf2cd5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The serum\r and plasma pharmacokinetic characteristics of antibody\r drug conjugate (ADC) and MMAE respectively following\r administration of brentuximab vedotin in combination with AVD were similar to\r that in monotherapy.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "a2769be6-6cc7-4b03-8b54-d776526a6de4", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Co\u2011administration of brentuximab\r vedotin did not affect the plasma exposure of AVD.</span></p>", "ID": "9e6d3415-6d58-4c89-ae18-f597c5b35bbd", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Co\u2011administration of brentuximab\r vedotin did not affect the plasma exposure of AVD.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "2c6ffba3-bd25-4812-bcb4-8ac5eac43076", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:windowtext\">Cyclophosphamide, Doxorubicin and Prednisone (CHP)</span></u></p>", "ID": "74f14d6b-532b-4c75-94f6-e4ebd799170b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Cyclophosphamide, Doxorubicin and Prednisone (CHP)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "6c58e318-1c8b-46a9-a56b-fde92413403d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">The serum and plasma pharmacokinetic characteristics\r of ADC and MMAE, respectively, following administration of brentuximab vedotin\r in combination with CHP were similar to that in monotherapy.</span></p>", "ID": "46c45e38-d74d-4b5f-a24a-dd79ae0dc8e0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The serum and plasma pharmacokinetic characteristics\r of ADC and MMAE, respectively, following administration of brentuximab vedotin\r in combination with CHP were similar to that in monotherapy.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "427cf8d6-0641-4e5f-a116-542df294b42e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Co\u2011administration of brentuximab\r vedotin is not expected to affect the exposure of CHP.</span></p>", "ID": "8fb2fcca-1fba-4e4f-88f9-0bc7a31e4370", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Co\u2011administration of brentuximab\r vedotin is not expected to affect the exposure of CHP.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\" style=\"color:windowtext\"></span></u></p>", "ID": "f418cf9b-777c-4c8a-a68f-702e5ee98706", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"color:windowtext\">Bleomycin</span></u></p>", "ID": "5a1a056e-843f-4f90-9738-a3893dfdd40e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Bleomycin", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "92d9a2a0-91f1-47af-88a6-1317db956ba7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">There were no formal drug\u2011drug interaction\r studies with brentuximab vedotin and bleomycin (B). In a phase 1 dose\r finding and safety study (SGN35\u2011009), unacceptable pulmonary toxicity\r (including 2 fatal events) was noted in 11 of 25 patients (44%)\r treated with brentuximab vedotin plus ABVD. No pulmonary toxicity or fatal\r events were reported with brentuximab vedotin + AVD. Therefore, co\u2011administration\r of ADCETRIS with bleomycin is contraindicated (see section 4.3).</span></p>", "ID": "db4ea920-9195-4e29-8ca4-8d1c43b2492f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "There were no formal drug\u2011drug interaction\r studies with brentuximab vedotin and bleomycin (B). In a phase 1 dose\r finding and safety study (SGN35\u2011009), unacceptable pulmonary toxicity\r (including 2 fatal events) was noted in 11 of 25 patients (44%)\r treated with brentuximab vedotin plus ABVD. No pulmonary toxicity or fatal\r events were reported with brentuximab vedotin + AVD. Therefore, co\u2011administration\r of ADCETRIS with bleomycin is contraindicated (see section 4.3).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "0a687920-4c21-4c68-81ee-85b9353a9e38", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h3><span lang=\"EN-GB\">4.6     </span><span lang=\"EN-GB\">Fertility,\r p</span><span lang=\"EN-GB\">regnancy and lactation</span></h3>", "ID": "6d52961d-72b5-4748-812e-751de24d0db4", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "4.6     Fertility,\r pregnancy and lactation", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "ab85de6f-dfe3-47b0-a4c3-2c0fb697362b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Women of\r childbearing potential </span></u></p>", "ID": "c812e673-9ca0-46b4-a7b7-60e827f16c4f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Women of\r childbearing potential ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "07b10f3a-4b96-419d-b287-84dd045d123d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Women of childbearing potential should be\r using two methods of effective contraception during treatment with ADCETRIS and\r until 6 months after treatment. </span></p>", "ID": "604b229f-340e-46ef-93b3-3565c669dbc7", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Women of childbearing potential should be\r using two methods of effective contraception during treatment with ADCETRIS and\r until 6 months after treatment. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "fb21a3fe-054b-4918-820a-ae84d4fd43bb", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy</span></u></p>", "ID": "6e7d5ad2-2c33-46a0-b2f7-9db242b4e3f5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Pregnancy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "0616a6bc-2624-40ff-8b56-9ce74bf8abc7", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">There are no data from the use of ADCETRIS\r in pregnant women. Studies in animals have shown reproductive toxicity (see\r section 5.3). </span></p>", "ID": "8b0987fe-fc68-4839-ac02-85f9863e6e9d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "There are no data from the use of ADCETRIS\r in pregnant women. Studies in animals have shown reproductive toxicity (see\r section 5.3). ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "0afa4471-5ee3-409a-acba-c21b6e621697", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">ADCETRIS should not be used during\r pregnancy unless the benefit to the mother outweighs the potential risks to the\r foetus. If a pregnant woman needs to be treated she should be clearly advised\r on the potential risk to the foetus.</span></p>", "ID": "fe0556c5-9a94-4458-9d45-b2b91ece0f78", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "ADCETRIS should not be used during\r pregnancy unless the benefit to the mother outweighs the potential risks to the\r foetus. If a pregnant woman needs to be treated she should be clearly advised\r on the potential risk to the foetus.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "2fb13ec2-9608-44bd-8e93-f33db93641a1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">See the fertility section below pertaining\r to advice for women whose male partners are being treated with ADCETRIS.</span></p>", "ID": "b62e5af1-7c4b-42d6-9e7f-6b125898b7ae", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "See the fertility section below pertaining\r to advice for women whose male partners are being treated with ADCETRIS.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "bb727afd-b354-4a5c-9271-b34f45e3b397", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast\u2011feeding</span></u></p>", "ID": "87f928e2-1aaa-42e8-bc43-a530ce657295", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Breast\u2011feeding", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "2416a4b9-904a-44c8-81d8-de560a2eead3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">There are no data as to whether brentuximab\r vedotin or its metabolites are excreted in human milk. </span></p>", "ID": "faed4d05-aa27-42c7-bc4e-8957d7cb29ee", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "There are no data as to whether brentuximab\r vedotin or its metabolites are excreted in human milk. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "29d9cea1-f795-4d6b-a00f-c74ce6537545", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">A risk to the newborn/infant cannot be\r excluded. </span></p>", "ID": "e4259466-ddda-4217-8b4f-945afb7c452a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "A risk to the newborn/infant cannot be\r excluded. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "8b56482f-dc72-4d05-b4b5-134a1160d97e", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">A decision should be made whether to\r discontinue breast\u2011feeding or to discontinue/abstain from this therapy,\r taking into account a potential risk of breast\u2011feeding for the child and\r the benefit of therapy for the woman.</span></p>", "ID": "1330f89c-5595-4775-8c77-4169e5c9b981", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "A decision should be made whether to\r discontinue breast\u2011feeding or to discontinue/abstain from this therapy,\r taking into account a potential risk of breast\u2011feeding for the child and\r the benefit of therapy for the woman.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "9bbe0088-7a51-4ff7-835d-0ce86fd6fda2", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Fertility</span></u></p>", "ID": "298a0aa7-d8d2-4c6e-afd1-bf25d678e33f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Fertility", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"></p>", "ID": "bb012e18-42af-48b7-8ca6-15e1667ea603", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In non\u2011clinical studies, </span><span lang=\"EN-GB\">brentuximab vedotin</span><span lang=\"EN-GB\"> treatment has resulted\r in testicular toxicity, and may alter male fertility. MMAE has been shown to\r have aneugenic properties (see section 5.3). Therefore, men being treated\r with this medicine are advised to have sperm samples frozen and stored before\r treatment. Men being treated with this medicine are advised not to father a\r child during treatment and for up to 6 months following the last dose. </span></p>", "ID": "b24ac050-e5d3-44c9-988b-d7ebd9130a62", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In non\u2011clinical studies, brentuximab vedotin treatment has resulted\r in testicular toxicity, and may alter male fertility. MMAE has been shown to\r have aneugenic properties (see section 5.3). Therefore, men being treated\r with this medicine are advised to have sperm samples frozen and stored before\r treatment. Men being treated with this medicine are advised not to father a\r child during treatment and for up to 6 months following the last dose. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "97bc56e0-50ac-45cb-91fc-3286a812d5a8", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h3><span lang=\"EN-GB\">4.7     Effects on ability to drive\r and use machines</span></h3>", "ID": "e306ae89-9150-4801-b260-df3b94748497", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "4.7     Effects on ability to drive\r and use machines", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "354963f8-7edf-4dcb-9aa9-4a859e4bdd2e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">ADCETRIS may have\r a moderate influence on the ability to drive and use machines (e.g. dizziness),\r see section 4.8. </span></p>", "ID": "43ac2c19-f791-47a5-b658-9be7cd63a1a6", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "ADCETRIS may have\r a moderate influence on the ability to drive and use machines (e.g. dizziness),\r see section 4.8. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "16acf4a5-790e-42a7-8c7d-f56cdc673274", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h3><span lang=\"EN-GB\">4.8     Undesirable effects</span></h3>", "ID": "e7a01196-aca6-40dd-9804-3421dfcb4a86", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "4.8     Undesirable effects", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"></p>", "ID": "cb1716d8-4409-4555-89ba-8155ba139f8f", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Summary\r of the safety profile</span></u></p>", "ID": "e228194f-1b45-4065-b12a-718beda87ff5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Summary\r of the safety profile", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"></p>", "ID": "b5fcbc38-f922-4d36-9dba-4bde1ed2f398", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The safety\r profile of ADCETRIS is based on available clinical trial data, the Named\r Patient Program (NPP), and post\u2011marketing experience to date. Frequencies\r of adverse reactions described below and in Table 5 have been determined\r based on data generated from clinical studies. </span></p>", "ID": "d646278d-441d-4dfd-9bf7-b907bce2fdc6", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The safety\r profile of ADCETRIS is based on available clinical trial data, the Named\r Patient Program (NPP), and post\u2011marketing experience to date. Frequencies\r of adverse reactions described below and in Table 5 have been determined\r based on data generated from clinical studies. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "b17eaeeb-ac3c-42b5-905e-e0c1931a1c72", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">Monotherapy</span></i></p>", "ID": "8e3b3f14-4d96-4c33-8e44-25e1f285f56d", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Monotherapy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"></p>", "ID": "f65a4df4-2811-4ea2-ac39-fc5700d0ad98", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:windowtext\">In the pooled dataset of </span><span lang=\"EN-GB\" style=\"color:windowtext\">ADCETRIS</span><span lang=\"EN-GB\" style=\"color:windowtext\">\r as monotherapy across HL, sALCL and CTCL studies (SG035\u20110003, SG035\u20110004,\r SGN35\u2011005, SGN35\u2011006, C25001 and C</span><span lang=\"EN-GB\" style=\"color:windowtext\">25007, see section 5.1)</span><span lang=\"EN-GB\" style=\"color:windowtext\"> the most frequent adverse reactions (\u2265 10%)\r were infections,</span><span lang=\"EN-GB\" style=\"color:windowtext\"> peripheral\r sensory neuropathy, nausea</span><span lang=\"EN-GB\" style=\"color:windowtext\">,\r fatigue, diarrhoea, pyrexia, upper respiratory tract infection, neutropenia, rash,\r cough, vomiting, arthralgia, peripheral motor neuropathy</span><span lang=\"EN-GB\" style=\"color:windowtext\">, infusion-related reactions, pruritus,\r constipation, dyspnoea, weight decreased, myalgia and abdominal pain.</span></p>", "ID": "10146626-383d-4ba1-8a81-0b0d5e19e8ae", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In the pooled dataset of ADCETRIS\r as monotherapy across HL, sALCL and CTCL studies (SG035\u20110003, SG035\u20110004,\r SGN35\u2011005, SGN35\u2011006, C25001 and C25007, see section 5.1) the most frequent adverse reactions (\u2265 10%)\r were infections, peripheral\r sensory neuropathy, nausea,\r fatigue, diarrhoea, pyrexia, upper respiratory tract infection, neutropenia, rash,\r cough, vomiting, arthralgia, peripheral motor neuropathy, infusion-related reactions, pruritus,\r constipation, dyspnoea, weight decreased, myalgia and abdominal pain.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "754ca1ad-e34f-4357-8643-6a5d432c97b6", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Serious adverse\r drug reactions occurred in 12% of patients. The frequency of unique serious\r adverse drug reactions was \u2264 1%.</span></p>", "ID": "1aa13f14-dddd-4f68-801c-6a9240116dd9", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Serious adverse\r drug reactions occurred in 12% of patients. The frequency of unique serious\r adverse drug reactions was \u2264 1%.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "7e1afb0f-97f0-4416-982a-31fae9686a3a", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Adverse events\r led to treatment discontinuation in 24% of patients receiving ADCETRIS. </span></p>", "ID": "cb2b66a9-80cb-4a12-9efa-0f84db81d132", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Adverse events\r led to treatment discontinuation in 24% of patients receiving ADCETRIS. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "e9f8ee67-f3c9-4a1d-905b-fa3fea5efec7", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:windowtext\">The safety data in patients retreated with ADCETRIS\r (SGN35\u2011006, see section 5.1) were consistent with those observed in\r the combined pivotal phase 2 studies, with the exception of peripheral\r motor neuropathy, which had a higher incidence (28% vs. 9% in the pivotal phase\r 2 studies) and was primarily Grade 2. Patients also had a higher incidence\r of arthralgia, Grade 3 anaemia, and back pain compared to patients\r observed in the combined pivotal phase 2 studies.</span></p>", "ID": "9ef3a7d7-902d-4ebe-95b2-82a48b9c1b3e", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The safety data in patients retreated with ADCETRIS\r (SGN35\u2011006, see section 5.1) were consistent with those observed in\r the combined pivotal phase 2 studies, with the exception of peripheral\r motor neuropathy, which had a higher incidence (28% vs. 9% in the pivotal phase\r 2 studies) and was primarily Grade 2. Patients also had a higher incidence\r of arthralgia, Grade 3 anaemia, and back pain compared to patients\r observed in the combined pivotal phase 2 studies.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "89f9bcaa-4178-4087-ab7f-9c77820bb8f7", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">T</span><span lang=\"EN-GB\">he safety data in\r patients with relapsed or refractory HL who had not received an autologous stem\r cell transplant and were treated with the recommended dose of 1.8 mg/kg\r every three weeks in a single\u2011arm phase 4 study (n = 60), the\r phase 1 dose escalation and clinical pharmacology studies (n = 15 patients)\r and in the NPP (n = 26 patients) (see section 5.1) were\r consistent with the safety profile of the pivotal clinical studies. </span></p>", "ID": "d3bfedd9-d5fe-49a8-a238-5562951ee89a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The safety data in\r patients with relapsed or refractory HL who had not received an autologous stem\r cell transplant and were treated with the recommended dose of 1.8 mg/kg\r every three weeks in a single\u2011arm phase 4 study (n = 60), the\r phase 1 dose escalation and clinical pharmacology studies (n = 15 patients)\r and in the NPP (n = 26 patients) (see section 5.1) were\r consistent with the safety profile of the pivotal clinical studies. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "475099aa-d088-47d6-85db-86e5ac758a79", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Combination\r therapy </span></i></p>", "ID": "d99173c0-4ec9-4d08-aa96-04cf1b750eba", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Combination\r therapy ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "0b6f6738-0ef5-4bae-b525-365ed534cc8d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For safety information of chemotherapy\r agents given in combination with ADCETRIS (doxorubicin, vinblastine and\r dacarbazine (AVD) or cyclophosphamide, doxorubicin and prednisone (CHP)), refer\r to their summary of product characteristics. </span></p>", "ID": "30d82147-e389-4c5f-9165-81ce91b7acc0", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "For safety information of chemotherapy\r agents given in combination with ADCETRIS (doxorubicin, vinblastine and\r dacarbazine (AVD) or cyclophosphamide, doxorubicin and prednisone (CHP)), refer\r to their summary of product characteristics. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "8a7c944c-55f0-4afb-8d7d-386659e9ee33", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the studies of ADCETRIS as combination\r therapy in 662 patients with previously untreated advanced HL (C25003) and\r 223 patients with previously untreated CD30+ </span>peripheral T-cell lymphoma\r (<span lang=\"EN-GB\">PTCL) (SGN35\u2011014), the most common adverse reactions\r (\u2265 10%) were: infections, neutropenia, peripheral sensory\r neuropathy, nausea, constipation, vomiting, diarrhoea, fatigue, pyrexia,\r alopecia, anaemia, weight decreased, stomatitis, febrile neutropenia, abdominal\r pain, decreased appetite, insomnia, bone pain, rash, cough, dyspnoea, arthralgia,\r myalgia, back pain, peripheral motor neuropathy, upper respiratory tract\r infection, and dizziness. </span></p>", "ID": "78e5f1f9-801f-4452-83f8-a250d49866d9", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In the studies of ADCETRIS as combination\r therapy in 662 patients with previously untreated advanced HL (C25003) and\r 223 patients with previously untreated CD30+ peripheral T-cell lymphoma\r (PTCL) (SGN35\u2011014), the most common adverse reactions\r (\u2265 10%) were: infections, neutropenia, peripheral sensory\r neuropathy, nausea, constipation, vomiting, diarrhoea, fatigue, pyrexia,\r alopecia, anaemia, weight decreased, stomatitis, febrile neutropenia, abdominal\r pain, decreased appetite, insomnia, bone pain, rash, cough, dyspnoea, arthralgia,\r myalgia, back pain, peripheral motor neuropathy, upper respiratory tract\r infection, and dizziness. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "886fa28a-d3a9-4c36-ad90-3d01756f6ec8", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In patients receiving ADCETRIS combination\r therapy, serious adverse reactions occurred in 34% of patients. Serious adverse\r reactions occurring in \u2265 3% of patients included febrile neutropenia\r (15%), pyrexia (5%), and neutropenia (3%). </span></p>", "ID": "eef0a9f3-2c43-4c38-aa44-4dba9f010a4a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In patients receiving ADCETRIS combination\r therapy, serious adverse reactions occurred in 34% of patients. Serious adverse\r reactions occurring in \u2265 3% of patients included febrile neutropenia\r (15%), pyrexia (5%), and neutropenia (3%). ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "6d6c5380-37a3-4cda-8af5-03cefb29dfac", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Adverse events led to treatment discontinuation\r in 10% of patients. Adverse events that led to treatment discontinuation in\r \u2265 2% of patients included peripheral sensory neuropathy, and peripheral\r neuropathy.</span></p>", "ID": "ddb80bec-b4a5-4f30-b90c-4cc41bce3b9d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Adverse events led to treatment discontinuation\r in 10% of patients. Adverse events that led to treatment discontinuation in\r \u2265 2% of patients included peripheral sensory neuropathy, and peripheral\r neuropathy.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "8f6f4b39-b623-4847-b67e-cfda899bbf50", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Tabulated\r list of adverse reactions</span></u></p>", "ID": "fc311f96-8158-4440-9426-5e28b49ad59f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Tabulated\r list of adverse reactions", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "9322aec2-82d7-419a-82a5-1aea99ea67e6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Adverse\r reactions for ADCETRIS are listed by MedDRA System Organ Class and Preferred\r Term (see Table 5). Within each System Organ Class, adverse reactions are\r listed under frequency categories of: Very common (\u2265 1/10); Common\r (\u2265 1/100 to &lt; 1/10); Uncommon (\u2265 1/1,000 to &lt; 1/100);\r Rare (\u2265 1/10,000 to &lt; 1/1,000); Very rare (&lt; 1/10,000);\r not known (cannot be estimated from the available data). </span><span lang=\"EN-GB\">Within each frequency grouping, adverse reactions are presented in\r the order of decreasing seriousness.</span></p>", "ID": "7969ca11-89b5-4271-bd9d-ae17f0cd3306", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Adverse\r reactions for ADCETRIS are listed by MedDRA System Organ Class and Preferred\r Term (see Table 5). Within each System Organ Class, adverse reactions are\r listed under frequency categories of: Very common (\u2265 1/10); Common\r (\u2265 1/100 to < 1/10); Uncommon (\u2265 1/1,000 to < 1/100);\r Rare (\u2265 1/10,000 to < 1/1,000); Very rare (< 1/10,000);\r not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in\r the order of decreasing seriousness.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "33fd4a6e-4954-4410-8f75-f1f04840380e", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 5:\r Adverse reactions to ADCETRIS <br/> <br/> </span></b></p>", "ID": "3ad2ec1f-6c78-4f46-a835-021c3acc421d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 5:\r Adverse reactions to ADCETRIS   ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:493.5pt;border-collapse:collapse;border:none\" width=\"658\"> <thead> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><a name=\"_Hlk5943718\"><b><span lang=\"EN-GB\">System organ class</span></b></a></p> </td> <td style=\"width:212.6pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Adverse reactions (monotherapy)</span></b></p> </td> <td style=\"width:169.15pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Adverse reactions <br/>\r    (combination therapy)</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Infections\r    and infestations</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very\r    common: </span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infection</span><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\">, upper respiratory tract\r    infection</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Infection</span><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\">, upper respiratory tract infection</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"PT\">Herpes\r    zoster, pneumonia, herpes simplex, oral candidiasis</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Pneumonia, oral candidiasis,\r    sepsis/septic shock, herpes zoster</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pneumocystis\r    jiroveci pneumonia, staphylococcal bacteraemia, cytomegalovirus infection or\r    reactivation,</span><span lang=\"EN-GB\"> sepsis/septic shock</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Herpes simplex, Pneumocystis jiroveci\r    pneumonia</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Frequency not known:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Progressive multifocal\r    leukoencephalopathy</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Blood\r    and lymphatic system disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very\r    common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Neutropenia</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Neutropenia<sup>a</sup>, anaemia,\r    febrile neutropenia</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaemia, thrombocytopenia</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Thrombocytopenia</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Febrile neutropenia</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Immune\r    system disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic reaction</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic transfusion reaction</span></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Metabolism\r    and nutrition disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very\r    common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Decreased appetite</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Hyperglycaemia</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Hyperglycaemia</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tumour lysis syndrome</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Tumour lysis syndrome</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Psychiatric disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Very common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Insomnia</span></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Nervous\r    system disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very\r    common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Peripheral sensory neuropathy,\r    peripheral motor neuropathy</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Peripheral sensory neuropathy<sup>a</sup>,\r    peripheral motor neuropathy<sup>a</sup>, dizziness</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Dizziness</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Demyelinating polyneuropathy</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Respiratory,\r    thoracic and mediastinal disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Very common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Cough, dyspnoea</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Cough, dyspnoea</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Gastrointestinal\r    disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very\r    common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Nausea, diarrhoea, vomiting, constipation,\r    abdominal pain</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Nausea, constipation, vomiting,\r    diarrhoea, abdominal pain, stomatitis</span></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Pancreatitis acute</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Pancreatitis acute</span></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Hepatobiliary\r    disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Alanine\r    aminotransferase/aspartate aminotransferase (ALT/AST) increased</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Alanine\r    aminotransferase/aspartate aminotransferase (ALT/AST) increased</span></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Skin\r    and subcutaneous tissue disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very\r    common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Rash<sup>a</sup>, pruritus</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Alopecia, rash<sup>a</sup></span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Alopecia</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Pruritus</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Uncommon:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stevens-Johnson syndrome/toxic epidermal\r    necrolysis</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Stevens-Johnson syndrome<sup>b</sup></span></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Musculoskeletal\r    and connective tissue disorders</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very\r    common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Arthralgia, myalgia</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Bone pain, arthralgia, myalgia, back\r    pain</span></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:14.35pt\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Back pain</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\"></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:15.1pt\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">General\r    disorders and administration site conditions</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Very\r    common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Fatigue,\r    pyrexia, infusion-related reactions<sup>a</sup></span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Fatigue,\r    pyrexia</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Chills</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infusion-related\r    reactions<sup>a</sup>, chills</span></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td colspan=\"3\" style=\"width:493.5pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"658\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Investigations</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:111.75pt;border:solid windowtext 1.0pt;\r    border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"149\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Very common:</span></p> </td> <td style=\"width:212.6pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"283\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Weight\r    decreased</span></p> </td> <td style=\"width:169.15pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"226\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Weight\r    decreased</span></p> </td> </tr> </thead> </table>", "ID": "59ee6aeb-9b68-40e5-99fe-469028560abf", "Styles": "width:493.5pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "    System organ class   Adverse reactions (monotherapy)   Adverse reactions \r    (combination therapy)     Infections\r    and infestations     Very\r    common:    Infectiona, upper respiratory tract\r    infection   Infectiona, upper respiratory tract infection     Common:   Herpes\r    zoster, pneumonia, herpes simplex, oral candidiasis   Pneumonia, oral candidiasis,\r    sepsis/septic shock, herpes zoster     Uncommon:   Pneumocystis\r    jiroveci pneumonia, staphylococcal bacteraemia, cytomegalovirus infection or\r    reactivation, sepsis/septic shock   Herpes simplex, Pneumocystis jiroveci\r    pneumonia     Frequency not known:   Progressive multifocal\r    leukoencephalopathy        Blood\r    and lymphatic system disorders     Very\r    common:   Neutropenia   Neutropeniaa, anaemia,\r    febrile neutropenia     Common:   Anaemia, thrombocytopenia   Thrombocytopenia     Uncommon:   Febrile neutropenia        Immune\r    system disorders     Uncommon:   Anaphylactic reaction   Anaphylactic transfusion reaction     Metabolism\r    and nutrition disorders     Very\r    common:      Decreased appetite     Common:   Hyperglycaemia   Hyperglycaemia     Uncommon:   Tumour lysis syndrome   Tumour lysis syndrome     Psychiatric disorders     Very common:      Insomnia     Nervous\r    system disorders     Very\r    common:   Peripheral sensory neuropathy,\r    peripheral motor neuropathy   Peripheral sensory neuropathya,\r    peripheral motor neuropathya, dizziness     Common:   Dizziness        Uncommon:   Demyelinating polyneuropathy        Respiratory,\r    thoracic and mediastinal disorders     Very common:   Cough, dyspnoea   Cough, dyspnoea     Gastrointestinal\r    disorders     Very\r    common:   Nausea, diarrhoea, vomiting, constipation,\r    abdominal pain   Nausea, constipation, vomiting,\r    diarrhoea, abdominal pain, stomatitis     Uncommon:   Pancreatitis acute   Pancreatitis acute     Hepatobiliary\r    disorders     Common:   Alanine\r    aminotransferase/aspartate aminotransferase (ALT/AST) increased   Alanine\r    aminotransferase/aspartate aminotransferase (ALT/AST) increased     Skin\r    and subcutaneous tissue disorders     Very\r    common:   Rasha, pruritus   Alopecia, rasha     Common:   Alopecia   Pruritus     Uncommon:   Stevens-Johnson syndrome/toxic epidermal\r    necrolysis   Stevens-Johnson syndromeb     Musculoskeletal\r    and connective tissue disorders     Very\r    common:   Arthralgia, myalgia   Bone pain, arthralgia, myalgia, back\r    pain     Common:   Back pain        General\r    disorders and administration site conditions     Very\r    common:   Fatigue,\r    pyrexia, infusion-related reactionsa   Fatigue,\r    pyrexia     Common:   Chills   Infusion-related\r    reactionsa, chills     Investigations     Very common:   Weight\r    decreased   Weight\r    decreased    ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in\"><sup><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Represents pooling\r of preferred terms.</span></p>", "ID": "ec2c8124-3fd7-4852-964b-12749001224f", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "a.Represents pooling\r of preferred terms.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in\"><sup><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">b.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Toxic epidermal\r necrolysis was not reported in the combination therapy setting.</span></p>", "ID": "df26b203-337a-4c7b-8aa3-b11f2267851d", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "b.Toxic epidermal\r necrolysis was not reported in the combination therapy setting.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "4ada8b6e-4a4a-46dc-96d9-29ba44368bcc", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Description\r of selected adverse reactions</span></u></p>", "ID": "c857745c-cb23-4c84-bb74-288520826c52", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Description\r of selected adverse reactions", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "f9136c66-ab84-45f7-b082-920adac1f2ec", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Neutropenia and febrile neutropenia</span></i></p>", "ID": "24abd427-5209-4f01-8af1-44ed2efa5ac2", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Neutropenia and febrile neutropenia", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;text-indent:28.35pt;page-break-after:\r avoid\"></p>", "ID": "f6cd47a1-192e-42a5-bd75-dee65ee57b22", "Styles": "margin-bottom:0in;text-indent:28.35pt;page-break-after:\r\navoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Monotherapy</span></p>", "ID": "62bd7dc8-7d81-4a91-bffd-61cb29a1bed2", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Monotherapy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "62bcb508-a0a3-4b6d-ba81-ce8491a403ca", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">In clinical trials, neutropenia</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> led to dose delays in 14% of patients. Grade 3\r neutropenia was reported in </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">13%\r and Grade 4 neutropenia was reported in 5% of patients. No patients\r required dose reduction or discontinued treatment for neutropenia. </span></p>", "ID": "8573ee7d-8112-4606-8955-429bbebe0a69", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In clinical trials, neutropenia led to dose delays in 14% of patients. Grade 3\r neutropenia was reported in 13%\r and Grade 4 neutropenia was reported in 5% of patients. No patients\r required dose reduction or discontinued treatment for neutropenia. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "d33fcd9c-60f0-4a8d-961c-7cfc965b4fb4", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Severe and prolonged (\u2265 1 week)\r neutropenia can occur with this treatment which may increase the risk of\r patients developing serious infections. Febrile neutropenia reported in &lt; 1%\r of the patients (see section 4.2).</span></p>", "ID": "a48c3aa6-af80-48e0-a59d-c1c2bed36a6b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Severe and prolonged (\u2265 1 week)\r neutropenia can occur with this treatment which may increase the risk of\r patients developing serious infections. Febrile neutropenia reported in < 1%\r of the patients (see section 4.2).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "3a991f9c-a645-4188-9809-f319146a0633", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">In the pivotal phase\r 2 population </span><span lang=\"EN-GB\" style=\"color:windowtext\">(SG035\u20110003\r and SG035\u20110004)</span><span lang=\"EN-GB\" style=\"color:windowtext\">, </span><span lang=\"EN-GB\" style=\"color:windowtext\">the median duration of Grade 3 or\r Grade 4 neutropenia was limited (1 week); 2% of patients had\r Grade 4 neutropenia that lasted \u2265 7 days. Less </span><span lang=\"EN-GB\" style=\"color:windowtext\">than half of the patients in the pivotal\r phase 2 population with Grade 3 or Grade 4 neutropenia had\r temporally associated infections, and the majority of temporally associated\r infections were Grade 1 or Grade 2.</span></p>", "ID": "afe61f3e-ff3e-40c8-8fd8-3c88a522ab93", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In the pivotal phase\r 2 population (SG035\u20110003\r and SG035\u20110004), the median duration of Grade 3 or\r Grade 4 neutropenia was limited (1 week); 2% of patients had\r Grade 4 neutropenia that lasted \u2265 7 days. Less than half of the patients in the pivotal\r phase 2 population with Grade 3 or Grade 4 neutropenia had\r temporally associated infections, and the majority of temporally associated\r infections were Grade 1 or Grade 2.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "7e5e4e47-2998-4bf9-8a24-9e6095d5b1c9", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:black\">Combination therapy</span></p>", "ID": "afbbe736-7418-4610-b73a-98e529261342", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Combination therapy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "63517c73-c07d-4ef4-803e-3365398542d7", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In the clinical\r trials of </span><span lang=\"EN-GB\">ADCETRIS</span><span lang=\"EN-GB\"> as\r combination therapy, neutropenia led to dose delays in 19% of patients. Grade 3\r neutropenia was reported in 17% and Grade 4 neutropenia was reported in 41%\r of patients. Two percent of patients required dose reduction and &lt; 1%\r discontinued one of more of the study drugs due to neutropenia. </span></p>", "ID": "93879423-ba2b-4624-bced-c0aae071b28e", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In the clinical\r trials of ADCETRIS as\r combination therapy, neutropenia led to dose delays in 19% of patients. Grade 3\r neutropenia was reported in 17% and Grade 4 neutropenia was reported in 41%\r of patients. Two percent of patients required dose reduction and < 1%\r discontinued one of more of the study drugs due to neutropenia. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "995b1a7d-747b-4238-9639-af2868fd2fa2", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Febrile\r neutropenia was reported in 20% of the patients who did not receive primary\r prophylaxis with G-CSF (see section 4.2). The frequency of febrile\r neutropenia was 13% in patients who received primary prophylaxis with G-CSF. </span></p>", "ID": "68b527ac-688d-4847-935e-552e0bf405d2", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Febrile\r neutropenia was reported in 20% of the patients who did not receive primary\r prophylaxis with G-CSF (see section 4.2). The frequency of febrile\r neutropenia was 13% in patients who received primary prophylaxis with G-CSF. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "03357b4a-ff4b-49ce-af5c-b29d113f1787", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Serious\r infections and opportunistic infections</span></i></p>", "ID": "bf2f09be-5be1-430f-ad50-0204e99d09ab", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Serious\r infections and opportunistic infections", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "21817383-590e-4233-ba27-a080df1e5f8c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Monotherapy</span></p>", "ID": "794db76a-3712-4ea9-abf1-f545aab44249", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Monotherapy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "2e8fb846-bc6a-43be-9c2d-c213b0223f6c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">In clinical\r trials, serious infections </span><span lang=\"EN-GB\">and opportunistic infections\r occurred in 10% of patients, sepsis or septic shock occurred in &lt; 1% of\r the patients. The most commonly reported opportunistic infections were herpes\r zoster and herpes simplex.</span></p>", "ID": "50f91fe3-efa5-409f-9ce6-1f69d970c5e2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In clinical\r trials, serious infections and opportunistic infections\r occurred in 10% of patients, sepsis or septic shock occurred in < 1% of\r the patients. The most commonly reported opportunistic infections were herpes\r zoster and herpes simplex.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "ec8b7757-5cdc-4570-8138-3d8606c80f99", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Combination therapy</span></p>", "ID": "53177d81-39f4-4b27-977b-1787fec3dd3d", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Combination therapy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"></p>", "ID": "ea481153-bc97-454f-b5c2-251998eeafb5", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">In the clinical trials of </span><span lang=\"EN-GB\">ADCETRIS</span><span lang=\"EN-GB\"> as combination therapy, </span><span lang=\"EN-GB\">serious infections\r including opportunistic infections occurred in 15% of patients; sepsis,\r neutropenic sepsis, septic shock or bacteraemia occurred in 4% of the patients.\r The most commonly reported opportunistic infections were herpes viral\r infections.</span></p>", "ID": "6467403f-6791-4898-9854-6195eb152295", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In the clinical trials of ADCETRIS as combination therapy, serious infections\r including opportunistic infections occurred in 15% of patients; sepsis,\r neutropenic sepsis, septic shock or bacteraemia occurred in 4% of the patients.\r The most commonly reported opportunistic infections were herpes viral\r infections.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "94836f70-c042-4a6d-9a30-488ac61b68b2", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Peripheral neuropathy</span></i></p>", "ID": "a0e219bd-dd9c-4bd5-a8ad-f3010eec5e6b", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Peripheral neuropathy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "9881d05d-09ee-481c-b003-e15e0797bcb8", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Monotherapy </span></p>", "ID": "11e2ae8d-91cc-42e9-9a3b-741c0c8247fc", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Monotherapy ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "af7cffaa-22ab-4070-bbf1-463e6ff23207", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span style=\"font-size:11.0pt\">In\r clinical trials treatment emergent neuropathy occurred </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">in 59% of the population, peripheral motor neuropathy occurred\r in 14% of patients. </span><span style=\"font-size:11.0pt\">Peripheral neuropathy\r led to treatment discontinuation in 15%, dose reductions in 15%, and </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">dose delays in 17% of patients. </span><span style=\"font-size:11.0pt\">For patients who experienced peripheral neuropathy the\r median time of onset of peripheral neuropathy was 12 weeks. The median\r duration of treatment for patients who discontinued due to peripheral\r neuropathy was 12 cycles.</span></p>", "ID": "1bf15bf0-6fcb-47ca-bffa-cc09434bec47", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In\r clinical trials treatment emergent neuropathy occurred in 59% of the population, peripheral motor neuropathy occurred\r in 14% of patients. Peripheral neuropathy\r led to treatment discontinuation in 15%, dose reductions in 15%, and dose delays in 17% of patients. For patients who experienced peripheral neuropathy the\r median time of onset of peripheral neuropathy was 12 weeks. The median\r duration of treatment for patients who discontinued due to peripheral\r neuropathy was 12 cycles.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "abb90302-190b-4dab-a120-61ed9a8cfe5d", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Among patients who\r experienced peripheral neuropathy in the pivotal phase 2 studies\r (SG035-0003 and SG035\u20110004) and randomised phase 3 monotherapy\r studies (SGN35\u2011005 and C25001), the median follow up time from end of\r treatment until last evaluation ranged from 48.9 to 98 weeks. At the time\r of last evaluation, most of the patients (82-85%) who experienced peripheral\r neuropathy had resolution or improvement of their peripheral neuropathy\r symptoms. The median time from onset to resolution or improvement for all\r events ranged from 16 to 23.4 weeks. </span></p>", "ID": "51813288-39c7-44a8-8f82-d106eddc54cd", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Among patients who\r experienced peripheral neuropathy in the pivotal phase 2 studies\r (SG035-0003 and SG035\u20110004) and randomised phase 3 monotherapy\r studies (SGN35\u2011005 and C25001), the median follow up time from end of\r treatment until last evaluation ranged from 48.9 to 98 weeks. At the time\r of last evaluation, most of the patients (82-85%) who experienced peripheral\r neuropathy had resolution or improvement of their peripheral neuropathy\r symptoms. The median time from onset to resolution or improvement for all\r events ranged from 16 to 23.4 weeks. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "122ce43a-59c3-434e-a8eb-b1046d27d48e", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In patients with relapsed or refractory HL\r or sALCL who were retreated with ADCETRIS (SGN35\u2011006), the majority of\r patients (80%) also had improvement or resolution of their peripheral\r neuropathy symptoms at the time of last evaluation.</span></p>", "ID": "a016de73-9d1d-4c6d-a114-f708aa0a84d6", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In patients with relapsed or refractory HL\r or sALCL who were retreated with ADCETRIS (SGN35\u2011006), the majority of\r patients (80%) also had improvement or resolution of their peripheral\r neuropathy symptoms at the time of last evaluation.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "f2ae2ebf-03b4-4385-95de-a00667753ae0", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><a name=\"_Hlk519675104\"><span lang=\"EN-GB\">Combination therapy</span></a></p>", "ID": "663ace8e-a038-469b-87d4-af37bc4352d2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Combination therapy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "90570e12-0fbe-4e3f-ae94-30ab4f1f4534", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">In the clinical\r trial of ADCETRIS as combination therapy with AVD, </span><span lang=\"EN-GB\" style=\"color:windowtext\">treatment emergent neuropathy occurred in 67% of the\r population; peripheral motor neuropathy occurred in 11% of patients. Peripheral\r neuropathy led to treatment discontinuation in 7%, dose reductions in 21%, and\r dose delays in 1% of patients. For patients who experienced peripheral\r neuropathy the median time of onset of peripheral neuropathy was 8 weeks.\r Patients who discontinued due to peripheral neuropathy received a median of 8\r doses of ADCETRIS+AVD (A+AVD) before discontinuation of one or more agents. </span></p>", "ID": "5f8104ba-c11e-451a-9f26-13914938ea04", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In the clinical\r trial of ADCETRIS as combination therapy with AVD, treatment emergent neuropathy occurred in 67% of the\r population; peripheral motor neuropathy occurred in 11% of patients. Peripheral\r neuropathy led to treatment discontinuation in 7%, dose reductions in 21%, and\r dose delays in 1% of patients. For patients who experienced peripheral\r neuropathy the median time of onset of peripheral neuropathy was 8 weeks.\r Patients who discontinued due to peripheral neuropathy received a median of 8\r doses of ADCETRIS+AVD (A+AVD) before discontinuation of one or more agents. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "9e711823-5ec0-4b41-bcd0-b9c1bf3686d4", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Among patients who\r experienced peripheral neuropathy, the median follow up time from end of\r treatment until last evaluation was approximately 91 weeks. At the time of\r last evaluation, most of the patients (76%) who experienced peripheral\r neuropathy had resolution or improvement of their peripheral neuropathy\r symptoms. The median time from onset to resolution or improvement of peripheral\r neuropathy events was 10 weeks (ranged from 0 weeks to 139 weeks).</span></p>", "ID": "4e2317b7-eb66-495e-9c66-9d5280ffdf44", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Among patients who\r experienced peripheral neuropathy, the median follow up time from end of\r treatment until last evaluation was approximately 91 weeks. At the time of\r last evaluation, most of the patients (76%) who experienced peripheral\r neuropathy had resolution or improvement of their peripheral neuropathy\r symptoms. The median time from onset to resolution or improvement of peripheral\r neuropathy events was 10 weeks (ranged from 0 weeks to 139 weeks).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "2bddc51e-b18d-4ba7-9322-6d1cc64d5d89", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the clinical trial of ADCETRIS as\r combination therapy with CHP, </span><span lang=\"EN-GB\" style=\"color:windowtext\">treatment\r emergent neuropathy occurred in 52% of the population; peripheral motor\r neuropathy occurred in 9% of patients. Peripheral neuropathy led to treatment\r discontinuation in 1%, dose reductions in 7% and dose delays in </span><span lang=\"EN-GB\">&lt;</span><span lang=\"EN-GB\" style=\"color:windowtext\">1% of patients.\r For patients who experienced peripheral neuropathy the median time of onset was\r 9.1 weeks. Patients who discontinued due to peripheral neuropathy received\r a median of 5 doses of ADCETRIS + CHP (A+CHP) before\r discontinuation of one or more agents.</span></p>", "ID": "46429630-19be-49a7-8824-585cdeb50b35", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In the clinical trial of ADCETRIS as\r combination therapy with CHP, treatment\r emergent neuropathy occurred in 52% of the population; peripheral motor\r neuropathy occurred in 9% of patients. Peripheral neuropathy led to treatment\r discontinuation in 1%, dose reductions in 7% and dose delays in <1% of patients.\r For patients who experienced peripheral neuropathy the median time of onset was\r 9.1 weeks. Patients who discontinued due to peripheral neuropathy received\r a median of 5 doses of ADCETRIS + CHP (A+CHP) before\r discontinuation of one or more agents.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "ba4f8c6b-1a5a-42af-8528-05f0ac87c0b5", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Among patients who\r experienced peripheral neuropathy, the median follow up time from end of\r treatment until last evaluation was approximately 177 weeks. At the time\r of last evaluation, 64% who experienced peripheral neuropathy had resolution or\r improvement of their peripheral neuropathy symptoms. The median time from onset\r to resolution or improvement of peripheral neuropathy events was 19.0 weeks\r (ranged from 0 weeks to 205 weeks).</span></p>", "ID": "1de0eb7e-4eb6-4179-90f7-e9f4d2361612", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Among patients who\r experienced peripheral neuropathy, the median follow up time from end of\r treatment until last evaluation was approximately 177 weeks. At the time\r of last evaluation, 64% who experienced peripheral neuropathy had resolution or\r improvement of their peripheral neuropathy symptoms. The median time from onset\r to resolution or improvement of peripheral neuropathy events was 19.0 weeks\r (ranged from 0 weeks to 205 weeks).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "47fc57f2-967e-4f2d-a395-b0ff75bddea1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Infusion-related\r reactions</span></i></p>", "ID": "59aa6612-e6f0-4b40-829a-5df5a600dc64", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Infusion-related\r reactions", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "ae13d127-a2a6-4f1e-903f-62490e25ff0c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Monotherapy</span></p>", "ID": "987626a9-8eee-48f5-8484-e06c28f52c02", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Monotherapy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "7c9ffcbe-9ad7-463a-8c51-bf79f6c024ba", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">IRRs, such as headache, rash, back pain,\r vomiting, chills, nausea, dyspnoea, pruritus and cough were reported in 13% of\r patients. </span><span lang=\"EN-GB\">Anaphylactic reactions have been reported\r (see section 4.4). Symptoms of an anaphylactic reaction may include, but\r are not limited to, urticaria, angioedema, hypotension and bronchospasm. </span></p>", "ID": "df373a58-0e28-489b-88a4-2035116da622", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "IRRs, such as headache, rash, back pain,\r vomiting, chills, nausea, dyspnoea, pruritus and cough were reported in 13% of\r patients. Anaphylactic reactions have been reported\r (see section 4.4). Symptoms of an anaphylactic reaction may include, but\r are not limited to, urticaria, angioedema, hypotension and bronchospasm. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "8f978428-6821-4252-8ffd-53c4074abc43", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Combination\r therapy</span></p>", "ID": "e064953a-0731-44dc-a20e-c15aed43a888", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Combination\r therapy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "eb8dcf33-7f2c-4041-8571-74745630b7a6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">IRRs, such as headache, rash, back pain,\r vomiting, chills, nausea, dyspnoea, pruritus, cough, infusion site pain and\r pyrexia were reported in 8% of patients. Anaphylactic reactions have been\r reported (see section 4.4). Symptoms of an anaphylactic reaction may\r include, but are not limited to, urticaria, angioedema, hypotension and\r bronchospasm.</span></p>", "ID": "30781f5b-35ad-4663-9dc2-e9879a4361b1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "IRRs, such as headache, rash, back pain,\r vomiting, chills, nausea, dyspnoea, pruritus, cough, infusion site pain and\r pyrexia were reported in 8% of patients. Anaphylactic reactions have been\r reported (see section 4.4). Symptoms of an anaphylactic reaction may\r include, but are not limited to, urticaria, angioedema, hypotension and\r bronchospasm.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "ad3b260e-f290-4cea-b11b-caac7e858cb1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Immunogenicity</span></i></p>", "ID": "99ee1355-ea92-403e-a691-d9c48552757c", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Immunogenicity", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"></p>", "ID": "b8944676-447e-4b37-8a86-7d3299b79fcd", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In clinical trials, patients were\r periodically tested for antibodies to brentuximab vedotin using a sensitive\r electrochemiluminescent immunoassay. There was a higher incidence of </span><span lang=\"EN-GB\">infusion-related reactions observed in</span><span lang=\"EN-GB\"> patients\r with antibodies </span><span lang=\"EN-GB\">to brentuximab vedotin relative to</span><span lang=\"EN-GB\"> patients </span><span lang=\"EN-GB\">who tested transiently positive or\r negative.</span></p>", "ID": "984cc0e6-e6d7-4879-8a60-fbd77d4e8316", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In clinical trials, patients were\r periodically tested for antibodies to brentuximab vedotin using a sensitive\r electrochemiluminescent immunoassay. There was a higher incidence of infusion-related reactions observed in patients\r with antibodies to brentuximab vedotin relative to patients who tested transiently positive or\r negative.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "3364ad65-2940-4cfb-b00a-c70864c44f2a", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The presence of antibodies to brentux</span><span lang=\"EN-GB\">imab vedotin did not correlate with a clinically meaningful\r reduction in serum brentuximab vedotin levels and did not result in a decrease\r in the efficacy of brentuximab vedotin. While the presence of antibodies to\r brentuximab vedotin does not necessarily predict the development of an IRR,\r there was a higher incidence of IRRs observed in patients with persistently\r positive anti-drug antibodies (ADA) relative to patients with transiently\r positive ADA and never positive ADA. </span></p>", "ID": "e2775334-9443-453b-a6e6-67e192cc67bf", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The presence of antibodies to brentuximab vedotin did not correlate with a clinically meaningful\r reduction in serum brentuximab vedotin levels and did not result in a decrease\r in the efficacy of brentuximab vedotin. While the presence of antibodies to\r brentuximab vedotin does not necessarily predict the development of an IRR,\r there was a higher incidence of IRRs observed in patients with persistently\r positive anti-drug antibodies (ADA) relative to patients with transiently\r positive ADA and never positive ADA. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "c845daa3-a461-458e-bcf7-d0ce039cce60", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">There was a trend of increased clearance of\r brentuximab vedotin in paediatric patients confirmed positive for ADAs. No\r patients aged &lt; 12 years (0 of 11) and 2 patients aged\r \u2265 12 years (2 of 23) became persistently ADA positive.</span></p>", "ID": "3597eb90-45b0-4d17-becc-ac8d170f6054", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "There was a trend of increased clearance of\r brentuximab vedotin in paediatric patients confirmed positive for ADAs. No\r patients aged < 12 years (0 of 11) and 2 patients aged\r \u2265 12 years (2 of 23) became persistently ADA positive.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\"></span></u></p>", "ID": "d99bc6de-3bda-4ceb-8dc4-f593595eebfb", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Paediatric population</span></u></p>", "ID": "9afd3c5c-3ca6-435b-aa37-be867eb72a3e", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Paediatric population", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"></p>", "ID": "f28984df-c855-4afc-97dd-07ec121a80a0", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:windowtext\">Safety was evaluated in a phase 1/2 study in\r paediatric patients aged 7\u201117 years of age (n = 36) with\r relapsed or refractory (r/r) HL and sALCL (see section 5.1).In\r this study in 36 patients, no new safety concerns were reported.</span></p>", "ID": "fc355733-5db0-4d21-8408-1c8916f9f84f", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Safety was evaluated in a phase 1/2 study in\r paediatric patients aged 7\u201117 years of age (n = 36) with\r relapsed or refractory (r/r) HL and sALCL (see section 5.1).In\r this study in 36 patients, no new safety concerns were reported.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "b6bc1996-d119-4613-af75-f8d4e0db9638", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Elderly </span></u></p>", "ID": "30106943-8085-4ad4-bcfa-76cca0eefcff", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Elderly ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "0aecb5eb-93d5-4ea8-ba68-f8e92626f635", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Monotherapy\r </span></i></p>", "ID": "db045909-f3d5-4817-87df-330e27941faa", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Monotherapy\r ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "c73464ac-f1d5-44f5-8a42-59a03cbc4a4a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety profile in elderly patients is\r generally in line with that of adult patients. However, elderly patients may be\r more susceptible to events such as pneumonia, neutropenia and febrile\r neutropenia.</span></p>", "ID": "71802b90-9ee4-4391-86b1-13f915fb01f7", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The safety profile in elderly patients is\r generally in line with that of adult patients. However, elderly patients may be\r more susceptible to events such as pneumonia, neutropenia and febrile\r neutropenia.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "b2a577f9-e55c-4469-9a52-d1bae0f1668f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Combination\r therapy </span></i></p>", "ID": "93e1c28b-1e23-40c4-8ed1-d0675ebfad6b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Combination\r therapy ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "69a2c3f7-2ca8-46fa-9a5a-d7d83ff75d20", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In older\r patients (\u2265 60 years of age; n = 186 [21%]), the incidence\r of adverse events was similar across treatment arms. More serious adverse\r events and dose modifications (including dose delays, reductions, and\r discontinuations) were reported in the older patients compared with the overall\r study population. Advanced age was a risk factor for febrile neutropenia in\r patients in both arms. Older patients who received G-CSF primary prophylaxis\r had lower incidence of neutropenia and febrile neutropenia than those who did\r not receive G-CSF primary prophylaxis.</span></p>", "ID": "92f8a7b7-28f7-4ba0-b325-d58048ce8918", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In older\r patients (\u2265 60 years of age; n = 186 [21%]), the incidence\r of adverse events was similar across treatment arms. More serious adverse\r events and dose modifications (including dose delays, reductions, and\r discontinuations) were reported in the older patients compared with the overall\r study population. Advanced age was a risk factor for febrile neutropenia in\r patients in both arms. Older patients who received G-CSF primary prophylaxis\r had lower incidence of neutropenia and febrile neutropenia than those who did\r not receive G-CSF primary prophylaxis.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\"></span></u></p>", "ID": "c3575f64-1ee2-46ad-8bb8-98a6f92d49d4", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions</span></u></p>", "ID": "6857c1b4-6d58-492a-aca5-e6ffe41413fa", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Reporting of suspected adverse reactions", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\"></span></u></p>", "ID": "dd5cb154-bc89-4ce3-a2c3-2ff143db3b3d", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Reporting\r suspected adverse reactions after authorisation of the medicinal product is\r important. It allows continued monitoring of the benefit/risk balance of the medicinal\r product. Healthcare professionals are asked to report any suspected adverse\r reactions via <span style=\"background:silver\">the national reporting system\r listed in </span></span><span lang=\"EN-GB\"><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background:silver\">Appendix V</span></a></span><span lang=\"EN-GB\">.</span></p>", "ID": "029e54b4-9398-4ff5-af59-6bfde00ca231", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Reporting\r suspected adverse reactions after authorisation of the medicinal product is\r important. It allows continued monitoring of the benefit/risk balance of the medicinal\r product. Healthcare professionals are asked to report any suspected adverse\r reactions via the national reporting system\r listed in Appendix V.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "ed5322e0-3f76-4f10-8daa-43012a5ae065", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h3><span lang=\"EN-GB\">4.9     Overdose</span></h3>", "ID": "50b86d84-fdf5-4ec8-b737-7f480c76acfd", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "4.9     Overdose", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "478ede4f-c0e3-4766-bbe3-0c34f8364227", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">There is no known antidote for overdose of ADCETRIS.\r In case of overdose, the patient should be closely monitored for adverse\r reactions, particularly neutropenia, and supportive treatment should be\r administered (see section 4.4). </span></p>", "ID": "f49ce9bc-46ae-44ac-981c-20e2188a949d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "There is no known antidote for overdose of ADCETRIS.\r In case of overdose, the patient should be closely monitored for adverse\r reactions, particularly neutropenia, and supportive treatment should be\r administered (see section 4.4). ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "27a4ed5b-ef20-4509-8290-b85d8974573a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "04671a44-d365-4497-a796-92d18cfa5558", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h2><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>5.       PHARMACOLOGICAL\r PROPERTIES</span></h2>", "ID": "7fc59b6b-9df0-4d7e-a7b2-d65a4bdb0f4a", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "5.       PHARMACOLOGICAL\r PROPERTIES", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "1c569f81-fed3-4d9a-a02b-927a58d23c40", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h3><span lang=\"EN-GB\">5.1     Pharmacodynamic properties</span></h3>", "ID": "904980f1-bfd3-4c08-9bdd-988c1823cc9b", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "5.1     Pharmacodynamic properties", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "91286a5d-53c7-4a95-9e10-efb87b1a71f1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pharmacotherapeutic group: Antineoplastic\r agents; other antineoplastic agents; monoclonal antibodies, ATC code: L01XC12.</span></p>", "ID": "fd06c78d-9790-45c6-9061-1822534beb34", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Pharmacotherapeutic group: Antineoplastic\r agents; other antineoplastic agents; monoclonal antibodies, ATC code: L01XC12.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"></p>", "ID": "1548dac0-23a9-4296-8b36-a1287d440c10", "Styles": "text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Mechanism\r of action</span></u></p>", "ID": "ef567545-4fec-4ddc-b989-6df47d45366a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Mechanism\r of action", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"paragraph0\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "3dbe210e-e94f-4dde-aee2-b54e875c1f1a", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['paragraph0']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"paragraph0\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Brentuximab vedotin</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> is an ADC that delivers an antineoplastic agent that\r results in apoptotic cell death selectively in CD30\u2011expressing tumour\r cells. Nonclinical data suggest that the biological activity of </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">brentuximab vedotin</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> results from a multi-step process. Binding of the ADC\r to CD30 on the cell surface initiates internalisation of the ADC\u2011CD30\r complex, which then traffics to the lysosomal compartment. Within the cell, a\r single defined active species, MMAE, is released via proteolytic cleavage.\r Binding of MMAE to tubulin disrupts the microtubule network within the cell,\r induces cell cycle arrest and results in apoptotic death of the CD30\u2011expressing\r tumour cell.</span></p>", "ID": "d0063f67-a904-40e4-a992-3c9ee6cb540e", "Styles": "margin-bottom:0in", "Classes": "['paragraph0']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Brentuximab vedotin is an ADC that delivers an antineoplastic agent that\r results in apoptotic cell death selectively in CD30\u2011expressing tumour\r cells. Nonclinical data suggest that the biological activity of brentuximab vedotin results from a multi-step process. Binding of the ADC\r to CD30 on the cell surface initiates internalisation of the ADC\u2011CD30\r complex, which then traffics to the lysosomal compartment. Within the cell, a\r single defined active species, MMAE, is released via proteolytic cleavage.\r Binding of MMAE to tubulin disrupts the microtubule network within the cell,\r induces cell cycle arrest and results in apoptotic death of the CD30\u2011expressing\r tumour cell.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"paragraph0\" style=\"margin-bottom:0in\"></p>", "ID": "9d8c6431-db36-434e-8224-52470b315c2a", "Styles": "margin-bottom:0in", "Classes": "['paragraph0']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"paragraph0\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Classical HL, sALCL and subtypes of CTCL (including MF\r and pcALCL) express CD30 as an antigen on the surface of their malignant cells.\r This expression is independent of disease stage, line of therapy or transplant\r status.</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> These features make\r CD30 a target for therapeutic intervention. Because of the CD30\u2011targeted\r mechanism of action brentuximab vedotin is able to overcome chemo-resistance as\r CD30 is consistently expressed in patients who are refractory to multi-agent\r chemotherapy, irrespective of prior transplant status. </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The CD30\u2011targeted mechanism of action of\r brentuximab vedotin, the consistent expression of CD30 throughout the classical\r HL, sALCL and CD30+ CTCL disease and therapeutic spectrums andclinical\r evidence in CD30\u2011positive malignancies following multiple lines of\r treatment provide a biologic rationale for its use in patients with relapsed\r and refractory classical HL, sALCL with or without prior ASCT and CD30+ CTCL after\r at least 1 prior systemic therapy.</span></p>", "ID": "6fb218ff-b079-49d9-a508-f49fc4635939", "Styles": "margin-bottom:0in", "Classes": "['paragraph0']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Classical HL, sALCL and subtypes of CTCL (including MF\r and pcALCL) express CD30 as an antigen on the surface of their malignant cells.\r This expression is independent of disease stage, line of therapy or transplant\r status. These features make\r CD30 a target for therapeutic intervention. Because of the CD30\u2011targeted\r mechanism of action brentuximab vedotin is able to overcome chemo-resistance as\r CD30 is consistently expressed in patients who are refractory to multi-agent\r chemotherapy, irrespective of prior transplant status. The CD30\u2011targeted mechanism of action of\r brentuximab vedotin, the consistent expression of CD30 throughout the classical\r HL, sALCL and CD30+ CTCL disease and therapeutic spectrums andclinical\r evidence in CD30\u2011positive malignancies following multiple lines of\r treatment provide a biologic rationale for its use in patients with relapsed\r and refractory classical HL, sALCL with or without prior ASCT and CD30+ CTCL after\r at least 1 prior systemic therapy.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"paragraph0\" style=\"margin-bottom:0in\"></p>", "ID": "4aacce8d-988a-473c-9276-0c60447eff70", "Styles": "margin-bottom:0in", "Classes": "['paragraph0']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"paragraph0\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Contributions to the mechanism of action by other\r antibody associated functions have not been excluded. </span></p>", "ID": "8ec9ac2b-ef2d-4b73-b8d5-c7a67e770555", "Styles": "margin-bottom:0in", "Classes": "['paragraph0']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Contributions to the mechanism of action by other\r antibody associated functions have not been excluded. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"paragraph0\" style=\"margin-bottom:0in\"></p>", "ID": "0a168e1f-3026-43c4-93dd-f15989360ae4", "Styles": "margin-bottom:0in", "Classes": "['paragraph0']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pharmacodynamic\r effects</span></u></p>", "ID": "239296fd-f416-4cbe-9a48-f1ca19c9fb93", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Pharmacodynamic\r effects", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "8c0c590a-b6df-43ad-a146-f9b3bfda47fa", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Cardiac\r electrophysiology</span></i></p>", "ID": "e21be431-e79e-42c9-8de3-d7d14f6f106d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Cardiac\r electrophysiology", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "088963e0-0a71-42bc-9d7d-71e36429e709", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Forty\u2011six (46) patients with CD30\u2011expressing\r haematologic malignancies were evaluable of the 52 patients who received\r 1.8 mg/kg of brentuximab vedotin every 3 weeks as part of a phase 1,\r single\u2011arm, open-label, multicenter cardiac safety study. The primary\r objective was to evaluate the effect of</span><span lang=\"EN-GB\"> brentuximab\r vedotin on cardiac ventricular re-polarization and the predefined primary\r analysis was the change in QTc from baseline to multiple time points in Cycle 1.</span></p>", "ID": "41880391-9b8e-4872-a430-15a7752ce32b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Forty\u2011six (46) patients with CD30\u2011expressing\r haematologic malignancies were evaluable of the 52 patients who received\r 1.8 mg/kg of brentuximab vedotin every 3 weeks as part of a phase 1,\r single\u2011arm, open-label, multicenter cardiac safety study. The primary\r objective was to evaluate the effect of brentuximab\r vedotin on cardiac ventricular re-polarization and the predefined primary\r analysis was the change in QTc from baseline to multiple time points in Cycle 1.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "a0cec9c1-65fa-4977-bd87-1ffaad2f8f7c", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The upper 90% confidence interval (CI)\r around the mean effect on QTc was &lt; 10</span><span lang=\"EN-GB\">msec at each of the Cycle 1 and Cycle 3 post-baseline time\r points. These data indicate the absence of clinically relevant QT prolongation\r due to brentuximab vedotin administered at a dose of 1.8 mg/kg every\r 3 weeks in patients with CD30\u2011expressing malignancies.</span></p>", "ID": "080a1802-5a39-4036-aad9-8706c5dc0f6c", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The upper 90% confidence interval (CI)\r around the mean effect on QTc was < 10msec at each of the Cycle 1 and Cycle 3 post-baseline time\r points. These data indicate the absence of clinically relevant QT prolongation\r due to brentuximab vedotin administered at a dose of 1.8 mg/kg every\r 3 weeks in patients with CD30\u2011expressing malignancies.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r text-autospace:none\"></p>", "ID": "b67a1a53-923b-4105-93c4-03fcee8d5b3a", "Styles": "text-align:justify;text-justify:inter-ideograph;\r\ntext-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Clinical efficacy and safety</span></u></p>", "ID": "b6fe1a83-c78c-4873-be08-5983e72df336", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Clinical efficacy and safety", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "2007b430-5465-4067-97c6-63b3cfaac5c1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Hodgkin lymphoma</span></i></p>", "ID": "049c17de-f648-4710-8bee-40bddcfb9466", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Hodgkin lymphoma", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "0ca9958f-820c-49a2-a645-00c528eb6c50", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Study C25003</span></p>", "ID": "a3df1990-6d79-48b6-82d8-80599ad928f6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Study C25003", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "58582abd-dfe7-4f8c-8c2c-ee04967936f8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy and safety of ADCETRIS were\r evaluated in a randomised, open-label, 2\u2011arm, multicenter trial in 1334 patients\r with previously untreated advanced HL in combination with chemotherapy\r (doxorubicin [A], vinblastine [V] and dacarbazine [D] [AVD]). All patients had\r a histologically confirmed CD30\u2011expressing disease. Sixty\u2011two\r percent of patients had extranodal site involvement. Of the 1334 patients,\r 664 patients were randomised to the ADCETRIS + AVD arm and 670 patients\r were randomised to the ABVD (doxorubicin [A], bleomycin [B], vinblastine [V]\r and dacarbazine [D]) arm and stratified by number of International Prognostic\r Factor Project (IPFP) risk factors and region. Patients were treated on days 1\r and 15 of each 28\u2011day cycle with 1.2 mg/kg of ADCETRIS administered\r as an intravenous infusion over 30 minutes + doxorubicin 25 mg/m<sup>2</sup>,\r vinblastine 6 mg/m<sup>2</sup>, and dacarbazine 375 mg/m<sup>2</sup>.\r The median number of cycles received was 6 (range, 1 to 6 cycles).\r Table 6 provides a summary of the baseline patient and disease\r characteristics.</span> There were no relevant differences in the patient and\r disease characteristics between the two arms.</p>", "ID": "2b79c4c5-55f3-4d82-a917-78dc59ca5c3e", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The efficacy and safety of ADCETRIS were\r evaluated in a randomised, open-label, 2\u2011arm, multicenter trial in 1334 patients\r with previously untreated advanced HL in combination with chemotherapy\r (doxorubicin [A], vinblastine [V] and dacarbazine [D] [AVD]). All patients had\r a histologically confirmed CD30\u2011expressing disease. Sixty\u2011two\r percent of patients had extranodal site involvement. Of the 1334 patients,\r 664 patients were randomised to the ADCETRIS + AVD arm and 670 patients\r were randomised to the ABVD (doxorubicin [A], bleomycin [B], vinblastine [V]\r and dacarbazine [D]) arm and stratified by number of International Prognostic\r Factor Project (IPFP) risk factors and region. Patients were treated on days 1\r and 15 of each 28\u2011day cycle with 1.2 mg/kg of ADCETRIS administered\r as an intravenous infusion over 30 minutes + doxorubicin 25 mg/m2,\r vinblastine 6 mg/m2, and dacarbazine 375 mg/m2.\r The median number of cycles received was 6 (range, 1 to 6 cycles).\r Table 6 provides a summary of the baseline patient and disease\r characteristics. There were no relevant differences in the patient and\r disease characteristics between the two arms.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "ac8b179d-528f-47f5-b397-511e1e71b86f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 6:\r Summary of baseline patient and disease characteristics in the phase 3 previously\r untreated HL study<br/> <br/> </span></b></p>", "ID": "7990dbda-df8e-4aa7-b2e4-1f44099424d8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 6:\r Summary of baseline patient and disease characteristics in the phase 3 previously\r untreated HL study  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:6.45in;border-collapse:collapse\" width=\"619\"> <tr style=\"height:26.4pt\"> <td style=\"width:252.9pt;border-top:windowtext;\r   border-left:windowtext;border-bottom:black;border-right:white;border-style:\r   solid;border-width:1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:26.4pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Patient\r   Characteristics </span></b></p> </td> <td style=\"width:117.0pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:26.4pt\" valign=\"top\" width=\"156\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS + AVD</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 664</span></b></p> </td> <td style=\"width:94.5pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:26.4pt\" valign=\"top\" width=\"126\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ABVD</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 670</span></b></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median age\r   (range) </span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">35 years\r   (18\u201182)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">37 years\r   (18\u201183)</span></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Patients\r   \u2265 65 years old n (%)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">60 (9)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">62 (9)</span></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Gender, n\r   (%)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">378M (57)</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">286F (43)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">398M (59)</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">272F (41)</span></p> </td> </tr> <tr style=\"height:13.2pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">ECOG\r   status, n (%)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"156\"></td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"126\"></td> </tr> <tr style=\"height:13.2pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">0 </span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">376 (57)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">378 (57)</span></p> </td> </tr> <tr style=\"height:13.2pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">1 </span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">260 (39)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">263 (39)</span></p> </td> </tr> <tr style=\"height:13.2pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">2</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28 (4)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">27 (4)</span></p> </td> </tr> <tr style=\"height:13.2pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">Missing</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:13.2pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">2</span></p> </td> </tr> <tr style=\"height:15.4pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\r   Characteristics </span></b></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"156\"></td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"126\"></td> </tr> <tr style=\"height:15.4pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\r   time from HL diagnosis to first dose (range)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">0.92 mo\r   (0.1\u201121.4)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">0.89 mo\r   (0.0\u201181.4)</span></p> </td> </tr> <tr style=\"height:15.4pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Disease\r   stage<sup>a</sup> at initial diagnosis of HL, n (%)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"156\"></td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"126\"></td> </tr> <tr style=\"height:15.4pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">III</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">237 (36)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">246 (37)</span></p> </td> </tr> <tr style=\"height:15.4pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">IV</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">425 (64)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">421 (63)</span></p> </td> </tr> <tr style=\"height:15.4pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">Not applicable</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">1 (&lt; 1)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">1 (&lt; 1)</span></p> </td> </tr> <tr style=\"height:15.4pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">Missing</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.4pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">2 (&lt; 1 )</span></p> </td> </tr> <tr style=\"height:15.85pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Extranodal\r   involvement at time of diagnosis, n (%)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">411 (62)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">416 (62)</span></p> </td> </tr> <tr style=\"height:15.85pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">IPFP<sup>b</sup>\r   risk factors, n (%)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> </td> </tr> <tr style=\"height:15.85pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">0\u20111</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">141 (21)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">141 (21)</span></p> </td> </tr> <tr style=\"height:15.85pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">2\u20113</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">354 (53)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">351 (52)</span></p> </td> </tr> <tr style=\"height:15.85pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">4\u20117</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">169 (25)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">178 (27)</span></p> </td> </tr> <tr style=\"height:15.85pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Bone\r   marrow involvement at time of diagnosis or study entry, n (%)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">147(22)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:15.85pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">151 (23)</span></p> </td> </tr> <tr style=\"height:16.75pt\"> <td style=\"width:252.9pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:.7pt 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"337\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">B symptoms<sup>a\r   </sup>n (%)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"156\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">400 (60)</span></p> </td> <td style=\"width:94.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"126\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">381 (57)</span></p> </td> </tr> </table>", "ID": "6b61574d-e263-43f8-b4cc-7a97797918cf", "Styles": "width:6.45in;border-collapse:collapse", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "   Patient\r   Characteristics    ADCETRIS + AVD n = 664   ABVD n = 670     Median age\r   (range)    35 years\r   (18\u201182)   37 years\r   (18\u201183)     Patients\r   \u2265 65 years old n (%)   60 (9)   62 (9)     Gender, n\r   (%)   378M (57) 286F (43)   398M (59) 272F (41)     ECOG\r   status, n (%)       0    376 (57)   378 (57)     1    260 (39)   263 (39)     2   28 (4)   27 (4)     Missing   0   2     Disease\r   Characteristics        Median\r   time from HL diagnosis to first dose (range)   0.92 mo\r   (0.1\u201121.4)   0.89 mo\r   (0.0\u201181.4)     Disease\r   stagea at initial diagnosis of HL, n (%)       III   237 (36)   246 (37)     IV   425 (64)   421 (63)     Not applicable   1 (< 1)   1 (< 1)     Missing   0   2 (< 1 )     Extranodal\r   involvement at time of diagnosis, n (%)   411 (62)   416 (62)     IPFPb\r   risk factors, n (%)           0\u20111   141 (21)   141 (21)     2\u20113   354 (53)   351 (52)     4\u20117   169 (25)   178 (27)     Bone\r   marrow involvement at time of diagnosis or study entry, n (%)   147(22)   151 (23)     B symptomsa\r   n (%)   400 (60)   381 (57)   ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\r Per Ann Arbor Staging.</span></p>", "ID": "df20ae36-65d7-41e4-aae6-4fac8f8320c6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "a\r Per Ann Arbor Staging.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">IPFP = International\r Prognostic Factor Project.</span></p>", "ID": "c8396645-73b0-4b7d-81a7-8e0537a8af8f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "bIPFP = International\r Prognostic Factor Project.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "c251161a-4882-410e-a768-caabca78cc3c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The primary\r endpoint in Study C25003 was modified PFS (mPFS) per independent review\r facility (IRF), defined as time from randomisation to disease progression,\r death, or evidence of non-complete response (non-CR) after completion of first-line\r therapy per IRF followed by subsequent anticancer therapy. Timing of the\r modified event was the date of the first PET scan post completion of first-line\r therapy demonstrating the absence of complete response (CR), defined as\r Deauville score of \u22653. The median modified PFS by IRF assessment was\r not reached in either treatment arm. The results in the intent-to-treat (ITT)\r population showed a statistically significant improvement in modified PFS for\r ADCETRIS+ AVD, with a stratified hazard ratio of 0.770 (95% CI, 0.603; 0.983,\r p =<sup> </sup>0.035), indicating a 23% reduction in the risk of modified\r PFS events for ADCETRIS+ AVD versus ABVD. </span></p>", "ID": "1ddab51a-f384-4430-a61e-d938d869d6b8", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The primary\r endpoint in Study C25003 was modified PFS (mPFS) per independent review\r facility (IRF), defined as time from randomisation to disease progression,\r death, or evidence of non-complete response (non-CR) after completion of first-line\r therapy per IRF followed by subsequent anticancer therapy. Timing of the\r modified event was the date of the first PET scan post completion of first-line\r therapy demonstrating the absence of complete response (CR), defined as\r Deauville score of \u22653. The median modified PFS by IRF assessment was\r not reached in either treatment arm. The results in the intent-to-treat (ITT)\r population showed a statistically significant improvement in modified PFS for\r ADCETRIS+ AVD, with a stratified hazard ratio of 0.770 (95% CI, 0.603; 0.983,\r p = 0.035), indicating a 23% reduction in the risk of modified\r PFS events for ADCETRIS+ AVD versus ABVD. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "c2a42e8e-7aaf-4634-967d-f8d5dfcfcea0", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\">A pre-specified subgroup\r analysis of mPFS <span lang=\"EN-GB\" style=\"letter-spacing:-.1pt\">by disease stage\r showed that patients with Stage IV disease had a larger effect compared\r with the ITT population</span><span lang=\"EN-GB\">,</span><span lang=\"EN-GB\">with an unstratified hazard ratio of 0.71 (95% CI, 0.53;\r 0.96), compatible with a 29% reduction in the risk of modified PFS events for\r ADCETRIS+ AVD versus ABVD. Of the ITT population, 846 patients (64%) had\r Stage IV disease.</span></p>", "ID": "2785f05b-0f32-47d0-8d81-7c1e9b4d0b64", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "A pre-specified subgroup\r analysis of mPFS by disease stage\r showed that patients with Stage IV disease had a larger effect compared\r with the ITT population,with an unstratified hazard ratio of 0.71 (95% CI, 0.53;\r 0.96), compatible with a 29% reduction in the risk of modified PFS events for\r ADCETRIS+ AVD versus ABVD. Of the ITT population, 846 patients (64%) had\r Stage IV disease.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "b0945ce1-7124-4216-a9e9-da9edbaf6c32", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Table 7 provides the efficacy results\r for modified PFS and overall survival (OS) in the ITT population and patients\r with Stage IV disease.</span></p>", "ID": "df4ff56e-3f1b-4c00-84cd-0911d771637b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 7 provides the efficacy results\r for modified PFS and overall survival (OS) in the ITT population and patients\r with Stage IV disease.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "dc672eef-62db-45bb-adb4-a72e070479b5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 7:\r Efficacy results for previously untreated HL patients treated with\r 1.2 mg/kg of ADCETRIS + AVD on days 1 and 15 of a 28-day cycle (ITT and\r Stage IV)</span></b></p>", "ID": "04551108-0d90-457d-9664-e7704d4757e1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 7:\r Efficacy results for previously untreated HL patients treated with\r 1.2 mg/kg of ADCETRIS + AVD on days 1 and 15 of a 28-day cycle (ITT and\r Stage IV)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "4fa7d619-2fc2-41e1-adbc-01d367a61d6b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:454.4pt;margin-left:-.15pt;border-collapse:collapse;border:none\" width=\"606\"> <tr style=\"page-break-inside:avoid;height:33.0pt\"> <td rowspan=\"2\" style=\"width:82.85pt;border:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:33.0pt\" width=\"110\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td colspan=\"3\" style=\"width:199.15pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:33.0pt\" width=\"266\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Intent to Treat (ITT) Population</span></b></p> </td> <td colspan=\"3\" style=\"width:172.4pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:33.0pt\" width=\"230\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Patients with Stage IV Disease</span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:33.0pt\"> <td style=\"width:66.8pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:33.0pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b><b><span lang=\"EN-GB\"> + AVD</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 664</span></b></p> </td> <td style=\"width:58.65pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:33.0pt\" valign=\"top\" width=\"78\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ABVD</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 670</span></b></p> </td> <td style=\"width:73.7pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:33.0pt\" valign=\"top\" width=\"98\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Stratified Hazard Ratio and p-value</span></b></p> </td> <td style=\"width:57.85pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:33.0pt\" valign=\"top\" width=\"77\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b><b><span lang=\"EN-GB\"> + AVD</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 425</span></b></p> </td> <td style=\"width:47.05pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:33.0pt\" valign=\"top\" width=\"63\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ABVD</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 421</span></b></p> </td> <td style=\"width:67.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:33.0pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Unstratified Hazard Ratio and p-value<sup>c</sup></span></b></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:50.05pt\"> <td style=\"width:82.85pt;border:solid windowtext 1.0pt;border-top:\r   none;padding:0in 0in 0in 0in;height:50.05pt\" width=\"110\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:8.0pt;\r   margin-left:4.9pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Number of\r   events (%)</span></b></p> </td> <td style=\"width:66.8pt;border-top:none;border-left:none;border-bottom:\r   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:.7pt 4.9pt 0in 4.9pt;\r   height:50.05pt\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">117 (18)</span></p> </td> <td style=\"width:58.65pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:50.05pt\" width=\"78\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">146 (22)</span></p> </td> <td rowspan=\"2\" style=\"width:73.7pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:50.05pt\" width=\"98\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">0.77</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">(95% CI [0.60, 0.98])</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">p-value=</span><span lang=\"EN-GB\" style=\"color:windowtext\">0.035</span></p> </td> <td style=\"width:57.85pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:50.05pt\" width=\"77\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">77 (18)</span></p> </td> <td style=\"width:47.05pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:50.05pt\" width=\"63\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">102 (24)</span></p> </td> <td rowspan=\"2\" style=\"width:67.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:50.05pt\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">0.71 </span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">(95% CI [0.53, 0.96])</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">p-value=0.023</span></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:33.5pt\"> <td style=\"width:82.85pt;border:solid windowtext 1.0pt;border-top:\r   none;padding:0in 0in 0in 0in;height:33.5pt\" width=\"110\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:8.0pt;\r   margin-left:4.9pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Estimated mPFS<sup>a</sup>\r   per IRF at 2 Year (%)</span></b></p> </td> <td style=\"width:66.8pt;border-top:none;border-left:none;border-bottom:\r   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:.7pt 4.9pt 0in 4.9pt;\r   height:33.5pt\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">82.1</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">(95% CI [78.8, 85.0])</span></p> </td> <td style=\"width:58.65pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:33.5pt\" width=\"78\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">77.2</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">(95% CI [73.7, 80.4])</span></p> </td> <td style=\"width:57.85pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:33.5pt\" width=\"77\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">82.0 (95%\r   CI [77.8, 85.5])</span></p> </td> <td style=\"width:47.05pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:33.5pt\" width=\"63\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">75.3 (95%\r   CI [70.6, 79.3])</span></p> </td> </tr> <tr style=\"page-break-inside:avoid;height:33.5pt\"> <td style=\"width:82.85pt;border:solid windowtext 1.0pt;border-top:\r   none;padding:0in 0in 0in 0in;height:33.5pt\" width=\"110\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:8.0pt;\r   margin-left:4.9pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Overall Survival<sup>b</sup>\r   Number of deaths (%)</span></b></p> </td> <td style=\"width:66.8pt;border-top:none;border-left:none;border-bottom:\r   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:.7pt 4.9pt 0in 4.9pt;\r   height:33.5pt\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">28 (4)</span></p> </td> <td style=\"width:58.65pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:33.5pt\" width=\"78\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">39 (6)</span></p> </td> <td style=\"width:73.7pt;border-top:none;border-left:none;border-bottom:\r   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\r   height:33.5pt\" width=\"98\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">0.73</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">(95% CI [0.45, 1.18])</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:8.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">p-value=0.199</span></p> </td> <td style=\"width:57.85pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:33.5pt\" width=\"77\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">14 (3)</span></p> </td> <td style=\"width:47.05pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 0in 0in 0in;height:33.5pt\" width=\"63\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">26 (6)</span></p> </td> <td style=\"width:67.5pt;border-top:none;border-left:none;border-bottom:\r   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;\r   height:33.5pt\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">0.51 </span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">(95% CI [0.27, 0.97])</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:2.0pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">p-value=0.037</span></p> </td> </tr> </table>", "ID": "a71445f5-7acb-47db-a180-600eec583f3e", "Styles": "width:454.4pt;margin-left:-.15pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "      Intent to Treat (ITT) Population   Patients with Stage IV Disease     ADCETRIS + AVD n = 664   ABVD n = 670   Stratified Hazard Ratio and p-value   ADCETRIS + AVD n = 425   ABVD n = 421   Unstratified Hazard Ratio and p-valuec     Number of\r   events (%)   117 (18)   146 (22)   0.77 (95% CI [0.60, 0.98]) p-value=0.035   77 (18)   102 (24)   0.71  (95% CI [0.53, 0.96]) p-value=0.023     Estimated mPFSa\r   per IRF at 2 Year (%)   82.1 (95% CI [78.8, 85.0])   77.2 (95% CI [73.7, 80.4])   82.0 (95%\r   CI [77.8, 85.5])   75.3 (95%\r   CI [70.6, 79.3])     Overall Survivalb\r   Number of deaths (%)   28 (4)   39 (6)   0.73 (95% CI [0.45, 1.18]) p-value=0.199   14 (3)   26 (6)   0.51  (95% CI [0.27, 0.97]) p-value=0.037   ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">At\r the time of analysis, the median modified PFS follow-up time for both arms was\r 24.6 months.</span></p>", "ID": "dd73a5c0-d755-42a8-8e12-88c411ed7df6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "aAt\r the time of analysis, the median modified PFS follow-up time for both arms was\r 24.6 months.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Data\r from an interim OS analysis. </span></p>", "ID": "660200c3-c6b3-4ab4-b32d-3fb7deb32406", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "bData\r from an interim OS analysis. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">p-value\r for Stage IV disease is not adjusted for multiplicity.</span></p>", "ID": "ebb93061-75b8-435c-a516-101b60ba3e0c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "cp-value\r for Stage IV disease is not adjusted for multiplicity.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "138d4cda-dcc4-48be-a6a2-d67decf16b4c", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Figure 1: Modified progression-free survival per IRF in the ITT\r population (ADCETRIS + AVD vs. ABVD)</span></b></p>", "ID": "4751c119-dcb9-477d-bb54-0753b0e53592", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Figure 1: Modified progression-free survival per IRF in the ITT\r population (ADCETRIS + AVD vs. ABVD)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"></p>", "ID": "eebc7735-7de9-4d13-a86e-640fe7abccb5", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\"><img border=\"0\" height=\"302\" src=\"Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image002.gif\" width=\"604\"/></span></p>", "ID": "2cf43109-516a-4c36-bf07-e90d9b0cae38", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "cd96cc72-3450-413b-a56f-dbe6a800ac35", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><a name=\"IDX\"></a><b><span lang=\"EN-GB\">Figure 2: Modified progression-free survival\r per IRF in patients with Stage IV disease (ADCETRIS + AVD vs. ABVD)</span></b></p>", "ID": "3a86ae4b-a794-4678-bcbf-0835c6b7ef4b", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Figure 2: Modified progression-free survival\r per IRF in patients with Stage IV disease (ADCETRIS + AVD vs. ABVD)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:150%;page-break-after:avoid\"></p>", "ID": "a336505e-a213-46ae-9661-7d9ee1307084", "Styles": "line-height:150%;page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"><img border=\"0\" height=\"284\" src=\"Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image003.gif\" width=\"598\"/></span></p>", "ID": "c0f46168-ff93-4b32-b7a1-035efc23ffe1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b></b></p>", "ID": "1d48f83b-cb77-4d30-ac66-ba383f2d7168", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Other secondary efficacy endpoints\r including CR rate and ORR at the end of randomisation regimen, CR rate at the\r end of first-line therapy, and the rate of PET negativity at the end of Cycle\r 2, duration of response (DOR), duration of complete remission (DOCR),\r disease-free survival (DFS) and event\u2011free survival (EFS) all trended in\r favour of ADCETRIS + AVD<a name=\"_Hlk519081083\"> in both the ITT and Stage IV\r population</a>.</span></p>", "ID": "c3a5ef7e-bc78-4afd-b6ba-8f1d81113c15", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Other secondary efficacy endpoints\r including CR rate and ORR at the end of randomisation regimen, CR rate at the\r end of first-line therapy, and the rate of PET negativity at the end of Cycle\r 2, duration of response (DOR), duration of complete remission (DOCR),\r disease-free survival (DFS) and event\u2011free survival (EFS) all trended in\r favour of ADCETRIS + AVD in both the ITT and Stage IV\r population.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "885d9d22-27c1-4b20-881d-52db97691cc3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pre\u2011specified subgroup analyses of\r modified PFS per IRF were performed for the ITT population including age,\r region, cancer stage at baseline, baseline extranodal sites, number of IPFP\r risk factors, baseline B symptoms, Cycle 2 PET assessment, Cycle 2 PET\r Deauville score, and receipt of alternative first-line medication (AFM). The\r analyses showed a consistent trend towards benefit for patients who received\r ADCETRIS + AVD compared with patients who received ABVD in most subgroups.\r The efficacy in elderly patient population (patients \u2265 60 years of\r age [n = 186] [HR = 1.00, 95% CI (0.58, 1.72)] and \u2265 65\r years of age [n = 122] [HR = 1.01, 95% CI (0.53, 1.94)])\r and patients with no extranodal sites (n = 445) (HR = 1.04,\r 95% CI [0.67, 1.62]) showed no clinically meaningful difference between the two\r arms.</span></p>", "ID": "afe4151a-6aa6-4472-9d76-5b9bae9180aa", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Pre\u2011specified subgroup analyses of\r modified PFS per IRF were performed for the ITT population including age,\r region, cancer stage at baseline, baseline extranodal sites, number of IPFP\r risk factors, baseline B symptoms, Cycle 2 PET assessment, Cycle 2 PET\r Deauville score, and receipt of alternative first-line medication (AFM). The\r analyses showed a consistent trend towards benefit for patients who received\r ADCETRIS + AVD compared with patients who received ABVD in most subgroups.\r The efficacy in elderly patient population (patients \u2265 60 years of\r age [n = 186] [HR = 1.00, 95% CI (0.58, 1.72)] and \u2265 65\r years of age [n = 122] [HR = 1.01, 95% CI (0.53, 1.94)])\r and patients with no extranodal sites (n = 445) (HR = 1.04,\r 95% CI [0.67, 1.62]) showed no clinically meaningful difference between the two\r arms.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "a085fc41-0e25-42c0-81ef-5de0f3d53d20", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Post\u2011hoc\r subgroup analyses of modified PFS per IRF for patients with Stage IV\r disease were performed including age, region, baseline extranodal sites, number\r of IPFP risk factors, baseline B symptoms, baseline ECOG status and gender. The\r analyses showed a consistent trend towards benefit for patients who received\r ADCETRIS + AVD compared with patients who received ABVD in most subgroups.\r P</span><span lang=\"EN-GB\" style=\"color:windowtext\">atients with Stage IV disease\r for whom extranodal disease was reported ([n = 722] [HR = 0.69,\r 95% CI (0.50, 0.94)]) showed an mPFS (per IRF) benefit. In patients with Stage\r IV disease for whom no extranodal disease was reported, n</span><span lang=\"EN-GB\" style=\"color:windowtext\">o benefit has been shown at time of\r analysis </span><span lang=\"EN-GB\" style=\"color:windowtext\">([n = 85]\r [HR = 1.49, 95% CI (0.51, 4.31)]). </span><span lang=\"EN-GB\" style=\"color:windowtext\">The significance of this finding in stage IV HL\r patients with no extranodal disease is not established due to small patient\r numbers and low event rates (14 events).</span><span lang=\"EN-GB\" style=\"color:windowtext\">The efficacy in elderly patients with Stage IV disease\r in the A + AVD arm (patients \u2265 60 years of age [n = 118]\r [HR = 0.80, 95% CI (0.42, 1.53)] and \u2265 65 years of age [n = 78]\r [HR = 0.78, 95% CI (0.36, 1.67)]) showed better benefit compared with\r elderly patients in ITT population.</span></p>", "ID": "4918eafa-d8f7-46ca-b502-1721cf274394", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Post\u2011hoc\r subgroup analyses of modified PFS per IRF for patients with Stage IV\r disease were performed including age, region, baseline extranodal sites, number\r of IPFP risk factors, baseline B symptoms, baseline ECOG status and gender. The\r analyses showed a consistent trend towards benefit for patients who received\r ADCETRIS + AVD compared with patients who received ABVD in most subgroups.\r Patients with Stage IV disease\r for whom extranodal disease was reported ([n = 722] [HR = 0.69,\r 95% CI (0.50, 0.94)]) showed an mPFS (per IRF) benefit. In patients with Stage\r IV disease for whom no extranodal disease was reported, no benefit has been shown at time of\r analysis ([n = 85]\r [HR = 1.49, 95% CI (0.51, 4.31)]). The significance of this finding in stage IV HL\r patients with no extranodal disease is not established due to small patient\r numbers and low event rates (14 events).The efficacy in elderly patients with Stage IV disease\r in the A + AVD arm (patients \u2265 60 years of age [n = 118]\r [HR = 0.80, 95% CI (0.42, 1.53)] and \u2265 65 years of age [n = 78]\r [HR = 0.78, 95% CI (0.36, 1.67)]) showed better benefit compared with\r elderly patients in ITT population.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "6e8c43ae-c06f-4ed3-bfd0-3f23cbff1d7a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><a name=\"_Hlk519587500\"><span lang=\"EN-GB\">In the ITT\r population, 33% fewer patients treated with ADCETRIS + AVD in the ITT\r population received subsequent salvage chemotherapy (n = 66) and\r high-dose chemotherapy and transplant (n = 36) compared with those\r treated with ABVD (n = 99 and n = 54, respectively). In the\r Stage IV population, 35% fewer patients treated with ADCETRIS + AVD received\r subsequent salvage chemotherapy (n = 45) compared with those treated\r with ABVD (n = 69) and 22% fewer patients treated with ADCETRIS + AVD\r received high-dose chemotherapy and transplant (n = 29) compared with\r those treated with ABVD (n = 37).</span></a></p>", "ID": "4447a910-573e-4c33-855c-895a4ca4d87c", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In the ITT\r population, 33% fewer patients treated with ADCETRIS + AVD in the ITT\r population received subsequent salvage chemotherapy (n = 66) and\r high-dose chemotherapy and transplant (n = 36) compared with those\r treated with ABVD (n = 99 and n = 54, respectively). In the\r Stage IV population, 35% fewer patients treated with ADCETRIS + AVD received\r subsequent salvage chemotherapy (n = 45) compared with those treated\r with ABVD (n = 69) and 22% fewer patients treated with ADCETRIS + AVD\r received high-dose chemotherapy and transplant (n = 29) compared with\r those treated with ABVD (n = 37).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "88b14b3a-8838-42c3-8f2e-fb8566644fa3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The European\r Organization for Research and Treatment of Cancer Quality of Life 30\u2011Item\r Questionnaire (EORTC\u2011QLQ\u2011C30) showed no clinically meaningful\r difference between the two arms in both the ITT and Stage IV population.</span></p>", "ID": "3f7754a0-4668-4c2e-992c-8dcdd67546ff", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The European\r Organization for Research and Treatment of Cancer Quality of Life 30\u2011Item\r Questionnaire (EORTC\u2011QLQ\u2011C30) showed no clinically meaningful\r difference between the two arms in both the ITT and Stage IV population.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"></span></u></p>", "ID": "cbff3a3c-7ed3-4406-b503-1a12e6458ce0", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Study SGN35\u2011005</span></p>", "ID": "f97feb65-a6c1-4953-b242-8830a4d7b3e4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Study SGN35\u2011005", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "0f9e3167-33ea-42f9-ac1c-3940ef032f26", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy and safety of ADCETRIS were\r evaluated in a randomised, double\u2011blind, placebo\u2011controlled, 2\u2011arm\r multicenter trial in 329 patients with HL at risk of relapse or\r progression following ASCT. Patients with known cerebral/meningeal disease,\r including history of PML were excluded from the study. See Table 8 for\r patient characteristics. Of the 329 patients, 165 patients were\r randomised to the treatment arm and 164 patients were randomised to the\r placebo arm. In the study, patients were to receive their first dose after\r recovery from ASCT (between days 30\u201145 following ASCT). Patients were\r treated with 1.8 mg/kg of ADCETRIS or matching placebo intravenously over\r 30 minutes every 3 weeks for up to 16 cycles.</span></p>", "ID": "69020a08-9b7f-4035-a20b-94733cf6a241", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The efficacy and safety of ADCETRIS were\r evaluated in a randomised, double\u2011blind, placebo\u2011controlled, 2\u2011arm\r multicenter trial in 329 patients with HL at risk of relapse or\r progression following ASCT. Patients with known cerebral/meningeal disease,\r including history of PML were excluded from the study. See Table 8 for\r patient characteristics. Of the 329 patients, 165 patients were\r randomised to the treatment arm and 164 patients were randomised to the\r placebo arm. In the study, patients were to receive their first dose after\r recovery from ASCT (between days 30\u201145 following ASCT). Patients were\r treated with 1.8 mg/kg of ADCETRIS or matching placebo intravenously over\r 30 minutes every 3 weeks for up to 16 cycles.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "891aeba7-0456-40e3-aff9-dfb059f4cd7e", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">Eligible patients were required to have at least one of the following\r risk factors: </span></p>", "ID": "06dc831e-6954-4d4c-84f1-ab207fe32ea5", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Eligible patients were required to have at least one of the following\r risk factors: ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt;font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">HL that was refractory\r to frontline treatment</span></p>", "ID": "7a7af86b-c139-4bef-a465-f3e535264aaf", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "\u00b7HL that was refractory\r to frontline treatment", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt;font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Relapsed or progressive\r HL that occurred &lt;12 months from the end of frontline treatment</span></p>", "ID": "1a31e3ba-5e44-46c9-a45b-24c4d436aca3", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:28.35pt;text-indent:-28.35pt", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "\u00b7Relapsed or progressive\r HL that occurred <12 months from the end of frontline treatment", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">Extranodal involvement at time of pre\u2011ASCT\r relapse, including extranodal extension of nodal masses into adjacent vital\r organs.</span></p>", "ID": "7a38c26c-aaf8-4c0c-8231-e770f92cf32d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "\u00b7Extranodal involvement at time of pre\u2011ASCT\r relapse, including extranodal extension of nodal masses into adjacent vital\r organs.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.5in\"></p>", "ID": "29b92790-083e-472b-9a70-eaea40349827", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.5in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-before:always;page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 8: Summary of baseline patient and disease characteristics in\r the phase 3 HL post\u2011ASCT Study<br/> <br/> </span></b></p>", "ID": "343581d4-7e1e-4d40-acbc-887ee7b909a0", "Styles": "page-break-before:always;page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 8: Summary of baseline patient and disease characteristics in\r the phase 3 HL post\u2011ASCT Study  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div align=\"center\"> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:444.45pt;border-collapse:collapse;border:none\" width=\"593\"> <tr style=\"height:15.1pt\"> <td style=\"width:215.95pt;border:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-bottom:3.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Patient characteristics</span></b></p> </td> <td style=\"width:112.5pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 165</span></b></p> </td> <td style=\"width:116.0pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Placebo</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 164</span></b></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:3.1pt;text-indent:5.5pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Median age, years (range)</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">33 years (18\u201171)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">32 years (18\u201176)</span></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt\"><span lang=\"EN-GB\">Gender</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">76M\r   (46%)/89F (54%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">97M\r   (59%)/67F (41%)</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt\"><span lang=\"EN-GB\">ECOG status</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> </tr> <tr style=\"height:12.75pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">87\r   (53%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">97\r   (59%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">1</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">77\r   (47%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">67\r   (41%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">2</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\r   (1%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:3.0pt;\r   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;\r   text-indent:-19.45pt\"><b><span lang=\"EN-GB\">Disease characteristics</span></b></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> </tr> <tr style=\"height:8.0pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median number of prior chemotherapy regimens (range)</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\r   (2\u20118)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\r   (2\u20117)</span></p> </td> </tr> <tr style=\"height:7.15pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median time from HL diagnosis to first dose (range)</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">18.7 mo\r   (6.1\u2011204.0)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">18.8 mo\r   (7.4\u2011180.8)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Disease stage at initial diagnosis of HL</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Stage I</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\r   (1%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5\r   (3%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Stage II</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">73\r   (44%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">61\r   (37%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Stage III</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">48\r   (29%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">45\r   (27%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Stage IV</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">43\r   (26%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">51\r   (31%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Unknown</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\r   (1%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">PET scan Status prior to ASCT</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">FDG\u2011AVID</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">64\r   (39%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">51\r   (31%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">FDG\u2011NEGATIVE</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">56\r   (34%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">57\r   (35%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">NOT DONE</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">45\r   (27%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">56\r   (34%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Extranodal involvement at time of pre\u2011ASCT relapse</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">54\r   (33%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">53\r   (32%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">B symptoms</span><sup><span lang=\"EN-GB\">a</span></sup></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">47\r   (28%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">40\r   (24%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Best response to salvage therapy pre\u2011ASCT<sup>b</sup></span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Complete\r   Response</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">61\r   (37%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">62\r   (38%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Partial\r   Response</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">57\r   (35%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">56\r   (34%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Stable Disease</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">47\r   (28%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">46\r   (28%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">HL Status after the end of frontline standard chemotherapy<sup>b</sup></span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Refractory</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">99\r   (60%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">97\r   (59%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Relapse\r   occurred &lt;12 months</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">53\r   (32%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">54\r   (33%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Relapse\r   occurred \u2265 12 months</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">13\r   (8%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">13\r   (8%)</span></p> </td> </tr> </table> </div>", "ID": "67cd39f6-4904-41df-a11f-ccfb0cf35724", "Styles": "None", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:444.45pt;border-collapse:collapse;border:none\" width=\"593\"> <tr style=\"height:15.1pt\"> <td style=\"width:215.95pt;border:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-bottom:3.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Patient characteristics</span></b></p> </td> <td style=\"width:112.5pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 165</span></b></p> </td> <td style=\"width:116.0pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Placebo</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 164</span></b></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:3.1pt;text-indent:5.5pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Median age, years (range)</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">33 years (18\u201171)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">32 years (18\u201176)</span></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt\"><span lang=\"EN-GB\">Gender</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">76M\r   (46%)/89F (54%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">97M\r   (59%)/67F (41%)</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt\"><span lang=\"EN-GB\">ECOG status</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> </tr> <tr style=\"height:12.75pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">87\r   (53%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">97\r   (59%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">1</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">77\r   (47%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">67\r   (41%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">2</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\r   (1%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:3.0pt;\r   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;\r   text-indent:-19.45pt\"><b><span lang=\"EN-GB\">Disease characteristics</span></b></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> </tr> <tr style=\"height:8.0pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median number of prior chemotherapy regimens (range)</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\r   (2\u20118)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\r   (2\u20117)</span></p> </td> </tr> <tr style=\"height:7.15pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median time from HL diagnosis to first dose (range)</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">18.7 mo\r   (6.1\u2011204.0)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">18.8 mo\r   (7.4\u2011180.8)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Disease stage at initial diagnosis of HL</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Stage I</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\r   (1%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5\r   (3%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Stage II</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">73\r   (44%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">61\r   (37%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Stage III</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">48\r   (29%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">45\r   (27%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Stage IV</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">43\r   (26%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">51\r   (31%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Unknown</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\r   (1%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">PET scan Status prior to ASCT</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">FDG\u2011AVID</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">64\r   (39%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">51\r   (31%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">FDG\u2011NEGATIVE</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">56\r   (34%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">57\r   (35%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">NOT DONE</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">45\r   (27%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">56\r   (34%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Extranodal involvement at time of pre\u2011ASCT relapse</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">54\r   (33%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">53\r   (32%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">B symptoms</span><sup><span lang=\"EN-GB\">a</span></sup></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">47\r   (28%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">40\r   (24%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Best response to salvage therapy pre\u2011ASCT<sup>b</sup></span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Complete\r   Response</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">61\r   (37%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">62\r   (38%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Partial\r   Response</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">57\r   (35%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">56\r   (34%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Stable Disease</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">47\r   (28%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">46\r   (28%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">HL Status after the end of frontline standard chemotherapy<sup>b</sup></span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Refractory</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">99\r   (60%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">97\r   (59%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Relapse\r   occurred &lt;12 months</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">53\r   (32%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">54\r   (33%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:215.95pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt\"><span lang=\"EN-GB\">Relapse\r   occurred \u2265 12 months</span></p> </td> <td style=\"width:112.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"150\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">13\r   (8%)</span></p> </td> <td style=\"width:116.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">13\r   (8%)</span></p> </td> </tr> </table>", "ID": "2aee98f7-22d8-4993-9066-e506c92250d7", "Styles": "width:444.45pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "   Patient characteristics   ADCETRIS n = 165   Placebo n = 164     Median age, years (range)   33 years (18\u201171)   32 years (18\u201176)     Gender   76M\r   (46%)/89F (54%)   97M\r   (59%)/67F (41%)     ECOG status           0   87\r   (53%)   97\r   (59%)     1   77\r   (47%)   67\r   (41%)     2   1\r   (1%)   0     Disease characteristics           Median number of prior chemotherapy regimens (range)   2\r   (2\u20118)   2\r   (2\u20117)     Median time from HL diagnosis to first dose (range)   18.7 mo\r   (6.1\u2011204.0)   18.8 mo\r   (7.4\u2011180.8)     Disease stage at initial diagnosis of HL           Stage I   1\r   (1%)   5\r   (3%)     Stage II   73\r   (44%)   61\r   (37%)     Stage III   48\r   (29%)   45\r   (27%)     Stage IV   43\r   (26%)   51\r   (31%)     Unknown   0   2\r   (1%)     PET scan Status prior to ASCT           FDG\u2011AVID   64\r   (39%)   51\r   (31%)     FDG\u2011NEGATIVE   56\r   (34%)   57\r   (35%)     NOT DONE   45\r   (27%)   56\r   (34%)     Extranodal involvement at time of pre\u2011ASCT relapse   54\r   (33%)   53\r   (32%)     B symptomsa   47\r   (28%)   40\r   (24%)     Best response to salvage therapy pre\u2011ASCTb           Complete\r   Response   61\r   (37%)   62\r   (38%)     Partial\r   Response   57\r   (35%)   56\r   (34%)     Stable Disease   47\r   (28%)   46\r   (28%)     HL Status after the end of frontline standard chemotherapyb           Refractory   99\r   (60%)   97\r   (59%)     Relapse\r   occurred <12 months   53\r   (32%)   54\r   (33%)     Relapse\r   occurred \u2265 12 months   13\r   (8%)   13\r   (8%)   ", "ParentId": "67cd39f6-4904-41df-a11f-ccfb0cf35724"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in\"><sup><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">For refractory disease, or upon progression or relapse after frontline therapy.</span></p>", "ID": "ac02b9c8-fc24-4d2f-aa5b-082550be0adb", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "a.For refractory disease, or upon progression or relapse after frontline therapy.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in\"><sup><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">b.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Stratification\r factors at randomisation.</span></p>", "ID": "5ef41943-3627-44db-b5e1-f8fbb55bd362", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "b.Stratification\r factors at randomisation.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "c9bbe3bf-ef9e-4626-a6ae-98bea9652e63", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "91147750-f4e3-47b4-8763-3ec3a2efeab0", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy results are shown in Table 9.\r The primary endpoint of PFS was met and showed a difference in median PFS of\r 18.8 months in favour of the treatment arm.</span></p>", "ID": "98023e9b-4d1c-495f-94d5-6dde9a0ea6ce", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The efficacy results are shown in Table 9.\r The primary endpoint of PFS was met and showed a difference in median PFS of\r 18.8 months in favour of the treatment arm.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:43.1pt;text-indent:-43.1pt\"></p>", "ID": "51872fea-88c0-463a-bbf4-ad4065ab9546", "Styles": "margin-left:43.1pt;text-indent:-43.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 9:\r Efficacy results in HL patients at increased risk of relapse or progression following\r ASCT treated with 1.8 mg/kg of ADCETRIS every 3 weeks<br/> <br/> </span></b></p>", "ID": "a3c1062e-5190-4222-b55b-361509f3ebc3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 9:\r Efficacy results in HL patients at increased risk of relapse or progression following\r ASCT treated with 1.8 mg/kg of ADCETRIS every 3 weeks  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:459.4pt;border-collapse:collapse;border:none\" width=\"613\"> <tr style=\"height:39.0pt\"> <td style=\"width:85.9pt;border:solid windowtext 1.0pt;padding:.7pt 4.9pt 0in 4.9pt;\r   height:39.0pt\" width=\"115\"></td> <td style=\"width:1.75in;border:solid windowtext 1.0pt;border-left:\r   none;padding:.7pt 4.9pt 0in 4.9pt;height:39.0pt\" width=\"168\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 165</span></b></p> </td> <td style=\"width:130.5pt;border:solid windowtext 1.0pt;border-left:\r   none;padding:.7pt 4.9pt 0in 4.9pt;height:39.0pt\" width=\"174\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Placebo</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 164</span></b></p> </td> <td style=\"width:117.0pt;border:solid windowtext 1.0pt;border-left:\r   none;padding:.7pt 4.9pt 0in 4.9pt;height:39.0pt\" width=\"156\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Stratified Hazard Ratio</span></b></p> </td> </tr> <tr style=\"height:19.3pt\"> <td rowspan=\"4\" style=\"width:85.9pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" width=\"115\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Progression\r   Free Survival<sup>a</sup> </span></b></p> </td> <td colspan=\"2\" style=\"width:256.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" width=\"342\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Median per IRF</span></b></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" valign=\"top\" width=\"156\"></td> </tr> <tr style=\"height:19.3pt\"> <td style=\"width:1.75in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" width=\"168\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">42.9 months</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [30.4, 42.9])</span></p> </td> <td style=\"width:130.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" width=\"174\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">24.1 months</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [11.5, -])</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" valign=\"top\" width=\"156\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">0.57</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [0.40, 0.81])</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Stratified log-rank test p=0.001</span></p> </td> </tr> <tr style=\"height:19.3pt\"> <td colspan=\"2\" style=\"width:256.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" width=\"342\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Median per Investigator </span></b></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" valign=\"top\" width=\"156\"></td> </tr> <tr style=\"height:19.3pt\"> <td style=\"width:1.75in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" width=\"168\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Not reached</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [26.4, -])</span></p> </td> <td style=\"width:130.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" width=\"174\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">15.8 months</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [8.5, -])</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" valign=\"top\" width=\"156\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">0.5</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [0.36, 0.70])<sup>b</sup></span></p> </td> </tr> <tr style=\"height:19.3pt\"> <td rowspan=\"2\" style=\"width:85.9pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" width=\"115\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Overall\r   Survival</span></b></p> </td> <td colspan=\"2\" style=\"width:256.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" width=\"342\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Number of deaths (%)</span></b></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:19.3pt\" valign=\"top\" width=\"156\"></td> </tr> <tr style=\"height:25.75pt\"> <td style=\"width:1.75in;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:25.75pt\" width=\"168\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">28 (17)</span></p> </td> <td style=\"width:130.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:25.75pt\" width=\"174\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">25 (15)</span></p> </td> <td style=\"width:117.0pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:.7pt 4.9pt 0in 4.9pt;height:25.75pt\" width=\"156\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">1.15</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [0.67, 1.97]</span></p> </td> </tr> </table>", "ID": "53b675b1-3b06-4315-9461-fb5a06b41b30", "Styles": "width:459.4pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "    ADCETRIS n = 165   Placebo n = 164   Stratified Hazard Ratio     Progression\r   Free Survivala    Median per IRF      42.9 months (95% CI [30.4, 42.9])   24.1 months (95% CI [11.5, -])   0.57 (95% CI [0.40, 0.81]) Stratified log-rank test p=0.001     Median per Investigator       Not reached (95% CI [26.4, -])   15.8 months (95% CI [8.5, -])   0.5 (95% CI [0.36, 0.70])b     Overall\r   Survival   Number of deaths (%)      28 (17)   25 (15)   1.15 (95% CI [0.67, 1.97]   ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">At the time of the\r primary analysis, the median follow-up time for both arms was 30 months (range,\r 0 to 50). </span></p>", "ID": "0b1dab27-b727-444e-9bab-27e7da078058", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "a.At the time of the\r primary analysis, the median follow-up time for both arms was 30 months (range,\r 0 to 50). ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">b.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Stratified log\u2011rank\r test was not performed for PFS per Investigator.</span></p>", "ID": "cdff2571-de5f-48ab-a744-73a0db8ae010", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "b.Stratified log\u2011rank\r test was not performed for PFS per Investigator.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "3755cf65-c276-43b1-afe6-ad6b04cb3cd0", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "db41c1b1-12e7-4b85-9912-82066195c01f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pre\u2011specified subgroup analyses of\r PFS per IRF were performed by patients\u2019 best response to pre\u2011ASCT\r salvage therapy, HL status after frontline therapy, age, gender, baseline\r weight, baseline ECOG performance status, number of treatments pre\u2011ASCT,\r geographic region, pre\u2011ASCT PET status, B symptom status after failure of\r frontline therapy, and pre\u2011ASCT extranodal disease status. The analyses\r showed a consistent trend towards benefit for patients who received ADCETRIS\r compared with patients who received placebo with the exception of patients\r \u226565 years of age (n = 8).</span></p>", "ID": "570f83e0-9b0e-4d88-b79f-4aa9676bf091", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Pre\u2011specified subgroup analyses of\r PFS per IRF were performed by patients\u2019 best response to pre\u2011ASCT\r salvage therapy, HL status after frontline therapy, age, gender, baseline\r weight, baseline ECOG performance status, number of treatments pre\u2011ASCT,\r geographic region, pre\u2011ASCT PET status, B symptom status after failure of\r frontline therapy, and pre\u2011ASCT extranodal disease status. The analyses\r showed a consistent trend towards benefit for patients who received ADCETRIS\r compared with patients who received placebo with the exception of patients\r \u226565 years of age (n = 8).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "5acd0fac-8bfc-4686-abc8-36035e3b4fdb", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">No differences were observed in quality of\r life between the treatment and placebo arms. Medical resource utilization (MRU)\r analysis showed that hospitalizations and outpatient visits, as well as working\r days/other activities missed by patients and caregivers were lower with ADCETRIS\r compared with placebo in patients with HL at increased risk of relapse.</span></p>", "ID": "b9116560-4416-42ea-8025-f1c066e0b6a1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "No differences were observed in quality of\r life between the treatment and placebo arms. Medical resource utilization (MRU)\r analysis showed that hospitalizations and outpatient visits, as well as working\r days/other activities missed by patients and caregivers were lower with ADCETRIS\r compared with placebo in patients with HL at increased risk of relapse.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "40a2d7f5-8afb-4227-8b6d-73d50a5af16b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">An updated analysis conducted after\r 3 years of follow\u2011up showed a sustained PFS improvement per IRF\r (HR = 0.58 [95% CI (0.41, 0.81)]).</span></p>", "ID": "a78ee4a8-50b2-4d23-8910-8173a894e63a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "An updated analysis conducted after\r 3 years of follow\u2011up showed a sustained PFS improvement per IRF\r (HR = 0.58 [95% CI (0.41, 0.81)]).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "a1d23d54-4f79-49e0-9c07-59c8c76eba28", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Post\u2011hoc\r Risk Factor Analyses</span></i></p>", "ID": "f6ab4ce3-bea8-4940-981a-7395fb9233e0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Post\u2011hoc\r Risk Factor Analyses", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "2e98e97d-421e-49e6-b63e-fa7072090c36", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Post\u2011hoc analyses were performed </span><span lang=\"EN-GB\">to evaluate the impact of increased</span><span lang=\"EN-GB\"> risk\r (number of risk factors) on clinical benefit (Table 10). </span><span lang=\"EN-GB\">Representative risk factors for these analyses were:</span></p>", "ID": "d0f3e7e3-5ca6-4695-b81d-dd794006dbee", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Post\u2011hoc analyses were performed to evaluate the impact of increased risk\r (number of risk factors) on clinical benefit (Table 10). Representative risk factors for these analyses were:", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">HL that occurred &lt;12 months or HL that\r was refractory to frontline therapy</span></p>", "ID": "8d694bed-b595-425d-ab52-df50764a9cdc", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpFirst']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "\u00b7HL that occurred <12 months or HL that\r was refractory to frontline therapy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">Best response of PR or SD to most recent salvage\r therapy as determined by CT and/or PET scanning </span></p>", "ID": "5165d12e-ce66-48c3-90b5-5973e60a9ede", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "\u00b7Best response of PR or SD to most recent salvage\r therapy as determined by CT and/or PET scanning ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">Extranodal disease at pre\u2011ASCT relapse</span></p>", "ID": "6746bbf2-37bc-41db-a9b0-b067f031cf0d", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "\u00b7Extranodal disease at pre\u2011ASCT relapse", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">B symptoms at pre\u2011ASCT relapse</span></p>", "ID": "84c8b938-293c-4124-aa63-52d367909a3b", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "\u00b7B symptoms at pre\u2011ASCT relapse", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">Two or more prior salvage therapies. </span></p>", "ID": "484ad29d-edc8-4b7b-9d9b-fcdffc7fe4ae", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "\u00b7Two or more prior salvage therapies. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpLast\"></p>", "ID": "87cf6947-43a7-40d4-888c-31fb7a4afb4f", "Styles": "None", "Classes": "['MsoListParagraphCxSpLast']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The results of these post\u2011hoc\r analyses suggest increased clinical benefit for patients with two or more risk\r factors but no difference based on any of the individual risk factors. No benefit\r in terms of PFS or OS has been observed in patients with one risk factor for\r relapse or progression.</span></p>", "ID": "7244b613-cbbb-4a49-a326-7662b3cb8262", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The results of these post\u2011hoc\r analyses suggest increased clinical benefit for patients with two or more risk\r factors but no difference based on any of the individual risk factors. No benefit\r in terms of PFS or OS has been observed in patients with one risk factor for\r relapse or progression.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:41.05pt;text-indent:-41.05pt\"></p>", "ID": "4238cbf3-50e2-46f3-8bf8-c0c9f158ad7b", "Styles": "margin-left:41.05pt;text-indent:-41.05pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:-4.5pt;text-indent:-.55pt;page-break-after:\r avoid\"><b><span lang=\"EN-GB\">Table 10: Summary of PFS per IRF and OS by number of\r risk factors in the phase 3 HL post\u2011ASCT Study <br/> <br/> </span></b></p>", "ID": "6c3356d8-314c-437f-87e5-13e3e337ea41", "Styles": "margin-left:-4.5pt;text-indent:-.55pt;page-break-after:\r\navoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 10: Summary of PFS per IRF and OS by number of\r risk factors in the phase 3 HL post\u2011ASCT Study   ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"613\"> <tr> <td colspan=\"7\" style=\"width:459.9pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"613\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">                                               Progression\r   Free Survival per IRF</span></b></p> </td> </tr> <tr> <td rowspan=\"2\" style=\"width:.95in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"91\"></td> <td colspan=\"2\" style=\"width:128.85pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"172\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Number of Risk Factors</span></b><span lang=\"EN-GB\"> <b>= 1</b></span></p> </td> <td colspan=\"2\" style=\"width:136.65pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"182\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Number of Risk Factors \u2265 2</span></b></p> </td> <td colspan=\"2\" style=\"width:1.75in;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Number of Risk Factors \u2265 3</span></b></p> </td> </tr> <tr> <td style=\"width:76.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 21</span></b></p> </td> <td style=\"width:52.35pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"70\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Placebo</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 28</span></b></p> </td> <td style=\"width:83.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"112\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 144</span></b></p> </td> <td style=\"width:52.7pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"70\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Placebo</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 136</span></b></p> </td> <td style=\"width:76.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 82</span></b></p> </td> <td style=\"width:49.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Placebo</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 84</span></b></p> </td> </tr> <tr> <td style=\"width:.95in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"91\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number of\r   patients with disease progression or death<sup>a </sup></span><span lang=\"EN-GB\">(%)</span></p> </td> <td style=\"width:76.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">9 (43)</span></p> </td> <td style=\"width:52.35pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"70\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">7 (25)</span></p> </td> <td style=\"width:83.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"112\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">51 (35)</span></p> </td> <td style=\"width:52.7pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"70\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">68 (50)</span></p> </td> <td style=\"width:76.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">32 (39)</span></p> </td> <td style=\"width:49.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">49 (58)</span></p> </td> </tr> <tr> <td style=\"width:.95in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"91\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Stratified\r   Hazard Ratio </span></p> </td> <td colspan=\"2\" style=\"width:128.85pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"172\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">1.65</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [0.60, 4.55])<sup>b</sup></span></p> </td> <td colspan=\"2\" style=\"width:136.65pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"182\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">0.49</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [0.34, 0.71])</span></p> </td> <td colspan=\"2\" style=\"width:1.75in;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">0.43 </span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [0.27, 0.68])</span></p> </td> </tr> <tr> <td colspan=\"7\" style=\"width:459.9pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"613\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Overall Survival </span></b></p> </td> </tr> <tr> <td rowspan=\"2\" style=\"width:.95in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"91\"></td> <td colspan=\"2\" style=\"width:128.85pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"172\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Number of Risk Factors = 1</span></b></p> </td> <td colspan=\"2\" style=\"width:136.65pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"182\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Number of Risk Factors \u2265 2</span></b></p> </td> <td colspan=\"2\" style=\"width:1.75in;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Number of Risk Factors \u2265 3</span></b></p> </td> </tr> <tr> <td style=\"width:76.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 21</span></b></p> </td> <td style=\"width:52.35pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"70\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Placebo</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 28</span></b></p> </td> <td style=\"width:83.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"112\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 144</span></b></p> </td> <td style=\"width:52.7pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"70\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Placebo</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 136</span></b></p> </td> <td style=\"width:76.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 82</span></b></p> </td> <td style=\"width:49.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Placebo</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 84</span></b></p> </td> </tr> <tr> <td style=\"width:.95in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"91\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Number of\r   deaths<sup>c </sup></span><span lang=\"EN-GB\">(%)</span></p> </td> <td style=\"width:76.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">5 (24)</span></p> </td> <td style=\"width:52.35pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"70\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">1 (4)</span></p> </td> <td style=\"width:83.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"112\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">23 (16)</span></p> </td> <td style=\"width:52.7pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"70\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">24 (18)</span></p> </td> <td style=\"width:76.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"102\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">15 (18)</span></p> </td> <td style=\"width:49.5pt;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">16 (19)</span></p> </td> </tr> <tr> <td style=\"width:.95in;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"91\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Stratified\r   Hazard Ratio </span></p> </td> <td colspan=\"2\" style=\"width:128.85pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"172\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">7.94</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [0.93, 68.06])<sup>b</sup></span></p> </td> <td colspan=\"2\" style=\"width:136.65pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"182\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">0.94</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [0.53, 1.67])</span></p> </td> <td colspan=\"2\" style=\"width:1.75in;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"168\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">0.92</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(95% CI [0.45, 1.88])</span></p> </td> </tr> </table>", "ID": "880b0edc-1950-4a50-8ede-00244079f5d5", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "                                                  Progression\r   Free Survival per IRF      Number of Risk Factors = 1   Number of Risk Factors \u2265 2   Number of Risk Factors \u2265 3     ADCETRIS n = 21   Placebo n = 28   ADCETRIS n = 144   Placebo n = 136   ADCETRIS n = 82   Placebo n = 84     Number of\r   patients with disease progression or deatha (%)   9 (43)   7 (25)   51 (35)   68 (50)   32 (39)   49 (58)     Stratified\r   Hazard Ratio    1.65  (95% CI [0.60, 4.55])b   0.49  (95% CI [0.34, 0.71])   0.43   (95% CI [0.27, 0.68])     Overall Survival       Number of Risk Factors = 1   Number of Risk Factors \u2265 2   Number of Risk Factors \u2265 3     ADCETRIS n = 21   Placebo n = 28   ADCETRIS n = 144   Placebo n = 136   ADCETRIS n = 82   Placebo n = 84     Number of\r   deathsc (%)   5 (24)   1 (4)   23 (16)   24 (18)   15 (18)   16 (19)     Stratified\r   Hazard Ratio    7.94  (95% CI [0.93, 68.06])b   0.94  (95% CI [0.53, 1.67])   0.92  (95% CI [0.45, 1.88])   ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Death without either prior progression or more than one missed assessment visit.</span></p>", "ID": "442baef0-c63d-473c-900b-bb33373ac5aa", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "a.Death without either prior progression or more than one missed assessment visit.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">b.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Indicates results\r from non-stratified analysis.</span></p>", "ID": "10c189c3-5889-49c8-9f35-b9a49663311d", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "b.Indicates results\r from non-stratified analysis.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">c.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Events are death due to any cause.</span></p>", "ID": "adf7cc2f-cd0b-48b5-9cb3-4767a4610bfd", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "c.Events are death due to any cause.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:41.05pt;text-indent:-41.05pt;page-break-after:\r avoid\"></p>", "ID": "df7a408b-fc72-45c1-a3c8-6e63e951bdb2", "Styles": "margin-left:41.05pt;text-indent:-41.05pt;page-break-after:\r\navoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">At the time of the updated analysis\r (3 years of follow-up) for patients with 2 or more risk factors, the\r hazard ratio for PFS per IRF was 0.49 (95% CI [0.34, 0.71]) and the hazard\r ratio for PFS per investigator was 0.41 (95% CI [0.29, 0.58]) (see Figures 3\r and 4).</span></p>", "ID": "0c2aecde-9c09-4c07-a7cb-e643742850af", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "At the time of the updated analysis\r (3 years of follow-up) for patients with 2 or more risk factors, the\r hazard ratio for PFS per IRF was 0.49 (95% CI [0.34, 0.71]) and the hazard\r ratio for PFS per investigator was 0.41 (95% CI [0.29, 0.58]) (see Figures 3\r and 4).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "3d26f8fe-35de-4518-88dd-d15e76c988ae", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Figure 3:\r Kaplan-Meier Plot of PFS per IRF in Patients with \u2265 2 Risk Factors</span></b></p>", "ID": "cbb36437-c8db-4e93-9a80-ee88ce8f49e6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Figure 3:\r Kaplan-Meier Plot of PFS per IRF in Patients with \u2265 2 Risk Factors", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"><img border=\"0\" height=\"299\" id=\"Picture 38\" src=\"Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image004.gif\" width=\"605\"/></span></p>", "ID": "b54c32d3-041d-43cb-873b-4d95938cf074", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "6fab8436-53a4-4a03-9725-cc33fbfa5349", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Figure 4:\r Kaplan-Meier Plot of PFS per Investigator in Patients with \u2265 2 Risk\r Factors</span></b></p>", "ID": "e2c0bc97-220f-4b6a-ae21-ff1c28462f2b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Figure 4:\r Kaplan-Meier Plot of PFS per Investigator in Patients with \u2265 2 Risk\r Factors", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"><img border=\"0\" height=\"299\" id=\"Picture 79\" src=\"Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image005.gif\" width=\"605\"/></span></p>", "ID": "848d08a5-e0ca-484d-8ec2-842d4183f32f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "8866a06d-c6fd-4871-bbd3-4c1646547731", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "c19bff8d-a670-4ee2-84f5-6f9850ec18a2", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Study SG035\u20110003</span></p>", "ID": "702864f3-72ea-4ab9-9788-42906d9a681e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Study SG035\u20110003", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "41460aff-e5b0-4e12-954e-774e78d83525", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">The efficacy and safety of </span><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">ADCETRIS</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> as a single\r agent was evaluated in a pivotal open-label, single\u2011arm, multicenter\r study in 102 patients with relapsed or refractory HL. See Table 11\r below for a summary of baseline patient and disease characteristics. </span></p>", "ID": "bdcb0892-605f-49c5-8c19-4473bcd8106e", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The efficacy and safety of ADCETRIS as a single\r agent was evaluated in a pivotal open-label, single\u2011arm, multicenter\r study in 102 patients with relapsed or refractory HL. See Table 11\r below for a summary of baseline patient and disease characteristics. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"></span></u></i></p>", "ID": "0462ed53-bd54-41a7-9ce6-d1a579618098", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Table 11: Summary of baseline patient and\r disease characteristics in the phase 2 relapsed or refractory HL study<br/> <br/> </span></b></p>", "ID": "93d9366e-dacd-4ded-bb64-72258a3a086b", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 11: Summary of baseline patient and\r disease characteristics in the phase 2 relapsed or refractory HL study  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div align=\"center\"> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:444.45pt;border-collapse:collapse;border:none\" width=\"593\"> <tr style=\"height:15.1pt\"> <td style=\"width:309.65pt;border:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-bottom:3.0pt;page-break-after:avoid\"><a name=\"OLE_LINK4\"></a><a name=\"RANGE!A1\"></a><b><span lang=\"EN-GB\">Patient\r   characteristics</span></b></p> </td> <td style=\"width:134.8pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><a name=\"OLE_LINK3\"><b><span lang=\"EN-GB\">n = 102</span></b></a></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:3.1pt;text-indent:5.5pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Median age, years (range)</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">31 years (15\u201177)</span></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Gender</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">48M (47%)/54F (53%)</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">ECOG status</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:12.75pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">42 (41%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">1</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">60 (59%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Prior ASCT</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">102 (100%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Prior chemotherapy Regimens</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">3.5 (1\u201113)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Time from ASCT to first post-transplant relapse</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">6.7 mo (0\u2011131)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Histologically confirmed CD30\u2011expressing\r   disease</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">102 (100%)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:3.0pt;\r   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;\r   text-indent:-19.45pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\r   characteristics</span></b></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:8.0pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Primary Refractory to frontline therapy<sup>a</sup></span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">72 (71%)</span></p> </td> </tr> <tr style=\"height:7.15pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Refractory to most recent therapy</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">43 (42%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Baseline B symptoms</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">35 (33%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Stage III at initial diagnosis</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">27 (26%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Stage IV at initial diagnosis</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">20 (20%)</span></p> </td> </tr> </table> </div>", "ID": "0b14fae6-46a6-4c43-929c-78390acd0381", "Styles": "None", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:444.45pt;border-collapse:collapse;border:none\" width=\"593\"> <tr style=\"height:15.1pt\"> <td style=\"width:309.65pt;border:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-bottom:3.0pt;page-break-after:avoid\"><a name=\"OLE_LINK4\"></a><a name=\"RANGE!A1\"></a><b><span lang=\"EN-GB\">Patient\r   characteristics</span></b></p> </td> <td style=\"width:134.8pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><a name=\"OLE_LINK3\"><b><span lang=\"EN-GB\">n = 102</span></b></a></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:3.1pt;text-indent:5.5pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Median age, years (range)</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">31 years (15\u201177)</span></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Gender</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">48M (47%)/54F (53%)</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">ECOG status</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:12.75pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">42 (41%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">1</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">60 (59%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Prior ASCT</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">102 (100%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Prior chemotherapy Regimens</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">3.5 (1\u201113)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Time from ASCT to first post-transplant relapse</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">6.7 mo (0\u2011131)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Histologically confirmed CD30\u2011expressing\r   disease</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">102 (100%)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:3.0pt;\r   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;\r   text-indent:-19.45pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\r   characteristics</span></b></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:8.0pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Primary Refractory to frontline therapy<sup>a</sup></span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">72 (71%)</span></p> </td> </tr> <tr style=\"height:7.15pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Refractory to most recent therapy</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">43 (42%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Baseline B symptoms</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">35 (33%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Stage III at initial diagnosis</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">27 (26%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:309.65pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"413\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Stage IV at initial diagnosis</span></p> </td> <td style=\"width:134.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"180\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">20 (20%)</span></p> </td> </tr> </table>", "ID": "97f00884-0b71-45f2-b35a-1f0e1a7f5f14", "Styles": "width:444.45pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "   Patient\r   characteristics   n = 102     Median age, years (range)   31 years (15\u201177)     Gender   48M (47%)/54F (53%)     ECOG status        0   42 (41%)     1   60 (59%)     Prior ASCT   102 (100%)     Prior chemotherapy Regimens   3.5 (1\u201113)     Time from ASCT to first post-transplant relapse   6.7 mo (0\u2011131)     Histologically confirmed CD30\u2011expressing\r   disease   102 (100%)     Disease\r   characteristics        Primary Refractory to frontline therapya   72 (71%)     Refractory to most recent therapy   43 (42%)     Baseline B symptoms   35 (33%)     Stage III at initial diagnosis   27 (26%)     Stage IV at initial diagnosis   20 (20%)   ", "ParentId": "0b14fae6-46a6-4c43-929c-78390acd0381"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:22.5pt;text-indent:-.25in\"><sup><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Primary refractory\r HL is defined as a failure to achieve a complete remission to, or progressed\r within 3 months of completing frontline therapy.</span></p>", "ID": "ff578a21-a046-45dd-bf0b-78a92ef8ff94", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:22.5pt;text-indent:-.25in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "a.Primary refractory\r HL is defined as a failure to achieve a complete remission to, or progressed\r within 3 months of completing frontline therapy.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "556795bc-e3ad-4bb6-b7ce-25e8ae4a637d", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">Eighteen (18) patients (18%) received 16 cycles of </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">ADCETRIS</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">; and the median number of cycles received was 9\r (ranging from 1 to 1</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">6).<sup> </sup></span></p>", "ID": "621342c0-0a79-45e8-9b17-1c02885d852b", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Eighteen (18) patients (18%) received 16 cycles of ADCETRIS; and the median number of cycles received was 9\r (ranging from 1 to 16). ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "447e83d8-6925-4477-9c95-6c126a5c1eb3", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">Response to treatment with </span><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">ADCETRIS</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> was assessed\r by Independent Review Facility (IRF) using the Revised Response Criteria for\r Malignant Lymphoma (Cheson, 2007). Treatment response was assessed by spiral CT\r of chest, neck, abdomen and pelvis; PET scans and clinical data. Response\r assessments were performed at cycles 2, 4, 7, 10, 13, and 16 with PET at cycles\r 4 and 7.</span></p>", "ID": "dc235a5f-7a07-4914-832a-296774d7bfbb", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Response to treatment with ADCETRIS was assessed\r by Independent Review Facility (IRF) using the Revised Response Criteria for\r Malignant Lymphoma (Cheson, 2007). Treatment response was assessed by spiral CT\r of chest, neck, abdomen and pelvis; PET scans and clinical data. Response\r assessments were performed at cycles 2, 4, 7, 10, 13, and 16 with PET at cycles\r 4 and 7.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">The objective response rate (ORR) per IRF assessment was 75% (76 of\r 102 patients in the intent\u2011to\u2011treat [ITT] set) and tumour\r reduction was achieved in 94% of patients. Complete remission (CR) was 33% (34\r of 102 patients in the ITT set). The median overall survival (OS) is\r 40.5 months (the median observation time (time to death or last contact)\r from first dose was 35.1 months (range 1.8 to 72.9+ months). The\r estimated overall survival rate at 5 years was 41% (95% CI [31%,\r 51%]).<a name=\"OLE_LINK8\"></a><a name=\"OLE_LINK9\"> The investigator assessments\r were generally consistent with the independent review of the scans.</a> </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Of the patients treated, 8 responding\r patients went on to receive an allogeneic SCT. </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">For further efficacy results see Table 12. </span></p>", "ID": "f136f283-ca9a-4803-a8c4-a4ced5589c5b", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The objective response rate (ORR) per IRF assessment was 75% (76 of\r 102 patients in the intent\u2011to\u2011treat [ITT] set) and tumour\r reduction was achieved in 94% of patients. Complete remission (CR) was 33% (34\r of 102 patients in the ITT set). The median overall survival (OS) is\r 40.5 months (the median observation time (time to death or last contact)\r from first dose was 35.1 months (range 1.8 to 72.9+ months). The\r estimated overall survival rate at 5 years was 41% (95% CI [31%,\r 51%]). The investigator assessments\r were generally consistent with the independent review of the scans. Of the patients treated, 8 responding\r patients went on to receive an allogeneic SCT. For further efficacy results see Table 12. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:131.75pt;text-indent:-131.75pt\"></p>", "ID": "e4ff1e13-bab5-4d77-bc20-a2100eadf852", "Styles": "margin-left:131.75pt;text-indent:-131.75pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 12:\r Efficacy results in relapsed or refractory Hodgkin lymphoma patients treated\r with 1.8 mg/kg of </span></b><b><span lang=\"EN-GB\">ADCETRIS</span><span lang=\"EN-GB\"> every 3 weeks<br/> <br/> </span></b></p>", "ID": "84e6418d-dca4-4fb6-bd86-7413a978865c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 12:\r Efficacy results in relapsed or refractory Hodgkin lymphoma patients treated\r with 1.8 mg/kg of ADCETRIS every 3 weeks  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"600\"> <tr style=\"height:15.1pt\"> <td nowrap=\"\" style=\"width:188.1pt;border:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Best\r   clinical response</span></b><b><sup></sup></b><b><span lang=\"EN-GB\">(n = 102</span></b><sup></sup><b><span lang=\"EN-GB\">)</span></b></p> </td> <td nowrap=\"\" style=\"width:1.95in;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">IRF n (%)</span></b></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">95% CI</span></b></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:188.1pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">   \r   Objective response rate (CR + PR)</span></p> </td> <td nowrap=\"\" style=\"width:1.95in;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">76 (75)</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">64.9, 82.6</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:188.1pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">         \r   Complete remission (CR)</span></p> </td> <td nowrap=\"\" style=\"width:1.95in;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">34 (33)</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">24.3, 43.4</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:188.1pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">         \r   Partial remission (PR)</span></p> </td> <td nowrap=\"\" style=\"width:1.95in;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">42 (41)</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">NA</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:188.1pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">   \r   Disease control rate (CR + PR + SD)</span></p> </td> <td nowrap=\"\" style=\"width:1.95in;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">98 (96)</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">90.3, 98.9</span></p> </td> </tr> <tr style=\"height:14.8pt\"> <td nowrap=\"\" style=\"width:188.1pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.8pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Duration\r   of response </span></b></p> </td> <td style=\"width:1.95in;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.8pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Median per IRF </span></b></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.8pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">95% CI</span></b></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:188.1pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">   \r   Objective response rate (CR + PR)<sup>a</sup></span></p> </td> <td nowrap=\"\" style=\"width:1.95in;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">6.7 months </span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">3.6, 14.8</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:188.1pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">   \r   Complete remission (CR)</span></p> </td> <td nowrap=\"\" style=\"width:1.95in;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">27.9 months</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">10.8, NE<sup>b</sup> </span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:188.1pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Overall\r   survival </span></b></p> </td> <td style=\"width:1.95in;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td style=\"width:121.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">95% CI</span></b></p> </td> </tr> <tr style=\"height:7.5pt\"> <td style=\"width:188.1pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median</span></p> </td> <td style=\"width:1.95in;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">40.5 months</span><b><sup></sup></b></p> </td> <td style=\"width:121.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">28.7, 61.9</span></p> </td> </tr> <tr style=\"height:7.5pt\"> <td style=\"width:188.1pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"251\"> <p class=\"MsoNormal\" style=\"margin-left:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Estimated 5\u2011year OS Rate</span></p> </td> <td style=\"width:1.95in;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"187\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">41%</span></p> </td> <td style=\"width:121.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">31%, 51%</span></p> </td> </tr> </table>", "ID": "27da16ad-859e-4440-8dc9-ace60ab6e5b7", "Styles": "margin-left:5.4pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "   Best\r   clinical response(n = 102)   IRF n (%)   95% CI        \r   Objective response rate (CR + PR)   76 (75)   64.9, 82.6              \r   Complete remission (CR)   34 (33)   24.3, 43.4              \r   Partial remission (PR)   42 (41)   NA        \r   Disease control rate (CR + PR + SD)   98 (96)   90.3, 98.9     Duration\r   of response    Median per IRF    95% CI        \r   Objective response rate (CR + PR)a   6.7 months    3.6, 14.8        \r   Complete remission (CR)   27.9 months   10.8, NEb      Overall\r   survival       95% CI     Median   40.5 months   28.7, 61.9     Estimated 5\u2011year OS Rate   41%   31%, 51%   ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">The range of DOR\r was 1.2+ months to 43+ months and the median follow-up time from\r first dose for patients who achieved objective response (OR) per IRF was\r 9.0 months.</span></p>", "ID": "44d81b3c-c350-4d08-a8ed-274288f4b449", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "a.The range of DOR\r was 1.2+ months to 43+ months and the median follow-up time from\r first dose for patients who achieved objective response (OR) per IRF was\r 9.0 months.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in\"><sup><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">b.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Not estimable.</span></p>", "ID": "1700ffb9-7e52-4ca8-8567-1ca0381eba12", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "b.Not estimable.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "53be85e0-3bad-4daa-ae80-390ae7eaebbd", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">An exploratory intra\u2011patient analysis showed that approximately\r 64% of the HL patients treated with ADCETRIS as part of the SG035\u20110003\r clinical study experienced an improvement in clinical benefit as measured by\r longer progression free survival (PFS) compared with their most recent prior\r line of therapy. </span></p>", "ID": "b5286102-76f4-4e84-98be-663a50eed911", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "An exploratory intra\u2011patient analysis showed that approximately\r 64% of the HL patients treated with ADCETRIS as part of the SG035\u20110003\r clinical study experienced an improvement in clinical benefit as measured by\r longer progression free survival (PFS) compared with their most recent prior\r line of therapy. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "57329e8f-71c6-467a-9a3c-54d5cfad2673", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">Of the 35 patients (33%) who had B symptoms at baseline,\r 27 patients (77%) experienced resolution of all B symptoms at a median\r time of 0.7 months from initiation of </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">ADCETRIS</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">.</span></p>", "ID": "52c6c422-cb23-47fc-aab9-e62f0ce416e4", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Of the 35 patients (33%) who had B symptoms at baseline,\r 27 patients (77%) experienced resolution of all B symptoms at a median\r time of 0.7 months from initiation of ADCETRIS.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "e18f760d-3169-4b73-963b-25a59431507f", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Data in HL\r Patients Who Are Not Stem Cell Transplant (SCT) Candidates</span></p>", "ID": "0ea05b6a-b19c-449e-9dbe-aa6b7df34dce", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Data in HL\r Patients Who Are Not Stem Cell Transplant (SCT) Candidates", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TableText\" style=\"margin-bottom:0in\"></p>", "ID": "ce955ec4-efed-49c9-a5dd-eadf22b63b38", "Styles": "margin-bottom:0in", "Classes": "['TableText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TableText\" style=\"margin-bottom:0in;page-break-after:avoid\"><span style=\"font-size:11.0pt\">Study\u2011C25007 </span></p>", "ID": "7b40762c-066b-4210-9bd2-244d74ba9266", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['TableText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Study\u2011C25007 ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "7ebf87da-7a36-4f48-a132-056be7f88dee", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">A phase 4 single-arm study was\r conducted in patients with relapsed or refractory HL (n = 60) who had\r received at least one prior chemotherapeutic regimen and at the time of\r treatment initiation with ADCETRIS were not considered candidates for SCT or\r multiagent chemotherapy. The median number of cycles was 7 (range 1 to 16\r cycles). Patients were treated with 1.8 mg/kg of ADCETRIS every 3 weeks.\r Per IRF, the objective response rate (ORR) in the ITT population was 50% (95%\r CI, 37; 63%). A best overall response of CR was reported for 7 patients\r (12%); PR was reported for 23 patients (38%). Among these 30 patients,\r the median time to response, defined as the time from first dose to the soonest\r of PR or CR, was 6 weeks (range, 5 to 39 weeks). The median time to best\r overall response, defined as the time from first dose to the clinical best\r response of CR or PR, was 11 weeks (range, 5 to 60 weeks). Twenty\u2011eight\r patients (47%) went on to receive SCT after a median of 7 cycles (range, 4 to 16\r cycles) of ADCETRIS treatment. The 32 patients (53%) who did not receive\r subsequent SCT also received ADCETRIS for a median of 7 cycles (range, 1 to\r 16 cycles). </span></p>", "ID": "f3b41a6e-9008-48da-ad1e-6a9134002079", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "A phase 4 single-arm study was\r conducted in patients with relapsed or refractory HL (n = 60) who had\r received at least one prior chemotherapeutic regimen and at the time of\r treatment initiation with ADCETRIS were not considered candidates for SCT or\r multiagent chemotherapy. The median number of cycles was 7 (range 1 to 16\r cycles). Patients were treated with 1.8 mg/kg of ADCETRIS every 3 weeks.\r Per IRF, the objective response rate (ORR) in the ITT population was 50% (95%\r CI, 37; 63%). A best overall response of CR was reported for 7 patients\r (12%); PR was reported for 23 patients (38%). Among these 30 patients,\r the median time to response, defined as the time from first dose to the soonest\r of PR or CR, was 6 weeks (range, 5 to 39 weeks). The median time to best\r overall response, defined as the time from first dose to the clinical best\r response of CR or PR, was 11 weeks (range, 5 to 60 weeks). Twenty\u2011eight\r patients (47%) went on to receive SCT after a median of 7 cycles (range, 4 to 16\r cycles) of ADCETRIS treatment. The 32 patients (53%) who did not receive\r subsequent SCT also received ADCETRIS for a median of 7 cycles (range, 1 to\r 16 cycles). ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "eebbcb98-275d-4d70-899c-49684ca4fa72", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Of the study\u2019s 60 patients, 49 patients\r (82%) received &gt; 1 prior cancer-related treatment and 11 patients\r (18%) received 1 prior cancer-related treatment. Per IRF, the ORR was 51% (95% CI [36%,\r 66%]) for the patients who had received &gt; 1 prior cancer-related\r treatment and 45% (95% CI [17%, 77%]) for the patients who had\r received 1 prior cancer-related treatment. For the patients who received\r &gt; 1 prior cancer-related treatment, a best overall response of CR was\r reported for 6 patients (12%); PR was reported for 19 patients (39%).\r For the patients who received 1 prior cancer-related treatment, CR was\r reported for 1 patient (9%) and PR was reported for 4 patients (36%).\r Out of the 49 patients receiving &gt; 1 line of prior treatment, 22 patients\r (45%) received subsequent SCT; of the 11 patients who had received 1 prior\r treatment, 6 patients (55%) received subsequent SCT.</span></p>", "ID": "6e1c9c6e-7245-4cba-92d4-4ccf15afee2e", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Of the study\u2019s 60 patients, 49 patients\r (82%) received > 1 prior cancer-related treatment and 11 patients\r (18%) received 1 prior cancer-related treatment. Per IRF, the ORR was 51% (95% CI [36%,\r 66%]) for the patients who had received > 1 prior cancer-related\r treatment and 45% (95% CI [17%, 77%]) for the patients who had\r received 1 prior cancer-related treatment. For the patients who received\r > 1 prior cancer-related treatment, a best overall response of CR was\r reported for 6 patients (12%); PR was reported for 19 patients (39%).\r For the patients who received 1 prior cancer-related treatment, CR was\r reported for 1 patient (9%) and PR was reported for 4 patients (36%).\r Out of the 49 patients receiving > 1 line of prior treatment, 22 patients\r (45%) received subsequent SCT; of the 11 patients who had received 1 prior\r treatment, 6 patients (55%) received subsequent SCT.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "0d4be93a-8834-483f-ba50-be7d118698a4", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Data were also collected from patients (n = 15)\r in phase 1 dose escalation and clinical pharmacology studies, and from\r patients (n = 26) in a NPP, with relapsed or refractory HL who had\r not received an ASCT, and who were treated with 1.8 mg/kg of ADCETRIS\r every 3 weeks.</span></p>", "ID": "0d2043d6-fc8f-460b-a81f-72f672960d4b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Data were also collected from patients (n = 15)\r in phase 1 dose escalation and clinical pharmacology studies, and from\r patients (n = 26) in a NPP, with relapsed or refractory HL who had\r not received an ASCT, and who were treated with 1.8 mg/kg of ADCETRIS\r every 3 weeks.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "18eb23ac-3a20-4954-8af7-6ea40d49b0d0", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Baseline patient characteristics showed\r failure from multiple prior chemotherapy regimens (median of 3 with a\r range of 1 to 7) before first administration with ADCETRIS. Fifty nine percent\r (59%) of patients had advanced stage disease (Stage III or IV) at initial\r diagnosis. </span></p>", "ID": "1c803122-f669-4e7e-aeaa-bbdf953be385", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Baseline patient characteristics showed\r failure from multiple prior chemotherapy regimens (median of 3 with a\r range of 1 to 7) before first administration with ADCETRIS. Fifty nine percent\r (59%) of patients had advanced stage disease (Stage III or IV) at initial\r diagnosis. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "c21c93a8-b100-48c1-a1b8-59c380b6f527", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Results from these phase 1 studies and from\r the NPP experience showed, that in patients with relapsed or refractory HL\r without prior ASCT, clinically meaningful responses can be achieved as\r evidenced by an investigator-assessed, objective response rate of 54% and a\r complete remission rate of 22% after a median of 5 cycles of ADCETRIS. </span></p>", "ID": "dcbbc9c9-15fd-46d9-b969-86f382c04491", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Results from these phase 1 studies and from\r the NPP experience showed, that in patients with relapsed or refractory HL\r without prior ASCT, clinically meaningful responses can be achieved as\r evidenced by an investigator-assessed, objective response rate of 54% and a\r complete remission rate of 22% after a median of 5 cycles of ADCETRIS. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "67960d39-c1f8-461c-92d0-7a106fe3c7fc", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Study SGN35\u2011006\r (Retreatment Study)</span></p>", "ID": "909575e5-4ee2-4005-aa2e-0b8148435095", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Study SGN35\u2011006\r (Retreatment Study)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"></span></u></p>", "ID": "be7d08af-480c-4ed5-a05d-570c8f4f4e07", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">The efficacy of retreatment in patients who had previously responded\r (CR or PR) to treatment with ADCETRIS was evaluated in a phase 2,\r open-label, multicenter trial. Twenty patients with relapsed or refractory HL\r received a starting dose of 1.8 mg/kg and one patient received a starting\r dose of 1.2 mg/kg of ADCETRIS administered intravenously over\r 30 minutes every 3 weeks. The median number of cycles was 7 (range, 2\r to 37 cycles).</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Of the 20 evaluable patients with HL,\r 6 patients (30%) achieved a CR and 6 patients (30%) achieved a PR\r with ADCETRIS retreatment, for an ORR of 60%. </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The median duration of response was 9.2 and\r 9.4 months in patients who achieved OR (CR+PR) and CR, respectively.</span></p>", "ID": "a3dff310-8d9c-43ee-8860-aea4ab0bcc19", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The efficacy of retreatment in patients who had previously responded\r (CR or PR) to treatment with ADCETRIS was evaluated in a phase 2,\r open-label, multicenter trial. Twenty patients with relapsed or refractory HL\r received a starting dose of 1.8 mg/kg and one patient received a starting\r dose of 1.2 mg/kg of ADCETRIS administered intravenously over\r 30 minutes every 3 weeks. The median number of cycles was 7 (range, 2\r to 37 cycles).Of the 20 evaluable patients with HL,\r 6 patients (30%) achieved a CR and 6 patients (30%) achieved a PR\r with ADCETRIS retreatment, for an ORR of 60%. The median duration of response was 9.2 and\r 9.4 months in patients who achieved OR (CR+PR) and CR, respectively.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "93f53c40-6f3f-4465-8da9-e46793062093", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Systemic anaplastic large cell lymphoma</span></i></p>", "ID": "8a1f4781-1394-49ef-a011-e470b6eaabb8", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Systemic anaplastic large cell lymphoma", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "1dfc495d-d4ef-4615-a75b-1124a9b74b1c", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Study SGN35\u2011014</span></p>", "ID": "6685aa6b-d575-4a3a-9fdc-ad5134b603b1", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Study SGN35\u2011014", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "acdda1d4-7514-405a-adb9-5486b70d377d", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">The efficacy and safety of ADCETRIS were evaluated in a randomised,\r double-blind, double-dummy, active-controlled, multicenter trial of 452 patients\r with previously untreated CD30+ PTCL in combination with cyclophosphamide [C],\r doxorubicin [H] and prednisone [P] (CHP). </span><span style=\"font-size:11.0pt\">For\r enrollment, the trial required CD30 expression \u226510% per\r immunohistochemistry. </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Only\r patients with CD30+ PTCLs who were eligible for a </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">cyclophosphamide [C], doxorubicin [H], vincristine [O]\r and prednisone [P]</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> (CHOP)-based\r regimen were included.</span><span style=\"font-size:11.0pt\"> The combination of\r ADCETRIS + CHP has not been studied in all PTCL subtypes. See Table\r 13 for enrolled PTCL subtypes. </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Of\r the 452 patients, 226 were randomised to treatment with ADCETRIS + CHP\r and 226 patients were randomised to treatment with CHOP. Randomisation was\r stratified by ALK-positive sALCL versus all other subtypes and by the\r International Prognostic Index (IPI) score. Patients were treated with ADCETRIS\r administered as an intravenous infusion over 30 minutes on day 1 of\r each 21\u2011day cycle for 6 to 8 cycles + CHP. The median number of\r cycles received was 6 (range, 1 to 8 cycles); 70% of patients\r received 6 cycles of treatment, and 18% received 8 cycles of\r treatment. Table 13 provides a summary of baseline patient and disease\r characteristics.</span></p>", "ID": "76e82b79-ceea-4743-98cf-fe65864b40b5", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The efficacy and safety of ADCETRIS were evaluated in a randomised,\r double-blind, double-dummy, active-controlled, multicenter trial of 452 patients\r with previously untreated CD30+ PTCL in combination with cyclophosphamide [C],\r doxorubicin [H] and prednisone [P] (CHP). For\r enrollment, the trial required CD30 expression \u226510% per\r immunohistochemistry. Only\r patients with CD30+ PTCLs who were eligible for a cyclophosphamide [C], doxorubicin [H], vincristine [O]\r and prednisone [P] (CHOP)-based\r regimen were included. The combination of\r ADCETRIS + CHP has not been studied in all PTCL subtypes. See Table\r 13 for enrolled PTCL subtypes. Of\r the 452 patients, 226 were randomised to treatment with ADCETRIS + CHP\r and 226 patients were randomised to treatment with CHOP. Randomisation was\r stratified by ALK-positive sALCL versus all other subtypes and by the\r International Prognostic Index (IPI) score. Patients were treated with ADCETRIS\r administered as an intravenous infusion over 30 minutes on day 1 of\r each 21\u2011day cycle for 6 to 8 cycles + CHP. The median number of\r cycles received was 6 (range, 1 to 8 cycles); 70% of patients\r received 6 cycles of treatment, and 18% received 8 cycles of\r treatment. Table 13 provides a summary of baseline patient and disease\r characteristics.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "7ca233a3-7e10-4937-819d-ac56ed374d72", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><a name=\"_Ref525816436\"><b><span lang=\"EN-GB\">Table </span></b></a><b><span lang=\"EN-GB\">13: Summary of baseline\r patient and disease characteristics in the phase 3 previously untreated PTCL\r study (ITT and sALCL)</span></b></p>", "ID": "c6d9271e-2ea4-4f44-93a7-c04fc851d7ae", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 13: Summary of baseline\r patient and disease characteristics in the phase 3 previously untreated PTCL\r study (ITT and sALCL)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "ab878fb1-62af-47ee-909f-8b6f5980409a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:459.4pt;border-collapse:collapse;border:none\" width=\"613\"> <thead> <tr> <td style=\"width:189.45pt;border:solid windowtext 1.0pt;\r    border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> </td> <td colspan=\"2\" style=\"width:133.95pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"179\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">ITT Population </span></b></p> </td> <td colspan=\"2\" style=\"width:136.0pt;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"181\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">sALCL Population<sup>b</sup></span></b></p> </td> </tr> <tr> <td style=\"width:189.45pt;border-top:none;border-left:\r    solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r    none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Patient\r    characteristics</span></b></p> </td> <td style=\"width:67.65pt;border:none;border-bottom:\r    solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">ADCETRIS + CHP</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">n=226</span></b></p> </td> <td style=\"width:66.3pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">CHOP</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">n=226</span></b></p> </td> <td style=\"width:69.55pt;border:none;border-bottom:\r    solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">ADCETRIS + CHP</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">n=162</span></b></p> </td> <td style=\"width:66.45pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">CHOP</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><b><span lang=\"EN-GB\">n=154</span></b></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\r    age (range)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">58.0 (18\u201185)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">58.0 (18\u201183)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">55.0 (18-85)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">54.0 (18-83)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Patients\r    \u2265 65 years old (%)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">69 (31)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">70 (31)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">38 (23)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">36 (23)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Male sex,\r    n (%)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">133 (59)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">151 (67)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">95 (59)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">110 (71)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">ECOG\r    status, n (%)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">84 (37)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">93 (41)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">58 (36)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">53 (34)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">1</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">90 (40)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">86 (38)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">62 (38)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">61 (40)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border-top:none;border-left:\r    solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r    none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">2</span></p> </td> <td style=\"width:67.65pt;border:none;border-bottom:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">51 (23)</span></p> </td> <td style=\"width:66.3pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">47 (21)</span></p> </td> <td style=\"width:69.55pt;border:none;border-bottom:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">41 (25)</span></p> </td> <td style=\"width:66.45pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">40 (26)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border-top:none;border-left:\r    solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r    none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\r    characteristics</span></b></p> </td> <td style=\"width:67.65pt;border:none;border-bottom:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.3pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:69.55pt;border:none;border-bottom:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.45pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">Diagnosis, per local assessment, n (%)<sup>a</sup></span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">sALCL</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">162 (72)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">154 (68)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">162 (100)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">154 (100)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.4in;page-break-after:avoid\"><span lang=\"EN-GB\">ALK-positive</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">49 (22)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">49 (22)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">49 (30)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">49 (32)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.4in;page-break-after:avoid\"><span lang=\"EN-GB\">ALK-negative</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">113 (50)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">105 (46)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">113 (70)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">105 (68)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"FR\">Peripheral T-cell lymphoma (PTCL-NOS)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">29 (13)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">43 (19)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">NA</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">NA</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">Angioimmunoblastic T-cell lymphoma (AITL)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">30 (13)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">24 (11)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">NA</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">NA</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">Adult T-cell leukemia/lymphoma (ATLL)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">4 (2)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">3 (1)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">NA</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">NA</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">Enteropathy-associated T-cell lymphoma (EATL)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">1 (0)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">2 (1)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">NA</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">NA</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">Median time from diagnosis to first dose, months (range)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">0.8 (0, 19)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">0.9 (0, 10)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">0.8 (0, 19)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">0.9 (0, 10)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">Disease stage at initial diagnosis of PTCL, n (%)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">Stage I</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">12 (5)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">9 (4)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">12 (7)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">7 (5)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">Stage II</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">30 (13)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">37 (16)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">22 (14)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">27 (18)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">Stage III</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">57 (25)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">67 (30)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">29 (18)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">46 (30)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">Stage IV</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">127 (56)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">113 (50)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">99 (61)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">74 (48)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">IPI score </span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">8 (4)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">16 (7)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">7 (4)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">14 (9)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">1</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">45 (20)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">32 (14)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">34 (21)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">18 (12)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">2</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">74 (33)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">78 (35)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">58 (36)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">60 (39)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">3</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">66 (29)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">66 (29)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">37 (23)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">40 (26)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">4</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">29 (13)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">25 (11)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">22 (14)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">16 (10)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">5</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">4 (2)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">9 (4)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">4 (2)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">6 (4)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">Extranodal involvement at time of diagnosis, n (%)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:.2in;margin-bottom:\r    0in;margin-left:.2in;margin-bottom:.0001pt;page-break-after:avoid\"><span lang=\"EN-GB\">\u2264 1 site</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">142 (63)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">146 (65)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">94 (58)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">95 (62)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">&gt;1 site</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">84 (37)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">80 (35)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">68 (42)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">59 (38)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.1in;page-break-after:avoid\"><span lang=\"EN-GB\">Baseline bone marrow biopsy-lymphoma involvement, n (%)</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"></p> </td> </tr> <tr> <td style=\"width:189.45pt;border:none;border-left:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">Yes</span></p> </td> <td style=\"width:67.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">30 (13)</span></p> </td> <td style=\"width:66.3pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">34 (15)</span></p> </td> <td style=\"width:69.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">15 (9)</span></p> </td> <td style=\"width:66.45pt;border:none;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">13 (8)</span></p> </td> </tr> <tr> <td style=\"width:189.45pt;border-top:none;border-left:\r    solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r    none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"margin-left:.2in;page-break-after:avoid\"><span lang=\"EN-GB\">No</span></p> </td> <td style=\"width:67.65pt;border:none;border-bottom:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">196 (87)</span></p> </td> <td style=\"width:66.3pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"88\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">192 (85)</span></p> </td> <td style=\"width:69.55pt;border:none;border-bottom:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"93\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">147 (91)</span></p> </td> <td style=\"width:66.45pt;border-top:none;border-left:\r    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"89\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r    avoid\"><span lang=\"EN-GB\">141 (92)</span></p> </td> </tr> </thead> </table>", "ID": "4c9fddfd-9894-4a0c-a56c-25e7729690b2", "Styles": "width:459.4pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "       ITT Population    sALCL Populationb     Patient\r    characteristics   ADCETRIS + CHP n=226   CHOP n=226   ADCETRIS + CHP n=162   CHOP n=154     Median\r    age (range)   58.0 (18\u201185)   58.0 (18\u201183)   55.0 (18-85)   54.0 (18-83)     Patients\r    \u2265 65 years old (%)   69 (31)   70 (31)   38 (23)   36 (23)     Male sex,\r    n (%)   133 (59)   151 (67)   95 (59)   110 (71)     ECOG\r    status, n (%)                 0   84 (37)   93 (41)   58 (36)   53 (34)     1   90 (40)   86 (38)   62 (38)   61 (40)     2   51 (23)   47 (21)   41 (25)   40 (26)     Disease\r    characteristics                 Diagnosis, per local assessment, n (%)a                 sALCL   162 (72)   154 (68)   162 (100)   154 (100)     ALK-positive   49 (22)   49 (22)   49 (30)   49 (32)     ALK-negative   113 (50)   105 (46)   113 (70)   105 (68)     Peripheral T-cell lymphoma (PTCL-NOS)   29 (13)   43 (19)   NA   NA     Angioimmunoblastic T-cell lymphoma (AITL)   30 (13)   24 (11)   NA   NA     Adult T-cell leukemia/lymphoma (ATLL)   4 (2)   3 (1)   NA   NA     Enteropathy-associated T-cell lymphoma (EATL)   1 (0)   2 (1)   NA   NA     Median time from diagnosis to first dose, months (range)   0.8 (0, 19)   0.9 (0, 10)   0.8 (0, 19)   0.9 (0, 10)     Disease stage at initial diagnosis of PTCL, n (%)                 Stage I   12 (5)   9 (4)   12 (7)   7 (5)     Stage II   30 (13)   37 (16)   22 (14)   27 (18)     Stage III   57 (25)   67 (30)   29 (18)   46 (30)     Stage IV   127 (56)   113 (50)   99 (61)   74 (48)     IPI score                  0   8 (4)   16 (7)   7 (4)   14 (9)     1   45 (20)   32 (14)   34 (21)   18 (12)     2   74 (33)   78 (35)   58 (36)   60 (39)     3   66 (29)   66 (29)   37 (23)   40 (26)     4   29 (13)   25 (11)   22 (14)   16 (10)     5   4 (2)   9 (4)   4 (2)   6 (4)     Extranodal involvement at time of diagnosis, n (%)                 \u2264 1 site   142 (63)   146 (65)   94 (58)   95 (62)     >1 site   84 (37)   80 (35)   68 (42)   59 (38)     Baseline bone marrow biopsy-lymphoma involvement, n (%)                 Yes   30 (13)   34 (15)   15 (9)   13 (8)     No   196 (87)   192 (85)   147 (91)   141 (92)    ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:17.85pt;text-indent:-17.85pt\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">      As\r per the 2008 WHO classification.</span></p>", "ID": "b24f6f75-52c7-4d7b-ab60-bcb7c1a6a772", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:17.85pt;text-indent:-17.85pt", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "a.      As\r per the 2008 WHO classification.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:17.85pt;text-indent:-17.85pt\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">b.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">      For\r patients with locally-diagnosed sALCL.</span></p>", "ID": "3314112c-37d3-40c6-8cba-8bba5cb26245", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:17.85pt;text-indent:-17.85pt", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "b.      For\r patients with locally-diagnosed sALCL.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "c435ab6a-203e-4106-8697-21232c605ceb", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The primary endpoint in SGN35\u2011014 was\r PFS per IRF, defined as the time from the date of randomisation to the date of\r first documentation of progressive disease, death due to any cause, or receipt\r of subsequent anticancer chemotherapy to treat residual or progressive disease,\r whichever occurs first. Receipt of post\u2011treatment consolidative\r radiotherapy, post-treatment chemotherapy for the purpose of mobilising\r peripheral blood stem cells, or consolidative autologous or allogeneic stem\r cell transplant were not considered as disease progression or as having started\r new anticancer therapy.</span></p>", "ID": "da094e5d-0789-40f5-886e-eab108887368", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The primary endpoint in SGN35\u2011014 was\r PFS per IRF, defined as the time from the date of randomisation to the date of\r first documentation of progressive disease, death due to any cause, or receipt\r of subsequent anticancer chemotherapy to treat residual or progressive disease,\r whichever occurs first. Receipt of post\u2011treatment consolidative\r radiotherapy, post-treatment chemotherapy for the purpose of mobilising\r peripheral blood stem cells, or consolidative autologous or allogeneic stem\r cell transplant were not considered as disease progression or as having started\r new anticancer therapy.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "668bc266-7d58-4a97-97a3-82b843b603cd", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Key secondary\r endpoints included PFS per IRF for patients with centrally-confirmed sALCL, CR\r rate per IRF </span><span style=\"font-size:11.0pt\">following the completion of\r study treatment</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">, OS and ORR\r per IRF </span><span style=\"font-size:11.0pt\">following the completion of study\r treatment</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> which were tested by\r a fixed sequence testing procedure following the statistical significance of\r PFS per IRF. </span></p>", "ID": "d064ca14-13ae-4d1c-9846-7c7e542ece2f", "Styles": "None", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Key secondary\r endpoints included PFS per IRF for patients with centrally-confirmed sALCL, CR\r rate per IRF following the completion of\r study treatment, OS and ORR\r per IRF following the completion of study\r treatment which were tested by\r a fixed sequence testing procedure following the statistical significance of\r PFS per IRF. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\"></p>", "ID": "97e3cef6-d05a-4572-a844-341fe728b18f", "Styles": "None", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The primary\r endpoint and alpha-protected, key secondary endpoints, which were evaluated\r hierarchically, were met. The median PFS per IRF for the ITT population was\r 48.2 months on the ADCETRIS + CHP arm versus 20.8 months on\r the CHOP arm. The stratified hazard ratio was 0.71 (95% CI: 0.54;\r 0.93, p=0.011), indicating a 29% reduction in the risk of PFS events for ADCETRIS + CHP\r versus CHOP. </span><span lang=\"EN-GB\">For overall survival, the stratified\r hazard ratio was </span><span lang=\"EN-GB\" style=\"color:windowtext\">0.66</span><span lang=\"EN-GB\"> (95% CI: </span><span lang=\"EN-GB\" style=\"color:windowtext\">0.46;\r 0.95, p=0.024),</span><span lang=\"EN-GB\"> a 34% reduction in the risk of OS\r events for ADCETRIS + CHP versus CHOP. </span></p>", "ID": "181377c5-784c-464b-80d5-0633d8a60ad2", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The primary\r endpoint and alpha-protected, key secondary endpoints, which were evaluated\r hierarchically, were met. The median PFS per IRF for the ITT population was\r 48.2 months on the ADCETRIS + CHP arm versus 20.8 months on\r the CHOP arm. The stratified hazard ratio was 0.71 (95% CI: 0.54;\r 0.93, p=0.011), indicating a 29% reduction in the risk of PFS events for ADCETRIS + CHP\r versus CHOP. For overall survival, the stratified\r hazard ratio was 0.66 (95% CI: 0.46;\r 0.95, p=0.024), a 34% reduction in the risk of OS\r events for ADCETRIS + CHP versus CHOP. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoCaption\" style=\"margin:0in;text-indent:0in;page-break-after:auto\"><a name=\"_Hlk7682306\"></a></p>", "ID": "99e6a90e-7c45-4e06-ab52-14042aade409", "Styles": "margin:0in;text-indent:0in;page-break-after:auto", "Classes": "['MsoCaption']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoCaption\" style=\"margin:0in;text-indent:0in;page-break-after:auto\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r font-weight:normal'>PFS per IRF for patients with centrally-confirmed sALCL was\r a pre-specified key secondary endpoint. The median PFS per IRF was\r 55.7 months on the ADCETRIS + CHP arm versus 54.2 months on\r the CHOP arm</span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r font-weight:normal'>. The stratified hazard ratio was 0.59 (95% CI:\r 0.42; 0.84), compatible with a statistically significant 41% reduction in the\r risk of PFS events for ADCETRIS + CHP versus CHOP (p\u2011value=0.003),\r see Figure 5 and Table 14.</span></p>", "ID": "67685fbf-ecc4-48a2-8f2a-89d5cb3d65d5", "Styles": "margin:0in;text-indent:0in;page-break-after:auto", "Classes": "['MsoCaption']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "PFS per IRF for patients with centrally-confirmed sALCL was\r a pre-specified key secondary endpoint. The median PFS per IRF was\r 55.7 months on the ADCETRIS + CHP arm versus 54.2 months on\r the CHOP arm. The stratified hazard ratio was 0.59 (95% CI:\r 0.42; 0.84), compatible with a statistically significant 41% reduction in the\r risk of PFS events for ADCETRIS + CHP versus CHOP (p\u2011value=0.003),\r see Figure 5 and Table 14.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoCaption\" style=\"margin:0in;text-indent:0in;page-break-after:auto\"></p>", "ID": "dbed57f9-839a-45bf-a012-681ca6eff8f9", "Styles": "margin:0in;text-indent:0in;page-break-after:auto", "Classes": "['MsoCaption']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoCaption\" style=\"margin:0in;text-indent:0in;page-break-after:auto\"><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;font-weight:normal'>Subgroup\r analyses were performed for patients with locally-diagnosed sALCL. For overall\r survival, the stratified hazard ratio was </span><span style='font-size:11.0pt;\r font-family:\"Times New Roman\",serif;color:windowtext;font-weight:normal'>0.54</span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;font-weight:normal'>\r (95% CI: </span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext;font-weight:normal'>0.34; 0.87),</span><span style='font-size:\r 11.0pt;font-family:\"Times New Roman\",serif;font-weight:normal'> a 46% reduction\r in the risk of OS events for ADCETRIS + CHP versus CHOP, see Figure 6.\r At the end of treatment, the CR rate by IRF assessment was 71.0% for patients on\r the ADCETRIS + CHP arm compared with 53.2% for patients on the CHOP\r arm with a difference of 17.7% (95% CI: 7.2%; 28.3%). At the end of treatment,\r the ORR rate by IRF assessment was 87.7% for patients on the ADCETRIS + CHP\r arm compared with 70.8% for patients on the CHOP arm with a difference of 16.9%\r (95% CI: 8.1%; 25.7%). In the subgroup of patients with ALK+ sALCL and ALK-\r sALCL the stratified hazard ratio for PFS per IRF was </span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;color:windowtext;\r font-weight:normal'>0.29</span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r font-weight:normal'> (95% CI: </span><span style='font-size:11.0pt;font-family:\r \"Times New Roman\",serif;color:windowtext;font-weight:normal'>0.11; 0.79) and 0.65</span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;font-weight:normal'>\r (95% CI: </span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:windowtext;font-weight:normal'>0.44; 0.95), respectively. </span></p>", "ID": "937ddc36-614e-4b41-94c2-c5df70d745b5", "Styles": "margin:0in;text-indent:0in;page-break-after:auto", "Classes": "['MsoCaption']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Subgroup\r analyses were performed for patients with locally-diagnosed sALCL. For overall\r survival, the stratified hazard ratio was 0.54\r (95% CI: 0.34; 0.87), a 46% reduction\r in the risk of OS events for ADCETRIS + CHP versus CHOP, see Figure 6.\r At the end of treatment, the CR rate by IRF assessment was 71.0% for patients on\r the ADCETRIS + CHP arm compared with 53.2% for patients on the CHOP\r arm with a difference of 17.7% (95% CI: 7.2%; 28.3%). At the end of treatment,\r the ORR rate by IRF assessment was 87.7% for patients on the ADCETRIS + CHP\r arm compared with 70.8% for patients on the CHOP arm with a difference of 16.9%\r (95% CI: 8.1%; 25.7%). In the subgroup of patients with ALK+ sALCL and ALK-\r sALCL the stratified hazard ratio for PFS per IRF was 0.29 (95% CI: 0.11; 0.79) and 0.65\r (95% CI: 0.44; 0.95), respectively. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "7abe3d45-37f4-4b15-9df5-316ab1e7cef3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "d9a57f5f-486b-42ec-ace5-63c1d6110a35", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 14:\r Efficacy results in patients with previously untreated sALCL with\r 1.8 mg/kg of ADCETRIS on day 1 of a 3\u2011week cycle </span></b></p>", "ID": "8ef73a06-dd46-4fd5-8f20-dac132317925", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 14:\r Efficacy results in patients with previously untreated sALCL with\r 1.8 mg/kg of ADCETRIS on day 1 of a 3\u2011week cycle ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "812be7eb-c1b2-4ff2-9a26-c9a2387ba449", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.35pt;border-collapse:collapse;border:none\" width=\"587\"> <tr style=\"height:30.35pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:30.35pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:5.1pt;text-align:left;\r   line-height:normal;page-break-after:avoid\"></p> </td> <td colspan=\"2\" style=\"width:112.5pt;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:30.35pt\" valign=\"top\" width=\"150\"> <p class=\"TableParagraph\" style=\"margin-top:0in;margin-right:15.35pt;\r   margin-bottom:0in;margin-left:9.0pt;margin-bottom:.0001pt;text-indent:-4.5pt;\r   line-height:125%;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>ADCETRIS + CHP</span></b></p> <p class=\"TableParagraph\" style=\"margin-top:0in;margin-right:15.35pt;\r   margin-bottom:0in;margin-left:9.0pt;margin-bottom:.0001pt;text-indent:-4.5pt;\r   line-height:125%;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>n=162<sup>a</sup></span></b></p> </td> <td style=\"width:1.5in;border:solid black 1.0pt;\r   border-left:none;padding:0in 0in 0in 0in;height:30.35pt\" valign=\"top\" width=\"144\"> <p class=\"TableParagraph\" style=\"margin-top:0in;margin-right:15.35pt;\r   margin-bottom:0in;margin-left:9.0pt;margin-bottom:.0001pt;text-indent:-4.5pt;\r   line-height:125%;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>CHOP</span></b></p> <p class=\"TableParagraph\" style=\"margin-top:0in;margin-right:15.35pt;\r   margin-bottom:0in;margin-left:9.0pt;margin-bottom:.0001pt;text-indent:-4.5pt;\r   line-height:125%;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>n=154<sup>a</sup></span></b></p> </td> </tr> <tr style=\"height:15.1pt\"> <td colspan=\"4\" style=\"width:440.4pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"bottom\" width=\"587\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:7.25pt;text-align:left;\r   text-indent:5.75pt;line-height:normal;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>PFS per IRF</span></b></p> </td> </tr> <tr style=\"height:15.8pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.8pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:26.5pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>Number\r   of patients with a PFS event, n (%)</span></p> </td> <td colspan=\"2\" style=\"width:112.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.8pt\" valign=\"top\" width=\"150\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>56 (34)</span></p> </td> <td style=\"width:1.5in;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;\r   height:15.8pt\" valign=\"top\" width=\"144\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>73 (48)</span></p> </td> </tr> <tr style=\"height:17.6pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:17.6pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:26.5pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>Median\r   PFS, months (95% CI)</span></p> </td> <td colspan=\"2\" style=\"width:112.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:17.6pt\" valign=\"top\" width=\"150\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>55.66 (48.20, NE)</span></p> </td> <td style=\"width:1.5in;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;\r   height:17.6pt\" valign=\"top\" width=\"144\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>54.18 (13.44, NE)</span></p> </td> </tr> <tr style=\"height:15.8pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.8pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:26.5pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>Hazard\r   ratio (95% CI)<sup>b</sup></span></p> </td> <td colspan=\"3\" style=\"width:220.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.8pt\" valign=\"top\" width=\"294\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>0.59 (0.42, 0.84)</span></p> </td> </tr> <tr style=\"height:15.0pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.0pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:26.5pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>p-value<sup>c</sup></span></p> </td> <td colspan=\"3\" style=\"width:220.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.0pt\" valign=\"top\" width=\"294\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>0.0031</span></p> </td> </tr> <tr style=\"height:15.0pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.0pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:13.0pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>Estimated\r   PFS (95% CI)</span></b><sup><span style='font-family:\"Times New Roman\",serif'>d</span></sup><b><span style='font-family:\"Times New Roman\",serif'> at:</span></b></p> </td> <td style=\"width:110.25pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.0pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"></p> </td> <td colspan=\"2\" style=\"width:110.25pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.0pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"></p> </td> </tr> <tr style=\"height:29.75pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:29.75pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:26.5pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>6\r   months</span></p> </td> <td style=\"width:110.25pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:29.75pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>88.0% </span></p> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>(81.8%, 92.2%)</span></p> </td> <td colspan=\"2\" style=\"width:110.25pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:29.75pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>68.4% </span></p> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>(60.3%, 75.2%)</span></p> </td> </tr> <tr style=\"height:26.6pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:26.6pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:26.5pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>12\r   months</span></p> </td> <td style=\"width:110.25pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:26.6pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>78.7% </span></p> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>(71.4%, 84.4%)</span></p> </td> <td colspan=\"2\" style=\"width:110.25pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:26.6pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>60.3% </span></p> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>(51.9%, 67.6%)</span></p> </td> </tr> <tr style=\"height:27.05pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:27.05pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:26.5pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>24\r   months</span></p> </td> <td style=\"width:110.25pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:27.05pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>68.4% </span></p> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>(60.4%, 75.2%)</span></p> </td> <td colspan=\"2\" style=\"width:110.25pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:27.05pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>53.9% </span></p> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>(45.5%, 61.5%)</span></p> </td> </tr> <tr style=\"height:27.05pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:27.05pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:26.5pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>36\r   months</span></p> </td> <td style=\"width:110.25pt;border-top:none;border-left:\r   none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:27.05pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>65.5% </span></p> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>(57.1%, 72.7%)</span></p> </td> <td colspan=\"2\" style=\"width:110.25pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:27.05pt\" valign=\"top\" width=\"147\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>50.2% </span></p> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>(41.6%, 58.1%)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td colspan=\"4\" style=\"width:440.4pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"bottom\" width=\"587\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-top:0in;margin-right:38.55pt;\r   margin-bottom:0in;margin-left:13.0pt;margin-bottom:.0001pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>OS</span></b><sup><span style='font-family:\"Times New Roman\",serif'>e</span></sup></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:.2in;text-align:left;\r   text-indent:12.1pt;line-height:normal;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>Number of deaths (%)</span></p> </td> <td colspan=\"2\" style=\"width:112.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"150\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>29 (18)</span></p> </td> <td style=\"width:1.5in;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;\r   height:15.1pt\" valign=\"top\" width=\"144\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>44 (29)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:.2in;text-align:left;\r   text-indent:12.1pt;line-height:normal;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>Median OS, months (95% CI)</span></p> </td> <td colspan=\"2\" style=\"width:112.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"150\"> <p class=\"TableParagraph\" style=\"margin-left:.25in;line-height:11.5pt;\r   page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>NE\r   (NE, NE)</span></p> </td> <td style=\"width:1.5in;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;\r   height:15.1pt\" valign=\"top\" width=\"144\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>NE (NE, NE)</span></p> </td> </tr> <tr style=\"height:17.6pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:17.6pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:.2in;text-align:left;\r   text-indent:12.1pt;line-height:normal;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>Hazard ratio (95% CI)<sup>b</sup></span></p> </td> <td colspan=\"3\" style=\"width:220.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:17.6pt\" valign=\"top\" width=\"294\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>0.54 (0.34, 0.87)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:.2in;text-align:left;\r   text-indent:12.1pt;line-height:normal;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>p-value<sup>c, f</sup></span></p> </td> <td colspan=\"3\" style=\"width:220.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"294\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>0.0096</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td colspan=\"4\" style=\"width:440.4pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"bottom\" width=\"587\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:13.0pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>CR\r   Rate</span></b><sup><span style='font-family:\"Times New Roman\",serif'>g</span></sup></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:.2in;text-align:left;\r   text-indent:12.1pt;line-height:normal;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>% (95% CI)</span></p> </td> <td colspan=\"2\" style=\"width:112.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"150\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>71% (63.3%, 77.8%)</span></p> </td> <td style=\"width:1.5in;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;\r   height:15.1pt\" valign=\"top\" width=\"144\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>53% (45.0%, 61.3%)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:.2in;text-align:left;\r   text-indent:12.1pt;line-height:normal;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>p-value<sup>f, h</sup></span></p> </td> <td colspan=\"3\" style=\"width:220.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"294\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>0.0004</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td colspan=\"4\" style=\"width:440.4pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"587\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:13.0pt;text-align:left;\r   line-height:11.5pt;page-break-after:avoid\"><b><span style='font-family:\"Times New Roman\",serif'>ORR</span></b><sup><span style='font-family:\"Times New Roman\",serif'>g</span></sup></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:.2in;text-align:left;\r   text-indent:12.1pt;line-height:normal;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>% (95% CI)</span></p> </td> <td colspan=\"2\" style=\"width:112.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"150\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>88% (81.6%, 92.3%)</span></p> </td> <td style=\"width:1.5in;border-top:none;border-left:none;\r   border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;\r   height:15.1pt\" valign=\"top\" width=\"144\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>71% (62.9%, 77.8%)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:219.9pt;border:solid black 1.0pt;\r   border-top:none;padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"293\"> <p align=\"left\" class=\"TableParagraph\" style=\"margin-left:.2in;text-align:left;\r   text-indent:12.1pt;line-height:normal;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>p-value<sup>f, h</sup></span></p> </td> <td colspan=\"3\" style=\"width:220.5pt;border-top:none;\r   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\r   padding:0in 0in 0in 0in;height:15.1pt\" valign=\"top\" width=\"294\"> <p class=\"TableParagraph\" style=\"line-height:11.5pt;page-break-after:avoid\"><span style='font-family:\"Times New Roman\",serif'>&lt;0.0001</span></p> </td> </tr> <tr height=\"0\"> <td style=\"border:none\" width=\"293\"></td> <td style=\"border:none\" width=\"147\"></td> <td style=\"border:none\" width=\"3\"></td> <td style=\"border:none\" width=\"144\"></td> </tr> </table>", "ID": "55febac4-6fa0-4508-9de7-77c9ca06a588", "Styles": "margin-left:5.35pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "      ADCETRIS + CHP n=162a   CHOP n=154a     PFS per IRF     Number\r   of patients with a PFS event, n (%)   56 (34)   73 (48)     Median\r   PFS, months (95% CI)   55.66 (48.20, NE)   54.18 (13.44, NE)     Hazard\r   ratio (95% CI)b   0.59 (0.42, 0.84)     p-valuec   0.0031     Estimated\r   PFS (95% CI)d at:           6\r   months   88.0%  (81.8%, 92.2%)   68.4%  (60.3%, 75.2%)     12\r   months   78.7%  (71.4%, 84.4%)   60.3%  (51.9%, 67.6%)     24\r   months   68.4%  (60.4%, 75.2%)   53.9%  (45.5%, 61.5%)     36\r   months   65.5%  (57.1%, 72.7%)   50.2%  (41.6%, 58.1%)     OSe     Number of deaths (%)   29 (18)   44 (29)     Median OS, months (95% CI)   NE\r   (NE, NE)   NE (NE, NE)     Hazard ratio (95% CI)b   0.54 (0.34, 0.87)     p-valuec, f   0.0096     CR\r   Rateg     % (95% CI)   71% (63.3%, 77.8%)   53% (45.0%, 61.3%)     p-valuef, h   0.0004     ORRg     % (95% CI)   88% (81.6%, 92.3%)   71% (62.9%, 77.8%)     p-valuef, h   <0.0001         ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">CR=complete remission; IRF=Independent Review Facility;\r NE: Not estimable; ORR=objective response rate; PFS=progression-free survival.</span></p>", "ID": "37d5e1ab-32bd-4194-998c-14da7d77a9e0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "CR=complete remission; IRF=Independent Review Facility;\r NE: Not estimable; ORR=objective response rate; PFS=progression-free survival.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TableFootnoteLetter\" style=\"margin-left:17.85pt;text-indent:-17.85pt;\r page-break-after:avoid\"><span style=\"color:black\">a</span>PFS per IRF is calculated using patients with centrally-confirmed\r sALCL, with n=163 patients in A+CHP arm and n=151 in CHOP arm. OS, CR, and ORR\r are calculated using patients with locally-diagnosed sALCL</p>", "ID": "1443b74a-77f4-4d70-b788-76cf5cbe39a1", "Styles": "margin-left:17.85pt;text-indent:-17.85pt;\r\npage-break-after:avoid", "Classes": "['TableFootnoteLetter']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "aPFS per IRF is calculated using patients with centrally-confirmed\r sALCL, with n=163 patients in A+CHP arm and n=151 in CHOP arm. OS, CR, and ORR\r are calculated using patients with locally-diagnosed sALCL", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TableFootnoteLetter\" style=\"margin-left:17.85pt;text-indent:-17.85pt;\r page-break-after:avoid\"><span style=\"color:black\">b</span>Hazard ratio (A+CHP/CHOP) and 95% confidence intervals are based\r on a stratified Cox\u2019s proportional hazard regression model with\r stratification factors (ALK-positive sALCL versus all others and International\r Prognostic Index [IPI] score at baseline). Hazard ratio &lt;1 favours A+CHP\r arm.</p>", "ID": "c8bb708d-eabd-4a37-9da3-0e6741fdbcb9", "Styles": "margin-left:17.85pt;text-indent:-17.85pt;\r\npage-break-after:avoid", "Classes": "['TableFootnoteLetter']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "bHazard ratio (A+CHP/CHOP) and 95% confidence intervals are based\r on a stratified Cox\u2019s proportional hazard regression model with\r stratification factors (ALK-positive sALCL versus all others and International\r Prognostic Index [IPI] score at baseline). Hazard ratio <1 favours A+CHP\r arm.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TableFootnoteLetter\" style=\"margin-left:17.85pt;text-indent:-17.85pt;\r page-break-after:avoid\"><span style=\"color:black\">c</span>p-value is calculated using a stratified log-rank test.</p>", "ID": "b875a989-5caa-40a1-8892-22fbd82188e4", "Styles": "margin-left:17.85pt;text-indent:-17.85pt;\r\npage-break-after:avoid", "Classes": "['TableFootnoteLetter']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "cp-value is calculated using a stratified log-rank test.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TableFootnoteLetter\"><span style=\"color:black\">d</span>PFS rate is estimated using Kaplan-Meier methods and 95% CI is\r calculated using the complementary log-log</p>", "ID": "9beba280-4413-4a53-a959-5f69fdde034b", "Styles": "None", "Classes": "['TableFootnoteLetter']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "dPFS rate is estimated using Kaplan-Meier methods and 95% CI is\r calculated using the complementary log-log", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TableFootnoteLetter\" style=\"margin-left:0in;text-indent:17.85pt\">transformation\r method.</p>", "ID": "200bcb3d-afae-4a19-b40a-6012d8602fbb", "Styles": "margin-left:0in;text-indent:17.85pt", "Classes": "['TableFootnoteLetter']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "transformation\r method.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TableFootnoteLetter\" style=\"margin-left:17.85pt;text-indent:-17.85pt;\r page-break-after:avoid\"><span style=\"color:black\">e</span>Median OS follow-up in the A+CHP arm was 38.5 months; in the CHOP\r arm was 41.0 months.</p>", "ID": "90e4268f-4baf-4987-80d4-0103f1469e1e", "Styles": "margin-left:17.85pt;text-indent:-17.85pt;\r\npage-break-after:avoid", "Classes": "['TableFootnoteLetter']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "eMedian OS follow-up in the A+CHP arm was 38.5 months; in the CHOP\r arm was 41.0 months.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TableFootnoteLetter\" style=\"margin-left:17.85pt;text-indent:-17.85pt;\r page-break-after:avoid\"><span style=\"color:black\">f</span>p-value is not adjusted for multiplicity. </p>", "ID": "f9697686-632a-4eea-8c1a-edccf16aa879", "Styles": "margin-left:17.85pt;text-indent:-17.85pt;\r\npage-break-after:avoid", "Classes": "['TableFootnoteLetter']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "fp-value is not adjusted for multiplicity. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TableFootnoteLetter\" style=\"margin-left:17.85pt;text-indent:-17.85pt;\r page-break-after:avoid\"><span style=\"color:black\">g</span>Response per 2007 International Working Group Criteria at end of\r treatment.</p>", "ID": "2a04b7b9-e650-4fc1-a642-6ed4b59b4491", "Styles": "margin-left:17.85pt;text-indent:-17.85pt;\r\npage-break-after:avoid", "Classes": "['TableFootnoteLetter']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "gResponse per 2007 International Working Group Criteria at end of\r treatment.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TableFootnoteLetter\" style=\"margin-left:17.85pt;text-indent:-17.85pt;\r page-break-after:avoid\"><span style=\"color:black\">h</span>p-value is calculated using a stratified Cochran-Mantel-Haenszel\r test.</p>", "ID": "4287b453-eb9a-4bd0-b244-265535f3564b", "Styles": "margin-left:17.85pt;text-indent:-17.85pt;\r\npage-break-after:avoid", "Classes": "['TableFootnoteLetter']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "hp-value is calculated using a stratified Cochran-Mantel-Haenszel\r test.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"> </p>", "ID": "9b34d572-12ad-41b8-8e0b-19a44bc88dd5", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": " ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Figure 5: </span></b><b><span style=\"font-size:11.0pt\">Progression-free\r survival per IRF in the sALCL population (ADCETRIS + CHP vs. CHOP)</span></b></p>", "ID": "b496d39f-7d28-4c5c-9919-9897803571d7", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Figure 5: Progression-free\r survival per IRF in the sALCL population (ADCETRIS + CHP vs. CHOP)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "bfc04593-ff5d-4270-8585-6535465d02eb", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span style=\"font-size:11.0pt\"><img border=\"0\" height=\"416\" src=\"Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image006.jpg\" width=\"605\"/></span></p>", "ID": "8cbc5cdb-03a1-4cd6-978f-aab12598d8df", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "8f50051a-04c0-4ffd-a37c-969d21f09f6e", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Figure 6: </span></b><b><span style=\"font-size:11.0pt\">Overall\r survival in the sALCL population (ADCETRIS + CHP vs. CHOP)</span></b></p>", "ID": "18a06ed6-e4fd-411c-8ccd-5e2345db23b4", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Figure 6: Overall\r survival in the sALCL population (ADCETRIS + CHP vs. CHOP)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "c8657401-0825-45e1-b99c-481f8508b4ad", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><img border=\"0\" height=\"340\" src=\"Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image007.jpg\" width=\"604\"/></p>", "ID": "f89abc63-1c6c-4c56-bbbc-b038ead1de9d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoCaption\" style=\"margin:0in;text-indent:0in;page-break-after:auto\"><span style='font-size:9.0pt;font-family:\"Times New Roman\",serif;font-weight:normal'>*p-value\r for overall survival is not adjusted for multiplicity.</span></p>", "ID": "23bc6ae6-b978-43d9-b353-838653fa79c4", "Styles": "margin:0in;text-indent:0in;page-break-after:auto", "Classes": "['MsoCaption']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "*p-value\r for overall survival is not adjusted for multiplicity.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "d67120e0-e413-4ebb-baa4-6007cfb9f4d5", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Study SG035\u20110004</span></p>", "ID": "74429c0a-83bc-493d-8b9b-f6d70cbdc3e1", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Study SG035\u20110004", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "b21e84bc-6343-4046-8fae-98846e972cd5", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The efficacy and safety of </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">ADCETRIS</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> as a single agent was evaluated in an open-label,\r single\u2011arm, multicenter study in 58 patients with relapsed or\r refractory sALCL. See Table 15 below for a summary of baseline patient and\r disease characteristics. </span></p>", "ID": "6e8287de-94f9-421a-994e-be34ad07e0b3", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The efficacy and safety of ADCETRIS as a single agent was evaluated in an open-label,\r single\u2011arm, multicenter study in 58 patients with relapsed or\r refractory sALCL. See Table 15 below for a summary of baseline patient and\r disease characteristics. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "1de839ad-1f12-4d98-9d83-79e13dc7c484", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Table 15: Summary of baseline patient and\r disease characteristics in the phase 2 relapsed or refractory sALCL study<br/> <br/> </span></b></p>", "ID": "ed3e446d-3d04-4d9b-b4e9-748a5cc948dc", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 15: Summary of baseline patient and\r disease characteristics in the phase 2 relapsed or refractory sALCL study  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div align=\"center\"> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:6.25in;border-collapse:collapse;border:none\" width=\"600\"> <tr style=\"height:23.65pt\"> <td style=\"width:288.05pt;border:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:23.65pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-bottom:3.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Patient characteristics</span></b></p> </td> <td style=\"width:161.95pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.65pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 58</span></b></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:3.1pt;text-indent:5.5pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Median age, years (range)</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">52 years (14\u201176)</span></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Gender</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">33M (57%)/25F (43%)</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">ECOG status<sup>a</sup></span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:12.75pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">19 (33%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">1</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">38 (66%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Prior ASCT</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">15 (26%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Prior chemotherapy Regimens (range)</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">2 (1\u20116)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Histologically confirmed CD30\u2011expressing\r   disease</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">57 (98%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Anaplastic lymphoma kinase (ALK)-negative disease</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">42 (72%)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:3.0pt;\r   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;\r   text-indent:-19.45pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\r   characteristics</span></b></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:8.0pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Primary Refractory to frontline therapy<sup>b</sup></span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">36 (62%)</span></p> </td> </tr> <tr style=\"height:7.15pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Refractory to most recent therapy</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">29 (50%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Relapsed to most recent therapy</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">29 (50%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Baseline B symptoms</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">17 (29%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Stage III at initial diagnosis</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">8 (14%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Stage IV at initial diagnosis</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">21 (36%)</span></p> </td> </tr> </table> </div>", "ID": "fc94d830-5cef-4d97-8f57-7d60363f24c5", "Styles": "None", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:6.25in;border-collapse:collapse;border:none\" width=\"600\"> <tr style=\"height:23.65pt\"> <td style=\"width:288.05pt;border:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:23.65pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-bottom:3.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Patient characteristics</span></b></p> </td> <td style=\"width:161.95pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.65pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 58</span></b></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:3.1pt;text-indent:5.5pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Median age, years (range)</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">52 years (14\u201176)</span></p> </td> </tr> <tr style=\"height:13.5pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Gender</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">33M (57%)/25F (43%)</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">ECOG status<sup>a</sup></span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:12.75pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">19 (33%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">1</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">38 (66%)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Prior ASCT</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">15 (26%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Prior chemotherapy Regimens (range)</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">2 (1\u20116)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Histologically confirmed CD30\u2011expressing\r   disease</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">57 (98%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;text-indent:-.15in;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Anaplastic lymphoma kinase (ALK)-negative disease</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">42 (72%)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:3.0pt;\r   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;\r   text-indent:-19.45pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\r   characteristics</span></b></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:8.0pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Primary Refractory to frontline therapy<sup>b</sup></span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">36 (62%)</span></p> </td> </tr> <tr style=\"height:7.15pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Refractory to most recent therapy</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">29 (50%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Relapsed to most recent therapy</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">29 (50%)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Baseline B symptoms</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">17 (29%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Stage III at initial diagnosis</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">8 (14%)</span></p> </td> </tr> <tr style=\"height:6.35pt\"> <td style=\"width:288.05pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"384\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Stage IV at initial diagnosis</span></p> </td> <td style=\"width:161.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"216\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">21 (36%)</span></p> </td> </tr> </table>", "ID": "a6a884de-03f7-4438-b4c3-6bcabc9b3306", "Styles": "width:6.25in;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "   Patient characteristics   n = 58     Median age, years (range)   52 years (14\u201176)     Gender   33M (57%)/25F (43%)     ECOG statusa        0   19 (33%)     1   38 (66%)     Prior ASCT   15 (26%)     Prior chemotherapy Regimens (range)   2 (1\u20116)     Histologically confirmed CD30\u2011expressing\r   disease   57 (98%)     Anaplastic lymphoma kinase (ALK)-negative disease   42 (72%)     Disease\r   characteristics        Primary Refractory to frontline therapyb   36 (62%)     Refractory to most recent therapy   29 (50%)     Relapsed to most recent therapy   29 (50%)     Baseline B symptoms   17 (29%)     Stage III at initial diagnosis   8 (14%)     Stage IV at initial diagnosis   21 (36%)   ", "ParentId": "fc94d830-5cef-4d97-8f57-7d60363f24c5"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">a.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">One patient had a\r baseline ECOG status of 2, which was prohibited by protocol and is captured as\r Inclusion Criteria Not Met.</span></p>", "ID": "263bdaf1-5e04-4161-82b5-784df70579c6", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "a.One patient had a\r baseline ECOG status of 2, which was prohibited by protocol and is captured as\r Inclusion Criteria Not Met.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">b.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Primary refractory sALCL\r is defined as a failure to achieve a complete remission to, or progressed\r within 3 months of completing frontline therapy.</span></p>", "ID": "a97f778b-a148-4330-84bf-84ead1a4c9f7", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "b.Primary refractory sALCL\r is defined as a failure to achieve a complete remission to, or progressed\r within 3 months of completing frontline therapy.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "fa41b28d-f364-4d0f-8a0c-588e45ba4464", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">The median time from initial sALCL diagnosis to first dose with ADCETRIS\r was 16.8 months. </span></p>", "ID": "b139373b-b025-415d-b36a-9ea3805f39f9", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The median time from initial sALCL diagnosis to first dose with ADCETRIS\r was 16.8 months. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "04922684-36d8-475d-b0bb-6f4bd58db534", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">Ten (10) patients (17%) received 16 cycles of </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">ADCETRIS</span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">; the median number of cycles received was 7 (range,\r 1 to 16). </span></p>", "ID": "412cbbef-9e70-4fe2-ba45-e11ed26f8ed1", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Ten (10) patients (17%) received 16 cycles of ADCETRIS; the median number of cycles received was 7 (range,\r 1 to 16). ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "5bf0184f-fce4-4734-b29e-846b0df2c03d", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Response to\r treatment with </span><span lang=\"EN-GB\">ADCETRIS</span><span lang=\"EN-GB\"> was\r assessed by Independent Review Facility (IRF) using the Revised Response\r Criteria for Malignant Lymphoma (Cheson, 2007). Treatment response was assessed\r by spiral CT of chest, neck, abdomen and pelvis; PET scans and clinical data.\r Response assessments were performed at cycles 2, 4, 7, 10, 13 and 16 with\r PET at cycles 4 and 7. </span></p>", "ID": "eab4d984-5a26-42fe-82cf-2c384591147b", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Response to\r treatment with ADCETRIS was\r assessed by Independent Review Facility (IRF) using the Revised Response\r Criteria for Malignant Lymphoma (Cheson, 2007). Treatment response was assessed\r by spiral CT of chest, neck, abdomen and pelvis; PET scans and clinical data.\r Response assessments were performed at cycles 2, 4, 7, 10, 13 and 16 with\r PET at cycles 4 and 7. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "74f6eaf0-8a2b-444e-8ae8-844a8f279651", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The ORR per IRF assessment was 86% (50 of\r 58 patients in the ITT set). CR was 59% (34 of 58 patients in the ITT\r set) and tumour reduction (of any degree) was achieved in 97% of patients. The\r estimated overall survival at 5 years was 60% (95% CI [47%,73%]). The\r median observation time (time to death or last contact) from first dose was\r 71.4 months. The investigator assessments were generally consistent with\r the independent review of the scans. Of the patients treated, 9 responding\r patients went on to receive an allogeneic stem cell transplant (SCT) and 9 responding\r patients went on to autologous SCT. For further efficacy results, see Table 16\r and Figure 7.</span></p>", "ID": "770ffe39-5cb0-4d23-9fc5-6c6bd1be2a20", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The ORR per IRF assessment was 86% (50 of\r 58 patients in the ITT set). CR was 59% (34 of 58 patients in the ITT\r set) and tumour reduction (of any degree) was achieved in 97% of patients. The\r estimated overall survival at 5 years was 60% (95% CI [47%,73%]). The\r median observation time (time to death or last contact) from first dose was\r 71.4 months. The investigator assessments were generally consistent with\r the independent review of the scans. Of the patients treated, 9 responding\r patients went on to receive an allogeneic stem cell transplant (SCT) and 9 responding\r patients went on to autologous SCT. For further efficacy results, see Table 16\r and Figure 7.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "fad65727-34f1-4d67-8628-0e94b85513b6", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 16:\r Efficacy results in relapsed or refractory sALCL patients treated with\r 1.8 mg/kg of </span></b><b><span lang=\"EN-GB\">ADCETRIS</span><span lang=\"EN-GB\"> every 3 weeks<br/> <br/> </span></b></p>", "ID": "0cbe1f13-071f-4267-bdec-9fc08e4fd79d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 16:\r Efficacy results in relapsed or refractory sALCL patients treated with\r 1.8 mg/kg of ADCETRIS every 3 weeks  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\" width=\"600\"> <tr style=\"height:15.1pt\"> <td nowrap=\"\" style=\"width:189.0pt;border:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Best\r   clinical response</span></b><b><sup></sup></b><b><span lang=\"EN-GB\">(n = 58</span></b><sup></sup><b><span lang=\"EN-GB\">)</span></b></p> </td> <td nowrap=\"\" style=\"width:139.5pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">IRF n (%)</span></b></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">95% CI</span></b></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:189.0pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">   \r   Objective response rate (CR + PR)</span></p> </td> <td nowrap=\"\" style=\"width:139.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">50 (86)</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">74.6, 93.9</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:189.0pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">         \r   Complete remission (CR)</span></p> </td> <td nowrap=\"\" style=\"width:139.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">34 (59)</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">44.9, 71.4</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:189.0pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">         \r   Partial remission (PR)</span></p> </td> <td nowrap=\"\" style=\"width:139.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">16 (28)</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">NA</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:189.0pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">   \r   Disease control rate (CR + PR + SD)</span></p> </td> <td nowrap=\"\" style=\"width:139.5pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">52 (90)</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">78.8, 96.1</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td nowrap=\"\" style=\"width:189.0pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Duration\r   of response</span></b><sup></sup></p> </td> <td style=\"width:139.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Median per IRF </span></b></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">95% CI</span></b></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:189.0pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"PT-BR\">   \r   Objective response (CR + PR)<sup>a</sup></span></p> </td> <td nowrap=\"\" style=\"width:139.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">13.2 </span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">5.7, 26.3 </span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td nowrap=\"\" style=\"width:189.0pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">   \r   Complete remission (CR)</span></p> </td> <td nowrap=\"\" style=\"width:139.5pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">26.3</span></p> </td> <td nowrap=\"\" style=\"width:121.5pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">13.2, NE<sup>b</sup></span></p> </td> </tr> <tr style=\"height:14.75pt\"> <td style=\"width:189.0pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.75pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Progression\r   Free Survival</span></b></p> </td> <td style=\"width:139.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.75pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Median per IRF</span></b></p> </td> <td style=\"width:121.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">95% CI</span></b></p> </td> </tr> <tr style=\"height:14.75pt\"> <td style=\"width:189.0pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.75pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"text-indent:9.05pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median</span></p> </td> <td style=\"width:139.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.75pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">14.6</span></p> </td> <td style=\"width:121.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">6.9, 20.6</span></p> </td> </tr> <tr style=\"height:14.75pt\"> <td style=\"width:189.0pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.75pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Overall\r   survival</span></b><sup></sup></p> </td> <td style=\"width:139.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.75pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Median</span></b></p> </td> <td style=\"width:121.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:14.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">95% CI</span></b></p> </td> </tr> <tr style=\"height:17.45pt\"> <td style=\"width:189.0pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:17.45pt\" valign=\"top\" width=\"252\"> <p class=\"MsoNormal\" style=\"text-indent:9.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median</span></p> </td> <td style=\"width:139.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:17.45pt\" valign=\"top\" width=\"186\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Not reached<sup> </sup></span></p> </td> <td style=\"width:121.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:17.45pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">21.3, NE<sup>b</sup></span></p> </td> </tr> </table>", "ID": "a80226c9-3349-45ca-8e22-a3f07573fbfc", "Styles": "margin-left:5.4pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "   Best\r   clinical response(n = 58)   IRF n (%)   95% CI        \r   Objective response rate (CR + PR)   50 (86)   74.6, 93.9              \r   Complete remission (CR)   34 (59)   44.9, 71.4              \r   Partial remission (PR)   16 (28)   NA        \r   Disease control rate (CR + PR + SD)   52 (90)   78.8, 96.1     Duration\r   of response   Median per IRF    95% CI        \r   Objective response (CR + PR)a   13.2    5.7, 26.3         \r   Complete remission (CR)   26.3   13.2, NEb     Progression\r   Free Survival   Median per IRF   95% CI     Median   14.6   6.9, 20.6     Overall\r   survival   Median   95% CI     Median   Not reached    21.3, NEb   ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">a.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">The range of DOR\r was 0.1 months to 39.1+ months and the median follow\u2011up time\r from first dose for patients who achieved objective response (OR) per IRF was\r 15.5 months. </span></p>", "ID": "324e5ba7-b8ae-45bc-9e23-e71e1d1c14e7", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "a.The range of DOR\r was 0.1 months to 39.1+ months and the median follow\u2011up time\r from first dose for patients who achieved objective response (OR) per IRF was\r 15.5 months. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:11.0pt\">b.</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Not estimable.</span></p>", "ID": "fca1e77d-31e4-4ad1-8112-15b9b68d491b", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "b.Not estimable.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "25c6ddc9-2e4f-4f48-952b-28c730ddb3c6", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Figure 7: Kaplan-Meier Plot of OS</span></b></p>", "ID": "b1876326-7720-47d8-88d3-ceb1ff99ac88", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Figure 7: Kaplan-Meier Plot of OS", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "ca50812e-4f58-43b2-b25a-86a76f8cbf3d", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\"><img border=\"0\" height=\"302\" src=\"Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image008.gif\" width=\"605\"/></span></p>", "ID": "8b27e97f-dbde-4ea9-8a94-06f30fdd59b9", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "7e220ceb-e728-45d9-b103-9e29e330df5f", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">An exploratory intra-patient analysis showed that approximately 69% of\r the sALCL patients treated with ADCETRIS as part of the SG035\u20110004\r clinical study experienced an improvement in clinical benefit as measured by\r longer progression free survival (PFS) compared with their most recent prior\r line of therapy.</span></p>", "ID": "59eb0ba6-2700-4fc4-b584-51a99220f287", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "An exploratory intra-patient analysis showed that approximately 69% of\r the sALCL patients treated with ADCETRIS as part of the SG035\u20110004\r clinical study experienced an improvement in clinical benefit as measured by\r longer progression free survival (PFS) compared with their most recent prior\r line of therapy.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "967d8fe3-8c17-4407-a777-0ecdbd74bb2d", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt;color:black\">Of the 17 patients (29%) who had B symptoms at\r baseline, 14 patients (82%) experienced resolution of all B symptoms in a\r median time from initiation of </span><span lang=\"EN-GB\" style=\"font-size:11.0pt;\r color:black\">ADCETRIS</span><span lang=\"EN-GB\" style=\"font-size:11.0pt;\r color:black\"> of 0.7 months.</span></p>", "ID": "fe26bfbd-a0f0-4427-bf45-eb98afd808a8", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Of the 17 patients (29%) who had B symptoms at\r baseline, 14 patients (82%) experienced resolution of all B symptoms in a\r median time from initiation of ADCETRIS of 0.7 months.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "22d96a82-37d5-4b90-ba1e-0e3704ad4d11", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Study SGN35\u2011006\r (Retreatment study)</span></p>", "ID": "9c616fde-a01d-4013-82df-c8a84edf8845", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Study SGN35\u2011006\r (Retreatment study)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "6bd031bf-7342-4ea4-b80a-d2f553821b20", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">The efficacy of\r retreatment in patients who had previously responded (CR or PR) to treatment\r with ADCETRIS was evaluated in a phase 2, open\u2011label, multicenter trial.\r Seven patients with relapsed sALCL received a starting dose of 1.8 mg/kg\r and one patient received a starting dose of 1.2 mg/kg of ADCETRIS\r administered intravenously over 30 minutes every 3 weeks. The median\r number of cycles was 8.5 (range, 2 to 30 cycles).</span><span lang=\"EN-GB\" style=\"color:windowtext\">Of\r the 8 sALCL patients, 3 were retreated twice for a total of\r 11 retreatment experiences. Retreatment with ADCETRIS resulted in\r 6 CRs (55%) and 4 PRs (36%), for an ORR of 91%. </span><span lang=\"EN-GB\" style=\"color:windowtext\">The median duration of response was 8.8 and\r 12.3 months in patients who achieved OR (CR+PR) and CR, respectively.</span></p>", "ID": "7f3097b5-ad63-403e-af3e-945c62a7b0fa", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The efficacy of\r retreatment in patients who had previously responded (CR or PR) to treatment\r with ADCETRIS was evaluated in a phase 2, open\u2011label, multicenter trial.\r Seven patients with relapsed sALCL received a starting dose of 1.8 mg/kg\r and one patient received a starting dose of 1.2 mg/kg of ADCETRIS\r administered intravenously over 30 minutes every 3 weeks. The median\r number of cycles was 8.5 (range, 2 to 30 cycles).Of\r the 8 sALCL patients, 3 were retreated twice for a total of\r 11 retreatment experiences. Retreatment with ADCETRIS resulted in\r 6 CRs (55%) and 4 PRs (36%), for an ORR of 91%. The median duration of response was 8.8 and\r 12.3 months in patients who achieved OR (CR+PR) and CR, respectively.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "fed85fab-c170-4cae-a92d-aaa7b16d6dcd", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Cutaneous\r T\u2011cell lymphoma</span></i></p>", "ID": "a18335ed-02e7-4c74-9cfe-b09547e0ffa8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Cutaneous\r T\u2011cell lymphoma", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"letter-spacing:-.1pt\"></span></u></p>", "ID": "efd4489c-3478-46aa-b245-864e014757ae", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Study C25001\r </span></p>", "ID": "c8d46462-e40d-46ba-99f5-2cac06fa6bca", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Study C25001\r ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "b8011757-5976-4e76-ab34-52d42b694831", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoBodyText\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The efficacy and\r safety of ADCETRIS as a single agent was evaluated in a pivotal phase 3,\r open-label, randomised, multicentre study in 128 patients with\r histologically confirmed CD30+ CTCL. </span><span style=\"font-size:11.0pt\">CD30\r positivity was defined as \u226510% target lymphoid cells demonstrating\r membrane, cytoplasmic, and/or Golgi staining pattern based on an\r immunohistochemistry assay (Ventana anti\u2011CD30 [Ber\u2011H2]). </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Patients with a diagnosis of mycosis\r fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]\r were considered eligible for the study. Patients were stratified by these\r disease types and randomised 1:1 to receive either ADCETRIS or the\r physician\u2019s choice of either methotrexate or bexarotene. Patients with\r pcALCL received either prior radiation therapy or at least 1 prior systemic\r therapy and patients with MF received at least 1 prior systemic therapy.\r Patients with a concurrent diagnosis of systemic ALCL, Sezary syndrome and\r other non\u2011Hodgkin lymphoma (except for lymphomatoid papulosis [LyP]) were\r excluded from this study. Patients were treated with 1.8 mg/kg of ADCETRIS\r intravenously over 30 minutes every 3 weeks for up to 16 cycles\r or physician\u2019s choice for up to 48 weeks. The median number of\r cycles was approximately 12 cycles in the ADCETRIS arm. In the\r physician\u2019s choice arm, the median duration of treatment (number of\r cycles) for patients receiving bexarotene was approximately 16 weeks (5.5 cycles)\r and 11 weeks (3 cycles) for patients receiving methotrexate. Table 17\r provides a summary of the baseline patient and disease characteristics.</span></p>", "ID": "f74881bb-a150-4e34-8ba7-576017b92e17", "Styles": "None", "Classes": "['MsoBodyText']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The efficacy and\r safety of ADCETRIS as a single agent was evaluated in a pivotal phase 3,\r open-label, randomised, multicentre study in 128 patients with\r histologically confirmed CD30+ CTCL. CD30\r positivity was defined as \u226510% target lymphoid cells demonstrating\r membrane, cytoplasmic, and/or Golgi staining pattern based on an\r immunohistochemistry assay (Ventana anti\u2011CD30 [Ber\u2011H2]). Patients with a diagnosis of mycosis\r fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]\r were considered eligible for the study. Patients were stratified by these\r disease types and randomised 1:1 to receive either ADCETRIS or the\r physician\u2019s choice of either methotrexate or bexarotene. Patients with\r pcALCL received either prior radiation therapy or at least 1 prior systemic\r therapy and patients with MF received at least 1 prior systemic therapy.\r Patients with a concurrent diagnosis of systemic ALCL, Sezary syndrome and\r other non\u2011Hodgkin lymphoma (except for lymphomatoid papulosis [LyP]) were\r excluded from this study. Patients were treated with 1.8 mg/kg of ADCETRIS\r intravenously over 30 minutes every 3 weeks for up to 16 cycles\r or physician\u2019s choice for up to 48 weeks. The median number of\r cycles was approximately 12 cycles in the ADCETRIS arm. In the\r physician\u2019s choice arm, the median duration of treatment (number of\r cycles) for patients receiving bexarotene was approximately 16 weeks (5.5 cycles)\r and 11 weeks (3 cycles) for patients receiving methotrexate. Table 17\r provides a summary of the baseline patient and disease characteristics.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p>", "ID": "5018d709-0254-41c2-b9f4-984eb3a39d9d", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 17:\r Summary of baseline patient and disease characteristics in the phase 3 CTCL\r Study (ITT Population)<br/> <br/> </span></b></p>", "ID": "666ad5c6-f4bc-47ad-a19d-858eeababb73", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 17:\r Summary of baseline patient and disease characteristics in the phase 3 CTCL\r Study (ITT Population)  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div align=\"center\"> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:455.6pt;border-collapse:collapse;border:none\" width=\"607\"> <tr style=\"height:15.1pt\"> <td colspan=\"2\" style=\"width:178.15pt;border:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-bottom:3.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Patient characteristics</span></b></p> </td> <td style=\"width:155.9pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 64</span></b></p> </td> <td style=\"width:121.55pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Physician\u2019s Choice (Methotrexate or Bexarotene)</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 64</span></b></p> </td> </tr> <tr style=\"height:13.5pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:3.1pt;text-indent:5.5pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Median age (range)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">62 years (22\u201183)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">58.5 years (22\u201183)</span></p> </td> </tr> <tr style=\"height:13.5pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Patients \u2265 65 years old n (%)</span></p> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Gender n (%)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">28 (44%)</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">33M (52%)/31F (48%)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">24 (38%)</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">37M (58%)/27F (42%)</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">ECOG status n (%)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:12.75pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">43 (67)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">46 (72)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">1</span></p> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">2</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">18 (28)</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">3 (5)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">16 (25)</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">2 (3)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:3.0pt;\r   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;\r   text-indent:-19.45pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\r   characteristics</span></b></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:8.0pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median number of prior therapies (range)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">4 (0\u201113)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">3.5 (1\u201115)</span></p> </td> </tr> <tr style=\"height:7.15pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median number of skin-directed therapies (range)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">1 (0\u20116)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">1 (0\u20119)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median number of systemic therapies (range)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">2 (0\u201111)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">2 (1\u20118)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:176.5pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   none;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"235\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">MF, n (%)</span></p> </td> <td colspan=\"2\" style=\"width:157.55pt;border:none;\r   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"210\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:-.85pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">48 (75)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:-.85pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">49 (77)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Early (IA\u2011IIA)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">15 (31)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">18 (37)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Advanced (IIB\u2011IVB<sup>a</sup>)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">32 (67)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">30 (61)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:176.5pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   none;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"235\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">pcALCL, n (%)</span></p> </td> <td colspan=\"2\" style=\"width:157.55pt;border:none;\r   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"210\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:-.85pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">16 (25)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:-.85pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">15 (23)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Skin only </span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">9 (56)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">11 (73)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Extracutaneous disease</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">7 (44)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">4 (27)</span></p> </td> </tr> <tr height=\"0\"> <td style=\"border:none\" width=\"235\"></td> <td style=\"border:none\" width=\"2\"></td> <td style=\"border:none\" width=\"208\"></td> <td style=\"border:none\" width=\"162\"></td> </tr> </table> </div>", "ID": "30b7253d-ad8d-4d3d-9d90-6c6674465a89", "Styles": "None", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:455.6pt;border-collapse:collapse;border:none\" width=\"607\"> <tr style=\"height:15.1pt\"> <td colspan=\"2\" style=\"width:178.15pt;border:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-bottom:3.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Patient characteristics</span></b></p> </td> <td style=\"width:155.9pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 64</span></b></p> </td> <td style=\"width:121.55pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Physician\u2019s Choice (Methotrexate or Bexarotene)</span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 64</span></b></p> </td> </tr> <tr style=\"height:13.5pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:3.1pt;text-indent:5.5pt;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Median age (range)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">62 years (22\u201183)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">58.5 years (22\u201183)</span></p> </td> </tr> <tr style=\"height:13.5pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Patients \u2265 65 years old n (%)</span></p> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Gender n (%)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">28 (44%)</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">33M (52%)/31F (48%)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.5pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">24 (38%)</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">37M (58%)/27F (42%)</span></p> </td> </tr> <tr style=\"height:12.75pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"text-indent:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">ECOG status n (%)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:12.75pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">0</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">43 (67)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:12.75pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">46 (72)</span></p> </td> </tr> <tr style=\"height:5.65pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">1</span></p> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">2</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">18 (28)</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">3 (5)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.65pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">16 (25)</span></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">2 (3)</span></p> </td> </tr> <tr style=\"height:15.1pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:3.0pt;\r   margin-left:19.45pt;text-align:justify;text-justify:inter-ideograph;\r   text-indent:-19.45pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Disease\r   characteristics</span></b></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:15.1pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:8.0pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median number of prior therapies (range)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">4 (0\u201113)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:8.0pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">3.5 (1\u201115)</span></p> </td> </tr> <tr style=\"height:7.15pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median number of skin-directed therapies (range)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">1 (0\u20116)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:7.15pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">1 (0\u20119)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Median number of systemic therapies (range)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">2 (0\u201111)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">2 (1\u20118)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:176.5pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   none;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"235\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">MF, n (%)</span></p> </td> <td colspan=\"2\" style=\"width:157.55pt;border:none;\r   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"210\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:-.85pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">48 (75)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:-.85pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">49 (77)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Early (IA\u2011IIA)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">15 (31)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">18 (37)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Advanced (IIB\u2011IVB<sup>a</sup>)</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">32 (67)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">30 (61)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td style=\"width:176.5pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   none;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"235\"> <p class=\"MsoNormal\" style=\"margin-left:8.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">pcALCL, n (%)</span></p> </td> <td colspan=\"2\" style=\"width:157.55pt;border:none;\r   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"210\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:-.85pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">16 (25)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:-.85pt;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\">15 (23)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid white 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Skin only </span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">9 (56)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid white 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">11 (73)</span></p> </td> </tr> <tr style=\"height:6.4pt\"> <td colspan=\"2\" style=\"width:178.15pt;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"238\"> <p class=\"MsoNormal\" style=\"margin-left:19.6pt;page-break-after:avoid\"><span lang=\"EN-GB\">Extracutaneous disease</span></p> </td> <td style=\"width:155.9pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"208\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">7 (44)</span></p> </td> <td style=\"width:121.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"162\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">4 (27)</span></p> </td> </tr> <tr height=\"0\"> <td style=\"border:none\" width=\"235\"></td> <td style=\"border:none\" width=\"2\"></td> <td style=\"border:none\" width=\"208\"></td> <td style=\"border:none\" width=\"162\"></td> </tr> </table>", "ID": "68840244-e0c0-4b5f-ac46-135edd9de7bb", "Styles": "width:455.6pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "   Patient characteristics   ADCETRIS n = 64   Physician\u2019s Choice (Methotrexate or Bexarotene) n = 64     Median age (range)   62 years (22\u201183)   58.5 years (22\u201183)     Patients \u2265 65 years old n (%) Gender n (%)   28 (44%) 33M (52%)/31F (48%)   24 (38%) 37M (58%)/27F (42%)     ECOG status n (%)           0   43 (67)   46 (72)     1 2   18 (28) 3 (5)   16 (25) 2 (3)     Disease\r   characteristics           Median number of prior therapies (range)   4 (0\u201113)   3.5 (1\u201115)     Median number of skin-directed therapies (range)   1 (0\u20116)   1 (0\u20119)     Median number of systemic therapies (range)   2 (0\u201111)   2 (1\u20118)     MF, n (%)   48 (75)   49 (77)     Early (IA\u2011IIA)   15 (31)   18 (37)     Advanced (IIB\u2011IVBa)   32 (67)   30 (61)     pcALCL, n (%)   16 (25)   15 (23)     Skin only    9 (56)   11 (73)     Extracutaneous disease   7 (44)   4 (27)         ", "ParentId": "30b7253d-ad8d-4d3d-9d90-6c6674465a89"}, {"Element": "<p class=\"MsoNormal\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">One patient in each arm had incomplete\r staging data and are not included in the table.</span></p>", "ID": "8cf177a1-d439-4de6-b002-32329b06908e", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "aOne patient in each arm had incomplete\r staging data and are not included in the table.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><b></b></p>", "ID": "965d8ad6-802a-46bb-b3f4-5c0d5d84e285", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The most common prior skin directed\r therapies in the ITT population were radiotherapy (64%), phototherapy (48%) and\r topical steroids (17%). The most common prior systemic therapies in the ITT\r population were chemotherapy (71%), immunotherapy (43%) and bexarotene (38%).</span></p>", "ID": "b12bbda4-1031-43cf-9ac0-d5e31f835c18", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The most common prior skin directed\r therapies in the ITT population were radiotherapy (64%), phototherapy (48%) and\r topical steroids (17%). The most common prior systemic therapies in the ITT\r population were chemotherapy (71%), immunotherapy (43%) and bexarotene (38%).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p>", "ID": "87fa4cc6-b82b-47bb-b94a-300d514f56c7", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The primary\r endpoint was objective response rate that lasts at least 4 months (ORR4)\r (duration from first response to last response \u2265 4 months), as\r determined by an independent review of the Global Response Score (GRS)\r consisting of skin evaluations (modified severity weighted assessment tool\r [mSWAT] as assessed per investigator), nodal and visceral radiographic\r assessment, and detection of circulating S\u00e9zary cells (Olsen 2011).\r Table 18 includes the results for ORR4 and other key secondary endpoints.</span></p>", "ID": "ce96c06f-449e-4d77-8661-6062ceabae29", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The primary\r endpoint was objective response rate that lasts at least 4 months (ORR4)\r (duration from first response to last response \u2265 4 months), as\r determined by an independent review of the Global Response Score (GRS)\r consisting of skin evaluations (modified severity weighted assessment tool\r [mSWAT] as assessed per investigator), nodal and visceral radiographic\r assessment, and detection of circulating S\u00e9zary cells (Olsen 2011).\r Table 18 includes the results for ORR4 and other key secondary endpoints.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><b></b></p>", "ID": "de189798-8ce0-4d29-a6e4-c9dc46e4dde3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 18:\r Efficacy results in CTCL patients treated with 1.8 mg/kg of ADCETRIS every\r 3 weeks (ITT population)<br/> <br/> </span></b></p>", "ID": "718fe894-32d1-48dc-b831-10b496b77c6d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 18:\r Efficacy results in CTCL patients treated with 1.8 mg/kg of ADCETRIS every\r 3 weeks (ITT population)  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\"> <tr> <td style=\"width:168.45pt;border:solid windowtext 1.0pt;\r   border-right:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> </td> <td style=\"width:92.1pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">ADCETRIS      (n = 64)</span></b></p> </td> <td style=\"width:87.7pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"117\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> </td> <td colspan=\"2\" style=\"width:116.1pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Physician\u2019s Choice (Methotrexate or\r   Bexarotene) </span></b></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">n = 64</span></b></p> </td> </tr> <tr> <td colspan=\"5\" style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Objective\r   Response Rate lasting at least 4 months (ORR4) per IRF</span></b></p> </td> </tr> <tr> <td style=\"width:168.45pt;border:none;border-left:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">n (%)</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Percent\r   Difference (95% CI)</span></p> </td> <td style=\"width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">36 (56.3)</span></p> </td> <td colspan=\"2\" style=\"width:99.25pt;border:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"132\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">43.8 (29.1, 58.4)</span></p> </td> <td style=\"width:104.55pt;border:none;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"139\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">8 (12.5)</span></p> </td> </tr> <tr> <td style=\"width:168.45pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">p-value</span></p> </td> <td style=\"width:92.1pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td colspan=\"2\" style=\"width:99.25pt;border:none;\r   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"132\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">&lt;0.001</span></p> </td> <td style=\"width:104.55pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"139\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr> <td colspan=\"5\" style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"IT\">Complete\r   Response (CR) per IRF</span></b></p> </td> </tr> <tr> <td style=\"width:168.45pt;border:none;border-left:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"225\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">n (%)</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Percent\r   Difference (95% CI)</span></p> </td> <td style=\"width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">10 (15.6)</span></p> </td> <td style=\"width:87.7pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"117\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">14.1 (-4.0, 31.5)</span></p> </td> <td colspan=\"2\" style=\"width:116.1pt;border:none;\r   border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">1 (1.6)</span></p> </td> </tr> <tr style=\"height:4.0pt\"> <td style=\"width:168.45pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   none;padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"225\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Adjusted\r   p-value<sup>a</sup></span></p> </td> <td style=\"width:92.1pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"123\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td style=\"width:87.7pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"117\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">0.0046</span></p> </td> <td colspan=\"2\" style=\"width:116.1pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:4.0pt\"> <td colspan=\"5\" style=\"width:464.35pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"619\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Progression\r   Free Survival (PFS) per IRF</span></b></p> </td> </tr> <tr style=\"height:4.0pt\"> <td style=\"width:168.45pt;border:none;border-left:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"225\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Median\r   (months)</span></p> </td> <td style=\"width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:4.0pt\" valign=\"top\" width=\"123\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">16.7</span></p> </td> <td style=\"width:87.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:4.0pt\" valign=\"top\" width=\"117\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td colspan=\"2\" style=\"width:116.1pt;border:none;\r   border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">3.5</span></p> </td> </tr> <tr style=\"height:4.0pt\"> <td style=\"width:168.45pt;border:none;border-left:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"225\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hazard\r   Ratio</span></p> </td> <td style=\"width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:4.0pt\" valign=\"top\" width=\"123\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td style=\"width:87.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:4.0pt\" valign=\"top\" width=\"117\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">0.270</span></p> </td> <td colspan=\"2\" style=\"width:116.1pt;border:none;\r   border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:4.0pt\"> <td style=\"width:168.45pt;border:none;border-left:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"225\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">95% CI</span></p> </td> <td style=\"width:92.1pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:4.0pt\" valign=\"top\" width=\"123\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td style=\"width:87.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:4.0pt\" valign=\"top\" width=\"117\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">(0.17, 0.43)</span></p> </td> <td colspan=\"2\" style=\"width:116.1pt;border:none;\r   border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr style=\"height:4.0pt\"> <td style=\"width:168.45pt;border-top:none;border-left:\r   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\r   none;padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"225\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Adjusted\r   p-value<sup>a</sup></span></p> </td> <td style=\"width:92.1pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"123\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> <td style=\"width:87.7pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"117\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"><span lang=\"EN-GB\">&lt;0.001</span></p> </td> <td colspan=\"2\" style=\"width:116.1pt;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:4.0pt\" valign=\"top\" width=\"155\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\r   avoid\"></p> </td> </tr> <tr height=\"0\"> <td style=\"border:none\" width=\"225\"></td> <td style=\"border:none\" width=\"123\"></td> <td style=\"border:none\" width=\"117\"></td> <td style=\"border:none\" width=\"15\"></td> <td style=\"border:none\" width=\"139\"></td> </tr> </table>", "ID": "d96d1c93-39b1-4f39-8fd8-68811103244f", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "         ADCETRIS      (n = 64)      Physician\u2019s Choice (Methotrexate or\r   Bexarotene)  n = 64     Objective\r   Response Rate lasting at least 4 months (ORR4) per IRF     n (%) Percent\r   Difference (95% CI)   36 (56.3)    43.8 (29.1, 58.4)   8 (12.5)     p-value      <0.001        Complete\r   Response (CR) per IRF     n (%) Percent\r   Difference (95% CI)   10 (15.6)    14.1 (-4.0, 31.5)   1 (1.6)     Adjusted\r   p-valuea      0.0046        Progression\r   Free Survival (PFS) per IRF     Median\r   (months)   16.7      3.5     Hazard\r   Ratio      0.270        95% CI      (0.17, 0.43)        Adjusted\r   p-valuea      <0.001             ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">   Calculated from a weighted\r Holm\u2019s procedure.</span></p>", "ID": "03a812ba-17d7-4181-b762-065e3f4c31c7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "a   Calculated from a weighted\r Holm\u2019s procedure.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "23e0ac1a-44f0-44f4-9d6f-783c86f2a4ba", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">Pre-specified\r subgroup analyses of ORR4 per IRF were performed by patients\u2019 CTCL\r subtype, physicians\u2019 choice of treatment, baseline ECOG status, age,\r gender, and geographic region. The analyses showed a consistent trend towards\r benefit for patients who received ADCETRIS compared with patients who received\r physician\u2019s choice. ORR4 was 50% and 75% in the ADCETRIS arm versus 10.2%\r and 20% in the physician\u2019s choice arm for MF and pcALCL, respectively.</span></p>", "ID": "51c552ee-e9c1-47fe-ae37-f2b34b28da0f", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Pre-specified\r subgroup analyses of ORR4 per IRF were performed by patients\u2019 CTCL\r subtype, physicians\u2019 choice of treatment, baseline ECOG status, age,\r gender, and geographic region. The analyses showed a consistent trend towards\r benefit for patients who received ADCETRIS compared with patients who received\r physician\u2019s choice. ORR4 was 50% and 75% in the ADCETRIS arm versus 10.2%\r and 20% in the physician\u2019s choice arm for MF and pcALCL, respectively.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p>", "ID": "99296372-6bd4-405a-aa55-8b24910aa819", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">No meaningful differences in quality of\r life (assessed by the EuroQol five dimensions questionnaire [EQ-5D] and\r Functional Assessment of Cancer Therapy-General [FACT-G]) were observed between\r the treatment arms.</span></p>", "ID": "a80a6b0c-1071-4bec-9478-b0ceaa539bc1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "No meaningful differences in quality of\r life (assessed by the EuroQol five dimensions questionnaire [EQ-5D] and\r Functional Assessment of Cancer Therapy-General [FACT-G]) were observed between\r the treatment arms.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "984c0086-0b76-496a-9b9f-e12df64abde4", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy and safety of ADCETRIS were\r evaluated in two additional open-label studies in 108 patients with\r relapsed CD30+ CTCL (including MF and pcALCL as well as SS, LyP and mixed CTCL\r histology), <span style=\"background:white\">regardless of CD30 expression level.\r Patients</span> were treated with ADCETRIS 1.8 mg/kg intravenously over 30 minutes\r every 3 weeks for up to 16 cycles. The safety and efficacy results in\r these studies were consistent with results in Study C25001. Overall response\r rates for MF were 54\u201166%; pcALCL, 67%; SS, 50%; LyP, 92%; and mixed CTCL\r histology, 82\u201185%.</span></p>", "ID": "616b8601-f994-4eda-aeac-6d44ba33cdbd", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The efficacy and safety of ADCETRIS were\r evaluated in two additional open-label studies in 108 patients with\r relapsed CD30+ CTCL (including MF and pcALCL as well as SS, LyP and mixed CTCL\r histology), regardless of CD30 expression level.\r Patients were treated with ADCETRIS 1.8 mg/kg intravenously over 30 minutes\r every 3 weeks for up to 16 cycles. The safety and efficacy results in\r these studies were consistent with results in Study C25001. Overall response\r rates for MF were 54\u201166%; pcALCL, 67%; SS, 50%; LyP, 92%; and mixed CTCL\r histology, 82\u201185%.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "b61c9a16-b8d4-4b6e-8dcd-9ab89638924e", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Paediatric population</span></i></p>", "ID": "f6b5f10a-16de-4eb2-a370-f5beb8402c85", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Paediatric population", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "ede8336f-48bd-40b8-abf3-000c11e6bbcc", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">The safety, pharmacokinetics and anti-tumour activity\r of ADCETRIS in 36 paediatric patients (7\u201117 years of age) with\r r/r HL and sALCL (children aged 7\u201111 years, n = 12 and\r adolescents aged 12 to 17 years, n = 24) were evaluated in\r a phase 1/2 open-label, single-agent, multicentre dose-escalation study\r (C25002). Phase 1 of the study assessed the safety profile (see\r section 4.8), determined the paediatric maximum tolerated dose (MTD)\r and/or recommended phase 2 dose (RP2D), and assessed the pharmacokinetics\r of ADCETRIS (see section 5.2). Phase 1 included 3 r/r HL\r patients treated at 1.4 mg/kg and 9 patients (7 r/r HL and\r 2 sALCL) treated at 1.8 mg/kg. The MTD was not reached. The RP2D was\r determined to be 1.8 mg/kg. Across the study, a total of 16 patients\r with r/r HL and 17 patients with r/r sALCL, of whom 10 were in first\r relapse, were treated with 1.8 mg/kg of ADCETRIS. The best overall\r response rate (ORR) per independent review facility (IRF) was analysed across\r both study phases at the RP2D. Of these 33 patients who received the RP2D,\r 32 were evaluable for response. The ORR was 47% in response-evaluable\r patients with r/r HL, 53% in patients with r/r sALCL and 60% in sALCL patients\r in first relapse. Eight HL patients and 9 sALCL patients went on to\r receive SCT following treatment with ADCETRIS. </span></p>", "ID": "2180e466-56cb-4020-9bf5-7381a2efd23c", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The safety, pharmacokinetics and anti-tumour activity\r of ADCETRIS in 36 paediatric patients (7\u201117 years of age) with\r r/r HL and sALCL (children aged 7\u201111 years, n = 12 and\r adolescents aged 12 to 17 years, n = 24) were evaluated in\r a phase 1/2 open-label, single-agent, multicentre dose-escalation study\r (C25002). Phase 1 of the study assessed the safety profile (see\r section 4.8), determined the paediatric maximum tolerated dose (MTD)\r and/or recommended phase 2 dose (RP2D), and assessed the pharmacokinetics\r of ADCETRIS (see section 5.2). Phase 1 included 3 r/r HL\r patients treated at 1.4 mg/kg and 9 patients (7 r/r HL and\r 2 sALCL) treated at 1.8 mg/kg. The MTD was not reached. The RP2D was\r determined to be 1.8 mg/kg. Across the study, a total of 16 patients\r with r/r HL and 17 patients with r/r sALCL, of whom 10 were in first\r relapse, were treated with 1.8 mg/kg of ADCETRIS. The best overall\r response rate (ORR) per independent review facility (IRF) was analysed across\r both study phases at the RP2D. Of these 33 patients who received the RP2D,\r 32 were evaluable for response. The ORR was 47% in response-evaluable\r patients with r/r HL, 53% in patients with r/r sALCL and 60% in sALCL patients\r in first relapse. Eight HL patients and 9 sALCL patients went on to\r receive SCT following treatment with ADCETRIS. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "f3f53f93-d420-4e93-a685-0a337657fa35", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The European\r Medicines Agency has deferred the obligation to submit the results of studies\r with </span><span lang=\"EN-GB\">ADCETRIS</span><span lang=\"EN-GB\"> in one or more\r subsets of the paediatric population in the treatment of Hodgkin lymphoma and\r treatment of anaplastic large cell lymphoma (see section 4.2 for\r information on paediatric use).</span></p>", "ID": "4b224666-03e8-45a5-b201-720346edf184", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The European\r Medicines Agency has deferred the obligation to submit the results of studies\r with ADCETRIS in one or more\r subsets of the paediatric population in the treatment of Hodgkin lymphoma and\r treatment of anaplastic large cell lymphoma (see section 4.2 for\r information on paediatric use).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p>", "ID": "26dc68ea-8aa1-4e6f-811b-d54470570a18", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">This medicinal\r product has been authorised under a so-called \u2018conditional\r approval\u2019 scheme. This means that further evidence on this medicinal\r product is awaited.</span></p>", "ID": "ba37fa18-bf85-4d31-b445-6cc79b8ff9c8", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "This medicinal\r product has been authorised under a so-called \u2018conditional\r approval\u2019 scheme. This means that further evidence on this medicinal\r product is awaited.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The European\r Medicines Agency will review new information on this medicinal product at least\r every year and this SmPC will be updated as necessary.</span></p>", "ID": "a7a1e41e-36ba-412e-b9c7-b861acbf8452", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The European\r Medicines Agency will review new information on this medicinal product at least\r every year and this SmPC will be updated as necessary.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "13c36daf-e545-4f61-98e4-ead7652e5a1a", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h3><span lang=\"EN-GB\">5.2     Pharmacokinetic properties</span></h3>", "ID": "5515860f-08e1-482a-9a10-8fe6d0b0373e", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "5.2     Pharmacokinetic properties", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r page-break-after:avoid\"></p>", "ID": "e764e4cf-7979-4aba-8ec1-75252356a30b", "Styles": "text-align:justify;text-justify:inter-ideograph;\r\npage-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Monotherapy</span></u></p>", "ID": "fe7324ef-7163-43f8-a80a-944bb7a1b89c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Monotherapy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"></span></u></p>", "ID": "8095d57a-e7bf-428b-a96f-3421cb835150", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The\r pharmacokinetics of </span><span lang=\"EN-GB\">brentuximab vedotin</span><span lang=\"EN-GB\"> were evaluated in phase 1 studies and in a population\r pharmacokinetic analysis of data from 314 patients. In all clinical\r trials, brentuximab vedotin was administered as an intravenous infusion. </span></p>", "ID": "cc8c786a-f02d-443d-9f2a-b53c13fbff73", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The\r pharmacokinetics of brentuximab vedotin were evaluated in phase 1 studies and in a population\r pharmacokinetic analysis of data from 314 patients. In all clinical\r trials, brentuximab vedotin was administered as an intravenous infusion. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"></p>", "ID": "508c32d9-088d-4ef7-a1d2-9269158d416a", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">Maximum concentrations of brentuximab vedotin ADC were typically\r observed at the end of infusion or the sampling timepoint closest to the end of\r infusion. A multiexponential decline in ADC serum concentrations was observed\r with a terminal half-life of approximately 4 to 6 days.\r Exposures were approximately dose proportional. Minimal to no accumulation of\r ADC was observed with multiple doses at the every 3\u2011week schedule,\r consistent with the terminal half-life estimate. Typical C<sub>max</sub> and\r AUC of ADC after a single 1.8 mg/kg in a phase 1 study was\r approximately </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">31.98 \u03bcg/ mL\r and 79.41 \u03bcg/ mL x day respectively.</span></p>", "ID": "65b66143-4c1a-4adc-a26f-452131131c8b", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Maximum concentrations of brentuximab vedotin ADC were typically\r observed at the end of infusion or the sampling timepoint closest to the end of\r infusion. A multiexponential decline in ADC serum concentrations was observed\r with a terminal half-life of approximately 4 to 6 days.\r Exposures were approximately dose proportional. Minimal to no accumulation of\r ADC was observed with multiple doses at the every 3\u2011week schedule,\r consistent with the terminal half-life estimate. Typical Cmax and\r AUC of ADC after a single 1.8 mg/kg in a phase 1 study was\r approximately 31.98 \u03bcg/ mL\r and 79.41 \u03bcg/ mL x day respectively.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "3dc49800-89e1-4a26-817a-1411ec45476e", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">MMAE is the major metabolite of brentuximab vedotin. Median C<sub>max</sub>,\r AUC and T<sub>max</sub> of MMAE after a single 1.8 mg/kg of the ADC in a\r phase 1 study was approximately 4.97 ng/ mL, 37.03 ng/ mL x\r day and 2.09 days respectively. MMAE exposures decreased after multiple\r doses of brentuximab vedotin with approximately 50% to 80% of the exposure of\r the first dose being observed at subsequent doses. MMAE is further metabolised\r mainly to an equally potent metabolite; however, its exposure is an order of\r magnitude lower than that of MMAE. Thus, it is not likely to have any\r substantial contribution to the systemic effects of MMAE.</span></p>", "ID": "5ce77d09-fdf1-47bb-a0c7-05ff750c5631", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "MMAE is the major metabolite of brentuximab vedotin. Median Cmax,\r AUC and Tmax of MMAE after a single 1.8 mg/kg of the ADC in a\r phase 1 study was approximately 4.97 ng/ mL, 37.03 ng/ mL x\r day and 2.09 days respectively. MMAE exposures decreased after multiple\r doses of brentuximab vedotin with approximately 50% to 80% of the exposure of\r the first dose being observed at subsequent doses. MMAE is further metabolised\r mainly to an equally potent metabolite; however, its exposure is an order of\r magnitude lower than that of MMAE. Thus, it is not likely to have any\r substantial contribution to the systemic effects of MMAE.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "5b63f359-c2bf-4336-a91e-5adfdfb042aa", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the first cycle, higher MMAE exposure\r was associated with an absolute decrease in neutrophil count.</span></p>", "ID": "6234dc3f-3f0f-4a65-bdc0-cfce2acade04", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In the first cycle, higher MMAE exposure\r was associated with an absolute decrease in neutrophil count.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "3bbd3694-8f7e-4fe1-a4c7-1d80c1e9a6ed", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Combination\r therapy</span></u></p>", "ID": "f08556dc-fe61-4241-8eac-8d0e08cdf2a3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Combination\r therapy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"></span></u></p>", "ID": "2696ed41-9e7e-4346-a6b7-2014fee393fd", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The pharmacokinetics of ADCETRIS in\r combination with AVD were evaluated in a single phase 3 study in 661 patients.\r Population pharmacokinetic analysis indicated that the pharmacokinetics of\r ADCETRIS in combination with AVD were consistent to that in monotherapy. </span></p>", "ID": "517ee043-ef58-4243-b7c7-9cc444c41a64", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The pharmacokinetics of ADCETRIS in\r combination with AVD were evaluated in a single phase 3 study in 661 patients.\r Population pharmacokinetic analysis indicated that the pharmacokinetics of\r ADCETRIS in combination with AVD were consistent to that in monotherapy. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "dfb821e3-38b4-4110-a487-8dc56a196928", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">After multiple\u2011dose, IV infusion of\r 1.2 mg/kg brentuximab vedotin every two weeks, maximal serum\r concentrations of ADC were observed near the end of the infusion and\r elimination exhibited a multi\u2011exponential decline with a t<sub>1/2z</sub>\r of approximately 4 to 5 days. Maximal plasma concentrations of MMAE\r were observed approximately 2 days after the end of infusion, and\r exhibited a mono\u2011exponential decline with a t<sub>1/2z </sub>of\r approximately 3 to 4 days.</span></p>", "ID": "638dd04b-f54f-49b5-ade9-80d840138d0c", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "After multiple\u2011dose, IV infusion of\r 1.2 mg/kg brentuximab vedotin every two weeks, maximal serum\r concentrations of ADC were observed near the end of the infusion and\r elimination exhibited a multi\u2011exponential decline with a t1/2z\r of approximately 4 to 5 days. Maximal plasma concentrations of MMAE\r were observed approximately 2 days after the end of infusion, and\r exhibited a mono\u2011exponential decline with a t1/2z of\r approximately 3 to 4 days.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "7474eb7d-a0f9-4085-9939-c77fce70b1ce", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">After multiple\u2011dose, IV infusion of\r 1.2 mg/kg brentuximab vedotin every two weeks, steady\u2011state trough\r concentrations of ADC and MMAE were achieved by Cycle 3. Once steady-state\r was achieved, the PK of ADC did not appear to change with time. ADC\r accumulation (as assessed by AUC<sub>14D</sub> between Cycle 1 and\r Cycle 3) was 1.27\u2011fold. The exposure of MMAE (as assessed by AUC<sub>14D</sub>\r between Cycle 1 and Cycle 3) appeared to decrease with time by\r approximately 50%.</span></p>", "ID": "d63f7d66-88d0-4b5d-8f81-a87784518f25", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "After multiple\u2011dose, IV infusion of\r 1.2 mg/kg brentuximab vedotin every two weeks, steady\u2011state trough\r concentrations of ADC and MMAE were achieved by Cycle 3. Once steady-state\r was achieved, the PK of ADC did not appear to change with time. ADC\r accumulation (as assessed by AUC14D between Cycle 1 and\r Cycle 3) was 1.27\u2011fold. The exposure of MMAE (as assessed by AUC14D\r between Cycle 1 and Cycle 3) appeared to decrease with time by\r approximately 50%.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "476edc75-14cc-4921-9985-dc750f7cffa1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The pharmacokinetics of ADCETRIS in\r combination with CHP were evaluated in a single phase 3 study in 223 patients\r (SGN35\u2011014). After multiple-dose IV infusion of 1.8 mg/kg ADCETRIS\r every 3 weeks, the pharmacokinetics of ADC and MMAE were similar to those\r of monotherapy.</span></p>", "ID": "40dadbb3-58e0-475d-b80e-d2dca7ccc4e0", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The pharmacokinetics of ADCETRIS in\r combination with CHP were evaluated in a single phase 3 study in 223 patients\r (SGN35\u2011014). After multiple-dose IV infusion of 1.8 mg/kg ADCETRIS\r every 3 weeks, the pharmacokinetics of ADC and MMAE were similar to those\r of monotherapy.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "8a51fa07-93aa-4a0d-9ccd-f51416205aa5", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Distribution</span></u></p>", "ID": "161b5cd1-eb10-464d-b778-f1877b559305", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Distribution", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "9c5650ae-9a37-44a6-8aea-4dce92756ec7", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In vitro</span></i><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">, </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">the binding of MMAE\r to human serum plasma proteins ranged from 68\u201182%. MMAE is not likely to\r displace or to be displaced by highly protein-bound medicines. <i>In vitro</i>,\r MMAE was a substrate of P\u2011gp and was not an inhibitor of P\u2011gp at\r clinical concentrations.</span></p>", "ID": "a4ed8e0c-0463-4292-b1c5-c00bfdbbb56c", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In vitro, the binding of MMAE\r to human serum plasma proteins ranged from 68\u201182%. MMAE is not likely to\r displace or to be displaced by highly protein-bound medicines. In vitro,\r MMAE was a substrate of P\u2011gp and was not an inhibitor of P\u2011gp at\r clinical concentrations.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "44d8aa9a-3fe2-4c25-b5e4-df84b0ff9405", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">In humans, the mean steady state volume of distribution was\r approximately 6\u201110 L for ADC. Based on population PK estimation the\r typical apparent central volume of distribution of MMAE was 35.5 L.</span></p>", "ID": "5dd98426-bebe-4b04-8e90-23d93804e69e", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In humans, the mean steady state volume of distribution was\r approximately 6\u201110 L for ADC. Based on population PK estimation the\r typical apparent central volume of distribution of MMAE was 35.5 L.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "0ac2d81a-f55a-4f44-8e17-0d8350c463f9", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Metabolism</span></u></p>", "ID": "b1e6c7cf-dbe4-48f4-8de2-da296f97ed8e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Metabolism", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"></p>", "ID": "d71eccf2-d1b1-4c09-a4e6-c69c6c66971e", "Styles": "margin-right:-.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The ADC is\r expected to be catabolised as a protein with component amino acids recycled or\r eliminated.</span></p>", "ID": "3b8e5386-225a-4a49-a0d3-00e45d3f2b5c", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The ADC is\r expected to be catabolised as a protein with component amino acids recycled or\r eliminated.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"></p>", "ID": "698a094c-6cb6-4c21-b5fc-eaf6580c6356", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><i><span lang=\"EN-GB\">In</span></i><span lang=\"EN-GB\"> <i>vivo</i> data in animals and humans suggest that only a small\r fraction of MMAE released from </span><span lang=\"EN-GB\">brentuximab vedotin is metabolised.\r The levels of MMAE metabolites have not been measured in human plasma. At least\r one metabolite of MMAE has been shown to be active <i>in vitro.</i> </span></p>", "ID": "14ec1231-687c-4381-9075-60aeec277154", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In vivo data in animals and humans suggest that only a small\r fraction of MMAE released from brentuximab vedotin is metabolised.\r The levels of MMAE metabolites have not been measured in human plasma. At least\r one metabolite of MMAE has been shown to be active in vitro. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p>", "ID": "4aa188af-80bf-420e-9490-d81c6e98c281", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">MMAE is a\r substrate of CYP3A4 and possibly CYP2D6. <i>In vitro</i> data indicate that the\r MMAE metabolism that occurs is primarily via oxidation by CYP3A4/5. <i>In vitro</i>\r studies using human liver microsomes indicate that MMAE inhibits only CYP3A4/5\r at concentrations much higher than was achieved during clinical application.\r MMAE does not inhibit other isoforms. </span></p>", "ID": "335e8219-e793-44ef-8f0e-f2a5985966d9", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "MMAE is a\r substrate of CYP3A4 and possibly CYP2D6. In vitro data indicate that the\r MMAE metabolism that occurs is primarily via oxidation by CYP3A4/5. In vitro\r studies using human liver microsomes indicate that MMAE inhibits only CYP3A4/5\r at concentrations much higher than was achieved during clinical application.\r MMAE does not inhibit other isoforms. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p>", "ID": "0483637f-78e4-4a07-afb5-99578dc603fb", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">MMAE did not\r induce any major CYP450 enzymes in primary cultures of human hepatocytes.</span></p>", "ID": "b46e76e7-e1cc-47db-aee3-52333bfc2e1b", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "MMAE did not\r induce any major CYP450 enzymes in primary cultures of human hepatocytes.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "a8172008-1fdb-4e76-a292-0fe91855eba7", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Elimination</span></u></p>", "ID": "6a253a56-7141-40dd-89b2-78014d078cd3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Elimination", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"><u><span lang=\"EN-GB\"></span></u></p>", "ID": "9941ac51-f2a3-496b-b3ad-3a4c696a8929", "Styles": "margin-right:-.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The ADC is\r eliminated by catabolism with a typical estimated CL and half life of 1.5 L/day\r and 4\u20116 days respectively. </span></p>", "ID": "6e52fa34-c4bd-407c-9eb9-e350094f5d45", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The ADC is\r eliminated by catabolism with a typical estimated CL and half life of 1.5 L/day\r and 4\u20116 days respectively. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p>", "ID": "679b0f9c-f66b-4c3d-8bbc-b32e1e2dbfa9", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The elimination\r of MMAE was limited by its rate of release from ADC, typical apparent CL and\r half life of MMAE was 19.99 L/day and 3\u20114 days respectively. </span></p>", "ID": "ea5f3412-ab05-4a10-a05b-f412bd512d78", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The elimination\r of MMAE was limited by its rate of release from ADC, typical apparent CL and\r half life of MMAE was 19.99 L/day and 3\u20114 days respectively. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p>", "ID": "03479491-0df2-4140-8070-a2715c5080a5", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">An excretion\r study was undertaken in patients who received a dose of 1.8 mg/kg of\r brentuximab vedotin. Approximately 24% of the total MMAE administered as part\r of the ADC during a brentuximab vedotin infusion was recovered in both urine\r and faeces over a 1\u2011week period. Of the recovered MMAE, approximately 72%\r was recovered in the faeces. A lesser amount of MMAE (28%) was excreted in the\r urine.</span></p>", "ID": "239e69de-8c28-432e-8534-2813882a7196", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "An excretion\r study was undertaken in patients who received a dose of 1.8 mg/kg of\r brentuximab vedotin. Approximately 24% of the total MMAE administered as part\r of the ADC during a brentuximab vedotin infusion was recovered in both urine\r and faeces over a 1\u2011week period. Of the recovered MMAE, approximately 72%\r was recovered in the faeces. A lesser amount of MMAE (28%) was excreted in the\r urine.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><u><span lang=\"EN-GB\"></span></u></p>", "ID": "fd50c750-7889-4963-9f4d-0791de2946e9", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pharmacokinetics\r in special populations</span></u></p>", "ID": "b5a375ae-2fba-4dbf-bc9b-cdb7e2b2d173", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Pharmacokinetics\r in special populations", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "00fb66df-daa0-4a06-8a98-51352bd998b0", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Population PK analysis showed that baseline\r serum albumin concentration was a significant covariate of MMAE clearance. The\r analysis indicated that MMAE clearance was 2\u2011fold lower in patients with\r low serum albumin concentrations &lt;3.0 g/dL compared with patients with\r serum albumin concentrations within the normal range.</span></p>", "ID": "cb65442f-ff33-483e-acb5-8b87c0b62b44", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Population PK analysis showed that baseline\r serum albumin concentration was a significant covariate of MMAE clearance. The\r analysis indicated that MMAE clearance was 2\u2011fold lower in patients with\r low serum albumin concentrations <3.0 g/dL compared with patients with\r serum albumin concentrations within the normal range.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "cb3a61b8-2251-4333-8009-7cdc4146c8e3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hepatic\r impairment</span></i></p>", "ID": "0cccce93-eb34-4973-8c12-33f1937f76cc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Hepatic\r impairment", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "afde2b36-8f1f-4300-aff3-3dcb93543468", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">A study\r evaluated the PK of brentuximab vedotin and MMAE after the administration of\r 1.2 mg/kg of ADCETRIS to patients with mild (Child-Pugh A; n = 1),\r moderate (Child-Pugh B; n = 5) and severe (Child-Pugh C; n = 1)\r hepatic impairment. Compared to patients with normal hepatic function, MMAE\r exposure increased approximately 2.3\u2011fold (90% CI 1.27\u20114.12\u2011fold)\r in patients with hepatic impairment.</span></p>", "ID": "07b2a3a5-cc74-4b6c-9a43-b8159c3a489d", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "A study\r evaluated the PK of brentuximab vedotin and MMAE after the administration of\r 1.2 mg/kg of ADCETRIS to patients with mild (Child-Pugh A; n = 1),\r moderate (Child-Pugh B; n = 5) and severe (Child-Pugh C; n = 1)\r hepatic impairment. Compared to patients with normal hepatic function, MMAE\r exposure increased approximately 2.3\u2011fold (90% CI 1.27\u20114.12\u2011fold)\r in patients with hepatic impairment.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p>", "ID": "47ca1373-8b89-4caa-8472-9b7ec6e7c393", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Renal\r impairment</span></i></p>", "ID": "460038fe-a33e-432c-bdb9-cfbefc93b012", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Renal\r impairment", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "c6ce9828-42d4-4557-adee-31805b102fa6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">A study\r evaluated the PK of brentuximab vedotin and MMAE after the administration of\r 1.2 mg/kg of ADCETRIS to patients with mild (n = 4), moderate (n = 3)\r and severe (n = 3) renal impairment. Compared to patients with normal\r renal function, MMAE exposure increased approximately 1.9\u2011fold (90% CI\r 0.85\u20114.21\u2011fold) in patients with severe renal impairment\r (creatinine clearance &lt; 30 mL/min). No effect was observed in\r patients with mild or moderate renal impairment.</span></p>", "ID": "f75226fa-d430-4859-9525-6b54c3d1eafc", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "A study\r evaluated the PK of brentuximab vedotin and MMAE after the administration of\r 1.2 mg/kg of ADCETRIS to patients with mild (n = 4), moderate (n = 3)\r and severe (n = 3) renal impairment. Compared to patients with normal\r renal function, MMAE exposure increased approximately 1.9\u2011fold (90% CI\r 0.85\u20114.21\u2011fold) in patients with severe renal impairment\r (creatinine clearance < 30 mL/min). No effect was observed in\r patients with mild or moderate renal impairment.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"></p>", "ID": "1b9dc5e7-96a1-457a-89d4-3ed193f2a309", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Elderly</span></i></p>", "ID": "1c36abe9-4937-40d5-9a80-9c2d0c701578", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Elderly", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "05d205cc-5147-4db0-b475-44239e92ef0a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The population pharmacokinetics of\r brentuximab vedotin were examined from several studies, including data from 380 patients\r up to 87 years old (34 patients </span><span lang=\"EN-GB\">\u226565\u2011&lt; 75\r and 17 patients \u226575 years of age</span><span lang=\"EN-GB\">). Additionally,\r the population pharmacokinetics of brentuximab vedotin in combination with AVD\r were examined, including data from 661 patients up to 82 years old (</span><span lang=\"EN-GB\">42 patients \u2265 65\u2011&lt; 75 and 17 patients \u2265 75 years\r of age). The influence of age on pharmacokinetics was investigated in each\r analysis and it was not a significant covariate.</span></p>", "ID": "08eaec81-fee4-4695-be3d-3de87018bf6c", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The population pharmacokinetics of\r brentuximab vedotin were examined from several studies, including data from 380 patients\r up to 87 years old (34 patients \u226565\u2011< 75\r and 17 patients \u226575 years of age). Additionally,\r the population pharmacokinetics of brentuximab vedotin in combination with AVD\r were examined, including data from 661 patients up to 82 years old (42 patients \u2265 65\u2011< 75 and 17 patients \u2265 75 years\r of age). The influence of age on pharmacokinetics was investigated in each\r analysis and it was not a significant covariate.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph\"><u><span lang=\"EN-GB\" style=\"background:yellow\"></span></u></p>", "ID": "0bc515f0-2a76-4dcc-a63e-8c40353249b0", "Styles": "text-align:justify;text-justify:inter-ideograph", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Paediatric\r population</span></i></p>", "ID": "0db0e94d-f379-455a-847e-30cf90af826d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Paediatric\r population", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r page-break-after:avoid\"></p>", "ID": "0aa31f23-5ceb-4bda-a2da-929fea7e3553", "Styles": "text-align:justify;text-justify:inter-ideograph;\r\npage-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The pharmacokinetics of brentuximab vedotin\r ADC and MMAE following a 30\u2011minute intravenous infusion of BV administered\r at 1.4 mg/kg or 1.8 mg/kg given every 3 weeks were evaluated in\r a phase 1/2 clinical trial of 36 paediatric patients (7\u201117 years\r of age) with r/r HL and sALCL (children aged 7\u201111 years, n = 12\r and adolescents aged 12 to 17 years, n = 24) (see section 5.1).\r The C<sub>max</sub> of ADC was typically observed at the end of infusion or the\r sampling closest to the end of infusion. A multi-exponential decline in ADC\r serum concentrations was observed with a terminal half-life of approximately 4\r to 5 days. Exposures were approximately dose proportional with a trend\r observed for lower ADC exposures at lower ages/ body weights in the study\r population. </span></p>", "ID": "9c8458c3-e06d-4322-b7a5-9d5f79756922", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The pharmacokinetics of brentuximab vedotin\r ADC and MMAE following a 30\u2011minute intravenous infusion of BV administered\r at 1.4 mg/kg or 1.8 mg/kg given every 3 weeks were evaluated in\r a phase 1/2 clinical trial of 36 paediatric patients (7\u201117 years\r of age) with r/r HL and sALCL (children aged 7\u201111 years, n = 12\r and adolescents aged 12 to 17 years, n = 24) (see section 5.1).\r The Cmax of ADC was typically observed at the end of infusion or the\r sampling closest to the end of infusion. A multi-exponential decline in ADC\r serum concentrations was observed with a terminal half-life of approximately 4\r to 5 days. Exposures were approximately dose proportional with a trend\r observed for lower ADC exposures at lower ages/ body weights in the study\r population. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Median ADC AUC in\r children and adolescents from this study was approx. 14% and 3% lower than in\r adult patients, respectively, while MMAE exposures were 53% lower and 13%\r higher, respectively, than in adult patients.</span><span lang=\"EN-GB\" style=\"color:windowtext\"> Median C<sub>max</sub> and AUC of ADC after a single\r 1.8 mg/kg dose were 29.8 \u00b5g/ mL and\r 67.9 \u00b5g*day/ mL, respectively, in patients &lt; 12 years\r of age and 34.4 \u00b5g/mL and 77.8 \u00b5g*day/mL, respectively,\r in patients \u2265 12 years of age. Median C<sub>max</sub>, AUC, and\r T<sub>max</sub> of MMAE after a single 1.8 mg/kg dose were\r 3.73 ng/mL, 17.3 ng*day/mL, and 1.92 days, respectively, in patients\r &lt; 12 years of age and 6.33 ng/mL, 42.3 ng*day/mL, and\r 1.82 days, respectively, in patients \u2265 12 years of age. </span><span lang=\"EN-GB\" style=\"color:windowtext\">There was a trend of increased clearance of\r brentuximab vedotin in paediatric patients confirmed positive for ADAs. No\r patients aged &lt; 12 years (0 of 11) and 2 patients aged\r \u2265 12 years (2 of 23) became persistently ADA positive.</span></p>", "ID": "d30e6654-8612-431a-95b1-45c060d82818", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Median ADC AUC in\r children and adolescents from this study was approx. 14% and 3% lower than in\r adult patients, respectively, while MMAE exposures were 53% lower and 13%\r higher, respectively, than in adult patients. Median Cmax and AUC of ADC after a single\r 1.8 mg/kg dose were 29.8 \u00b5g/ mL and\r 67.9 \u00b5g*day/ mL, respectively, in patients < 12 years\r of age and 34.4 \u00b5g/mL and 77.8 \u00b5g*day/mL, respectively,\r in patients \u2265 12 years of age. Median Cmax, AUC, and\r Tmax of MMAE after a single 1.8 mg/kg dose were\r 3.73 ng/mL, 17.3 ng*day/mL, and 1.92 days, respectively, in patients\r < 12 years of age and 6.33 ng/mL, 42.3 ng*day/mL, and\r 1.82 days, respectively, in patients \u2265 12 years of age. There was a trend of increased clearance of\r brentuximab vedotin in paediatric patients confirmed positive for ADAs. No\r patients aged < 12 years (0 of 11) and 2 patients aged\r \u2265 12 years (2 of 23) became persistently ADA positive.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><u><span lang=\"EN-GB\"></span></u></p>", "ID": "14bc9544-6d62-4d25-b2ac-ee619eb3d837", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h3><span lang=\"EN-GB\">5.3     Preclinical safety data</span></h3>", "ID": "93af311a-6e5e-49d4-a985-a548c3740e7a", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "5.3     Preclinical safety data", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in;page-break-after:avoid\"></p>", "ID": "938ab78c-f74a-4ec1-b405-d0f093b7444f", "Styles": "margin-bottom:0in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">MMAE has been shown\r to have aneugenic properties in an <i>in vivo</i> rat bone marrow micronucleus\r study. These results were consistent with the pharmacological effect of MMAE on\r the mitotic apparatus (disruption of the microtubule network) in cells.</span></p>", "ID": "faf2e1ea-22b9-491b-a6b5-6d22b02a54d6", "Styles": "None", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "MMAE has been shown\r to have aneugenic properties in an in vivo rat bone marrow micronucleus\r study. These results were consistent with the pharmacological effect of MMAE on\r the mitotic apparatus (disruption of the microtubule network) in cells.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\"></p>", "ID": "f23d92ac-a7c9-4edf-8f21-9aff5c557d6e", "Styles": "None", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The effects of </span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">brentuximab vedotin on human male and\r female fertility have not been studied. However, results of repeat-dose\r toxicity studies in rats indicate the potential for brentuximab vedotin to\r impair male reproductive function and fertility. Testicular atrophy and\r degeneration were partially reversible following a 16\u2011week treatment-free\r period.</span></p>", "ID": "2a6e044b-95b6-43f4-8652-889231eef0dc", "Styles": "None", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The effects of brentuximab vedotin on human male and\r female fertility have not been studied. However, results of repeat-dose\r toxicity studies in rats indicate the potential for brentuximab vedotin to\r impair male reproductive function and fertility. Testicular atrophy and\r degeneration were partially reversible following a 16\u2011week treatment-free\r period.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\"></p>", "ID": "b29746da-e82b-43c3-a315-213f5c1ec86f", "Styles": "None", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListBullet\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Brentuximab vedotin caused embryo-foetal\r lethality in pregnant female rats. </span></p>", "ID": "0f615844-7e7b-4bd7-ab55-92ede7c6a1de", "Styles": "margin-left:0in;text-indent:0in", "Classes": "['MsoListBullet']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Brentuximab vedotin caused embryo-foetal\r lethality in pregnant female rats. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "b5a2455c-5474-4da3-915c-1a079c28ef34", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In nonclinical studies, lymphoid depletion\r and reduced thymic weight were observed, consistent with the pharmacologic\r disruption of microtubules caused by MMAE derived from brentuximab vedotin.</span></p>", "ID": "77bb678a-cb3b-46d3-949f-abee01876861", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In nonclinical studies, lymphoid depletion\r and reduced thymic weight were observed, consistent with the pharmacologic\r disruption of microtubules caused by MMAE derived from brentuximab vedotin.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "f7661b75-84fd-4e27-b7c0-ca6b4e371284", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "ced01ec1-4266-4342-bcd3-b603abcbb8b1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h2><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>6.       PHARMACEUTICAL\r PARTICULARS</span></h2>", "ID": "223108b3-57fe-4ac6-8fe4-fb1dc4a77de2", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "6.       PHARMACEUTICAL\r PARTICULARS", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "7cd14c14-93cf-4448-8820-788189553af2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h3><span lang=\"EN-GB\">6.1     List of excipients</span></h3>", "ID": "b5213448-96c2-4a24-a1dc-02dff14c3294", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "6.1     List of excipients", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "fad8e8ef-f6a1-4701-a7f1-5a85327345e7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:windowtext\">Citric acid monohydrate </span><span style=\"color:windowtext\">(for pH-adjustment)</span></p>", "ID": "2b9966c2-265f-4c93-bfb7-54ce7667623b", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Citric acid monohydrate (for pH-adjustment)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\" style=\"color:windowtext\">Sodium citrate dihydrate </span><span style=\"color:windowtext\">(for pH-adjustment)</span></p>", "ID": "f8b5354f-ad91-483e-8e26-a34feaa28d85", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Sodium citrate dihydrate (for pH-adjustment)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">\u03b1,\u03b1\u2011Trehalose dihydrate</span></p>", "ID": "c2ce1e6e-278d-4e1e-b74a-275fc82ed3c0", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "\u03b1,\u03b1\u2011Trehalose dihydrate", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Polysorbate 80</span></p>", "ID": "cc97db1a-ad6e-4fd9-94e8-659751cdabff", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Polysorbate 80", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "55ca00dc-24bf-4d54-964f-eb0cfefd37ad", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h3><span lang=\"EN-GB\">6.2     Incompatibilities</span></h3>", "ID": "5c06a336-acab-40aa-a99d-daedc28f5c83", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "6.2     Incompatibilities", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "3bf9d03f-0240-42bc-b3a0-1369da025153", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the absence of compatibility studies,\r this medicinal product must not be mixed with other medicinal products except\r those mentioned in section 6.6.</span></p>", "ID": "19b66213-5d80-48e7-800e-44765cc2ff05", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In the absence of compatibility studies,\r this medicinal product must not be mixed with other medicinal products except\r those mentioned in section 6.6.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "6a392c06-b8c1-4bd5-b2f6-aabe7491782a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h3><span lang=\"EN-GB\">6.3     Shelf life</span></h3>", "ID": "58e2b5a4-9508-4c4f-bcde-d39a3a5b88b9", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "6.3     Shelf life", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "ca744683-caf7-49e6-864b-75e29bfdbde4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">4 years.</span></p>", "ID": "e6941e99-d5b1-4bb0-b0c9-959edd0c4540", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "4 years.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "819628a7-58f3-4733-a23b-8c67bb383827", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">After reconstitution/dilution, from a\r microbiological point of view, the product should be used immediately. However,\r chemical and physical in\u2011use stability has been demonstrated for\r 24 hours at 2 </span><span lang=\"EN-GB\">\u00b0</span><span lang=\"EN-GB\">C\u20118 </span><span lang=\"EN-GB\">\u00b0</span><span lang=\"EN-GB\">C.</span></p>", "ID": "e31d51f2-93dc-48bb-b2a4-cd0d4461debe", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "After reconstitution/dilution, from a\r microbiological point of view, the product should be used immediately. However,\r chemical and physical in\u2011use stability has been demonstrated for\r 24 hours at 2 \u00b0C\u20118 \u00b0C.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "626e5914-f9b4-42d2-9d8f-ae226d422ad4", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h3><span lang=\"EN-GB\">6.4     Special precautions for\r storage</span></h3>", "ID": "94f1fd3a-4301-474f-902b-74b36a5531af", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "6.4     Special precautions for\r storage", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "3145ed54-6aa5-4e4f-bb86-67765b4b9a4f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Store in a\r refrigerator (2 \u00b0C\u20118 \u00b0C). </span></p>", "ID": "9e6f83dd-ffce-4da7-a7cd-5de9f31129d0", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Store in a\r refrigerator (2 \u00b0C\u20118 \u00b0C). ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "e3e86705-fe5e-4856-93ec-9155bc8c2e2d", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Do not freeze. </span></p>", "ID": "dd63bac6-82fe-4dd0-99b3-a2a711790ef6", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Do not freeze. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "c5eabd9e-612a-4700-8504-eb0cea7169ef", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Keep the vial\r in the original carton in order to protect from light.</span></p>", "ID": "c7d42f1b-e225-42e1-83ec-46e3f340f971", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Keep the vial\r in the original carton in order to protect from light.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "f545b56c-3d9e-47d6-ae19-2b4b6b7ede05", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">For storage\r conditions after reconstitution and dilution of the medicinal product, see\r section 6.3.</span></p>", "ID": "2cd29bd7-b16c-4667-9bd5-d8d1205ff15b", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "For storage\r conditions after reconstitution and dilution of the medicinal product, see\r section 6.3.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "5cc9025c-bc0d-4d14-a892-62f8cc521b74", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h3><span lang=\"EN-GB\">6.5     Nature and contents of\r container </span></h3>", "ID": "ddfc2725-b38c-4cf6-9d39-ce82fb084045", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "6.5     Nature and contents of\r container ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "cfb7469f-da03-4c47-82b2-eed864f6fb80", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Type I glass vial with a butyl rubber\r stopper and an aluminium/plastic flip-off seal, containing 50 mg powder.</span></p>", "ID": "58f5f859-9f24-4983-a016-1191ea24e0df", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Type I glass vial with a butyl rubber\r stopper and an aluminium/plastic flip-off seal, containing 50 mg powder.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "cbc92be5-05ba-479f-a272-96706fbee33c", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pack of 1 vial. </span></p>", "ID": "6496d2b1-aef5-4681-ac56-1058a114671a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Pack of 1 vial. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "59a26c50-628b-4811-9d11-216992fab9b3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h3><a name=\"OLE_LINK1\"><span lang=\"EN-GB\">6.6     Special\r precautions for disposal and other handling</span></a></h3>", "ID": "a08a825d-8ee3-4b26-901f-b6996f813422", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "6.6     Special\r precautions for disposal and other handling", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"></span></u></p>", "ID": "006b732f-6d4b-40cc-82d9-5e26f63a2e93", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">General\r precautions</span></u></p>", "ID": "c907a3d7-eb5f-4efa-aaf7-e5300945a0d9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "General\r precautions", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\" style=\"page-break-after:avoid\"></p>", "ID": "aee9641a-2afb-4d75-ae43-95d50cb94353", "Styles": "page-break-after:avoid", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:\r 11.0pt\">Procedures for proper handling and disposal of anticancer medicinal\r products should be considered. </span></p>", "ID": "0337ac11-46b9-4c11-b9b3-b450aec1841d", "Styles": "margin-bottom:0in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Procedures for proper handling and disposal of anticancer medicinal\r products should be considered. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\"></p>", "ID": "d25911f8-a130-4141-8202-b748053bcdab", "Styles": "None", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Proper aseptic\r technique throughout the handling of this medicinal product should be followed.</span></p>", "ID": "ae5ebefd-4c50-4c8d-9760-59bf8fa46b50", "Styles": "None", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Proper aseptic\r technique throughout the handling of this medicinal product should be followed.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "635c78e0-983d-447d-bf6d-b838257986be", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Instructions\r for reconstitution </span></u></p>", "ID": "65c0faa4-50e5-4615-a389-f39bf331a4ca", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Instructions\r for reconstitution ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "f30daea4-0876-43d0-8113-f8ddb6d6b539", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Each single use vial must be reconstituted\r with 10.5 mL of water for injections to a final concentration of\r 5 mg/ mL. Each vial contains a 10% overfill giving 55 mg of\r ADCETRIS per vial and a total reconstituted volume of 11 mL.</span></p>", "ID": "74bc3972-1b2d-4a65-8bf5-723f70263387", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Each single use vial must be reconstituted\r with 10.5 mL of water for injections to a final concentration of\r 5 mg/ mL. Each vial contains a 10% overfill giving 55 mg of\r ADCETRIS per vial and a total reconstituted volume of 11 mL.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "dd727d04-39ff-461e-8d5a-1e0c8d7c846c", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">1.</span><span lang=\"EN-GB\">Direct the stream toward the wall of the vial\r and not directly at the cake or powder. </span></p>", "ID": "978fc3b8-4102-4af2-ae24-5aa2ffb3012d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpFirst']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "1.Direct the stream toward the wall of the vial\r and not directly at the cake or powder. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\">2.</span><span lang=\"EN-GB\">Gently swirl the vial to aid dissolution. DO NOT\r SHAKE.</span></p>", "ID": "0adf7111-2c56-4fdd-b5e6-ab47bb9fdfd3", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "2.Gently swirl the vial to aid dissolution. DO NOT\r SHAKE.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\">3.</span><span lang=\"EN-GB\">The reconstituted solution in the vial is a\r clear to slightly opalescent, colourless solution with a final pH of 6.6. </span></p>", "ID": "c8283990-c5d7-4e25-8afe-1f36b234539e", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "3.The reconstituted solution in the vial is a\r clear to slightly opalescent, colourless solution with a final pH of 6.6. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">4.</span><span lang=\"EN-GB\">The reconstituted solution should be inspected\r visually for any foreign particulate matter and/or discolouration. In the event\r of either being observed, discard the medicinal product. </span></p>", "ID": "37ae6f96-551c-4418-8dd6-b669cebb643c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpLast']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "4.The reconstituted solution should be inspected\r visually for any foreign particulate matter and/or discolouration. In the event\r of either being observed, discard the medicinal product. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Default\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"></span></u></p>", "ID": "6bdffa35-520c-4896-b766-85184e929086", "Styles": "None", "Classes": "['Default']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Preparation\r of infusion solution</span></u></p>", "ID": "ff42eff8-82c5-49e7-82b8-f8cdc459c998", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Preparation\r of infusion solution", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "893e5807-7edb-4973-8b81-5d3b5b086471", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The appropriate amount of reconstituted\r ADCETRIS must be withdrawn from the vial(s) and added to an infusion bag\r containing sodium chloride 9 mg/ mL (0.9%) solution for injection in\r order to achieve a final concentration of 0.4\u20111.2 mg/ mL\r ADCETRIS. The recommended diluent volume is 150 mL. The already\r reconstituted ADCETRIS can also be diluted into 5% dextrose for injection or\r Lactated Ringer's for injection. </span></p>", "ID": "7e0225d5-06cd-446e-99b1-e249db6a6720", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The appropriate amount of reconstituted\r ADCETRIS must be withdrawn from the vial(s) and added to an infusion bag\r containing sodium chloride 9 mg/ mL (0.9%) solution for injection in\r order to achieve a final concentration of 0.4\u20111.2 mg/ mL\r ADCETRIS. The recommended diluent volume is 150 mL. The already\r reconstituted ADCETRIS can also be diluted into 5% dextrose for injection or\r Lactated Ringer's for injection. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "9cc70eba-dd75-4e1f-b319-27ba9e2678de", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Gently invert the bag to mix the solution\r containing ADCETRIS. DO NOT SHAKE. </span></p>", "ID": "6676bef1-93b4-4e5b-9143-3a0a248e51aa", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Gently invert the bag to mix the solution\r containing ADCETRIS. DO NOT SHAKE. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "9140070e-71d6-421f-a3c6-4d49a852eb39", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Any portion left in the vial, after\r withdrawal of the volume to be diluted, must be disposed of in accordance with local\r requirements. </span></p>", "ID": "f9d8098b-4f61-4983-ad26-25f79846181c", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Any portion left in the vial, after\r withdrawal of the volume to be diluted, must be disposed of in accordance with local\r requirements. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "07f8ce3e-738c-447a-9dc9-3aa9a3e84f5b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not add other medicinal products to the\r prepared ADCETRIS infusion solution or intravenous infusion set. The infusion\r line should be flushed following administration with sodium chloride 9 mg/ mL\r (0.9%) solution for injection, 5% dextrose for injection, or Lactated Ringer's\r for injection. </span></p>", "ID": "8d1e6a64-c193-41bb-bde8-5c67c5545daa", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Do not add other medicinal products to the\r prepared ADCETRIS infusion solution or intravenous infusion set. The infusion\r line should be flushed following administration with sodium chloride 9 mg/ mL\r (0.9%) solution for injection, 5% dextrose for injection, or Lactated Ringer's\r for injection. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "9a694e12-e842-457a-bd86-7b5bab2491e7", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Following dilution, infuse the ADCETRIS\r solution immediately at the recommended infusion rate. </span></p>", "ID": "10b59db6-01a2-45e9-b157-ff8515327e68", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Following dilution, infuse the ADCETRIS\r solution immediately at the recommended infusion rate. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "6396806b-069e-4a92-8e93-f87fd76fbbc3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Total storage time of the solution from\r reconstitution to infusion should not exceed 24 hours. </span></p>", "ID": "ff41143d-d0d9-47a4-b304-c063d9499e0c", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Total storage time of the solution from\r reconstitution to infusion should not exceed 24 hours. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "7c8573a1-00ea-499d-88e4-385a6bae68d3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Determining\r dosage amount:</span></u></p>", "ID": "7f7174a8-9f1d-4d68-9975-4a8c0c26e3cb", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Determining\r dosage amount:", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "558b8b02-f384-40e1-b926-7ba6530c1933", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Calculation\r to determine the total ADCETRIS dose (mL) to be further diluted (see section 4.2):\r </span></p>", "ID": "cd2c348e-6e33-4f4e-b336-525daaa2e901", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Calculation\r to determine the total ADCETRIS dose (mL) to be further diluted (see section 4.2):\r ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "82d2964d-fe42-44fc-813d-6ee57f2df861", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:496.15pt;margin-left:5.4pt;border-collapse:collapse\" width=\"662\"> <tr> <td style=\"width:255.15pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"340\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">ADCETRIS\r   dose (mg/kg) x patient\u2019s body weight (kg)</span></p> </td> <td rowspan=\"2\" style=\"width:241.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"321\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> = Total ADCETRIS\r   dose (mL) to be further diluted</span></p> </td> </tr> <tr> <td style=\"width:255.15pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"340\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Reconstituted\r   vial concentration (5 mg/mL)</span></p> </td> </tr> </table>", "ID": "41fa44e6-89a1-4cd2-b18f-e77946740b9e", "Styles": "width:496.15pt;margin-left:5.4pt;border-collapse:collapse", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "   ADCETRIS\r   dose (mg/kg) x patient\u2019s body weight (kg)    = Total ADCETRIS\r   dose (mL) to be further diluted     Reconstituted\r   vial concentration (5 mg/mL)   ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "a89fa004-59b3-404f-84ce-cd9b1ef8ac8f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Note: If patient\u2019s weight is more\r than 100 kg, the dose calculation should use 100 kg. The maximal\r recommended dose is 180 mg. </span></p>", "ID": "dee6b9ed-67a3-42e7-b8f1-99d91863104f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Note: If patient\u2019s weight is more\r than 100 kg, the dose calculation should use 100 kg. The maximal\r recommended dose is 180 mg. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "f2042b7d-68f3-44a0-a634-4d45ef6d38b7", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Calculation\r to determine the total number of ADCETRIS vials needed: </span></i></p>", "ID": "81a5f69b-72a2-49d5-acfe-f00399222655", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L4", "Text": "Calculation\r to determine the total number of ADCETRIS vials needed: ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;page-break-after:\r avoid\"></p>", "ID": "cbe01d1a-3c3a-4603-a525-361cda5d2c1a", "Styles": "margin-left:.5in;text-indent:-.5in;page-break-after:\r\navoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:496.15pt;margin-left:5.4pt;border-collapse:collapse\" width=\"662\"> <tr> <td style=\"width:255.15pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"340\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Total\r   ADCETRIS dose (mL) to be administered</span></p> </td> <td rowspan=\"2\" style=\"width:241.0pt;padding:0in 5.4pt 0in 5.4pt\" width=\"321\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> = Number of ADCETRIS vials\r   needed</span></p> </td> </tr> <tr> <td style=\"width:255.15pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"340\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Total\r   volume per vial (10 mL/vial)</span></p> </td> </tr> </table>", "ID": "5e269a5f-a67a-429f-8154-6a16abacef30", "Styles": "width:496.15pt;margin-left:5.4pt;border-collapse:collapse", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "   Total\r   ADCETRIS dose (mL) to be administered    = Number of ADCETRIS vials\r   needed     Total\r   volume per vial (10 mL/vial)   ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "b2e59151-bfbb-4007-8327-28de73db099e", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 19:\r Sample calculations for patients receiving the recommended dose of\r 1.8 mg/kg of ADCETRIS for weights ranging from 60 kg to 120 kg<br/> <br/> </span></b></p>", "ID": "1f2fa2d5-1533-4332-84c0-f9959f6959f6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 19:\r Sample calculations for patients receiving the recommended dose of\r 1.8 mg/kg of ADCETRIS for weights ranging from 60 kg to 120 kg  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\"> <tr> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Patient\r   weight (kg)</span></b></p> </td> <td style=\"width:126.45pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Total\r   dose = </span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">patient\r   weight multiplied by recommended dose [1.8 mg/kg<sup>a</sup>])</span></b></p> </td> <td style=\"width:148.8pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Total\r   volume to be diluted<sup>b</sup> = total dose divided by reconstituted\r   vial concentration [5 mg/ mL])</span></b></p> </td> <td style=\"width:136.95pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Number\r   of vials needed = </span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">total\r   volume to be diluted divided by total volume per vial [10 mL/vial])</span></b></p> </td> </tr> <tr> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">60 kg</span></p> </td> <td style=\"width:126.45pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">108 mg</span></p> </td> <td style=\"width:148.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">21.6 mL</span></p> </td> <td style=\"width:136.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">2.16 vials</span></p> </td> </tr> <tr> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">80 kg</span></p> </td> <td style=\"width:126.45pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">144 mg</span></p> </td> <td style=\"width:148.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28.8 mL</span></p> </td> <td style=\"width:136.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">2.88 vials</span></p> </td> </tr> <tr> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">100 kg</span></p> </td> <td style=\"width:126.45pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">180 mg</span></p> </td> <td style=\"width:148.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">36 mL</span></p> </td> <td style=\"width:136.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3.6 vials</span></p> </td> </tr> <tr> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">120 kg<sup>c</sup></span></p> </td> <td style=\"width:126.45pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">180 mg<sup>\r   d</sup></span></p> </td> <td style=\"width:148.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">36 mL</span></p> </td> <td style=\"width:136.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3.6 vials</span></p> </td> </tr> </table>", "ID": "d513b7f4-a648-46cb-be18-a79804cc5e16", "Styles": "margin-left:5.4pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "   Patient\r   weight (kg)   Total\r   dose =  patient\r   weight multiplied by recommended dose [1.8 mg/kga])   Total\r   volume to be dilutedb = total dose divided by reconstituted\r   vial concentration [5 mg/ mL])   Number\r   of vials needed =  total\r   volume to be diluted divided by total volume per vial [10 mL/vial])     60 kg   108 mg   21.6 mL   2.16 vials     80 kg   144 mg   28.8 mL   2.88 vials     100 kg   180 mg   36 mL   3.6 vials     120 kgc   180 mg\r   d   36 mL   3.6 vials   ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">a.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">For a reduced dose, use\r 1.2 mg/kg for the calculation.</span></p>", "ID": "44ad2f08-19a1-4aba-acd3-491e6b734fc1", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "a.For a reduced dose, use\r 1.2 mg/kg for the calculation.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">b.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">To be diluted in 150 mL\r of diluent and administered by intravenous infusion over 30 minutes every\r 3 weeks.</span></p>", "ID": "93e79c45-f546-4fe6-9d51-203727f5da37", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "b.To be diluted in 150 mL\r of diluent and administered by intravenous infusion over 30 minutes every\r 3 weeks.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">c.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">If patient\u2019s\r weight is more than 100 kg, the dose calculation should use 100 kg.</span></p>", "ID": "66e46bb3-f85b-496e-bc1f-f9877b2be430", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "c.If patient\u2019s\r weight is more than 100 kg, the dose calculation should use 100 kg.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">d.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">The maximal recommended\r dose is 180 mg.</span></p>", "ID": "ef98f052-c285-4768-b5db-1bcd3c57a2ac", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "d.The maximal recommended\r dose is 180 mg.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "0a768d34-c127-4394-82e6-721a74c9c6ed", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:4.5pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 20: Sample calculations for patients receiving the recommended\r dose of 1.2 mg/kg of ADCETRIS for weights ranging from 60 kg to\r 120 kg as combination therapy or when a reduced dose is required<br/> <br/> </span></b></p>", "ID": "67cfdca3-a72d-4265-ad64-d19f3fa66132", "Styles": "margin-left:4.5pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Table 20: Sample calculations for patients receiving the recommended\r dose of 1.2 mg/kg of ADCETRIS for weights ranging from 60 kg to\r 120 kg as combination therapy or when a reduced dose is required  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\"> <tr> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Patient\r   weight (kg)</span></b></p> </td> <td style=\"width:126.45pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Total\r   dose = </span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">patient\r   weight multiplied by recommended dose [1.2 mg/kg<sup>a</sup>])</span></b></p> </td> <td style=\"width:148.8pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Total\r   volume to be diluted<sup>b</sup> = total dose divided by reconstituted\r   vial concentration [5 mg/mL])</span></b></p> </td> <td style=\"width:136.95pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Number\r   of vials needed = </span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">total\r   volume to be diluted divided by total volume per vial [10 mL/vial])</span></b></p> </td> </tr> <tr> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">60 kg</span></p> </td> <td style=\"width:126.45pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">72 mg</span></p> </td> <td style=\"width:148.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">14.4 mL</span></p> </td> <td style=\"width:136.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">1.44 vials</span></p> </td> </tr> <tr> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">80 kg</span></p> </td> <td style=\"width:126.45pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">96 mg</span></p> </td> <td style=\"width:148.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">19.2 mL</span></p> </td> <td style=\"width:136.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">1.92 vials</span></p> </td> </tr> <tr style=\"height:20.4pt\"> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:20.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">100 kg</span></p> </td> <td style=\"width:126.45pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:20.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">120 mg</span></p> </td> <td style=\"width:148.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:20.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">24 mL</span></p> </td> <td style=\"width:136.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:20.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">2.4 vials</span></p> </td> </tr> <tr> <td style=\"width:44.55pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">120 kg<sup>c</sup></span></p> </td> <td style=\"width:126.45pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">120 mg<sup>\r   d</sup></span></p> </td> <td style=\"width:148.8pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"198\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">24 mL</span></p> </td> <td style=\"width:136.95pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"183\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">2.4 vials</span></p> </td> </tr> </table>", "ID": "94c059ec-514f-4217-a1aa-fe7d1c95e862", "Styles": "margin-left:5.4pt;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "   Patient\r   weight (kg)   Total\r   dose =  patient\r   weight multiplied by recommended dose [1.2 mg/kga])   Total\r   volume to be dilutedb = total dose divided by reconstituted\r   vial concentration [5 mg/mL])   Number\r   of vials needed =  total\r   volume to be diluted divided by total volume per vial [10 mL/vial])     60 kg   72 mg   14.4 mL   1.44 vials     80 kg   96 mg   19.2 mL   1.92 vials     100 kg   120 mg   24 mL   2.4 vials     120 kgc   120 mg\r   d   24 mL   2.4 vials   ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">a.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">For a reduced dose, use\r 0.9 mg/kg for the calculation.</span></p>", "ID": "c98fdfd6-1248-43dc-bec1-0139580a913f", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "a.For a reduced dose, use\r 0.9 mg/kg for the calculation.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">b.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">To be diluted in\r 150 mL of diluent and administered by intravenous infusion over\r 30 minutes every 2 weeks as combination therapy or every 3 weeks when a\r reduced dose of the monotherapy is required.</span></p>", "ID": "8f7fa708-042d-415c-b20a-c0ec2567e4ea", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "b.To be diluted in\r 150 mL of diluent and administered by intravenous infusion over\r 30 minutes every 2 weeks as combination therapy or every 3 weeks when a\r reduced dose of the monotherapy is required.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">c.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">If patient\u2019s\r weight is more than 100 kg, the dose calculation should use 100 kg.</span></p>", "ID": "c6a1e4e8-d866-41d1-bd7d-fc7ad849dec7", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "c.If patient\u2019s\r weight is more than 100 kg, the dose calculation should use 100 kg.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"Paragraph\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r margin-left:.25in;text-indent:-.25in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\">d.</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">The maximal recommended\r dose for combination therapy is 120 mg.</span></p>", "ID": "dd6cc90e-616b-4e2a-8846-305e2e840909", "Styles": "margin-top:0in;margin-right:0in;margin-bottom:0in;\r\nmargin-left:.25in;text-indent:-.25in;page-break-after:avoid", "Classes": "['Paragraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "d.The maximal recommended\r dose for combination therapy is 120 mg.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "b2d743d6-ac18-4296-912c-52ff9f5e9b00", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Disposal</span></u></p>", "ID": "b421d57f-ce6b-4c70-9f5a-221ad808ec62", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Disposal", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "c693dc85-72fe-460b-834e-d8e5bf25f4f3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">ADCETRIS is for single use only. </span></p>", "ID": "6df8e250-c0ed-47b4-ab78-e595c89fcc7a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "ADCETRIS is for single use only. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Any unused product or waste material should\r be disposed of in accordance with local requirements.</span></p>", "ID": "6c57b09b-9c43-47ec-a078-ec649642aac8", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Any unused product or waste material should\r be disposed of in accordance with local requirements.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "75f5d7d3-b7ca-4094-aece-638f75ed8e6d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "65ef1827-b437-4156-92d9-7e912f0d91ae", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h1 align=\"left\" style=\"text-align:left;page-break-after:avoid\"><span lang=\"EN-GB\">7.   MARKETING\r AUTHORISATION HOLDER</span></h1>", "ID": "03ce199d-ada2-4894-885d-7aae6fe824c6", "Styles": "text-align:left;page-break-after:avoid", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "7.   MARKETING\r AUTHORISATION HOLDER", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "bbd32eac-56a8-4272-8fea-d1c4d6074849", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Takeda\r Pharma A/S</span></p>", "ID": "cdf958fb-c2d3-4eef-b421-6dab6be10051", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Takeda\r Pharma A/S", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DA\">Dybendal Alle 10</span></p>", "ID": "0b6e15a1-98a5-4e6e-9b48-a88753978ceb", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Dybendal Alle 10", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DA\">2630 Taastrup</span></p>", "ID": "105f628f-f5d5-4f54-a098-ccd29e7635cc", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "2630 Taastrup", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DA\">Denmark </span></p>", "ID": "400f753c-740c-4cc5-a279-df99dbb9c16a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Denmark ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "4e1198bd-42ff-48a5-a38c-2bf5ad1e4b6e", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "c23dc65d-c358-4753-8210-861946f7a7d2", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h1 align=\"left\" style=\"text-align:left;page-break-after:avoid\"><span lang=\"DA\">8.   MARKETING\r AUTHORISATION NUMBER </span></h1>", "ID": "a7568174-7191-4ba9-9276-14713c746f72", "Styles": "text-align:left;page-break-after:avoid", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "8.   MARKETING\r AUTHORISATION NUMBER ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "aa71bf40-fb6b-4153-82a6-cc1a28ff9188", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DA\">EU/1/12/794/001</span></p>", "ID": "ca00094b-fbfb-4858-9f20-2b6ab8c97396", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "EU/1/12/794/001", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "77438cf6-7751-41e7-a406-2be463f5b1df", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "cdd4e0a6-be42-4279-a4f6-9aff7e99a6d0", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h1 align=\"left\" style=\"margin-left:17.85pt;text-align:left;text-indent:-17.85pt;\r page-break-after:avoid\"><span lang=\"EN-GB\">9.   DATE OF FIRST\r AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></h1>", "ID": "218b3a61-39b5-44e3-8e94-488d9bffc42b", "Styles": "margin-left:17.85pt;text-align:left;text-indent:-17.85pt;\r\npage-break-after:avoid", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "9.   DATE OF FIRST\r AUTHORISATION/RENEWAL OF THE AUTHORISATION", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "9acd6657-3f08-4b42-9dc1-15e451533c1c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of first authorisation: 25 October\r 2012</span></p>", "ID": "85f6a123-9bde-4c77-b584-23ae5e1ea75d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Date of first authorisation: 25 October\r 2012", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of latest renewal: 19 September 2019</span></p>", "ID": "a63ac7ff-f0ee-49ac-bb6b-37f459338316", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Date of latest renewal: 19 September 2019", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "1cda6448-0077-4cbb-a07c-38dabd62cec9", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "934ba375-5895-4943-b45c-9f92b3dab540", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h1 align=\"left\" style=\"text-align:left;page-break-after:avoid\"><span lang=\"EN-GB\">10. DATE\r OF REVISION OF THE TEXT</span></h1>", "ID": "985c9741-cf39-4d8b-9ce0-0504b368bf9e", "Styles": "text-align:left;page-break-after:avoid", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "10. DATE\r OF REVISION OF THE TEXT", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "810bf930-2300-426b-9594-80e118abffd5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "7846becd-30ac-414d-ac22-966a49dbed01", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Detailed information on this medicinal\r product is available on the website of the European Medicines Agency <a href=\"http://www.ema.europa.eu/\">http://www.ema.europa.eu</a></span></p>", "ID": "6d3aa07f-98d8-4cd3-a761-632f3d8ed12c", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Detailed information on this medicinal\r product is available on the website of the European Medicines Agency http://www.ema.europa.eu", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"/> </span>", "ID": "ad79963a-bc60-40b6-9d99-5fa6560813c4", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\r\ncolor:black", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": " ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "a48fe057-e7a8-4f4f-9723-de819cdb30d0", "Styles": "page-break-before:always", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "ad79963a-bc60-40b6-9d99-5fa6560813c4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "95afd2a2-d7ed-4883-8809-309b9e6e94be", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "e4cb710c-f007-434a-b2bc-c390e0fcc7a5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "d44f4096-b78d-4eee-8806-00c6a167dc67", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "355af7f3-7c45-4ef1-b5f9-d35057b4038e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "fe3ec1df-16e6-4ade-b429-c716fd6b6f3a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "e9319b26-657f-4e9f-8052-218d489dbe91", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "fffcf584-3024-4d10-8867-05742f984ae7", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "8ed111bf-144e-4fd1-ba73-f5ae4ac79619", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "367569c0-314d-4601-b9db-78ebe38dec2b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "70c9b79d-c9f9-4539-b980-703332ad8c18", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "92f2f829-06ac-40c0-9555-1241001a73cb", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "83d2e6be-f8b2-4054-b5f3-2960040ade60", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "cae42922-9d4f-48ac-b314-eafc72e9b35b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "b961ddf4-edde-45f1-aea9-3b2e81009f93", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "09bcb60b-afa7-447b-a82b-6e399f2120f2", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "feab56ca-51df-4561-bee3-29bcb049d37d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "26ffffe1-1e46-45cd-ac36-d98b5762cf4c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "8d01418f-dce7-4f7b-b39e-21b5d65ad274", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "87e23704-db0f-4f15-89e3-2a60da20e020", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "7f124fb3-482b-4178-b813-1e0f8e023232", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "f1159f6c-5b97-41b7-92d5-ccccf6f4fc84", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "f581ee9f-6e1f-4db8-a53c-c39a6f29d9ba", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "54cb1cde-b844-44c3-b0f3-fe49bf760737", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif;text-transform:uppercase'>Annex\r II</span></p>", "ID": "77250b8b-7c91-47c0-b835-69e0f745e202", "Styles": "margin:0in;text-align:center", "Classes": "['No-numheading3Agency']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Annex\r II", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "ead44891-1b83-4854-bb7f-c14999219dc4", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">A.      MANUFACTURERS OF THE BIOLOGICAL\r ACTIVE SUBSTANCE AND <span style=\"text-transform:uppercase\">manufacturerS\r responsible for batch release </span></span></b></p>", "ID": "7bb6352e-f761-439e-bad4-8e783480d908", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "A.      MANUFACTURERS OF THE BIOLOGICAL\r ACTIVE SUBSTANCE AND manufacturerS\r responsible for batch release ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "eed3f043-07c8-4f8d-bcaf-6784bfaecb8a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">B.      Conditions\r or restrictions regarding supply and use</span></b></p>", "ID": "3b7c0653-73b4-41d9-a9ad-4520f83b79f1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "B.      Conditions\r or restrictions regarding supply and use", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "efc6b1c7-52c7-49ee-8e7a-01b28f303f67", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">C.      Other\r conditions and requirements of the marketing authorisation</span></b></p>", "ID": "fc76c5ac-d271-4da8-92d4-257b1510407c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "C.      Other\r conditions and requirements of the marketing authorisation", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "ffcc3fbd-20bf-41b8-b878-27f9b5648956", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">D.      CONDITIONS\r OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL\r PRODUCT</span></b></p>", "ID": "4f68bf3c-6c22-4860-aebf-fa6132db062a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "D.      CONDITIONS\r OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL\r PRODUCT", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "ddbb3606-ef07-4854-9c55-ccbff3c38efa", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">E.      SPECIFIC\r OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL\r MARKETING AUTHORISATION</span></b></p>", "ID": "930d2f12-9ccc-47c4-b383-bcc08504fa98", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "E.      SPECIFIC\r OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL\r MARKETING AUTHORISATION", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "4106bab4-7c74-4d79-ae4d-992a9faf0cdc", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"NormalAgency\"></p>", "ID": "7261b106-1c3c-47b7-8062-44fe7769159a", "Styles": "None", "Classes": "['NormalAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"NormalAgency\"></p>", "ID": "723a2764-6952-4845-a9de-3e9d07e41f0a", "Styles": "None", "Classes": "['NormalAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TitleB\" style=\"page-break-before:always\"><span lang=\"EN-GB\">A.      MANUFACTURERS\r OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH\r RELEASE</span></p>", "ID": "cae8ebf3-36e9-4e66-ab1e-004531ff1e43", "Styles": "page-break-before:always", "Classes": "['TitleB']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "A.      MANUFACTURERS\r OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH\r RELEASE", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p>", "ID": "1217f691-e899-48f2-85ec-4cab2e6ce305", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['BodytextAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Name and address of the manufacturers of\r the biological active substance </span></u></p>", "ID": "407a2bcb-3225-4b0d-81e4-ea19207e4351", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Name and address of the manufacturers of\r the biological active substance ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "dc1b7ca4-ba3f-4d36-beba-d8a2ee305453", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Piramal Healthcare UK Ltd.</span></p>", "ID": "eaba529e-f005-482d-930d-afc69d99366b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Piramal Healthcare UK Ltd.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Earls Road, Grangemouth</span></p>", "ID": "9519a7a2-9e55-41fd-b323-f96564ec91fc", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Earls Road, Grangemouth", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Stirlingshire, Scotland FK3 8XG</span></p>", "ID": "c718d750-785a-45d7-b707-9e5cd0901b2d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Stirlingshire, Scotland FK3 8XG", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">United Kingdom</span></p>", "ID": "24bb1d69-26b7-49b2-8106-4f36df8a364d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "United Kingdom", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "21496871-17df-4829-b4a0-e4724bc2aa1f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lonza AG</span></p>", "ID": "3da01743-4861-4642-b772-06f0dcdc9afd", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Lonza AG", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lonzastrasse</span></p>", "ID": "ad8bdf53-15a7-46f2-8b28-bd649f9b863c", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Lonzastrasse", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">3930 Visp</span></p>", "ID": "7fd29108-d636-46a1-a107-f6334ab3730d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "3930 Visp", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Switzerland</span></p>", "ID": "88389937-37ce-4fa6-b8ec-a93f415f99b2", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Switzerland", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p>", "ID": "62aa1c4d-ab53-45ca-9ac3-bdf71b776fb2", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['BodytextAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><u><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Name\r and address of the manufacturers responsible for batch release</span></u></p>", "ID": "d977344f-3ae7-4286-9656-734f4cb59bc6", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['BodytextAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L3", "Text": "Name\r and address of the manufacturers responsible for batch release", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p>", "ID": "0514e3a9-6964-4736-8fa2-e1d347947889", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['BodytextAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Takeda Austria GmbH</span></p>", "ID": "fafcc32d-3b43-4dc6-b31f-03b097276fea", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Takeda Austria GmbH", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">St. Peter\u2011Stra\u03b2e 25</span></p>", "ID": "5d0ceb3e-2735-4716-b096-67b604e659cd", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "St. Peter\u2011Stra\u03b2e 25", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\">A\u20114020 Linz</span></p>", "ID": "1bc9b9ce-738d-4529-8bda-91fdd6161e93", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "A\u20114020 Linz", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\">Austria</span></p>", "ID": "95dc37f1-7469-415b-b18f-0a6fe3d527ae", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Austria", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "951a22b6-5c88-49fa-bd74-722e11ba73b7", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\">Delpharm Novara S.r.l.</span></p>", "ID": "104d9e0c-f998-424d-bc61-6a1fdc6546b7", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Delpharm Novara S.r.l.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\">Via Crosa, 86</p>", "ID": "2570af21-16c1-4c57-912a-1ca466baafe3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Via Crosa, 86", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">28065 Cerano (NO)</span></p>", "ID": "3d6f2464-7742-47d4-938a-18516f3a5e30", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "28065 Cerano (NO)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Italy</span></p>", "ID": "431186b0-6616-4d65-856c-869504edf746", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Italy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "f219b44d-1065-4d72-a497-93848a746c85", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The printed package leaflet of the\r medicinal product must state the name and address of the manufacturer\r responsible for the release of the concerned batch.</span></p>", "ID": "9a2e4734-5ffe-4007-af07-aec432477bf1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The printed package leaflet of the\r medicinal product must state the name and address of the manufacturer\r responsible for the release of the concerned batch.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"NormalAgency\"></p>", "ID": "3189f586-b5bd-4190-b986-166b5823293f", "Styles": "None", "Classes": "['NormalAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"NormalAgency\"></p>", "ID": "690ceaa9-c11a-4cbb-8a5c-c40fc9afc0d1", "Styles": "None", "Classes": "['NormalAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TitleB\"><span lang=\"EN-GB\">B.      CONDITIONS OR\r RESTRICTIONS REGARDING SUPPLY AND USE</span></p>", "ID": "5d434703-be24-4e5d-824b-3088246a976b", "Styles": "None", "Classes": "['TitleB']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "B.      CONDITIONS OR\r RESTRICTIONS REGARDING SUPPLY AND USE", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p>", "ID": "28453632-57f3-4125-ba01-41afd22984da", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['BodytextAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Medicinal\r product subject to restricted medical prescription (see Annex I: Summary of\r Product Characteristics, section 4.2).</span></p>", "ID": "17e2c912-75cb-4d02-b796-2631c921ea76", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['BodytextAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Medicinal\r product subject to restricted medical prescription (see Annex I: Summary of\r Product Characteristics, section 4.2).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p>", "ID": "6de60302-91d6-4c29-891f-143c8e6702d3", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['BodytextAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"NormalAgency\"></p>", "ID": "b81f8798-9f83-47ed-abd8-567163bee59c", "Styles": "None", "Classes": "['NormalAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TitleB\"><span lang=\"EN-GB\">C.      OTHER\r CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>", "ID": "f0812b66-503c-4cde-8488-a5c628fcae1f", "Styles": "None", "Classes": "['TitleB']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "C.      OTHER\r CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p>", "ID": "3e2c4c2f-3251-4a1b-b754-4cbbec98c4d2", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['BodytextAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><b><span lang=\"EN-GB\">Periodic safety update reports (PSURs) </span></b></p>", "ID": "2f38648b-db9f-43b2-9e87-072fa179e07c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;\r\ntext-autospace:none", "Classes": "['MsoListParagraphCxSpFirst']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "\u00b7Periodic safety update reports (PSURs) ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpLast\" style=\"text-autospace:none\"></p>", "ID": "a52d43d6-0416-42f7-8e19-5c122d401011", "Styles": "text-autospace:none", "Classes": "['MsoListParagraphCxSpLast']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The\r requirements for submission of PSURs for this medicinal product are set out in\r the list of Union reference dates (EURD list) provided for under Article\r 107c(7) of Directive 2001/83/EC and any subsequent updates published on the\r European medicines web-portal.</span></p>", "ID": "b4a58146-3d6b-4913-bd69-72a67ba39dc6", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The\r requirements for submission of PSURs for this medicinal product are set out in\r the list of Union reference dates (EURD list) provided for under Article\r 107c(7) of Directive 2001/83/EC and any subsequent updates published on the\r European medicines web-portal.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "cd4bf40d-550f-49b7-8fa9-a3f418848c37", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "bb87b5f9-8fb8-4d6e-8758-3f7eca3b60a3", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TitleB\"><span lang=\"EN-GB\">D.      CONDITIONS OR\r RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p>", "ID": "dd5f012c-32f1-4770-9d88-03b542dca955", "Styles": "None", "Classes": "['TitleB']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "D.      CONDITIONS OR\r RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"DraftingNotesAgency\" style=\"margin-bottom:0in;line-height:normal\"></p>", "ID": "983afe8d-05fb-42e5-9b9a-9160839d9b49", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['DraftingNotesAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><b><span lang=\"EN-GB\">Risk management plan (RMP)</span></b></p>", "ID": "30ba0285-7885-47bc-8cbc-3215079ee9b8", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;\r\ntext-autospace:none", "Classes": "['MsoListParagraph']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "\u00b7Risk management plan (RMP)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p>", "ID": "b39bfef7-83fe-4056-ad58-83bbfd32bc6a", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['BodytextAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>The marketing\r authorisation holder (MAH) shall perform the required pharmacovigilance\r activities and interventions detailed in the agreed RMP presented in Module\r 1.8.2 of the marketing authorisation and any agreed subsequent updates of the\r RMP.</span></p>", "ID": "a525f84f-0528-42f1-9118-1420491c7e8b", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['BodytextAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The marketing\r authorisation holder (MAH) shall perform the required pharmacovigilance\r activities and interventions detailed in the agreed RMP presented in Module\r 1.8.2 of the marketing authorisation and any agreed subsequent updates of the\r RMP.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"NormalAgency\"></p>", "ID": "ab6ad99a-bd99-474d-ae6c-5b87fe037a8f", "Styles": "None", "Classes": "['NormalAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"NormalAgency\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>An updated RMP\r should be submitted:</span></p>", "ID": "f0d870b0-27f1-47c5-8667-fb2f3bdd1bec", "Styles": "page-break-after:avoid", "Classes": "['NormalAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "An updated RMP\r should be submitted:", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"NormalAgency\" style=\"margin-left:27.5pt;text-indent:-27.5pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>At\r the request of the European Medicines Agency; </span></p>", "ID": "ed9417ff-c4d4-4dae-a672-37c6a70582e5", "Styles": "margin-left:27.5pt;text-indent:-27.5pt", "Classes": "['NormalAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "\u00b7At\r the request of the European Medicines Agency; ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"NormalAgency\" style=\"margin-left:27.5pt;text-indent:-27.5pt\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Whenever\r the risk management system is modified, especially as the result of new\r information being received that may lead to a significant change to the benefit/risk\r profile or as the result of an important (pharmacovigilance or risk\r minimisation) milestone being reached</span></p>", "ID": "c9f55406-d58f-415c-b88e-9668ed0a6b1e", "Styles": "margin-left:27.5pt;text-indent:-27.5pt", "Classes": "['NormalAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "\u00b7Whenever\r the risk management system is modified, especially as the result of new\r information being received that may lead to a significant change to the benefit/risk\r profile or as the result of an important (pharmacovigilance or risk\r minimisation) milestone being reached", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"NormalAgency\"></p>", "ID": "60b4f82f-ef0e-4181-bc36-5c8579a33862", "Styles": "None", "Classes": "['NormalAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p>", "ID": "c91d9505-fa6a-48a4-9217-3f9838872250", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['BodytextAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TitleB\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">E.      <span style=\"text-transform:uppercase\">Specific Obligation to complete\r post-authorisation measures for the conditional marketing authorisation</span> </span></p>", "ID": "4825533c-78ff-4dc5-9ba4-30422b8c762b", "Styles": "page-break-after:avoid", "Classes": "['TitleB']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "E.      Specific Obligation to complete\r post-authorisation measures for the conditional marketing authorisation ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"NormalAgency\" style=\"page-break-after:avoid\"></p>", "ID": "13613757-3117-4952-94e7-b6b21457187e", "Styles": "page-break-after:avoid", "Classes": "['NormalAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>This\r being a conditional marketing authorisation and pursuant to Article 14a(4) of\r Regulation (EC) No<span style=\"layout-grid-mode:line\"> 726/2004, the MAH shall\r complete, within the stated timeframe, the following measure:</span></span></p>", "ID": "5cc3a98b-c78e-45a0-ac21-170f657ab1d0", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['BodytextAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "This\r being a conditional marketing authorisation and pursuant to Article 14a(4) of\r Regulation (EC) No 726/2004, the MAH shall\r complete, within the stated timeframe, the following measure:", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p>", "ID": "000b452b-38cd-4455-a060-7bc36f4b1ec7", "Styles": "margin-bottom:0in;line-height:normal", "Classes": "['BodytextAgency']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"98%\"> <thead> <tr> <td style=\"width:55.38%;border:solid windowtext 1.0pt;\r    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"55%\"> <p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><b><span lang=\"EN-GB\">Description</span></b></p> </td> <td style=\"width:44.62%;border:solid windowtext 1.0pt;\r    border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"44%\"> <p class=\"MsoNormal\" style=\"margin-right:-.05pt\"><b><span lang=\"EN-GB\">Due date</span></b></p> </td> </tr> </thead> <tr> <td style=\"width:55.38%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"55%\"> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r   color:black'>To perform a single\u2011arm study in a similar patient\r   population as the sALCL population investigating response rate, duration of\r   response, rate of (second) ASCT and data in subpopulations (including but not\r   necessarily restricted to ALK status and age) based on a CHMP agreed protocol\r   (Study C25006).</span></p> </td> <td style=\"width:44.62%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"44%\"> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"></p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r   color:black'>Final Study Report by: Q4 2021</span></p> </td> </tr> </table>", "ID": "53a4cecc-d8cd-415b-882a-bf69f9c96104", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "    Description   Due date      To perform a single\u2011arm study in a similar patient\r   population as the sALCL population investigating response rate, duration of\r   response, rate of (second) ASCT and data in subpopulations (including but not\r   necessarily restricted to ALK status and age) based on a CHMP agreed protocol\r   (Study C25006).    Final Study Report by: Q4 2021   ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "d3f1b214-fffd-4f9e-89ea-9034079555d7", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"/> </span>", "ID": "7c4b322f-eaef-4231-b649-96beb5f130ce", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\r\ncolor:black", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": " ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "07ad6a73-2590-42b8-9b19-1c281b547997", "Styles": "page-break-before:always", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "7c4b322f-eaef-4231-b649-96beb5f130ce"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "fb653892-3d63-49f5-8e09-c6042250c878", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "7143666f-7d19-42e3-8d83-5f63c266e14a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "7faaeead-bc21-40f4-a24e-fe3a015d3851", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "96a09d5a-a007-41ba-a7b3-3666b3d9de73", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "285d1eac-a9f1-47b8-92f6-78fd5f4255db", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "17e0a2e0-fae0-4b0e-95ad-dcb33f575373", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "5fd50f75-396a-4846-9274-dab4388f7dc1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "733791e6-c1e4-48ab-b950-f43cfc2f5300", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "175f1c1d-fe06-4c96-b02b-6cfc0628ecfa", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "15935a58-6482-4f7d-b68c-5b5c9ccfb7a5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "64fd38c1-babf-43be-9ff2-eedc94fe799e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "a80eb63d-9331-4437-95d7-f57009dd68c1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "f16ac145-a77f-4275-8ae3-3620aa68b750", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "36d7e435-d9bd-4858-b3b9-291d11919ee1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "f3e5a19e-502f-4e00-90e7-1c5e3de4fd17", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "6de2e6b0-e298-4e68-9650-d40ef712fb97", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "38b938b5-0372-4f11-90a3-31c576868577", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "88370344-0523-4193-a4df-cd21d7a6a562", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "71ba6334-3c77-4463-92a3-8047ad11e66d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "b2cf4a81-b226-4506-bea8-f42180cbb078", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "24d6da50-e804-4030-b9cc-8cd6bee4bf26", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "a97a8d2f-e4cd-4850-91de-4e72861e6473", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "2a2ff08f-52ee-4de7-8d67-4a39835637fd", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h1><span lang=\"EN-GB\">ANNEX III</span></h1>", "ID": "53afb564-324a-4ac1-991c-46ad23ab6f8b", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "ANNEX III", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "a1c411a1-1b80-4d90-92ea-011720e836ef", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<h1><span lang=\"EN-GB\">LABELLING AND PACKAGE LEAFLET</span></h1>", "ID": "61ed3410-d921-44a0-84cc-9fc62a1dafd9", "Styles": "None", "Classes": "None", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "LABELLING AND PACKAGE LEAFLET", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"/> </span>", "ID": "3c3bc02e-d622-490c-9b16-f7c2c9012d1d", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\r\ncolor:black", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": " ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "0a7ceb4c-400c-4eba-9fb8-58fce879409a", "Styles": "page-break-before:always", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "3c3bc02e-d622-490c-9b16-f7c2c9012d1d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "12a407ff-d5e2-4084-8758-158ef44810a3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "ebab8937-f5f5-4a9b-ae8f-6a3a5f72fdf4", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "de350a1e-206f-4438-a513-4d95c57c121e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "62ab3f56-8f7e-4a6d-8c07-9d62d911ec7a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "d78ae942-f917-4084-9d9a-68dd4e32427e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "b3243be1-ed63-4931-a8c5-0325fa1f423e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "f145d8ee-5d28-4182-b252-f645c8c12783", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "a36a644d-a59f-47a2-b725-bd8846be0454", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "263abc95-0228-4a58-8ba5-f4e46ac2ce6a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "97382122-d761-4a25-a660-e1cd8002d6d5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "c05804b0-9409-4dd1-834d-e4be92f0d02e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "fd4acc56-b143-4d04-86b9-413d7bea16b7", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "150b1181-5073-4a27-9179-57c02f853ec0", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "c357afcb-5342-448b-aa5a-143ccab88907", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "b8be8615-869c-4bb3-a3c1-6103c61a771a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "bcbbbb2b-8295-4175-8d39-4a8551b87bba", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "1dc07d24-9d2c-4880-bba6-c5470d7b62cf", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "c53aeab2-cb1e-40d2-a7fa-4cf09c23814e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "16e80c86-77a5-49ab-a379-3ae58de59a6d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "fdc209bf-37ac-483d-ba80-c682a6501024", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "e168a959-e54c-477b-b55b-39d0750f4ac9", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "aa08e860-3aef-4e7b-8a7e-ef6e97e80181", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "c1bc1dd3-ccdf-46b5-b32d-d4b9cf9542f1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TitleA\"><span lang=\"EN-GB\">A. LABELLING</span></p>", "ID": "1a00b968-a36a-458d-856f-ce79086a91a9", "Styles": "None", "Classes": "['TitleA']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "A. LABELLING", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"/> </span>", "ID": "084bbc2d-9327-421e-af28-3067ac4bc82d", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\r\ncolor:black", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": " ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "846d85b6-661b-49f4-baea-c5c96a7d9e83", "Styles": "page-break-before:always", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "084bbc2d-9327-421e-af28-3067ac4bc82d"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "37d7fd79-e1c4-477f-bd5e-b75b6022a177", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS\r TO APPEAR ON THE OUTER PACKAGING</span></b></p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"></p> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">OUTER\r CARTON</span></b></p> </div>", "ID": "ddfa7e40-5236-451d-93ba-b684346924ed", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "    ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS\r TO APPEAR ON THE OUTER PACKAGING</span></b></p>", "ID": "bfd6ba79-e98e-4cb5-8662-fcd74d71217a", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "PARTICULARS\r TO APPEAR ON THE OUTER PACKAGING", "ParentId": "ddfa7e40-5236-451d-93ba-b684346924ed"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"></p>", "ID": "dea893fc-8748-4254-931d-79aaee7d0c5a", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "ddfa7e40-5236-451d-93ba-b684346924ed"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">OUTER\r CARTON</span></b></p>", "ID": "bce9e0e2-1534-4fbf-a6bc-63cb37e85334", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "OUTER\r CARTON", "ParentId": "ddfa7e40-5236-451d-93ba-b684346924ed"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "b78ee5af-d298-4b24-a7aa-7eec97b822ad", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "d478871a-62ad-405d-a26f-0961f4d1f03c", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME\r OF THE MEDICINAL PRODUCT</span></b></p> </div>", "ID": "b806eda1-416a-4927-8681-ced664060edb", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME\r OF THE MEDICINAL PRODUCT</span></b></p>", "ID": "1285388c-8aa9-47b1-8173-66c32b66443f", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "1.       NAME\r OF THE MEDICINAL PRODUCT", "ParentId": "b806eda1-416a-4927-8681-ced664060edb"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "bec8f90b-b879-4506-a0d8-231266e8fdf8", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">ADCETRIS 50 mg powder for concentrate\r for solution for infusion</span></p>", "ID": "802da470-cfa7-4a77-b4af-f4f800994b85", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "ADCETRIS 50 mg powder for concentrate\r for solution for infusion", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">brentuximab vedotin</span></p>", "ID": "5f2ec619-8341-4512-b81f-57dcc36ce3a7", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "brentuximab vedotin", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "a1a3e2ab-3a03-44bf-96ab-728604a44a5e", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "cc2e2585-f807-4024-b32a-1aaed462d590", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       STATEMENT\r OF ACTIVE SUBSTANCE(S)</span></b></p> </div>", "ID": "b36fe840-ffab-45b0-ba2a-97a88a353caf", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       STATEMENT\r OF ACTIVE SUBSTANCE(S)</span></b></p>", "ID": "b8d0065d-25ac-4add-b77f-4fd16f538cac", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "2.       STATEMENT\r OF ACTIVE SUBSTANCE(S)", "ParentId": "b36fe840-ffab-45b0-ba2a-97a88a353caf"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "009bae62-e4a6-4191-ad4d-74b1da32806a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Each vial contains 50 mg of\r brentuximab vedotin</span></p>", "ID": "eff0895f-fd59-43d2-934a-e6344b44bbf9", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Each vial contains 50 mg of\r brentuximab vedotin", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "bf1f5e8b-8cee-4894-8626-077bd247e6fc", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">After reconstitution each vial contains\r 5 mg/ml of brentuximab vedotin</span></p>", "ID": "bee436f8-ec45-46c2-b080-fb08f6f0f746", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "After reconstitution each vial contains\r 5 mg/ml of brentuximab vedotin", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "90fc9b2f-e7ab-4db9-b5ca-6f7d48f9bd52", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "d80c6ef1-aaba-455d-9ee5-2424c1af17a1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       LIST\r OF EXCIPIENTS</span></b></p> </div>", "ID": "cb54b0f7-3aae-454d-b00c-52d40eb63098", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       LIST\r OF EXCIPIENTS</span></b></p>", "ID": "ec8a364c-70aa-4e75-95b0-aa8e8496ce2a", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "3.       LIST\r OF EXCIPIENTS", "ParentId": "cb54b0f7-3aae-454d-b00c-52d40eb63098"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "b5c96bf8-8097-4463-aaf2-9f7adbf61256", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Excipients: Ci</span><span lang=\"EN-GB\">tric\r acid monohydrate</span><span lang=\"EN-GB\">, s</span><span lang=\"EN-GB\">odium\r citrate dihydrate</span><span lang=\"EN-GB\">, </span><span lang=\"EN-GB\">\u03b1,\u03b1\u2011</span><span lang=\"EN-GB\">t</span><span lang=\"EN-GB\">rehalose dihydrate,</span><span lang=\"EN-GB\">\r p</span><span lang=\"EN-GB\">olysorbate 80</span></p>", "ID": "e1848d6b-37c3-4685-beb7-9f58bd7302ab", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Excipients: Citric\r acid monohydrate, sodium\r citrate dihydrate, \u03b1,\u03b1\u2011trehalose dihydrate,\r polysorbate 80", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">See package\r leaflet for further information</span></p>", "ID": "ec637c76-8ebb-455c-9238-1975f1668071", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "See package\r leaflet for further information", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "2e4054bc-30f6-456d-8dbc-a3d9e9f370fb", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "3d35a3c1-86c5-40d3-984f-a86aaecb92c3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL\r FORM AND CONTENTS</span></b></p> </div>", "ID": "6f878903-15c7-49b4-9cee-c69a55a39095", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL\r FORM AND CONTENTS</span></b></p>", "ID": "a0735117-9e23-4056-8458-2feddd8cd6d8", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "4.       PHARMACEUTICAL\r FORM AND CONTENTS", "ParentId": "6f878903-15c7-49b4-9cee-c69a55a39095"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "2ac38dd0-6883-47c4-b2bc-a0ed01986c6b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Powder for\r concentrate for solution for infusion</span></i></p>", "ID": "31f90803-cbc3-417c-a7d5-09873e822c19", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": null, "Text": "Powder for\r concentrate for solution for infusion", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">1 vial</span></p>", "ID": "cfb0166b-18a2-417b-a699-b239308bfe5f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "1 vial", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "d3dc8c20-76d1-4768-845f-6f5e97b0e2fd", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "9d3c7156-1960-4668-b813-908eba0d29a4", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       METHOD\r AND ROUTE(S) OF ADMINISTRATION</span></b></p> </div>", "ID": "d47b06ae-94d8-4c61-a9d7-1bc2bc270cfb", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       METHOD\r AND ROUTE(S) OF ADMINISTRATION</span></b></p>", "ID": "0f102038-51e4-439b-98ca-c64873f88e0b", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "5.       METHOD\r AND ROUTE(S) OF ADMINISTRATION", "ParentId": "d47b06ae-94d8-4c61-a9d7-1bc2bc270cfb"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "6838a9f6-d830-474d-85db-deea099344b2", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For intravenous use after reconstitution\r and dilution </span></p>", "ID": "e78fdfff-1079-4ff6-8257-c8bcf7e09ccd", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "For intravenous use after reconstitution\r and dilution ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Read the package leaflet</span></p>", "ID": "cf69c65b-594a-4f2b-b690-a42f40480f9f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Read the package leaflet", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "1a5614d8-df09-40b9-b598-7c0342f04b9d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "c02343a0-7e2d-4c1b-a39c-2db938f00f7f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">6.      SPECIAL\r WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN</span></b></p> </div>", "ID": "f599a2c8-3917-499a-bceb-a7a571476f95", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">6.      SPECIAL\r WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN</span></b></p>", "ID": "cc4f3745-3e34-433d-9caf-53a830b4a74a", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;border:none;\r\npadding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "6.      SPECIAL\r WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN", "ParentId": "f599a2c8-3917-499a-bceb-a7a571476f95"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "4943fe6f-b7c5-4bde-bedf-25c1a188a629", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children</span></p>", "ID": "18f1d719-c615-4b91-87c9-25304ddca9ae", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Keep out of the sight and reach of children", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "abae57c3-00c6-4c2a-9ac4-4127b776da22", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "edce7564-2120-49f0-8cc0-d2dd6b6d53d6", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">7.       OTHER\r SPECIAL WARNING(S), IF NECESSARY</span></b></p> </div>", "ID": "341b3c8c-4123-4aaf-a7e7-2f048fbaa7e4", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">7.       OTHER\r SPECIAL WARNING(S), IF NECESSARY</span></b></p>", "ID": "e1237b7d-996e-4a0c-80cf-9e76ff903572", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "7.       OTHER\r SPECIAL WARNING(S), IF NECESSARY", "ParentId": "341b3c8c-4123-4aaf-a7e7-2f048fbaa7e4"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "d3783390-14cb-41d9-a1d7-0e9536e0fdbb", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "146277ca-6ba2-42d3-943d-c3f0cf4a15cf", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">8.       EXPIRY\r DATE</span></b></p> </div>", "ID": "bbe9647d-fe20-4eb1-ae13-d6a51bc6d23e", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">8.       EXPIRY\r DATE</span></b></p>", "ID": "bc6a80e7-94c6-4303-9902-7a52d73d8f15", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "8.       EXPIRY\r DATE", "ParentId": "bbe9647d-fe20-4eb1-ae13-d6a51bc6d23e"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "2e18fc8a-ee5b-443e-b95f-78f6e6acac2b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>", "ID": "cbf27d06-2b5b-419d-b0c1-ea0b6b763efc", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "EXP", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "24a2453b-b16e-4967-a5dc-3ffdf7d50932", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "eac20728-cf55-430f-b664-66075cbfa3c3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"page-break-before:always;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS</span></b></p> </div>", "ID": "2f27bb38-3e95-4e78-97b4-05fe76e9297a", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-before:always;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS</span></b></p>", "ID": "cf593a39-244b-44d6-8d35-778048cfceb9", "Styles": "page-break-before:always;border:none;padding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "9.       SPECIAL STORAGE CONDITIONS", "ParentId": "2f27bb38-3e95-4e78-97b4-05fe76e9297a"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "a65d5db8-8370-4ed2-b572-6909eb21b1fd", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Store in a refrigerator </span></p>", "ID": "e45b7489-f324-4027-b8fb-8f40363b8830", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Store in a refrigerator ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not freeze</span></p>", "ID": "143c718c-7d7e-479b-8923-d1d126ee6b0e", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Do not freeze", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the vial in the outer carton in order\r to protect from light.</span></p>", "ID": "84abe285-41ca-4c20-ac5a-873fac3f57c8", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Keep the vial in the outer carton in order\r to protect from light.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "870fb54c-1158-4c2c-a27b-73a9e05342ab", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "86576451-0c21-4a75-9bcd-f57aeae05d51", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">10.    SPECIAL PRECAUTIONS FOR\r DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH\r MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p> </div>", "ID": "ba2b9aaa-ffc8-418f-bce9-2e67908c53e0", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">10.    SPECIAL PRECAUTIONS FOR\r DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH\r MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>", "ID": "d38944ce-1a19-4180-beef-db8e3aa18e49", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;border:none;\r\npadding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "10.    SPECIAL PRECAUTIONS FOR\r DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH\r MEDICINAL PRODUCTS, IF APPROPRIATE", "ParentId": "ba2b9aaa-ffc8-418f-bce9-2e67908c53e0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "43052f1e-3dc6-4550-9d55-17a69bd1bd96", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For single use only</span></p>", "ID": "8e7af4a1-bccb-486a-888a-3daf647951c7", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "For single use only", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "317dd78e-60a6-4e4d-94b7-9c43f474f566", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "3fae6239-038b-4d8b-915e-63f5bd239440", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">11.    NAME AND ADDRESS OF THE\r MARKETING AUTHORISATION HOLDER</span></b></p> </div>", "ID": "48252e00-d695-4511-885e-ae45fab91d19", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">11.    NAME AND ADDRESS OF THE\r MARKETING AUTHORISATION HOLDER</span></b></p>", "ID": "fd896cd6-5fec-4e82-955b-5f8624afdd5d", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;border:none;\r\npadding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "11.    NAME AND ADDRESS OF THE\r MARKETING AUTHORISATION HOLDER", "ParentId": "48252e00-d695-4511-885e-ae45fab91d19"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "5702f58f-e61e-4471-bc8b-afe2c8c0c0a3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\">Takeda Pharma A/S</span></p>", "ID": "20e3a479-2889-4f84-a58e-176f41e04965", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Takeda Pharma A/S", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\">Dybendal Alle 10</span></p>", "ID": "18929bb5-c27c-4d64-ab29-45cb1333495a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Dybendal Alle 10", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">2630 Taastrup</span></p>", "ID": "9c60547d-aade-4731-a356-ac71092134d8", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "2630 Taastrup", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Denmark </span></p>", "ID": "c19bdb27-6668-4aa8-947e-03733e6bf2a0", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Denmark ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "a1da5071-0766-4cf0-bb09-b6ba97532744", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "fb2a38e4-5c42-4754-8f71-f1ab22e56601", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">12.    MARKETING AUTHORISATION\r NUMBER(S) </span></b></p> </div>", "ID": "29c4c275-cd72-41df-8844-085cf7be46c2", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">12.    MARKETING AUTHORISATION\r NUMBER(S) </span></b></p>", "ID": "2f4a99d1-7576-4ff7-ad3e-f8d7d23a2b6a", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;border:none;\r\npadding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "12.    MARKETING AUTHORISATION\r NUMBER(S) ", "ParentId": "29c4c275-cd72-41df-8844-085cf7be46c2"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "49b51e1d-f63d-4b12-b07f-f34d7c327536", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/12/794/001</span></p>", "ID": "2c5ce92e-e666-4e0e-ae15-4b8ab659796f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "EU/1/12/794/001", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "719cb16a-4b3a-43e2-855a-dd21af85ce16", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "92163b5c-3832-4555-94b6-0eedf00cb4b2", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">13.    BATCH NUMBER</span></b></p> </div>", "ID": "1c0cd31a-fc4e-42a3-870a-13359dd92086", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">13.    BATCH NUMBER</span></b></p>", "ID": "ef24c1f6-3108-4750-9db6-abf957c3790d", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;border:none;\r\npadding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "13.    BATCH NUMBER", "ParentId": "1c0cd31a-fc4e-42a3-870a-13359dd92086"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "9fba32e6-2db0-4106-8ed8-8d1025f1420b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lot</span></p>", "ID": "3926f10c-a732-4f86-89b1-ca2cc29c23d4", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Lot", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "13f1ee68-79d6-4609-b899-d27506fb6a28", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "66fa53a5-011a-4000-b75f-ea78c1c6c8d6", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">14.    GENERAL CLASSIFICATION\r FOR SUPPLY</span></b></p> </div>", "ID": "bd2861f2-f7ee-4ca3-b8f9-0d6f66ded6eb", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">14.    GENERAL CLASSIFICATION\r FOR SUPPLY</span></b></p>", "ID": "f0d3625f-a80e-4a0c-8327-30e4f63ef34a", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;border:none;\r\npadding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "14.    GENERAL CLASSIFICATION\r FOR SUPPLY", "ParentId": "bd2861f2-f7ee-4ca3-b8f9-0d6f66ded6eb"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "1f9e31d5-f0f7-4517-b8bd-ab93fe5b5d66", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicinal product subject to medical\r prescription</span></p>", "ID": "a975b96a-6048-4a47-9ce9-7c7cfb92d006", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Medicinal product subject to medical\r prescription", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "294d0c52-2db1-43f4-b633-9a3fec1789ba", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "718d8769-19cf-414e-8158-f337ca56cfe9", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">15.    INSTRUCTIONS ON USE</span></b></p> </div>", "ID": "0cfd3f82-32a9-46d7-a570-6bf25920016c", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">15.    INSTRUCTIONS ON USE</span></b></p>", "ID": "a0f389b0-7523-47f7-9e83-37d99e72c30b", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;border:none;\r\npadding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "15.    INSTRUCTIONS ON USE", "ParentId": "0cfd3f82-32a9-46d7-a570-6bf25920016c"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "9f2b7c98-7189-429d-a059-a905c406e44d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "a0f55f4f-b98c-4d26-9d45-8a98347e8179", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">16.    INFORMATION IN BRAILLE</span></b></p> </div>", "ID": "faa9c054-cd4a-42c4-a86d-bb068c13793c", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">16.    INFORMATION IN BRAILLE</span></b></p>", "ID": "65531cc4-8dcb-45f2-b0c2-44b3b0e58cf3", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;border:none;\r\npadding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "16.    INFORMATION IN BRAILLE", "ParentId": "faa9c054-cd4a-42c4-a86d-bb068c13793c"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "a1bfb50e-4b0d-4a3a-9d8a-70a4279e29f8", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\" style=\"background:silver\">Justification\r for not including Braille accepted</span></i></p>", "ID": "b53780fd-3a96-4dab-8b85-e6eb8946198b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": true, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": null, "Text": "Justification\r for not including Braille accepted", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "6450d395-32d2-4520-b636-4b8e84884280", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "ec4279d6-cea1-43f1-ae03-8f492260076a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.       UNIQUE\r IDENTIFIER \u2013 2D BARCODE</span></b></p> </div>", "ID": "cf76151c-d25a-4aad-bb44-185d9c94e5f8", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.       UNIQUE\r IDENTIFIER \u2013 2D BARCODE</span></b></p>", "ID": "c410107e-bc61-4bb9-90cb-ef543edf3cb5", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "17.       UNIQUE\r IDENTIFIER \u2013 2D BARCODE", "ParentId": "cf76151c-d25a-4aad-bb44-185d9c94e5f8"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "28808588-afb9-44ec-8666-02acc58d828e", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">2D barcode\r carrying the unique identifier included.</span></p>", "ID": "a5680e64-e8fc-400a-86d2-64a8a03965f2", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "2D barcode\r carrying the unique identifier included.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "389431ee-763e-4fed-b34d-6751f7eac2f4", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "a8e5a2c6-428f-4949-bd75-6881677ea08f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.       UNIQUE\r IDENTIFIER - HUMAN READABLE DATA</span></b></p> </div>", "ID": "a9234fdf-6d74-4024-8bf5-e3a5c664f873", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.       UNIQUE\r IDENTIFIER - HUMAN READABLE DATA</span></b></p>", "ID": "87c635ce-f84e-4a94-8cc2-ae0d9cfe515f", "Styles": "border:none;padding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "18.       UNIQUE\r IDENTIFIER - HUMAN READABLE DATA", "ParentId": "a9234fdf-6d74-4024-8bf5-e3a5c664f873"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "f82df8f5-bb47-4688-a1a4-9b30202ed8b1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">PC: </span></p>", "ID": "d1649033-4e4c-4927-a1fe-c3292a216d4a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "PC: ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">SN: </span></p>", "ID": "bfb39a72-b82d-4384-8398-31ae92f18bb6", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "SN: ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">NN:</span></p>", "ID": "d58828fe-e89b-4ba1-adf3-a88755f58033", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "NN:", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"/> </span>", "ID": "501edebf-2039-4872-a621-9e6a114defa3", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\r\ncolor:black", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": " ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "3b034675-096b-4324-a07c-6bab6017ed8c", "Styles": "page-break-before:always", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "501edebf-2039-4872-a621-9e6a114defa3"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "ea52fa47-1c59-4838-8a0a-36e6189e0426", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON SMALL\r IMMEDIATE PACKAGING UNITS</span></b></p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"></p> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">VIAL LABEL</span></b></p> </div>", "ID": "dbed4ca4-9aff-4cf8-bd80-ef86d635a39b", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "    ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON SMALL\r IMMEDIATE PACKAGING UNITS</span></b></p>", "ID": "3a77286a-40fd-4503-8af4-c3ae1139bc6d", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;border:none;\r\npadding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "MINIMUM PARTICULARS TO APPEAR ON SMALL\r IMMEDIATE PACKAGING UNITS", "ParentId": "dbed4ca4-9aff-4cf8-bd80-ef86d635a39b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"></p>", "ID": "5fc5a35d-d4af-4562-929d-ce4ac6c912cf", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;border:none;\r\npadding:0in", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "dbed4ca4-9aff-4cf8-bd80-ef86d635a39b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">VIAL LABEL</span></b></p>", "ID": "2a9f41c7-68b0-4888-ba42-193514b72cd3", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;border:none;\r\npadding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "VIAL LABEL", "ParentId": "dbed4ca4-9aff-4cf8-bd80-ef86d635a39b"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "a267d61c-207d-4d53-a523-d6e0be375974", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "f68b959e-8070-4db7-a468-ae00d7d2a09b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">1.      NAME OF THE\r MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p> </div>", "ID": "b9f1e762-e76f-43cb-a96b-57cb6ebcc6c1", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">1.      NAME OF THE\r MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>", "ID": "39e950ee-ef8f-44e3-acf5-dba0b10ab477", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;border:none;\r\npadding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "1.      NAME OF THE\r MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION", "ParentId": "b9f1e762-e76f-43cb-a96b-57cb6ebcc6c1"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "7594b881-1eac-4e26-a4f6-eb49e2652004", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">ADCETRIS 50 mg powder for concentrate\r for solution for infusion</span></p>", "ID": "710c274b-4417-4761-a769-3f6ff32c6622", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "ADCETRIS 50 mg powder for concentrate\r for solution for infusion", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">brentuximab vedotin</span></p>", "ID": "24ad3a54-e8b5-4140-ba91-8336505a2c2b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "brentuximab vedotin", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">IV use</span></p>", "ID": "3d4437d2-51bc-4a9a-a3a5-2752171c33eb", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "IV use", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "a9e42598-23d3-44b2-86f8-89c331c81397", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "82a5f7b2-4e5e-4ba9-89fc-b30202642f8d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">2.      METHOD OF\r ADMINISTRATION</span></b></p> </div>", "ID": "c8c76841-4085-4a62-9b42-fb0002e819d5", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">2.      METHOD OF\r ADMINISTRATION</span></b></p>", "ID": "084a0863-f7c8-4dce-9dfc-254f6750ce2c", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;border:none;\r\npadding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "2.      METHOD OF\r ADMINISTRATION", "ParentId": "c8c76841-4085-4a62-9b42-fb0002e819d5"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "76f3f99e-bc45-4771-b9d9-665b5c7b55c4", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For intravenous use after reconstitution\r and dilution </span></p>", "ID": "9e396283-14fe-4f80-a9e6-5456ddd0711e", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "For intravenous use after reconstitution\r and dilution ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "b6c0425f-ff99-4bd6-896a-5d147d561277", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "ec831f58-e511-41e9-84ec-7cfde05177fb", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">3.      EXPIRY DATE</span></b></p> </div>", "ID": "472ac3e7-b9ee-4c33-ab74-940b84ab5da7", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">3.      EXPIRY DATE</span></b></p>", "ID": "570180ad-ca31-43f6-b337-0763fcf50dd2", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;border:none;\r\npadding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "3.      EXPIRY DATE", "ParentId": "472ac3e7-b9ee-4c33-ab74-940b84ab5da7"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "c294c3d7-824c-481b-9656-444565864b5a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>", "ID": "ec039439-af42-49ae-a9a4-2250aede6aae", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "EXP", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "0ad195a2-1fc6-479a-bdc8-f2a4c478870d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "d4330ec5-8a09-4738-ab8b-2a1d592632c4", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">4.      BATCH NUMBER</span></b></p> </div>", "ID": "10080858-3b6e-471f-a977-5037c8a0e9e5", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">4.      BATCH NUMBER</span></b></p>", "ID": "b36094e9-32d0-40c0-9e96-8861f01e7c14", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;border:none;\r\npadding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "4.      BATCH NUMBER", "ParentId": "10080858-3b6e-471f-a977-5037c8a0e9e5"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "0277dab8-9872-464e-a28b-7c878cc97fc8", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lot</span></p>", "ID": "c5fb44a3-056c-4ec5-a681-ddb4e3bbdfc5", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Lot", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "50083c59-ae9c-4802-918b-c33c490f10f9", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "3c711a4f-10fa-40d1-b305-75773fcbb8d0", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">5.      CONTENTS BY\r WEIGHT, BY VOLUME OR BY UNIT</span></b></p> </div>", "ID": "2957da72-08b9-4ad8-bdf7-9ab6e976aa3f", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">5.      CONTENTS BY\r WEIGHT, BY VOLUME OR BY UNIT</span></b></p>", "ID": "2cb4b4d7-01ea-4152-af9c-c79b04f5a0eb", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;border:none;\r\npadding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "5.      CONTENTS BY\r WEIGHT, BY VOLUME OR BY UNIT", "ParentId": "2957da72-08b9-4ad8-bdf7-9ab6e976aa3f"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "776f7521-36a2-4698-9d72-803e3b2a3b5a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">50 mg</span></p>", "ID": "e2948e0b-2ff4-4d81-9e64-7cc62bf0f18f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "50 mg", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "6e56cb28-f286-4f4c-9450-2c04df684256", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "3fb530cb-7719-4a5e-a119-fbc6e2568917", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">6.      OTHER</span></b></p> </div>", "ID": "53554b96-d779-4682-8b26-c5648c256afd", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": true, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "  ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;border:none;\r padding:0in\"><b><span lang=\"EN-GB\">6.      OTHER</span></b></p>", "ID": "b876eed9-4c3e-4731-9d21-400eb7bbcfca", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;border:none;\r\npadding:0in", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "6.      OTHER", "ParentId": "53554b96-d779-4682-8b26-c5648c256afd"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "41895774-c17b-4eea-8cd6-1c1845d9a223", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "391f4054-5831-4b90-bc43-1e61e7609169", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"/> </span>", "ID": "59200830-b13d-40bb-bd3a-5f5f2ae9ba72", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\r\ncolor:black", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": " ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "ae25d387-998a-4e68-945d-ca5f599a6fef", "Styles": "page-break-before:always", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "59200830-b13d-40bb-bd3a-5f5f2ae9ba72"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "a4b28b9c-f5e1-4a6a-9248-4e9530275f79", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "fd733a42-389e-4ad1-ba8e-05c2218452e5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "c25f49f6-f82b-4ec7-b83c-5b24e90ce075", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "f4dcae80-7f4a-4ad1-873c-45c3bfb0eeb8", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "6fdf68a9-2f32-4e3d-9216-532c3ade771a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "41b02f82-1ae3-4030-90ba-ca27101c8ae6", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "0a6d58fd-efe4-4b5e-9c6f-bfd0d827ce98", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "36cc0816-364d-4824-b629-8ca2df08b429", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "38a22315-06c7-4db0-9d43-c959512402b9", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "140ebb03-7774-4730-b45e-6db6c57558a9", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "b9ef77da-ee96-4f31-8727-a9b93ada5cd3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "e00dccef-4c66-4101-89f1-27aac7c2e905", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "47632167-7faf-4ba8-a4bf-c377fb251227", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "4ec6bd6b-13f6-4c89-87d9-1495b634b1f0", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "3040d200-fea4-45e5-98a0-87271256ef4e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "893c299a-1267-43eb-abd5-4c811afc19de", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "8ba8cb60-11d1-4369-96a2-2b5ca604c3f2", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "3d2c2325-c8df-43a3-b023-f4893a4198b2", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "54f4fb0d-f79b-417e-963f-578f13a92648", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "98698f64-a11b-4822-ab06-36263a63bdd5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "46d04999-cb69-4259-8b17-f3a29a62438c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "8d8cedbc-2fb0-4a2b-97f2-a4feac497ab5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "004a924f-21d8-470f-9c0d-0683685c73db", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"TitleA\"><span lang=\"EN-GB\">B. PACKAGE LEAFLET</span></p>", "ID": "5fd699dd-295a-4d9e-bcd9-532ab653f954", "Styles": "None", "Classes": "['TitleA']", "Bold": true, "Italics": false, "Uppercased": true, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": null, "Text": "B. PACKAGE LEAFLET", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"/> </span></b>", "ID": "3c6fdb4f-0a78-461a-b927-577924efe89f", "Styles": "None", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"/> </span>", "ID": "8c08af92-d30d-4f1a-891e-01fddba31ef7", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\r\ncolor:black", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": " ", "ParentId": "3c6fdb4f-0a78-461a-b927-577924efe89f"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "ec0fc560-227a-47ad-ab86-21f770d11176", "Styles": "page-break-before:always", "Classes": "None", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "8c08af92-d30d-4f1a-891e-01fddba31ef7"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "bd68c386-3ed6-431e-b01c-1531da3d052c", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Package\r leaflet: Information for the patient</span></b></p>", "ID": "8ecd7b9f-bd1b-4da4-94e2-d879d05915b0", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Package\r leaflet: Information for the patient", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"></p>", "ID": "6a6846c2-714e-4636-aebf-4cd8ba5a36fa", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Adcetris\r 50 mg powder for concentrate for solution for infusion</span></b></p>", "ID": "167e432a-247d-4fc4-b605-a5d8b5fd1093", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Adcetris\r 50 mg powder for concentrate for solution for infusion", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">brentuximab\r vedotin</span></b></p>", "ID": "b9186ed5-47cf-4bb1-8269-146c7d15dbb7", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "brentuximab\r vedotin", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "2ea4637c-938a-4be5-909a-6d42b4f8193a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\"><img alt=\"Description: Description: Description: BT_1000x858px\" border=\"0\" height=\"18\" id=\"Picture 2\" src=\"Adcetris-ema-combined-h-2455-en-IB-SOB-C2500_files/image009.gif\" width=\"21\"/></span><span lang=\"EN-GB\">This medicine is subject to additional monitoring. This will allow\r quick identification of new safety information. You can help by reporting any\r side effects you may get. See the end of section 4 for how to report side\r effects.</span></p>", "ID": "db21bea5-86b9-43cd-9ca3-e30a9af5f471", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "This medicine is subject to additional monitoring. This will allow\r quick identification of new safety information. You can help by reporting any\r side effects you may get. See the end of section 4 for how to report side\r effects.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "7e7a391f-0f5e-4394-bb4d-8c6d954a13c7", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Read all\r of this leaflet carefully before you start using this medicine because it\r contains important information for you.</span></b></p>", "ID": "0470ec3b-9e2e-488b-91ea-79a62145216a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Read all\r of this leaflet carefully before you start using this medicine because it\r contains important information for you.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r page-break-after:avoid\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it\r again.</span></p>", "ID": "e6d008dd-7495-4527-a5c4-da4712e8ea40", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;\r\npage-break-after:avoid", "Classes": "['MsoListParagraphCxSpFirst']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-Keep this leaflet. You may need to read it\r again.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">If you have any further questions, ask your\r doctor.</span></p>", "ID": "8a96d7d7-6826-427a-8300-f152d5eb4b84", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt;page-break-after:avoid", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-If you have any further questions, ask your\r doctor.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">If you get any side effects, talk to your\r doctor. This includes any possible side effects not listed</span></p>", "ID": "2b44d446-26ff-40ea-891c-bb5333c32462", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt;page-break-after:avoid", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-If you get any side effects, talk to your\r doctor. This includes any possible side effects not listed", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:0in;page-break-after:avoid\"><span lang=\"EN-GB\">           in this\r leaflet. See section 4.</span></p>", "ID": "b1462a61-ff2e-4ffb-b65b-e68f36ac0948", "Styles": "margin-left:0in;page-break-after:avoid", "Classes": "['MsoListParagraphCxSpLast']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "           in this\r leaflet. See section 4.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "80baa033-bb13-4dc5-afed-5c78acd69bb7", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What is\r in this leaflet</span></b></p>", "ID": "91d4b355-00f3-4b55-a91c-195073881d31", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "What is\r in this leaflet", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "c772101e-999f-447e-ad57-2f3f864af40e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">1.       What Adcetris is and what it\r is used for</span></p>", "ID": "618e2f8e-3d23-4ed5-9074-e0d05e95fbe4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "1.       What Adcetris is and what it\r is used for", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">2.       What you need to know before\r you are given Adcetris</span></p>", "ID": "d2ffde4b-1765-45f8-b462-461ad1fab115", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "2.       What you need to know before\r you are given Adcetris", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">3.       How Adcetris will be given</span></p>", "ID": "1a5fa38f-9936-4002-b341-9b24465700c3", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "3.       How Adcetris will be given", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">4.       Possible side effects</span></p>", "ID": "41b4d32f-3f23-4617-9b94-65a59430855b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "4.       Possible side effects", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">5.       How to store Adcetris</span></p>", "ID": "59d38b2a-e57c-41f1-8920-a095af3c0749", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "5.       How to store Adcetris", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">6.       Contents of the pack and\r other information</span></p>", "ID": "17b61865-5e61-4eb1-9b03-ce4894ca4590", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "6.       Contents of the pack and\r other information", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "25dfd772-1fd5-460e-bb45-a7df17873fe5", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "27b5d864-bf01-475c-99b2-e9c51610573d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoHeading7\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">1.       What\r Adcetris is and what it is used for</span></p>", "ID": "c147947f-d60b-499c-8bfc-40ce527d1492", "Styles": "page-break-after:avoid", "Classes": "['MsoHeading7']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "1.       What\r Adcetris is and what it is used for", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "50dbef69-7ff3-4190-b2d4-8e4235d10094", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Adcetris contains the active substance <b>brentuximab\r vedotin</b>, an anti-cancer agent, which is made up of a monoclonal antibody\r linked to a substance intended to kill cancer cells. This substance is\r delivered to cancer cells by the monoclonal antibody. A monoclonal antibody is\r a protein which recognises certain cancer cells. </span></p>", "ID": "e9e44d64-be07-46d1-9f7b-9d9c8bfab3f1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Adcetris contains the active substance brentuximab\r vedotin, an anti-cancer agent, which is made up of a monoclonal antibody\r linked to a substance intended to kill cancer cells. This substance is\r delivered to cancer cells by the monoclonal antibody. A monoclonal antibody is\r a protein which recognises certain cancer cells. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "a44a793c-58b7-4bad-816f-6bc6be537b62", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hodgkin lymphoma, systemic anaplastic large\r cell lymphoma and cutaneous T\u2011cell lymphoma are types of cancer of the\r white blood cells.</span></p>", "ID": "dca2570d-3426-4d4e-89a0-a4767e20d475", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Hodgkin lymphoma, systemic anaplastic large\r cell lymphoma and cutaneous T\u2011cell lymphoma are types of cancer of the\r white blood cells.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "b7c45f8a-89e1-48c3-a8dc-842647438d7f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Classical Hodgkin lymphoma expresses\r specific proteins on the cell surface that are different from non-classical\r Hodgkin lymphoma. </span></p>", "ID": "65eebb8d-6512-4d86-9b2a-e27f4fcf6a4d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Classical Hodgkin lymphoma expresses\r specific proteins on the cell surface that are different from non-classical\r Hodgkin lymphoma. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "3de336e7-44f5-4fb8-95a7-761ee7cc729b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Adcetris is used to treat patients with advanced\r classical Hodgkin lymphoma who have not had treatment before.</span><span lang=\"EN-GB\"> Adcetris will be given to you together with doxorubicin,\r vinblastine and dacarbazine which are other chemotherapy medicines used to\r treat Hodgkin lymphoma. </span></p>", "ID": "4f32840e-ac5d-4ee4-838c-076babf86d80", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Adcetris is used to treat patients with advanced\r classical Hodgkin lymphoma who have not had treatment before. Adcetris will be given to you together with doxorubicin,\r vinblastine and dacarbazine which are other chemotherapy medicines used to\r treat Hodgkin lymphoma. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "fbb54be6-01cd-4a87-a0c1-3f3c73fef9d2", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Adcetris is used alone to lower the\r likelihood of classical Hodgkin lymphoma coming back after an autologous stem\r cell transplant in patients with certain risk factors.</span></p>", "ID": "6c33eaf0-f318-4709-b2c5-ea826b7291e5", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Adcetris is used alone to lower the\r likelihood of classical Hodgkin lymphoma coming back after an autologous stem\r cell transplant in patients with certain risk factors.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "8c8084c1-5ad6-4eb0-a9d0-800e0066dd08", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Adcetris is also used alone to treat\r classical Hodgkin lymphoma that has:</span></p>", "ID": "324dcc59-25da-431a-ac9b-a3f4ad0d8fe0", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Adcetris is also used alone to treat\r classical Hodgkin lymphoma that has:", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">come back after or not responded to an infusion\r of your own healthy stem cells into your body (autologous stem cell\r transplant), or</span></p>", "ID": "3e2f72d4-3544-4166-8b76-dbeb75c056d7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpFirst']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-come back after or not responded to an infusion\r of your own healthy stem cells into your body (autologous stem cell\r transplant), or", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">come back after or never responded to at least\r two previous therapies, and where you cannot receive additional combination\r anti-cancer treatments or have an autologous stem cell transplant.</span></p>", "ID": "adf91b67-8fba-4ae4-96f3-487ca3edc45a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpLast']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-come back after or never responded to at least\r two previous therapies, and where you cannot receive additional combination\r anti-cancer treatments or have an autologous stem cell transplant.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "efa12c51-9406-4ab8-b0a8-a36e379330f0", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Systemic anaplastic large cell lymphoma is\r a type of non\u2011Hodgkin lymphoma found in your lymph nodes and/or\r throughout other parts of your body.</span></p>", "ID": "02346e13-5b48-43d5-8686-55b2ff2cb30b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Systemic anaplastic large cell lymphoma is\r a type of non\u2011Hodgkin lymphoma found in your lymph nodes and/or\r throughout other parts of your body.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "3574689a-e48b-49d5-989a-bf5725a6db27", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Adcetris is used to treat patients with systemic\r anaplastic large cell lymphoma who have not had treatment before.</span><span lang=\"EN-GB\"> Adcetris will be given to you together with </span><span lang=\"EN-GB\">cyclophosphamide, doxorubicin and prednisone</span><span lang=\"EN-GB\">\r which are other chemotherapy medicines used to treat these conditions.</span></p>", "ID": "af0d4c41-7faf-4568-b7de-debd8c4a5c24", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Adcetris is used to treat patients with systemic\r anaplastic large cell lymphoma who have not had treatment before. Adcetris will be given to you together with cyclophosphamide, doxorubicin and prednisone\r which are other chemotherapy medicines used to treat these conditions.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "6076197c-2aa7-426b-b59a-e616f174efbb", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Adcetris is also used to treat systemic\r anaplastic large cell lymphoma that has:</span></p>", "ID": "70f8603b-4476-40b6-8da5-2132e890d1c1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Adcetris is also used to treat systemic\r anaplastic large cell lymphoma that has:", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">not responded to other types of anti-cancer\r treatments, or </span></p>", "ID": "accebcdd-c87a-4544-8233-32bbe000009b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpFirst']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-not responded to other types of anti-cancer\r treatments, or ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">come back after previous anti-cancer treatment.</span></p>", "ID": "fded6aab-3476-4392-865e-c891ad508fce", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpLast']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-come back after previous anti-cancer treatment.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "dbfc9578-d8a1-488f-ac33-844d8f3ec80b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span style=\"color:windowtext\">Cutaneous T\u2011cell\r lymphoma is a cancer of a certain type of white blood cell called a \u2018T\u2011cell\u2019\r that mainly affects the skin. </span><span lang=\"EN-GB\" style=\"color:windowtext\">Adcetris\r is used to treat cutaneous T\u2011cell lymphoma where a specific type of\r protein is present on the cells\u2019 surface.</span></p>", "ID": "2a56a5dc-7b42-48b5-92e6-48b069685237", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Cutaneous T\u2011cell\r lymphoma is a cancer of a certain type of white blood cell called a \u2018T\u2011cell\u2019\r that mainly affects the skin. Adcetris\r is used to treat cutaneous T\u2011cell lymphoma where a specific type of\r protein is present on the cells\u2019 surface.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "3da4ff54-9dc8-41bb-ad2e-41531e890c67", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Adcetris is used\r to treat cutaneous T\u2011cell lymphoma in patients who have previously\r received at least one anti-cancer medicine that travels through the\r bloodstream.</span></p>", "ID": "ed467822-8422-4a5a-a9c6-0df02232e41c", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Adcetris is used\r to treat cutaneous T\u2011cell lymphoma in patients who have previously\r received at least one anti-cancer medicine that travels through the\r bloodstream.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "52f7809c-29a0-4631-8493-0f7fcf6bc5a4", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:17.65pt\"></p>", "ID": "ffe96446-7b25-4082-bde2-1eddec23fe31", "Styles": "margin-right:17.65pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoHeading7\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">2.       What\r you need to know before you are given Adcetris</span></p>", "ID": "0eabedf6-cd34-4824-8dc5-115eb54053d3", "Styles": "page-break-after:avoid", "Classes": "['MsoHeading7']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "2.       What\r you need to know before you are given Adcetris", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "98cc0b7b-bcd0-4038-bdd4-c8d697add399", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Do NOT\r use Adcetris if you</span></b></p>", "ID": "deac5695-ac4f-4d53-8fc2-416218577398", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Do NOT\r use Adcetris if you", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "e40cb468-5936-4190-b308-bc7b36a79b83", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">are allergic to brentuximab vedotin or any of\r the other ingredients of this medicine (listed in section 6). </span></p>", "ID": "c15615e8-5317-435e-aa6e-515884ae02e7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpFirst']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-are allergic to brentuximab vedotin or any of\r the other ingredients of this medicine (listed in section 6). ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">are currently using bleomycin, an anti-cancer\r agent. </span></p>", "ID": "39385863-2666-4a40-a01f-e15301bbb4f4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpLast']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-are currently using bleomycin, an anti-cancer\r agent. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "eae87445-c2b8-4b7c-9500-4ecdc0eefbab", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Warnings\r and precautions</span></b></p>", "ID": "26031a09-2c9e-4869-b598-3628a49cc3e8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Warnings\r and precautions", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "7df8beff-c079-4332-8009-c42bc74272d9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">When you\r first receive this medicine and during the course of treatment, tell your\r doctor if you:</span></p>", "ID": "72b88aa3-d4af-4b3e-af24-608ce176da77", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "When you\r first receive this medicine and during the course of treatment, tell your\r doctor if you:", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">have confusion, trouble thinking, memory loss,\r blurred or loss of vision, decreased strength, decreased control or sensation\r in one arm or leg, a change in the way of walking, or loss of balance, as these\r may be symptoms of a serious and potentially fatal brain condition known as\r progressive multifocal leukoencephalopathy (PML). If you have these symptoms\r prior to treatment with this medicine, tell your doctor immediately about any\r changes in these symptoms. You should also inform your partner or caregivers\r about your treatment, since they may notice symptoms that you are not aware of</span></p>", "ID": "3a4fb912-08a4-4a6f-8708-a26138ca4fd7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-have confusion, trouble thinking, memory loss,\r blurred or loss of vision, decreased strength, decreased control or sensation\r in one arm or leg, a change in the way of walking, or loss of balance, as these\r may be symptoms of a serious and potentially fatal brain condition known as\r progressive multifocal leukoencephalopathy (PML). If you have these symptoms\r prior to treatment with this medicine, tell your doctor immediately about any\r changes in these symptoms. You should also inform your partner or caregivers\r about your treatment, since they may notice symptoms that you are not aware of", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">have severe and persistent stomach pain, with or\r without nausea and vomiting, as these may be symptoms of a serious and\r potentially fatal condition known as pancreatitis (inflammation of the\r pancreas)</span></p>", "ID": "a2851612-4cde-4abe-813b-8e69ae23a07a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-have severe and persistent stomach pain, with or\r without nausea and vomiting, as these may be symptoms of a serious and\r potentially fatal condition known as pancreatitis (inflammation of the\r pancreas)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">have new or worsening shortness of breath or\r cough as these may be symptoms of a serious and potentially fatal lung\r complication (pulmonary toxicity)</span></p>", "ID": "b8391210-1985-4bf5-8dac-eb2aac2569a8", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-have new or worsening shortness of breath or\r cough as these may be symptoms of a serious and potentially fatal lung\r complication (pulmonary toxicity)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">are taking, or have previously taken, medicines\r which may affect your immune system, such as chemotherapy or immunosuppressive\r agents </span></p>", "ID": "6af3ddcd-cc32-482b-8cb3-827b0b5ce9b9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-are taking, or have previously taken, medicines\r which may affect your immune system, such as chemotherapy or immunosuppressive\r agents ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">have, or think you have, an infection. Some\r infections may be serious and can be due to viruses, bacteria, or other causes\r that may be life-threatening</span></p>", "ID": "c3eebef9-58b4-448f-b8da-3d79d6f8edb3", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-have, or think you have, an infection. Some\r infections may be serious and can be due to viruses, bacteria, or other causes\r that may be life-threatening", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">experience a whistling sound during breathing\r (wheezing)/difficulty breathing, hives, itching, or swelling (signs of an\r infusion reaction). For more detailed information, see \u201cInfusion reactions\u201d\r in section 4</span></p>", "ID": "8bafae34-e9e1-432b-9d9f-52917fd7b534", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-experience a whistling sound during breathing\r (wheezing)/difficulty breathing, hives, itching, or swelling (signs of an\r infusion reaction). For more detailed information, see \u201cInfusion reactions\u201d\r in section 4", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">have any problems with a change in the\r sensitivity of the skin, especially in the hands or feet, such as numbness,\r tingling, a burning sensation, pain, discomfort or weakness (neuropathy)</span></p>", "ID": "f5b268e8-02da-40c6-9233-545824b42443", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-have any problems with a change in the\r sensitivity of the skin, especially in the hands or feet, such as numbness,\r tingling, a burning sensation, pain, discomfort or weakness (neuropathy)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">have headaches, feel tired, experience dizziness,\r look pale (anaemia), or have unusual bleeding or bruising under the skin,\r longer than usual bleeding after your blood has been drawn, or bleeding from\r your gums (thrombocytopenia) </span></p>", "ID": "e2ec2796-6327-490b-a152-34bcc56c035f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-have headaches, feel tired, experience dizziness,\r look pale (anaemia), or have unusual bleeding or bruising under the skin,\r longer than usual bleeding after your blood has been drawn, or bleeding from\r your gums (thrombocytopenia) ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">develop chills or shivering, or feel warm; you\r should take your temperature as you may have a fever. A fever with a low white\r blood cell count may be a sign of serious infection </span></p>", "ID": "9b148b95-ef77-4883-908f-2fcb3c5a10a9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-develop chills or shivering, or feel warm; you\r should take your temperature as you may have a fever. A fever with a low white\r blood cell count may be a sign of serious infection ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">experience dizziness, decreased urination,\r confusion, vomiting, nausea, swelling, shortness of breath, or heart rhythm\r disturbances (this may be a potentially life-threatening complication known as\r tumour lysis syndrome)</span></p>", "ID": "e1596d85-cdd2-47d4-8b5c-5eb496788a13", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-experience dizziness, decreased urination,\r confusion, vomiting, nausea, swelling, shortness of breath, or heart rhythm\r disturbances (this may be a potentially life-threatening complication known as\r tumour lysis syndrome)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">experience flu-like symptoms followed by a\r painful red or purplish rash that spreads and blisters including extensive\r detachment of the skin that may be life-threatening (this may be a serious skin\r reaction known as Stevens-Johnson syndrome and toxic epidermal necrolysis)</span></p>", "ID": "a20c92a3-0645-4782-aebc-44ab20990f31", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-experience flu-like symptoms followed by a\r painful red or purplish rash that spreads and blisters including extensive\r detachment of the skin that may be life-threatening (this may be a serious skin\r reaction known as Stevens-Johnson syndrome and toxic epidermal necrolysis)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">have new or worsening stomach pain, nausea,\r vomiting, constipation as these may be symptoms of a serious and potentially\r fatal stomach or intestinal complication (gastrointestinal complications)</span></p>", "ID": "508cd4a0-9fa8-47a5-b65d-8a0a1a93c0df", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-have new or worsening stomach pain, nausea,\r vomiting, constipation as these may be symptoms of a serious and potentially\r fatal stomach or intestinal complication (gastrointestinal complications)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">have abnormal liver test results as this may be\r related to a serious and potentially fatal liver injury (hepatotoxicity). Liver\r disease and other medical conditions that may have been present before you\r start taking Adcetris and some medications that you are currently taking might\r increase the risk of liver injury</span></p>", "ID": "7aa9eec7-3dc6-48e6-9163-1cb24a59332e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-have abnormal liver test results as this may be\r related to a serious and potentially fatal liver injury (hepatotoxicity). Liver\r disease and other medical conditions that may have been present before you\r start taking Adcetris and some medications that you are currently taking might\r increase the risk of liver injury", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">feel tired, have frequent urination, increased\r thirst, increased appetite with unintended weight loss, or irritability\r (hyperglycaemia)</span></p>", "ID": "58b9ecfc-c0bc-4124-8e7b-8704e6eaa75a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-feel tired, have frequent urination, increased\r thirst, increased appetite with unintended weight loss, or irritability\r (hyperglycaemia)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">have kidney or liver problems</span></p>", "ID": "e5328a75-c8e4-4093-a623-371d3051ba07", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-have kidney or liver problems", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-left:31.5pt\"></p>", "ID": "baa4792c-957a-4446-a277-c226e267d571", "Styles": "margin-left:31.5pt", "Classes": "['MsoListParagraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Your doctor will perform regular blood\r tests to make sure that it is safe for you to receive this medicine.</span></p>", "ID": "976b9817-4299-48e2-97cd-d9e78310e206", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Your doctor will perform regular blood\r tests to make sure that it is safe for you to receive this medicine.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "5cbbad77-6142-4289-8e0c-de1f5ad2a71a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Other\r medicines and Adcetris</span></b></p>", "ID": "5997ea8e-e407-432f-8489-d3b3fb36e188", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Other\r medicines and Adcetris", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "a57c05e0-e88d-4dab-8427-11b28d2535a1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor if you are taking any\r other medicines, if you have taken any recently, or if you start taking new ones.\r This includes herbal medicines and other medicines you can obtain without a\r prescription. </span></p>", "ID": "c2ff5631-22da-4b07-889e-18681326e3d7", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Tell your doctor if you are taking any\r other medicines, if you have taken any recently, or if you start taking new ones.\r This includes herbal medicines and other medicines you can obtain without a\r prescription. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "7f30177c-70d1-44c9-a2ee-9e233374f7dc", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Pregnancy,\r breast\u2011feeding and fertility</span></b></p>", "ID": "f84e6c28-5ef8-4e35-b58c-5f62b40c68ef", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Pregnancy,\r breast\u2011feeding and fertility", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "feef0a37-4602-45b2-9358-048146222e5d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">You and your partner must use two methods\r of effective contraception during your treatment with this medicine. Women must\r continue using contraception for 6 months following the last dose of\r Adcetris.</span></p>", "ID": "2894a4da-fd43-4adc-b080-11f3906566f0", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "You and your partner must use two methods\r of effective contraception during your treatment with this medicine. Women must\r continue using contraception for 6 months following the last dose of\r Adcetris.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "f94dd810-2b6a-4e15-962a-2ede64569b4f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">You should not use this medicine if you are\r pregnant unless you and your doctor decide that the benefit to you outweighs\r the potential risk to the unborn baby. </span></p>", "ID": "b89f954d-a760-4c42-96bd-84573ac1e492", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "You should not use this medicine if you are\r pregnant unless you and your doctor decide that the benefit to you outweighs\r the potential risk to the unborn baby. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "67148e53-1a4e-4ab1-84b3-38ecc4b2026e", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">It is important to tell your doctor before\r and during treatment if you are pregnant, think you may be pregnant, or are\r planning to get pregnant.</span></p>", "ID": "1c4c4a25-c020-45c7-8ade-321c01694fe8", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "It is important to tell your doctor before\r and during treatment if you are pregnant, think you may be pregnant, or are\r planning to get pregnant.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "8685a4fd-1dac-45b4-be64-82d63e061041", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you are breast\u2011feeding, you should\r discuss with your doctor whether you should receive this medicine.</span></p>", "ID": "8d2bbfa3-f134-4832-a9be-716b809a68b9", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "If you are breast\u2011feeding, you should\r discuss with your doctor whether you should receive this medicine.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "9c903f22-8155-4cc3-8c1b-993a2aa71979", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Men being treated with this medicine are\r advised to have sperm samples frozen and stored before treatment. Men are\r advised not to father a child during treatment with this medicine and for up to\r 6 months following the last dose of this medicine. </span></p>", "ID": "5fbb51f3-9ddf-49e7-b647-6b3859139368", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Men being treated with this medicine are\r advised to have sperm samples frozen and stored before treatment. Men are\r advised not to father a child during treatment with this medicine and for up to\r 6 months following the last dose of this medicine. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "f6fe050c-a104-450a-9ab2-ea40695800dc", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Driving\r and using machines</span></b></p>", "ID": "a44568c6-3279-4824-b33d-e33ae777614e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Driving\r and using machines", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "e524e374-6f59-42ca-88d5-da7428d40316", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Your treatment may influence your ability\r to drive or operate machines. If you feel unwell during treatment then do not\r drive or operate machines.</span></p>", "ID": "bc2cd574-9ebb-4304-90c3-accb910502d8", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Your treatment may influence your ability\r to drive or operate machines. If you feel unwell during treatment then do not\r drive or operate machines.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "1de88a9b-d645-4c6b-9f28-f112c22e9bec", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Adcetris\r contains sodium</span></b></p>", "ID": "f1535846-0a6f-4ceb-925b-4165ddbd3ce4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Adcetris\r contains sodium", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "b988e08e-fa1f-4560-b618-f8655ded6819", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">This medicine\r contains 13.2 mg sodium (main component of cooking/table salt) in each\r vial. This is equivalent to 0.7% of the recommended maximum daily dietary\r intake of sodium for an adult</span><span lang=\"EN-GB\">.</span></p>", "ID": "7f413ff4-1d00-45f0-a2c4-7f97fd3392f5", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "This medicine\r contains 13.2 mg sodium (main component of cooking/table salt) in each\r vial. This is equivalent to 0.7% of the recommended maximum daily dietary\r intake of sodium for an adult.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "21b6a731-eec5-4fd5-a407-b3965782dca1", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "87c529f1-91cf-439e-ba16-997b2098c080", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoHeading7\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3.       How\r Adcetris will be given</span></p>", "ID": "490fa8ad-8159-42bf-9630-70c8202dd420", "Styles": "page-break-after:avoid", "Classes": "['MsoHeading7']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "3.       How\r Adcetris will be given", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "9cd94df5-5544-4d39-9cf5-d0332cfb7983", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you have any questions on the use of\r this medicine, ask the doctor or nurse who is giving you the infusion. </span></p>", "ID": "8bab0d72-74b4-4b31-bcac-bd075f492db2", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "If you have any questions on the use of\r this medicine, ask the doctor or nurse who is giving you the infusion. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "5cc8ef9d-d4cf-4d23-9996-833a559e5cd7", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Dose and\r frequency</span></b></p>", "ID": "47707987-efad-4e8a-9379-3e6112808d20", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Dose and\r frequency", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "ff2294f1-8f06-4eed-8a93-91f35f0c0dcd", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The dose of\r this medicine depends on your body weight. </span></p>", "ID": "a86688d4-035a-48b8-9d22-c28539416260", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The dose of\r this medicine depends on your body weight. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "46fe22ed-6c87-43fb-9fe3-6ca5746332ca", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">The usual dose of Adcetris given in combination\r with </span><span lang=\"EN-GB\">doxorubicin, vinblastine and dacarbazine</span><span lang=\"EN-GB\"> is </span><span lang=\"EN-GB\">1.2 mg/kg given every 2 weeks\r for 6 months. </span></p>", "ID": "d444b8fa-84d4-4439-9125-34b06bf49a58", "Styles": "margin-left:.25in;text-indent:-.25in;text-autospace:\r\nnone", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "\u00b7The usual dose of Adcetris given in combination\r with doxorubicin, vinblastine and dacarbazine is 1.2 mg/kg given every 2 weeks\r for 6 months. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;text-autospace:none\"></p>", "ID": "0674ec6f-4bb4-495a-91db-6f118db0fd2f", "Styles": "margin-left:.25in;text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">The usual dose of Adcetris given in combination\r with cyclophosphamide, doxorubicin and prednisone is </span><span lang=\"EN-GB\">1.8 mg/kg\r given every 3 weeks for approximately 4\u20116 months.</span></p>", "ID": "dc40cc74-bd2b-43eb-ac26-16eb21f2b8b2", "Styles": "margin-left:.25in;text-indent:-.25in;text-autospace:\r\nnone", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": true, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "\u00b7The usual dose of Adcetris given in combination\r with cyclophosphamide, doxorubicin and prednisone is 1.8 mg/kg\r given every 3 weeks for approximately 4\u20116 months.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "c239ccb7-df89-449d-9f44-c71ade96e2d5", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">See the package\r leaflets for these medicines given in combination with Adcetris for additional\r information on their use and effects. After the first dose of Adcetris in\r combination with chemotherapy, your doctor may also give you a medicine that\r will help prevent development or reduce the severity of neutropenia (decrease\r of white blood cell count) which can increase the risk of infection. Tell your\r doctor </span><span lang=\"EN-GB\">if you have kidney or liver problems as your\r doctor may lower your starting dose or may not recommend Adcetris.</span></p>", "ID": "06361061-b964-4fe6-acd1-18412b598609", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "See the package\r leaflets for these medicines given in combination with Adcetris for additional\r information on their use and effects. After the first dose of Adcetris in\r combination with chemotherapy, your doctor may also give you a medicine that\r will help prevent development or reduce the severity of neutropenia (decrease\r of white blood cell count) which can increase the risk of infection. Tell your\r doctor if you have kidney or liver problems as your\r doctor may lower your starting dose or may not recommend Adcetris.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"></p>", "ID": "4b5d2b7f-22f9-4131-9727-c06ca3c26d53", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in;text-autospace:\r none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7</span><span lang=\"EN-GB\">The usual dose of Adcetris given alone is\r 1.8 mg/kg, given once every 3 weeks for no more than one year. Your\r doctor may lower your starting dose to 1.2 mg/kg if you have kidney or\r liver problems.</span></p>", "ID": "41f63dac-9f2a-4cf8-bcde-760e51a4ca4c", "Styles": "margin-left:.25in;text-indent:-.25in;text-autospace:\r\nnone", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "\u00b7The usual dose of Adcetris given alone is\r 1.8 mg/kg, given once every 3 weeks for no more than one year. Your\r doctor may lower your starting dose to 1.2 mg/kg if you have kidney or\r liver problems.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "e6c57c3f-43b3-4716-b0d1-e641d5ed2dbd", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Adcetris is to be given to adults only. It\r is not for use in children. </span></p>", "ID": "2926fa38-29fb-4e3e-a303-5406f0b0f8d5", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Adcetris is to be given to adults only. It\r is not for use in children. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "ffbb2993-778e-4b6d-8e8c-f9c14831364e", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">How\r Adcetris is given</span></b></p>", "ID": "803b0704-fa1e-4d41-9ebe-ab340ddf0a3d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "How\r Adcetris is given", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "ce8207a3-b845-4113-a4a1-925cd45cb538", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">This medicine is given to you into a vein\r (intravenously) as an infusion. It is given by your doctor or nurse over\r 30 minutes. Your doctor or nurse will also monitor you during and after\r the infusion. </span></p>", "ID": "e1237539-db30-410a-9392-43f6161eb7ae", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "This medicine is given to you into a vein\r (intravenously) as an infusion. It is given by your doctor or nurse over\r 30 minutes. Your doctor or nurse will also monitor you during and after\r the infusion. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "0e3d390a-54a7-419a-9fd0-3a2299f879cd", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you have any other questions on the use\r of this medicine, ask your doctor.</span></p>", "ID": "da7c2402-676d-4b52-ba0b-cbd655c78293", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "If you have any other questions on the use\r of this medicine, ask your doctor.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:17.65pt\"></p>", "ID": "f2e1a270-4874-4f5c-8656-2791bc79fac9", "Styles": "margin-right:17.65pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:17.65pt\"></p>", "ID": "de3f8990-af9a-443b-8518-a044ac161381", "Styles": "margin-right:17.65pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoHeading7\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">4.       Possible\r side effects </span></p>", "ID": "0b9194f0-14be-489b-8f6b-ff3b3b521ede", "Styles": "page-break-after:avoid", "Classes": "['MsoHeading7']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "4.       Possible\r side effects ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "d509b388-de09-47d7-8b7c-718d9a2aa703", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Like all medicines, this medicine may cause\r side effects, although not everybody gets them. </span></p>", "ID": "24c315b7-e521-418c-be4e-6740fbb64615", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Like all medicines, this medicine may cause\r side effects, although not everybody gets them. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "56af27ff-8bc7-48bd-9e47-100356a7d86b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Infusion\r reactions</span></b></p>", "ID": "210345b3-9cce-4507-a330-4dcb03a7503a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Infusion\r reactions", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "987df90a-b6e3-404b-ae86-4fbc142ce59e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Medicines of\r this type (monoclonal antibodies) can cause infusion reactions such as:</span></p>", "ID": "d3a2590a-ae61-4765-b028-73624cc14905", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Medicines of\r this type (monoclonal antibodies) can cause infusion reactions such as:", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">a rash </span></p>", "ID": "eb205504-0444-4b10-b847-180d13858f98", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpFirst']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-a rash ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">shortness of breath</span></p>", "ID": "18213bb4-ed48-40f8-a7ad-979cd055e129", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-shortness of breath", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">difficulty breathing</span></p>", "ID": "17170f60-5e41-49e7-b1b6-60ff66e7fc14", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-difficulty breathing", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">cough</span></p>", "ID": "7e85a8e5-62d2-4f95-bd01-a810f9b98214", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-cough", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">a tight chest </span></p>", "ID": "bae74540-3811-44ad-a469-42713c50cd3f", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-a tight chest ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">fever</span></p>", "ID": "b23c6c0f-1346-42e0-a7b8-0532dbdca0b5", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-fever", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">back pain</span></p>", "ID": "647563a6-61c1-4fe6-b676-19759adc4959", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-back pain", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">chills</span></p>", "ID": "91001370-a310-46ab-b501-8ad6cb1b98e8", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt;page-break-after:avoid", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-chills", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">headache</span></p>", "ID": "cf96818d-be02-488b-9d99-72943bdc0f5f", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt;page-break-after:avoid", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-headache", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">feeling sick (nausea) or being sick (vomiting).</span></p>", "ID": "5db8a3eb-6c5f-4a9d-9e5a-3ed7cc2bebfa", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpLast']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-feeling sick (nausea) or being sick (vomiting).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "16a638a8-9e30-4e9a-8af9-3dee66afba85", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infusion\r reactions to this medicine may affect more than 1 in 10 people. </span></p>", "ID": "6958af31-058d-4cbb-a5b4-fc38728f215d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Infusion\r reactions to this medicine may affect more than 1 in 10 people. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoDate\" style=\"page-break-after:avoid\"></p>", "ID": "fc9f3612-3702-4ada-8840-6f21e31316ea", "Styles": "page-break-after:avoid", "Classes": "['MsoDate']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In general, these types of reactions occur\r within minutes to several hours following completion of the infusion. However,\r they may develop more than several hours after completion of the infusion but\r this is uncommon. These infusion reactions can be serious or even fatal (known\r as an anaphylactic reaction). It is not known how frequently infusion-related\r reactions to this medicine are serious or fatal. </span></p>", "ID": "69f3f9f7-99ea-4d7d-912d-d6674969ccc0", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In general, these types of reactions occur\r within minutes to several hours following completion of the infusion. However,\r they may develop more than several hours after completion of the infusion but\r this is uncommon. These infusion reactions can be serious or even fatal (known\r as an anaphylactic reaction). It is not known how frequently infusion-related\r reactions to this medicine are serious or fatal. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "0029eaa8-4469-46fb-89ea-fc84d14cf8a2", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">You may be given other medicines such as </span></p>", "ID": "f0c8a7f6-f3a7-452c-9b24-2487cba363ca", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "You may be given other medicines such as ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">anti-histamines, corticosteroids or paracetamol </span></p>", "ID": "44e322f8-809f-495d-a652-7f6a0947769b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraph']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-anti-histamines, corticosteroids or paracetamol ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">to help reduce any of the reactions above\r if you have already experienced these when receiving this type of medicine. </span></p>", "ID": "51430a26-9727-4f17-b7cf-601a6774bcf2", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "to help reduce any of the reactions above\r if you have already experienced these when receiving this type of medicine. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "436de721-3d3e-4684-a899-cb255abff443", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you think you have previously had a\r similar reaction, tell your doctor BEFORE you are given this medicine. </span></p>", "ID": "4446dda8-1d93-4342-ac39-bf6fe2f0f734", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "If you think you have previously had a\r similar reaction, tell your doctor BEFORE you are given this medicine. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you develop infusion reactions (as\r stated previously), your doctor may stop giving this medicine and start support\r treatment.</span></p>", "ID": "5a17c56e-a908-4ba7-8e67-f3004231e0d9", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "If you develop infusion reactions (as\r stated previously), your doctor may stop giving this medicine and start support\r treatment.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If your infusion is restarted, your doctor\r may increase the time over which your infusion is given so that you may be able\r to tolerate it better. </span></p>", "ID": "b9ad2fda-49d3-4eb0-8fcf-9f2bc99bc935", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "If your infusion is restarted, your doctor\r may increase the time over which your infusion is given so that you may be able\r to tolerate it better. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "7e0be88c-eddf-4d3b-ba21-c7161a0c51c6", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Tell your\r doctor straight away if you notice any of the following symptoms because some\r of them may be signs of a serious or possibly fatal condition:</span></b></p>", "ID": "d1949948-fce5-4341-aed9-1da75c19da4f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Tell your\r doctor straight away if you notice any of the following symptoms because some\r of them may be signs of a serious or possibly fatal condition:", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">progressive multifocal leukoencephalopathy (PML)\r symptoms such as confusion, trouble thinking, memory loss, blurred or loss of\r vision, decreased strength, decreased control or sensation in one arm or leg, a\r change in the way of walking, or loss of balance (for more detailed\r information, see section 2) (affects less than 1 in 100 people)</span></p>", "ID": "3b3de68d-fbfc-4038-9834-2f7f60110f22", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpFirst']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-progressive multifocal leukoencephalopathy (PML)\r symptoms such as confusion, trouble thinking, memory loss, blurred or loss of\r vision, decreased strength, decreased control or sensation in one arm or leg, a\r change in the way of walking, or loss of balance (for more detailed\r information, see section 2) (affects less than 1 in 100 people)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">symptoms of inflammation of the pancreas\r (pancreatitis) such as severe and persistent stomach pain, with or without\r nausea and vomiting (may affect up to 1 in 100 people).</span></p>", "ID": "bd2ec03e-ac8f-4fd0-a855-b83dc6fe50a7", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-symptoms of inflammation of the pancreas\r (pancreatitis) such as severe and persistent stomach pain, with or without\r nausea and vomiting (may affect up to 1 in 100 people).", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">shortness of breath or cough (may affect more\r than 1 in 10 people)</span></p>", "ID": "6811d872-f732-4ccf-8a60-78ac3da00158", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-shortness of breath or cough (may affect more\r than 1 in 10 people)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">flu-like symptoms followed by a painful red or\r purplish rash that spreads and blisters including extensive detachment of the\r skin (may affect up to 1 in 100 people)</span></p>", "ID": "4c3bdea8-c4d3-495f-a4c2-e75bfc8e235d", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-flu-like symptoms followed by a painful red or\r purplish rash that spreads and blisters including extensive detachment of the\r skin (may affect up to 1 in 100 people)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">a change in feeling or sensitivity, especially\r in the skin, numbness, tingling, discomfort, a burning sensation, weakness, or\r pain in the hands or feet (neuropathy; may affect more than 1 in\r 10 people)</span></p>", "ID": "d4f9ece9-04b8-4c37-b7ce-9400853140b8", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-a change in feeling or sensitivity, especially\r in the skin, numbness, tingling, discomfort, a burning sensation, weakness, or\r pain in the hands or feet (neuropathy; may affect more than 1 in\r 10 people)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">a feeling of weakness (may affect more than 1 in\r 10 people)</span></p>", "ID": "d5495697-cbde-4a14-9aa6-e97d37d4b7e2", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-a feeling of weakness (may affect more than 1 in\r 10 people)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">constipation (may affect more than 1 in\r 10 people)</span></p>", "ID": "f2b2061e-7fb9-460b-b9a5-ba01182436b9", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-constipation (may affect more than 1 in\r 10 people)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">diarrhoea, vomiting (may affect more than 1 in\r 10 people)</span></p>", "ID": "d835bb8f-37c9-4a43-8f57-e27582cbcbd8", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-diarrhoea, vomiting (may affect more than 1 in\r 10 people)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">chills or shivering (may affect up to 1 in\r 10 people)</span></p>", "ID": "0c598d37-762e-433d-8a34-aa90864d4eb2", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-chills or shivering (may affect up to 1 in\r 10 people)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">feeling tired, frequent urination, increased\r thirst, increased appetite with unintended weight loss, and irritability (these\r may be signs of hyperglycaemia, which may affect up to 1 in 10 people)</span></p>", "ID": "db601ef6-cc3e-43f4-ad10-3fcc9d0dd89e", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-feeling tired, frequent urination, increased\r thirst, increased appetite with unintended weight loss, and irritability (these\r may be signs of hyperglycaemia, which may affect up to 1 in 10 people)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">unusual bleeding or bruising under the skin,\r longer than usual bleeding after your blood has been drawn, or bleeding from\r your gums (these may be signs of thrombocyopenia which may affect up to 1 in\r 10 people)</span></p>", "ID": "a8d8b68a-1bfc-4409-8cd4-7442d000c9ee", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-unusual bleeding or bruising under the skin,\r longer than usual bleeding after your blood has been drawn, or bleeding from\r your gums (these may be signs of thrombocyopenia which may affect up to 1 in\r 10 people)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">headaches, experience dizziness, look pale\r (these may be signs of anaemia, which may affect more than 1 in 10 people)</span></p>", "ID": "ba138034-1308-42b6-b8e8-35e026df561b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpLast']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-headaches, experience dizziness, look pale\r (these may be signs of anaemia, which may affect more than 1 in 10 people)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "886b776f-904e-4d7d-b186-c6b5a931cff7", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">You may\r experience the following side effects:</span></p>", "ID": "da5abf86-5b98-4924-a68f-6c6f9c900a58", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "You may\r experience the following side effects:", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "80f3da5b-1eaf-4d18-b01c-21daf4221722", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The\r following side effects have been reported with Adcetris alone:</span></p>", "ID": "b957bcd4-663e-468f-8ebd-1f4833f37f29", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The\r following side effects have been reported with Adcetris alone:", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "0cea70eb-0d36-4e2f-87ed-c45375223245", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;page-break-after:avoid\"><b><span lang=\"EN-GB\">Very common side effects</span></b><span lang=\"EN-GB\"> (may affect\r more than 1 in 10 people)</span></p>", "ID": "6ae725f3-9d53-4604-be2a-fed3f67acf44", "Styles": "margin-left:.25in;page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Very common side effects (may affect\r more than 1 in 10 people)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">decreased level of white blood cells</span></p>", "ID": "d66af9b2-9939-4135-b3cd-8e74fc084ef2", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpFirst']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-decreased level of white blood cells", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">upper respiratory tract infection</span></p>", "ID": "c30917d5-ed2e-45a1-9473-7b07ef9f1168", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-upper respiratory tract infection", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">decrease in weight</span></p>", "ID": "dee062e5-3a1d-412c-9a3e-6315a65309d2", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-decrease in weight", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">infection</span></p>", "ID": "b51ed864-3d6c-4bbb-b1d2-ab2ef62f3271", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-infection", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">nausea</span></p>", "ID": "49f529d4-6b30-483b-82ae-c7c91f943f9f", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-nausea", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">abdominal pain</span></p>", "ID": "2bfef224-df07-48bf-9185-c1f1e145663e", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-abdominal pain", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">itching</span></p>", "ID": "2e4f0d05-ccbb-4f7d-9b8c-9f58e1c63479", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-itching", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">muscle pain</span></p>", "ID": "3debd7a5-e61a-44f5-82c5-3bbd636cad5d", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-muscle pain", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">joint pain or painful, swollen joints</span></p>", "ID": "ab36f4cd-55ea-4491-9201-79d26dbf7277", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpLast']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-joint pain or painful, swollen joints", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "c9b343c2-cc11-49b0-9619-e3cd0af52d65", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;page-break-after:avoid\"><b><span lang=\"EN-GB\">Common side effects</span></b><span lang=\"EN-GB\"> (may affect up to 1\r in 10 people)</span></p>", "ID": "450389f4-7ac0-4517-b2d1-153ba8c86519", "Styles": "margin-left:.25in;page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Common side effects (may affect up to 1\r in 10 people)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">pneumonia</span></p>", "ID": "2f6e84d1-cc4c-48f9-a76e-b61882068cbd", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpFirst']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-pneumonia", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">sore, creamy-yellow, raised patches in the mouth\r (thrush)</span></p>", "ID": "6f46f911-739c-44fa-8d5b-2a1f97cd9584", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-sore, creamy-yellow, raised patches in the mouth\r (thrush)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">decreased level of blood platelets</span></p>", "ID": "a1625a92-b23f-47d9-80b8-acd01cc9345d", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-decreased level of blood platelets", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">dizziness</span></p>", "ID": "5dc98d4f-c78c-40de-b142-ef70f04baa3f", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-dizziness", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">blisters which may crust or scab</span></p>", "ID": "a6057c5c-09d7-4b1c-86c2-d47616f579d1", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-blisters which may crust or scab", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">increased level of blood sugar</span></p>", "ID": "0b6bf49d-a908-4b11-8d39-b40c816049c1", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-increased level of blood sugar", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">increased liver enzyme levels </span></p>", "ID": "1f78a8c1-256b-439f-8eee-98afea46d332", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-increased liver enzyme levels ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">unusual hair loss or thinning</span></p>", "ID": "69b187e5-5a2d-4615-bd5e-616ffae413c5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpLast']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-unusual hair loss or thinning", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "3ad222f0-6ed4-43a8-a134-b37a0f888451", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:21.3pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Uncommon side effects</span></b><span lang=\"EN-GB\"> (may affect up to\r 1 in 100 people)</span></p>", "ID": "b964809a-7f7e-4959-8b4b-3b5e59732e8e", "Styles": "margin-left:21.3pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Uncommon side effects (may affect up to\r 1 in 100 people)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">Tumour lysis syndrome \u2013 a potentially-life\r threatening condition in which you may experience dizziness, decreased\r urination, confusion, vomiting, nausea, swelling, shortness of breath, or heart\r rhythm disturbances. </span></p>", "ID": "f63040ba-ef31-423c-b3c0-fac769dea732", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpFirst']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-Tumour lysis syndrome \u2013 a potentially-life\r threatening condition in which you may experience dizziness, decreased\r urination, confusion, vomiting, nausea, swelling, shortness of breath, or heart\r rhythm disturbances. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">new or recurring cytomegalovirus (CMV) infection</span></p>", "ID": "bdbd8160-b194-4ea1-bd06-d042c442c8be", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-new or recurring cytomegalovirus (CMV) infection", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">an infection in the blood (sepsis) and/or septic\r shock (a life-threatening form of sepsis)</span></p>", "ID": "3980e6b6-3e17-4b3b-a5c6-ba257447a71f", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-an infection in the blood (sepsis) and/or septic\r shock (a life-threatening form of sepsis)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">Stevens-Johnson syndrome and toxic epidermal\r necrolysis - a rare, serious disorder in which you may experience flu-like\r symptoms followed by a painful red or purplish rash that spreads and blisters\r including extensive detachment of the skin </span></p>", "ID": "e010b7fe-5573-4b32-8b04-52ad0eea3aa4", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-Stevens-Johnson syndrome and toxic epidermal\r necrolysis - a rare, serious disorder in which you may experience flu-like\r symptoms followed by a painful red or purplish rash that spreads and blisters\r including extensive detachment of the skin ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">decreased level of white blood cells with a fever</span></p>", "ID": "3e17e6e1-263a-4abf-b801-0576efffbb31", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-decreased level of white blood cells with a fever", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">damage to the nerves and nerve coverings\r (demyelinating polyneuropathy)</span></p>", "ID": "30a2abec-35c5-40b1-9861-38968ead6c31", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpLast']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-damage to the nerves and nerve coverings\r (demyelinating polyneuropathy)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "dc0c1897-f977-4bb9-8535-d347caf69b45", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The\r following side effects have been reported with Adcetris in combination with\r chemotherapy medicines:</span></p>", "ID": "d9d41607-209e-4d26-9513-7f4f3897efa9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The\r following side effects have been reported with Adcetris in combination with\r chemotherapy medicines:", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "72792199-283d-49ca-a9ba-a71a7aaca2c1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;page-break-after:avoid\"><b><span lang=\"EN-GB\">Very common side effects</span></b><span lang=\"EN-GB\"> (may affect\r more than 1 in 10 people)</span></p>", "ID": "cccb7771-ff85-4d7e-bfb1-8412934a7068", "Styles": "margin-left:.25in;page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Very common side effects (may affect\r more than 1 in 10 people)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">decreased level of white blood cells</span></p>", "ID": "88d63bcd-03ce-4253-bd51-1ca675c8b8f4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpFirst']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-decreased level of white blood cells", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">decreased level of blood platelets</span></p>", "ID": "bda24945-8609-48cc-95f9-61fb2360ba51", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-decreased level of blood platelets", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">decreased level of white blood cells with a\r fever</span></p>", "ID": "a2cfb20c-035f-4c1e-9d9f-c2bc876a9734", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-decreased level of white blood cells with a\r fever", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">upper respiratory tract infection</span></p>", "ID": "de87bf29-8b6c-42f5-be0d-c136564592ba", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-upper respiratory tract infection", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">decrease in weight</span></p>", "ID": "0daafdc8-02ad-4b96-a111-2785e7e5806a", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-decrease in weight", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">infection</span></p>", "ID": "7aacd27b-454b-429c-ba02-c9647a07e81f", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-infection", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">nausea</span></p>", "ID": "9c6a4125-d087-4201-98c4-0cb8c1215cf0", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-nausea", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">abdominal pain</span></p>", "ID": "ff653fb9-e090-4aa3-842a-c5aed5a1b4c2", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-abdominal pain", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">unusual hair loss or thinning</span></p>", "ID": "5fdd2f28-9243-42f9-810a-240f0e258674", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-unusual hair loss or thinning", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">muscle pain</span></p>", "ID": "e7c39ffa-21ae-43ec-b25b-20bd51289ece", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-muscle pain", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">joint pain or painful, swollen joints</span></p>", "ID": "76d7aa0e-2bf8-4fe7-b678-111f50470ec9", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-joint pain or painful, swollen joints", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">dizziness</span></p>", "ID": "95eeb386-4ded-4b28-96b7-86aadd60900b", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-dizziness", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">decreased appetite</span></p>", "ID": "c01d25a4-73fb-4752-aeea-19b0401f24f2", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-decreased appetite", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">not being able to sleep</span></p>", "ID": "d423ab93-f4e2-4e47-a0c2-83ad2fd21eb3", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-not being able to sleep", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">bone pain</span></p>", "ID": "fc4607cb-1499-4b4e-94e3-74de1e3d9ff3", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-bone pain", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">blisters which may crust or scab</span></p>", "ID": "693059bf-f2eb-4206-a446-28affba58aa6", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpLast']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-blisters which may crust or scab", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt\"></p>", "ID": "6db9791c-d76a-4d6c-9a8c-5d421cc91c12", "Styles": "margin-left:28.35pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;page-break-after:avoid\"><b><span lang=\"EN-GB\">Common side effects</span></b><span lang=\"EN-GB\"> (may affect up to 1\r in 10 people)</span></p>", "ID": "9510eb7e-a23d-4499-83a2-e907c2a47717", "Styles": "margin-left:.25in;page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Common side effects (may affect up to 1\r in 10 people)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">an infection in the blood (sepsis) and/or septic\r shock (a life-threatening form of sepsis); pneumonia</span></p>", "ID": "e8bbe5d1-ced4-42d7-b6e8-0aa542988c68", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpFirst']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-an infection in the blood (sepsis) and/or septic\r shock (a life-threatening form of sepsis); pneumonia", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">sore or inflammation in the mouth</span></p>", "ID": "5a5f76d7-5b14-4beb-9f81-d3c81b90a416", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-sore or inflammation in the mouth", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">sore, creamy-yellow, raised patches in the mouth\r (thrush)</span></p>", "ID": "c9c7e2ec-6574-45f8-886a-85d4679a456c", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-sore, creamy-yellow, raised patches in the mouth\r (thrush)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">itching</span></p>", "ID": "8d176e7a-a78c-4e89-91c8-cbb2b4db135f", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-itching", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">increased level of blood sugar</span></p>", "ID": "027924db-baf9-4b6a-b5eb-caffc96d8ebf", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-increased level of blood sugar", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">increased liver enzyme levels</span></p>", "ID": "856ee4e1-ad4c-4a15-af3e-16e178284462", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpLast']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-increased liver enzyme levels", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "ad3c215b-8b6d-462d-ab36-9b01d9553e91", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:21.3pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Uncommon side effects</span></b><span lang=\"EN-GB\"> (may affect up to\r 1 in 100 people)</span></p>", "ID": "783e3eeb-2ead-420f-998d-f1e4e6854743", "Styles": "margin-left:21.3pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Uncommon side effects (may affect up to\r 1 in 100 people)", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">Tumour lysis syndrome \u2013 a potentially-life\r threatening condition in which you may experience dizziness, decreased\r urination, confusion, vomiting, nausea, swelling, shortness of breath, or heart\r rhythm disturbances </span></p>", "ID": "4e7bd703-264b-42e8-8ee4-b19b64211827", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpFirst']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-Tumour lysis syndrome \u2013 a potentially-life\r threatening condition in which you may experience dizziness, decreased\r urination, confusion, vomiting, nausea, swelling, shortness of breath, or heart\r rhythm disturbances ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">Stevens\u2011Johnson syndrome - a rare, serious\r disorder in which you may experience flu\u2011like symptoms followed by a\r painful red or purplish rash that spreads and blisters including extensive\r detachment of the skin </span></p>", "ID": "cdf79ace-9aa1-417b-b6b8-cdd6bdc5c2cf", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-Stevens\u2011Johnson syndrome - a rare, serious\r disorder in which you may experience flu\u2011like symptoms followed by a\r painful red or purplish rash that spreads and blisters including extensive\r detachment of the skin ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">new or recurring cytomegalovirus (CMV) infection</span></p>", "ID": "61b40742-cac3-4967-9c48-c49caacdba7c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpLast']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-new or recurring cytomegalovirus (CMV) infection", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "6fcdd380-a5bb-4e4f-9854-1d3c4502e8dc", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">If you are an\r older patient (\u2265 65 years of age) you may experience serious\r adverse events more frequently. </span></p>", "ID": "f15b3169-c125-4430-a0b4-cbfb49ca3e56", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "If you are an\r older patient (\u2265 65 years of age) you may experience serious\r adverse events more frequently. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "7e2077bd-24e1-4242-afd0-4acd2335e5e6", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Reporting\r of side effects</span></b></p>", "ID": "afce3461-74f3-4271-94cb-76048ce542e4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Reporting\r of side effects", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "895e9ded-5325-4c64-9ef4-5536e8c3959f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you get any side effects, talk to your\r doctor. This includes any possible side effects not listed in this leaflet.</span><span lang=\"EN-GB\"> You can also report side effects directly via <span style=\"background:silver\">the national reporting system listed in </span></span><span lang=\"EN-GB\"><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background:silver\">Appendix V</span></a><a name=\"_Hlt351112648\"></a><a name=\"_Hlt351112647\"></a></span><span lang=\"EN-GB\">. By reporting side effects\r you can help provide more information on the safety of this medicine.</span></p>", "ID": "65ff66df-9fb6-4e62-990d-3f427de448bb", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "If you get any side effects, talk to your\r doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects\r you can help provide more information on the safety of this medicine.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "51871461-0010-4d95-8bc9-569d24e900b0", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "00ec2247-d45b-47ec-8868-3e2161a971bd", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoHeading7\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">5.       How\r to store Adcetris </span></p>", "ID": "1303940c-f15a-46a5-96ec-cddffc8b898c", "Styles": "page-break-after:avoid", "Classes": "['MsoHeading7']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "5.       How\r to store Adcetris ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "4fd344b2-4edf-4f6e-8e4a-c5010e330bfa", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Keep this\r medicine out of the sight and reach of children.</span></p>", "ID": "5f8e0541-df15-4102-a9af-d234629791ec", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Keep this\r medicine out of the sight and reach of children.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "828acadd-64fb-4f97-a787-acb722c40ac4", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not use this medicine after the expiry\r date which is stated on the vial label and the carton after EXP. The expiry\r date refers to the last day of that month. </span></p>", "ID": "8d60963b-d61e-45ac-8f6d-2ef97fc35626", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Do not use this medicine after the expiry\r date which is stated on the vial label and the carton after EXP. The expiry\r date refers to the last day of that month. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "70e89da9-319d-4e8a-acad-115134cb4d86", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Unopened vial:</span></b><span lang=\"EN-GB\"> Store in a refrigerator (2 \u00b0C\u20118 \u00b0C). Do not\r freeze.</span></p>", "ID": "3fcb6083-353f-41d2-ad1c-70e278b8f617", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Unopened vial: Store in a refrigerator (2 \u00b0C\u20118 \u00b0C). Do not\r freeze.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep the vial in the original carton in\r order to protect from light. </span></p>", "ID": "3d280e40-5b9c-4e85-bece-993fbf0c3c8c", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Keep the vial in the original carton in\r order to protect from light. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "f45a80d8-7d1b-42fb-9b55-d52b749b3bd1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Reconstituted/diluted solution:</span></b><span lang=\"EN-GB\">Use immediately or </span><span lang=\"EN-GB\">store\r in a refrigerator (2 </span><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b0</span><span lang=\"EN-GB\">C\u20118 \u00b0C) and use within 24 hours.</span></p>", "ID": "1c94d261-ed70-4e17-baf3-c6b78d1c3dab", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Reconstituted/diluted solution:Use immediately or store\r in a refrigerator (2 \u00b0C\u20118 \u00b0C) and use within 24 hours.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "99bb1e59-ab00-46b2-ba72-7f709c77e098", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not use this medicine if you notice any\r particulate matter or discolouration prior to administration. </span></p>", "ID": "8902fa8b-8758-4511-891e-ecb2a593b61e", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Do not use this medicine if you notice any\r particulate matter or discolouration prior to administration. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "5852deec-a7de-4869-8b30-47f92d2df32b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not throw away any medicines via\r wastewater or household waste. The doctor or nurse will dispose of this\r medicine. These measures will help protect the environment. </span></p>", "ID": "aa4e1da6-1b66-4e4b-9510-217e1fcba2eb", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Do not throw away any medicines via\r wastewater or household waste. The doctor or nurse will dispose of this\r medicine. These measures will help protect the environment. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "bbf50e3f-f3c0-441d-9266-be4d6a0f6874", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "42f761b4-97cd-4fc4-8a29-5e8f0df87944", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoHeading7\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">6.       Contents\r of the pack and other information</span></p>", "ID": "fad05ca3-82cd-478c-a1a8-e910c6fb4c2f", "Styles": "page-break-after:avoid", "Classes": "['MsoHeading7']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L1", "Text": "6.       Contents\r of the pack and other information", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "5ff35ee5-737d-458b-a43e-3108a2d7ee47", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What\r Adcetris contains</span></b></p>", "ID": "162b764f-63d3-4cc9-aab0-29af1add496b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "What\r Adcetris contains", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "6ecc74d7-f672-4e65-ac41-2c40673d235a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">The active substance is brentuximab vedotin.\r Each vial contains 50 mg of brentuximab vedotin. After reconstitution each mL\r of solution contains </span><span lang=\"EN-GB\">5 mg of Adcetris. </span></p>", "ID": "14c0c949-5d03-4ecb-ab78-0b3ae25ecbab", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpFirst']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-The active substance is brentuximab vedotin.\r Each vial contains 50 mg of brentuximab vedotin. After reconstitution each mL\r of solution contains 5 mg of Adcetris. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>-</span><span lang=\"EN-GB\">The other ingredients are citric acid\r monohydrate, sodium citrate dihydrate, \u03b1,\u03b1\u2011trehalose dihydrate,\r and polysorbate 80 See section 2 for further information about sodium. </span></p>", "ID": "df507889-704e-4720-aaf3-7d81dcf702d3", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpLast']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "-The other ingredients are citric acid\r monohydrate, sodium citrate dihydrate, \u03b1,\u03b1\u2011trehalose dihydrate,\r and polysorbate 80 See section 2 for further information about sodium. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "52d4e678-2ea7-48f1-b317-5a1fd20565bb", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What\r Adcetris looks like and contents of the pack</span></b></p>", "ID": "b50251ff-2c04-45d1-ace0-1980b6311568", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "What\r Adcetris looks like and contents of the pack", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "1523f041-92c3-42c8-9436-e25eaa1c230c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Adcetris is a white to off-white cake or\r powder for concentrate for solution for infusion provided in a glass vial. </span></p>", "ID": "edb2e010-3911-4324-956d-de218ffa50e1", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Adcetris is a white to off-white cake or\r powder for concentrate for solution for infusion provided in a glass vial. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "881abb05-aeec-49cc-a20f-4a56548eaa01", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Each pack of Adcetris consists of one vial.\r </span></p>", "ID": "a104dd5e-fae8-45f4-8d97-6d0b50c86844", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Each pack of Adcetris consists of one vial.\r ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "2a6c71b5-60dc-427c-a060-2a94c3fd9c70", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><a name=\"_Hlk19873870\"><b><span lang=\"EN-GB\">Marketing\r Authorisation Holder</span></b></a></p>", "ID": "0e54fb60-e240-40ea-ae74-26fa1454dcdd", "Styles": "None", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Marketing\r Authorisation Holder", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "8b6ac4a9-ece3-44cb-9bd0-0f81fa0b41b3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Takeda Pharma A/S</span></p>", "ID": "1e85a30a-41aa-4768-977b-a0d64a362582", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Takeda Pharma A/S", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Dybendal Alle 10</span></p>", "ID": "05210b71-f9b8-4302-abe3-2837ffab4cca", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Dybendal Alle 10", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">2630 Taastrup</span></p>", "ID": "59debef5-0854-4e91-b817-563aec9c2bc2", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "2630 Taastrup", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Denmark </span></p>", "ID": "5fdb76f3-4f8d-4d51-8ad5-2044189d8b60", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Denmark ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "f87a567c-004b-4f4e-92fa-6b40d5275c53", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Manufacturer</span></b></p>", "ID": "49667401-bffe-4fd8-bab0-0a015a320fa3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Manufacturer", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "70477ca0-7464-468d-8b21-cd0d0f94b271", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:silver\">Takeda Austria GmbH</span></p>", "ID": "07d5fb3d-2cd4-4aff-96bd-f62976b43be2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Takeda Austria GmbH", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:silver\">St. Peter\u2011Stra\u03b2e 25</span></p>", "ID": "6b131594-2d4f-4e93-822d-b38f26b7b3e8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "St. Peter\u2011Stra\u03b2e 25", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"PT\" style=\"background:silver\">A\u20114020 Linz</span></p>", "ID": "cecff840-042d-40b3-b447-93d062bd5621", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "A\u20114020 Linz", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\" style=\"background:silver\">Austria</span></p>", "ID": "8a8af3c2-9d4a-46c1-b935-a6cb81d644ba", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Austria", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "5b950343-61db-4da9-8497-fc01282fd2a9", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"PT\">Delpharm Novara S.r.l.</span></p>", "ID": "9a70b901-0e8f-4830-b044-1a18a19a44b5", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Delpharm Novara S.r.l.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Via Crosa, 86</span></p>", "ID": "c0ddd8f1-284d-4825-a38a-550e9d22905e", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Via Crosa, 86", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">28065 Cerano (NO) </span></p>", "ID": "e5ee22ad-a9a0-4f78-b539-7f66d27049a4", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "28065 Cerano (NO) ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Italy</span></p>", "ID": "262e3011-a4b6-402b-9803-053c738a1682", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Italy", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "f3112b34-2a22-4b6b-bc67-52f3a3bc816a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">For any\r information about this medicine, please contact the local representative of the\r Marketing Authorisation Holder:</span></p>", "ID": "058c67de-03f4-4099-b2df-04fea53be7fd", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "For any\r information about this medicine, please contact the local representative of the\r Marketing Authorisation Holder:", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "02e87d54-e942-451a-9588-ca94649edc9d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\"> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><b><span lang=\"DE\" style=\"color:windowtext\">Belgi\u00eb/Belgique/Belgien</span></b></p> <p class=\"MsoNormal\"><span lang=\"DE\" style=\"color:windowtext\">Takeda Belgium</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"DE\" style=\"color:windowtext\">T\u00e9l/Tel: +32 2 464 06 11</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">takeda-belgium@takeda.com</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"FI\" style=\"color:windowtext\">Lietuva</span></b></p> <p class=\"MsoNormal\"><span lang=\"FI\" style=\"color:windowtext\">Takeda, UAB</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"FI\" style=\"color:windowtext\">Tel: +370 521 09 070</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"FI\" style=\"color:windowtext\">lt-info@takeda.com</span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p> <p class=\"MsoPlainText\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\r   \"Times New Roman\",serif'>\u0422\u0430\u043a\u0435\u0434\u0430\r   \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></p> <p class=\"MsoPlainText\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\r   \"Times New Roman\",serif'>\u0422\u0435\u043b.: + 359 2 958 27 36</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"DE\" style=\"color:windowtext\">Luxembourg</span></b><b><span lang=\"DE\" style=\"color:windowtext\">/Luxemburg</span></b></p> <p class=\"MsoNormal\"><span lang=\"DE\" style=\"color:windowtext\">Takeda Belgium</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"DE\" style=\"color:windowtext\">T\u00e9l:/Tel: +32 2 464 06 11</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">takeda-belgium@takeda.com<span class=\"MsoHyperlink\"></span></span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">\u010cesk\u00e1 republika</span></b></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Takeda\r   Pharmaceuticals </span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Czech Republic\r   s.r.o.</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:windowtext\">Tel: + 420 23<span style=\"letter-spacing:1.9pt\">4</span>72<span style=\"letter-spacing:1.9pt\">2</span>722 </span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">Magyarorsz\u00e1g</span></b></p> <p class=\"MsoPlainText\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\r   \"Times New Roman\",serif'>Takeda Pharma Kft.</span></p> <p class=\"MsoPlainText\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\r   \"Times New Roman\",serif'>Tel.: +361 2707030</span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">Danmark</span></b></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">Takeda Pharma A/S</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">Tlf: +45 46 77 11 11</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"FI\" style=\"color:windowtext\">Malta</span></b></p> <p class=\"MsoPlainText\"><span lang=\"FI\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Takeda\r   Italia S.p.A.</span></p> <p class=\"MsoPlainText\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\r   \"Times New Roman\",serif'>Tel: +39 06 502601</span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r   page-break-after:avoid\"><b><span lang=\"DE\" style=\"color:windowtext\">Deutschland</span></b></p> <p class=\"MsoPlainText\"><span lang=\"DE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Takeda\r   GmbH</span></p> <p class=\"MsoPlainText\"><span lang=\"DE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Tel:\r   +49 (0) 800 825 3325</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"DE\" style=\"color:windowtext\">medinfo@takeda.de</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"SV\" style=\"color:windowtext\">Nederland</span></b></p> <p class=\"MsoPlainText\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Takeda\r   Nederland bv</span></p> <p class=\"MsoPlainText\"><span lang=\"SV\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Tel:\r   +31 23 56 68 777</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"SV\" style=\"color:windowtext\">nl.medical.info@takeda.com</span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"PT-BR\" style=\"color:windowtext\">Eesti</span></b></p> <p class=\"MsoNormal\"><span lang=\"PT-BR\" style=\"color:windowtext\">Takeda Pharma AS</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"PT-BR\" style=\"color:windowtext\">Tel: +372 6177 669</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"NO-NYN\" style=\"color:windowtext\">Norge</span></b></p> <p class=\"MsoNormal\"><span lang=\"NO-NYN\" style=\"color:windowtext\">Takeda AS</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"NO-NYN\" style=\"color:windowtext\">Tlf: +47 6676 3030</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"NO-NYN\" style=\"color:windowtext\">infonorge@takeda.com</span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p> <p class=\"MsoNormal\"><span lang=\"NO-NYN\" style=\"color:windowtext\">TAKEDA </span><span lang=\"EN-GB\" style=\"color:windowtext\">\u0395\u039b\u039b\u0391\u03a3</span><span lang=\"EN-GB\" style=\"color:windowtext\">\u0391</span><span lang=\"NO-NYN\" style=\"color:windowtext\">.</span><span lang=\"EN-GB\" style=\"color:windowtext\">\u0395</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"NO-NYN\" style=\"color:windowtext\">T</span><span lang=\"EL\" style=\"color:windowtext\">\u03b7\u03bb</span><span lang=\"EN-GB\" style=\"color:windowtext\">: +30 210 6387800</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"DE\" style=\"color:windowtext\">gr.info@takeda.com</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"DE\" style=\"color:windowtext\">\u00d6sterreich</span></b></p> <p class=\"Default\"><span lang=\"DE\" style=\"font-size:11.0pt;color:windowtext\">Takeda\r   Pharma Ges.m.b.H. </span></p> <p class=\"MsoPlainText\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\r   \"Times New Roman\",serif'>Tel: +43 (0) 800 20 80 50 </span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"ES\" style=\"color:windowtext\">Espa\u00f1a</span></b></p> <p class=\"MsoNormal\"><span lang=\"ES\" style=\"color:windowtext\">Takeda\r   Farmac\u00e9utica Espa\u00f1a S.A</span></p> <p class=\"MsoPlainText\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\r   \"Times New Roman\",serif'>Tel: +34 </span><span style='font-size:11.0pt;\r   font-family:\"Times New Roman\",serif'>917 90 42 22</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">spain@takeda.com</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"PL\" style=\"color:windowtext\">Polska</span></b></p> <p class=\"MsoNormal\"><span lang=\"PL\" style=\"color:windowtext\">Takeda Pharma sp. z\r   o.o.</span></p> <p class=\"MsoNormal\"><span lang=\"FR\" style=\"color:windowtext\">Tel.: + 48 22 608\r   13 00</span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"FR\" style=\"color:windowtext\">France</span></b></p> <p class=\"MsoNormal\"><span lang=\"FR\" style=\"color:windowtext\">Takeda France </span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l</span><span lang=\"EN-GB\">:</span><span lang=\"FR\" style=\"color:windowtext\"> +33 1 46 25 16 16</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"PT-BR\" style=\"color:windowtext\">Portugal</span></b></p> <p class=\"MsoPlainText\"><span lang=\"PT-BR\" style='font-size:11.0pt;font-family:\r   \"Times New Roman\",serif'>Takeda Farmac\u00eauticos Portugal, Lda.</span></p> <p class=\"MsoNormal\"><span lang=\"FR\" style=\"color:windowtext\">Tel: + 351 21 120\r   1457</span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span style=\"color:windowtext\">Hrvats</span></b><b><span lang=\"EN-GB\" style=\"color:windowtext\">ka</span></b></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">Takeda Pharmaceuticals Croatia d.o.o.</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">Tel: +385 1 377 88 96</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">Rom\u00e2nia\r   </span></b></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Takeda\r   Pharmaceuticals SRL</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">Tel: +40 21 335 03 91</span></p> <p class=\"MsoNormal\" style=\"text-indent:28.35pt\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">Ireland</span></b></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Takeda Products\r   Ireland Limited</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Tel: +44 (0)1628\r   537 900</span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"NO-NYN\" style=\"color:windowtext\">Slovenija</span></b></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"NO-NYN\" style=\"color:windowtext\">Takeda GmbH, Podru\u017enica Slovenija</span></p> <p class=\"MsoNormal\"><span lang=\"NO-NYN\" style=\"color:windowtext\">Tel: + 386 (0)\r   59 082 480</span></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">\u00cdsland</span></b></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Vistor hf. </span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi:</span><span lang=\"EN-GB\" style=\"color:windowtext\"> +354 535 7000</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">vistor@vistor.is</span></p> <p class=\"MsoNormal\" style=\"text-indent:28.35pt\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">Slovensk\u00e1 republika</span></b></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Takeda\r   Pharmaceuticals Slovakia s.r.o.</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Tel: +421 (2) 20\r   602 600</span></p> <p class=\"MsoNormal\"></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoPlainText\" style=\"page-break-after:avoid\"><b><span lang=\"ES\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Italia </span></b></p> <p class=\"MsoPlainText\"><span lang=\"ES\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Takeda\r   Italia S.p.A.</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">Tel: +39 06\r   502601</span></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"SV\" style=\"color:windowtext\">Suomi/Finland</span></b></p> <p class=\"MsoNormal\"><span lang=\"SV\" style=\"color:windowtext\">Takeda Oy</span></p> <p class=\"MsoNormal\"><span lang=\"SV\">Puh/Tel:</span><span lang=\"SV\" style=\"color:windowtext\"> +358 20 746 5000</span></p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"color:windowtext\">infoposti@takeda.com</span></p> <p class=\"MsoNormal\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:windowtext\">A. POTAMITIS MEDICARE LTD</span></p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"color:windowtext\">T\u03b7\u03bb: +357 22583333</span></p> <p class=\"MsoNormal\"><span lang=\"LV\" style=\"color:windowtext\">info@potamitismedicare.com</span></p> <p class=\"MsoNormal\"><span lang=\"LV\" style=\"color:windowtext\"><a href=\"mailto:info@potamitismedicare.com\"></a></span></p> <p class=\"MsoNormal\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"SV\" style=\"color:windowtext\">Sverige</span></b></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"SV\" style=\"color:windowtext\">Takeda Pharma AB</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"SV\" style=\"color:windowtext\">Tel: +46 8 731 28 00</span></p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"color:windowtext\">infosweden@takeda.com</span></p> <p class=\"MsoNormal\" style=\"text-indent:28.35pt\"></p> </td> </tr> <tr> <td style=\"width:232.15pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r   page-break-after:avoid\"><b><span lang=\"FI\" style=\"color:windowtext\">Latvija</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FI\" style=\"color:windowtext\">Takeda Latvia SIA</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"FI\" style=\"color:windowtext\">Tel: +371 67840082</span></p> <p class=\"MsoNormal\" style=\"text-indent:28.35pt;page-break-after:avoid\"></p> </td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r   page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"color:windowtext\">United\r   Kingdom</span></b></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">Takeda UK Ltd</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:windowtext\">Tel: +44 (0)1628 537 900</span></p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p> </td> </tr> </table>", "ID": "0b94363a-86e4-41e8-bd9b-95a2912269c9", "Styles": "border-collapse:collapse", "Classes": "['MsoNormalTable']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "   Belgi\u00eb/Belgique/Belgien Takeda Belgium T\u00e9l/Tel: +32 2 464 06 11 takeda-belgium@takeda.com    Lietuva Takeda, UAB Tel: +370 521 09 070 lt-info@takeda.com      \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f \u0422\u0430\u043a\u0435\u0434\u0430\r   \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f \u0422\u0435\u043b.: + 359 2 958 27 36    Luxembourg/Luxemburg Takeda Belgium T\u00e9l:/Tel: +32 2 464 06 11 takeda-belgium@takeda.com      \u010cesk\u00e1 republika Takeda\r   Pharmaceuticals  Czech Republic\r   s.r.o. Tel: + 420 234722722     Magyarorsz\u00e1g Takeda Pharma Kft. Tel.: +361 2707030      Danmark Takeda Pharma A/S Tlf: +45 46 77 11 11    Malta Takeda\r   Italia S.p.A. Tel: +39 06 502601      Deutschland Takeda\r   GmbH Tel:\r   +49 (0) 800 825 3325 medinfo@takeda.de    Nederland Takeda\r   Nederland bv Tel:\r   +31 23 56 68 777 nl.medical.info@takeda.com      Eesti Takeda Pharma AS Tel: +372 6177 669    Norge Takeda AS Tlf: +47 6676 3030 infonorge@takeda.com      \u0395\u03bb\u03bb\u03ac\u03b4\u03b1 TAKEDA \u0395\u039b\u039b\u0391\u03a3\u0391.\u0395 T\u03b7\u03bb: +30 210 6387800 gr.info@takeda.com    \u00d6sterreich Takeda\r   Pharma Ges.m.b.H.  Tel: +43 (0) 800 20 80 50       Espa\u00f1a Takeda\r   Farmac\u00e9utica Espa\u00f1a S.A Tel: +34 917 90 42 22 spain@takeda.com    Polska Takeda Pharma sp. z\r   o.o. Tel.: + 48 22 608\r   13 00      France Takeda France  T\u00e9l: +33 1 46 25 16 16    Portugal Takeda Farmac\u00eauticos Portugal, Lda. Tel: + 351 21 120\r   1457      Hrvatska Takeda Pharmaceuticals Croatia d.o.o. Tel: +385 1 377 88 96    Rom\u00e2nia\r    Takeda\r   Pharmaceuticals SRL Tel: +40 21 335 03 91      Ireland Takeda Products\r   Ireland Limited Tel: +44 (0)1628\r   537 900    Slovenija Takeda GmbH, Podru\u017enica Slovenija Tel: + 386 (0)\r   59 082 480     \u00cdsland Vistor hf.  S\u00edmi: +354 535 7000 vistor@vistor.is    Slovensk\u00e1 republika Takeda\r   Pharmaceuticals Slovakia s.r.o. Tel: +421 (2) 20\r   602 600       Italia  Takeda\r   Italia S.p.A. Tel: +39 06\r   502601   Suomi/Finland Takeda Oy Puh/Tel: +358 20 746 5000 infoposti@takeda.com      \u039a\u03cd\u03c0\u03c1\u03bf\u03c2 A. POTAMITIS MEDICARE LTD T\u03b7\u03bb: +357 22583333 info@potamitismedicare.com     Sverige Takeda Pharma AB Tel: +46 8 731 28 00 infosweden@takeda.com      Latvija Takeda Latvia SIA Tel: +371 67840082    United\r   Kingdom Takeda UK Ltd Tel: +44 (0)1628 537 900    ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "4910a296-04f0-47f7-806c-1e2ccfa7b060", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">This\r leaflet was last revised in</span></b></p>", "ID": "27f2de75-e34e-41e3-8ac6-c411a61a9b70", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "This\r leaflet was last revised in", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;page-break-after:avoid\"></p>", "ID": "35997b79-663e-4499-bfe1-727150f58b65", "Styles": "margin-right:-.1pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">This medicine\r has been given \u2018conditional approval\u2019. This means that there is\r more evidence to come about this medicine.</span></p>", "ID": "668cb964-aed3-4d02-bfc3-49dea898f304", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "This medicine\r has been given \u2018conditional approval\u2019. This means that there is\r more evidence to come about this medicine.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt\"><span lang=\"EN-GB\">The European\r Medicines Agency will review new information on this medicine at least every\r year and this leaflet will be updated as necessary.</span></p>", "ID": "3de0f42c-fe39-4bff-a427-d314d07f1eed", "Styles": "margin-right:-.1pt", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The European\r Medicines Agency will review new information on this medicine at least every\r year and this leaflet will be updated as necessary.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "58cd2131-db01-4dfc-af48-72cfb359ab22", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Detailed information on this medicine is\r available on the European Medicines Agency website: </span><u><span lang=\"EN-GB\" style=\"color:blue\">http://www.ema.europa.eu/</span></u></p>", "ID": "45ab7501-45e4-4af7-bddf-7aa1787343d9", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": true, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": null, "Text": "Detailed information on this medicine is\r available on the European Medicines Agency website: http://www.ema.europa.eu/", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "d6384757-6506-4910-b872-873968d88c69", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "40a53285-9407-40a1-9bbb-7134cff45f4b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">----------------------------------------------------------------------------------------------------------------------</span></p>", "ID": "8013e9c5-850d-45c2-9779-59635f4e1f60", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "----------------------------------------------------------------------------------------------------------------------", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The following information is intended for\r healthcare professionals only:</span></p>", "ID": "85473f25-1e38-4beb-afa1-8cee1a2b1d9b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The following information is intended for\r healthcare professionals only:", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "b8e6423c-72db-40fb-bff3-8050cab26c50", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Traceability</span></b></p>", "ID": "8661c13a-e468-4a64-98a8-bc696a7a7caf", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Traceability", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "d56551a1-3ec1-419e-b4c2-6a2eb2cd969e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">In order to\r improve the traceability of biological medicinal products, the name and the\r batch number of the administered product should be clearly recorded.</span></p>", "ID": "716ab475-b650-4844-942d-47d99e4d631c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "In order to\r improve the traceability of biological medicinal products, the name and the\r batch number of the administered product should be clearly recorded.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "f96f9b72-9e81-4e58-9d30-bc212953b97f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Disposal </span></b></p>", "ID": "e19ad527-0b96-4ec3-ba53-e10175cf8b70", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Disposal ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "85a94486-7ff5-44b8-b900-12837512b7fc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Adcetris is for single use only. </span></p>", "ID": "b32b2ae5-f91b-4e9e-9b1c-10f8a30cb405", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Adcetris is for single use only. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "07ae409e-145e-43bb-abcd-ad24e7627a03", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Any unused product or waste material should\r be disposed of in accordance with local requirements.</span></p>", "ID": "e8549887-9e61-40b9-a7b8-899823d423f3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Any unused product or waste material should\r be disposed of in accordance with local requirements.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "5a2923d3-5467-4b1e-bc34-1913c40c2620", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Instructions\r for reconstitution </span></b></p>", "ID": "38ef0938-3bb5-46b9-881a-b0fe36dfe2fe", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Instructions\r for reconstitution ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "319d97fe-a2c3-46d8-bccb-3c5ad032b0ba", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Each single use vial must be reconstituted\r with 10.5 mL of water for injections to a final concentration of\r 5 mg/mL. Each vial contains a 10% overfill giving 55 mg of Adcetris\r per vial and a total reconstituted volume of 11 mL.</span></p>", "ID": "80d8824b-3732-4985-af55-87ff644ff83a", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Each single use vial must be reconstituted\r with 10.5 mL of water for injections to a final concentration of\r 5 mg/mL. Each vial contains a 10% overfill giving 55 mg of Adcetris\r per vial and a total reconstituted volume of 11 mL.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">1.</span><span lang=\"EN-GB\">Direct the stream toward the wall of the vial\r and not directly at the cake or powder. </span></p>", "ID": "e9a7697b-e976-4bf0-a7e9-a794ee75b96e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpFirst']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "1.Direct the stream toward the wall of the vial\r and not directly at the cake or powder. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\">2.</span><span lang=\"EN-GB\">Gently swirl the vial to aid dissolution. DO NOT\r SHAKE. </span></p>", "ID": "25a245b8-0f9f-4ec7-9f67-669933b1ca11", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "2.Gently swirl the vial to aid dissolution. DO NOT\r SHAKE. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent:\r -28.35pt\"><span lang=\"EN-GB\">3.</span><span lang=\"EN-GB\">The reconstituted solution in the vial is a\r clear to slightly opalescent, colourless solution with a final pH of 6.6. </span></p>", "ID": "1e6cb585-6605-4bb8-9459-65a148584892", "Styles": "margin-left:28.35pt;text-indent:\r\n-28.35pt", "Classes": "['MsoListParagraphCxSpMiddle']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "3.The reconstituted solution in the vial is a\r clear to slightly opalescent, colourless solution with a final pH of 6.6. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">4.</span><span lang=\"EN-GB\">The reconstituted solution should be inspected\r visually for any foreign particulate matter and/or discolouration. In the event\r of either being observed, discard the medicinal product.</span></p>", "ID": "761c83c1-b9e3-4ffb-9065-d57d303ff281", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoListParagraphCxSpLast']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": true, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "4.The reconstituted solution should be inspected\r visually for any foreign particulate matter and/or discolouration. In the event\r of either being observed, discard the medicinal product.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "dc106bef-eae2-4b1d-ada2-72dc1ce7cf96", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Preparation\r of Infusion Solution</span></b></p>", "ID": "08033f95-0114-450a-bc1d-2ce0e72cb8a9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": true, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": true, "IsHeadingType": "L2", "Text": "Preparation\r of Infusion Solution", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"></p>", "ID": "50a97cd8-a169-4344-8737-4bc7e88d9a67", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The appropriate amount of reconstituted\r Adcetris must be withdrawn from the vial(s) and added to an infusion bag\r containing sodium chloride 9 mg/mL (0.9%) solution for injection in order\r to achieve a final concentration of 0.4\u20111.2 mg/mL Adcetris. The\r recommended diluent volume is 150 mL. The already reconstituted Adcetris\r can also be diluted into 5% dextrose for injection or Lactated Ringer's for\r injection. </span></p>", "ID": "6c4b57fd-a872-4fb6-b66b-5aac73c08662", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "The appropriate amount of reconstituted\r Adcetris must be withdrawn from the vial(s) and added to an infusion bag\r containing sodium chloride 9 mg/mL (0.9%) solution for injection in order\r to achieve a final concentration of 0.4\u20111.2 mg/mL Adcetris. The\r recommended diluent volume is 150 mL. The already reconstituted Adcetris\r can also be diluted into 5% dextrose for injection or Lactated Ringer's for\r injection. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "60e704b8-bf52-42e5-b804-dedc7849fd2d", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Gently invert the bag to mix the solution\r containing Adcetris. DO NOT SHAKE. </span></p>", "ID": "107e8f5e-1b01-44ae-8e87-da6f288b896b", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Gently invert the bag to mix the solution\r containing Adcetris. DO NOT SHAKE. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "c1613e01-d0c3-4634-afb6-87c8fe28227f", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Any portion left in the vial, after\r withdrawal of the volume to be diluted, must be disposed of in accordance with\r local requirements. </span></p>", "ID": "544ac32a-75d3-44fa-88e6-f033a9314081", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Any portion left in the vial, after\r withdrawal of the volume to be diluted, must be disposed of in accordance with\r local requirements. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "1f064680-c32b-49b6-8819-3f5277692fc9", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not add other medicinal products to the\r prepared Adcetris infusion solution or intravenous infusion set. The infusion\r line should be flushed following administration with sodium chloride\r 9 mg/mL (0.9%) solution for injection, 5% dextrose for injection, or\r Lactated Ringer's for injection. </span></p>", "ID": "fb0a372b-62f2-4441-a880-1b8fd0cad034", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Do not add other medicinal products to the\r prepared Adcetris infusion solution or intravenous infusion set. The infusion\r line should be flushed following administration with sodium chloride\r 9 mg/mL (0.9%) solution for injection, 5% dextrose for injection, or\r Lactated Ringer's for injection. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "3c00a006-a1cc-4dbc-ad95-a6bf407a1672", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Following dilution, infuse the Adcetris\r solution immediately at the recommended infusion rate. </span></p>", "ID": "393b59ce-ce39-46b1-9c71-b4af14605451", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Following dilution, infuse the Adcetris\r solution immediately at the recommended infusion rate. ", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"></p>", "ID": "3cbb8d62-eaaa-4706-8b8e-6d7cede0d0ba", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Total storage time of the solution from\r reconstitution to infusion should not exceed 24 hours.</span></p>", "ID": "2c852b92-3227-4786-ba7f-5e16c55f19c3", "Styles": "None", "Classes": "['MsoNormal']", "Bold": false, "Italics": false, "Uppercased": false, "Underlined": false, "Indexed": false, "IsListItem": false, "HasBorder": false, "IsPossibleHeading": false, "IsHeadingType": null, "Text": "Total storage time of the solution from\r reconstitution to infusion should not exceed 24 hours.", "ParentId": "5e28ec10-a96d-47c4-ab03-42178b2c86a0"}]}